	PMID	PT	OT	MH	SI	TI	GR
0	32361195	Comment;Letter	O  NNLM;*Autoinflammatory syndrome;*CAPs;*Capillary leaklike syndrome;*IL6;*IVIG;*SARSCoV2	Betacoronavirus;COVID19;*Coronavirus Infections;Humans;Immunoglobulins, Intravenous;Pandemics;Pneumonia, Viral;SARSCoV2;*Severe Acute Respiratory Syndrome;DA 2020/06/10 06:00		SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human 	
1	32497632	Journal Article;Review		Aminoquinolines/therapeutic use;AntiBacterial Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/*isolation & purification;COVID19;COVID19 Vaccines;Coronavirus Infections/*drug therapy/prevention & control/virology;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/08/25 06:00		Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical 	
2	32560227	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;coronavirus;therapies;vaccines	DA 2020/06/21 06:01		Vaccines and Therapies in Development for SARS-CoV-2 Infections.	R01AI13976802/National Institute of Allergy and Infectious Diseases/
3	32859477	Journal Article;Multicenter Study;Observational Study	O  NNLM;*COVID19;*Disease severity;*Hydroxychloroquine;*Inflammation;*Mortality	Aged;Aged, 80 and over;COVID19/*drug therapy/*mortality;Female;Hospital Mortality;Humans;Hydroxychloroquine/*therapeutic use;Italy;Male;Middle Aged;Retrospective Studies;Treatment Outcome;DA 2020/12/29 06:00		Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with 	
4	32623357	Journal Article	O  NNLM;COVID19;Docking;Molecular dynamics simulation;Mpro;SARSCoV2	Antiviral Agents/chemistry/pharmacology;Betacoronavirus/drug effects/*enzymology;COVID19;Coronavirus 3C Proteases;Coronavirus Infections/*drug therapy;Cysteine Endopeptidases/chemistry/metabolism;*Drug Evaluation, Preclinical;*Drug Repositioning;Humans;Molecular Dynamics Simulation;Pandemics;Pneumonia, Viral/*drug therapy;Protease Inhibitors/chemistry/*pharmacology;Protein Conformation;SARSCoV2;Viral Nonstructural Proteins/*antagonists & inhibitors/chemistry/metabolism;DA 2020/11/20 06:00		Virtual screening of approved drugs as potential SARS-CoV-2 main protease 	P41 GM103311/GM/NIGMS NIH HHS/United States
5	33154646	Case Reports	O  NNLM;COVID19;computed tomography;critical care;followup;pulmonary fibrosis;viral disease	DA 2020/11/07 06:01		A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following 	
6	32798473	Journal Article;Multicenter Study;Observational Study		Adult;Aged;Aged, 80 and over;*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/drug therapy/*epidemiology;Female;FollowUp Studies;Hematologic Neoplasms/*epidemiology/therapy;Humans;Inpatients;Italy/epidemiology;Leukemia/epidemiology/therapy;Lymphoma, NonHodgkin/epidemiology/therapy;Male;Middle Aged;Myeloproliferative Disorders/epidemiology/therapy;Neoplasms, Plasma Cell/epidemiology/therapy;*Pandemics;Pneumonia, Viral/*epidemiology;Retrospective Studies;Risk Factors;SARSCoV2;Young Adult;DA 2020/10/03 06:00	ClinicalTrials.gov/NCT04352556	Clinical characteristics and risk factors associated with COVID-19 severity in 	
7	32600363	Clinical Trial Protocol;Letter	O  NNLM;Absorption;COVID19;Drugdrug interaction;Hydroxychloroquine;Microdosing;Midazolam;Pantoprazole;Randomised controlled trial;Trial protocol;Yohimbine	Adolescent;Adult;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Interactions;Humans;Hydroxychloroquine/*pharmacokinetics/therapeutic use;Middle Aged;Pandemics;Pantoprazole/*pharmacology;Pneumonia, Viral/*drug therapy;*Randomized Controlled Trials as Topic;SARSCoV2;Young Adult;DA 2020/07/08 06:00		Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug 	
8	32784499	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;antiviral;coronavirus;remdesivir;vaccine	DA 2020/08/14 06:01		Emerging Therapeutic Modalities against COVID-19.	1R01CA24119401A1/NH/NIH HHS/United States;1R01HL14702801A1/NH/NIH HHS/United States
9	33495967	Journal Article;Review	O  NNLM;COVID;COVID19;Coronavirus;Evidence;Narrative review;Pharmacologic;Review;Therapy;Treatment	DA 2021/01/27 06:01		COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options.	
10	32838307	Journal Article		DA 2020/08/25 06:01		COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre 	
11	32316118	Editorial	O  NNLM;ACE2 receptor;COVID19;antimalarials;coronavirus disease;epidemiological paradox;malaria	DA 2020/04/23 06:01		Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in 	
12	32277351	Journal Article		COVID19;Contraindications, Drug;Coronavirus Infections/*immunology;Dermatitis, Atopic/drug therapy;Hidradenitis Suppurativa/drug therapy;Humans;*Immunomodulation;Immunosuppressive Agents/*therapeutic use;*Pandemics;Pneumonia, Viral/*immunology;Psoriasis/drug therapy;Skin Diseases/*drug therapy/immunology;DA 2020/06/13 06:00		Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.	
13	32792851	Journal Article;Review	O  NNLM;*COVID19;*Immune response;*Immunecheckpoints;*Sepsis;*Tcell exhaustion	Adrenal Cortex Hormones/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;Biomarkers;Blood Coagulation Disorders/immunology;COVID19;Coronavirus Infections/*immunology/*physiopathology;Cytokines/metabolism;Humans;Immune System;Immunity, Innate;Interferons/metabolism;Lymphopenia/immunology;Pandemics;Phenotype;Platelet Activation;Pneumonia, Viral/*immunology/*physiopathology;SARSCoV2;Sepsis/*physiopathology;DA 2020/09/01 06:00		Immune Response and COVID-19: A mirror image of Sepsis.	
14	33011243	Journal Article;Review	O  NNLM;COVID19;IL6Induced endothelial dysfunction;Neprilysin;Neutrophilmediated inflammation;Roflumilast;TGFβ1induced pulmonary fibrosis;cAMP	Aminopyridines/*pharmacology/*therapeutic use;Benzamides/*pharmacology/*therapeutic use;COVID19/*drug therapy;Cyclopropanes/pharmacology/therapeutic use;Humans;Neprilysin/*drug effects;Pandemics;SARSCoV2;DA 2020/12/22 06:00		New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of 	
15	33238464	Journal Article;Review	O  NNLM;COVID19;HIV;USFDA;drug repurposing/reprofiling;zidovudine	DA 2020/11/27 06:01		Drug Repurposing Approaches to Combating Viral Infections.	P51 OD011132/OD/NIH HHS/United States;R01 DA052845/DA/NIDA NIH HHS/United States;R01 DA042524/DA/NIDA NIH HHS/United States;P30 MH062261/MH/NIMH NIH HHS/United States;R01AI129745, P30MH062261, R01DA042524, R01DA050169 , P51OD011133/NH/NIH HHS/United 
16	33347987	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Antiinflammation;*Antiviral;*COVID19;*Nitric oxide;*Vasodilation	Administration, Inhalation;AntiInflammatory Agents/blood/*therapeutic use;Anticoagulants/blood/*therapeutic use;Antiviral Agents/blood/*therapeutic use;COVID19/blood/*drug therapy/pathology/virology;Endothelial Cells/drug effects/pathology/virology;Humans;Inflammation;Lung/blood supply/*drug effects/virology;Mitochondria/drug effects/virology;Nitric Oxide/blood/*therapeutic use;SARSCoV2/drug effects/pathogenicity;Severity of Illness Index;Vasodilation/drug effects;DA 2021/01/28 06:00		The role of NO in COVID-19 and potential therapeutic strategies.	
17	32444415	Journal Article	O  NNLM;*autoimmune diseases;*autoimmunity;*inflammation	Adult;Aged;*Betacoronavirus;COVID19;China;Coronavirus Infections/*complications/pathology/virology;Diarrhea/virology;Fatigue/virology;Female;Fever/virology;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications/pathology/virology;Respiratory Insufficiency/virology;Retrospective Studies;Rheumatic Diseases/*virology;SARSCoV2;Symptom Flare Up;DA 2020/07/23 06:00		Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.	
18	33033561	Journal Article;Review	O  NNLM;COVID19 disease;COVID19 pneumonia;Lung damage;Mesenchymal stem cell secretome;Mesenchymal stem cells;Stem/progenitor cells	DA 2020/10/10 06:01		Perspectives on mesenchymal stem/progenitor cells and their derivates as potential 	
19	32205186	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Cytokine release syndrome;DMARDs;Rheumatoid arthritis;Treatment	Antirheumatic Agents/*therapeutic use;Arthritis, Rheumatoid/complications/*immunology/virology;*Betacoronavirus;COVID19;China;Coronavirus Infections/complications/*drug therapy;Humans;*Immunocompromised Host;Pandemics;Pneumonia, Viral/complications/*drug therapy;SARSCoV2;DA 2020/04/22 06:00		COVID-19 infection and rheumatoid arthritis: Faraway, so close!	
20	32853631	Journal Article	O  NNLM;*COVID19;*immunosuppression;*kidney transplantation;*mortality;*prognosis	Adult;Aged;Aged, 80 and over;COVID19/complications/*mortality/therapy;Deprescriptions;Female;France/epidemiology;Humans;Immunosuppression;Kidney Transplantation/*mortality;Male;Middle Aged;Pandemics/statistics & numerical data;Postoperative Complications/*mortality/virology;*Registries;Retrospective Studies;Risk Factors;Young Adult;DA 2020/12/22 06:00		An initial report from the French SOT COVID Registry suggests high mortality due to 	
21	33199179	Journal Article;Review	O  NNLM;*Biomarker;*COVID19;*Complications;*Cytokine storm;*Immunopathology;*Lung	Biomarkers/analysis/*blood;COVID19/blood/complications/*diagnosis/*therapy;Chemokines/analysis/blood;Cytokine Release Syndrome/diagnosis/etiology/therapy;Cytokines/analysis/blood;Humans;Immunity, Innate/*physiology;Monitoring, Physiologic/*methods;Prognosis;Respiratory Distress Syndrome/diagnosis/etiology/therapy;SARSCoV2/physiology;DA 2021/04/21 06:00		Predictive monitoring and therapeutic immune biomarkers in the management of 	
22	32971210	Journal Article	O  NNLM;CMap;COVID19 drug;Network proximity;OpenVigil;Pharmacovigilance;Side effect	Antineoplastic Agents/*adverse effects/therapeutic use;Antiviral Agents/*adverse effects/therapeutic use;Betacoronavirus/drug effects;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Humans;Immunologic Factors/*adverse effects/therapeutic use;Pandemics;*Pharmacovigilance;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/10/22 06:00		Comprehensive assessment of side effects in COVID-19 drug pipeline from a network 	
23	32599589	Journal Article;Review	O  NNLM;*COVID19;*Cytokine storm;*Therapy	Adrenal Cortex Hormones/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Betacoronavirus;CCR5 Receptor Antagonists/therapeutic use;COVID19;Chloroquine/therapeutic use;Coronavirus Infections/drug therapy/immunology/*therapy;Cytokine Release Syndrome/immunology/*therapy;Enzyme Inhibitors/therapeutic use;Extracorporeal Membrane Oxygenation;HIV Antibodies/therapeutic use;Hemoperfusion;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive;Immunoglobulins, Intravenous/therapeutic use;Immunologic Factors/therapeutic use;Immunomodulation;Interleukin 1 Receptor Antagonist Protein/therapeutic use;Janus Kinase Inhibitors/therapeutic use;Lung Injury/immunology/therapy;Mesenchymal Stem Cell Transplantation;Multiple Organ Failure;Pandemics;Plasma Exchange;Plasmapheresis;Pneumonia, Viral/immunology/*therapy;Receptors, Interleukin6/antagonists & inhibitors;Respiratory Distress Syndrome/immunology/*therapy;SARSCoV2;Tumor Necrosis Factor Inhibitors/therapeutic use;DA 2020/09/25 06:00		Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.	UL1 TR002649/TR/NCATS NIH HHS/United States
24	33134740	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;outbreak;pandemic;therapeutic, vaccine;transmission	DA 2020/11/03 06:01		Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and 	
25	32234468	Journal Article	O  NNLM;COVID19;Clinical trials;Diagnosis;Isolation;Pandemic;Remdesivir	Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;COVID19 Testing;Clinical Laboratory Techniques;Clinical Trials as Topic;*Coronavirus Infections/diagnosis/drug therapy/epidemiology;Humans;*Pandemics;*Pneumonia, Viral/diagnosis/drug therapy/epidemiology;SARSCoV2;DA 2020/05/29 06:00		The epidemiology, diagnosis and treatment of COVID-19.	
26	32687917	Journal Article;Review	O  NNLM;Antiviral drugs;COVID19;Convalescent plasma;SARSCoV2;Vaccines	Antiviral Agents/pharmacology;Betacoronavirus/*immunology/pathogenicity;COVID19;Chemokines;Coronavirus/drug effects;Coronavirus Infections/*complications/drug ;Cytokines/metabolism;Humans;Inflammation/immunology;Lung/drug effects;Pandemics;Phylogeny;Pneumonia, Viral/*complications/immunology/*therapy;SARSCoV2;Severe Acute Respiratory Syndrome/immunology/pathology/virology;DA 2020/09/30 06:00		An updated insight into the molecular pathogenesis, secondary complications and 	
27	33485973	Journal Article;Systematic Review	O  NNLM;Active ingredients;Broadspectrum antiviral;Chinese herbal medicine;Organ protection;SARSCov2	Animals;COVID19/*drug therapy;Drugs, Chinese Herbal/*therapeutic use;Humans;*Medicine, Chinese Traditional;*SARSCoV2;DA 2021/02/16 06:00		Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.	
28	32359447	Editorial		Betacoronavirus/*immunology/isolation & purification;COVID19;Coronavirus Infections/immunology/*therapy;Humans;Immunization, Passive/methods;Pandemics;Plasma/*immunology;Pneumonia, Viral/immunology/*therapy;SARSCoV2;DA 2020/07/01 06:00		The resurgence of convalescent plasma therapy.	
29	32503662	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Chloroquine;Oropharyngeal sampling;Polymerase chain reaction;Pragmatic trial;Protocol;Randomized controlled trial;Viral load	*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/virology;Female;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Male;Norway;Pandemics;Pneumonia, Viral/*drug therapy/virology;*Pragmatic Clinical Trials as Topic;Research Design;SARSCoV2;Viral Load;DA 2020/07/01 06:00	ClinicalTrials.gov/NCT04316377	Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to 	
30	33253920	Journal Article;Review		*Antiviral Agents/classification/pharmacology;*COVID19/drug therapy/epidemiology/prevention & control;COVID19 Vaccines/*pharmacology;*Compassionate Use Trials/methods/trends;Drug Approval;Humans;SARSCoV2;United States;DA 2021/04/02 06:00		Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations 	
31	32426740	Journal Article;Review	O  NNLM;coronavirus disease 2019;guidelines;knowledge translation;misinformation;pandemic	DA 2020/05/20 06:01		Misinformation During the Coronavirus Disease 2019 Outbreak: How Knowledge Emerges 	
32	32585805	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;convalescent plasma;drug repurposing;stem cell therapy;vaccine interventions	DA 2020/06/27 06:01		Emerging Prevention and Treatment Strategies to Control COVID-19.	
33	32853599	Comment;Letter	O  NNLM;*Adaptive immunity;*COVID19;*Coronavirus;*Interferonᵧ;*SARSCoV2;*Tcells	*COVID19;China;Humans;Immunity, Cellular;Prospective Studies;Retrospective Studies;*SARSCoV2;Severity of Illness Index;TLymphocytes;DA 2021/02/25 06:00		COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to 	
34	32895747	Journal Article;Review	O  NNLM;Autoimmune;COVID19;DMARD;Immunosuppressive;Medications;Rheumatic	Antirheumatic Agents/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*immunology;Cytokine Release Syndrome/immunology;Deprescriptions;Disease Management;Humans;Immunosuppressive Agents/*therapeutic use;Pandemics;Pneumonia, Viral/drug therapy/*immunology;Rheumatic Diseases/*drug therapy;SARSCoV2;DA 2020/10/24 06:00		Managing rheumatic diseases during COVID-19.	
35	33161277	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*ACE2;*Antivirals;*COVID19;*Drug development;*Existing drugs;*Immunomodulators;*Monoclonal antibodies;*Repurposed use;*SARSCoV2;*Spike protein;*Therapeutic targets;*Virus life cycle	Animals;Antibodies, Monoclonal/administration & dosage/immunology/metabolism;Antiviral Agents/*administration & dosage/immunology/metabolism;COVID19/*drug therapy/immunology/metabolism;Drug Development/*methods/trends;Humans;Immunologic Factors/administration & dosage/immunology/metabolism;Time Factors;Virus Internalization/drug effects;DA 2020/12/29 06:00		COVID-19 update: The race to therapeutic development.	
36	33293238	Journal Article;Review	O  NNLM;*ACE2;*COVID19;*Chemokines;*Cytokines;*Immunity;*Spike protein;*Vaccines	AngiotensinConverting Enzyme 2/physiology;*Antiviral Agents/isolation & purification/therapeutic use;COVID19/*drug therapy/immunology/*prevention & control;COVID19 Vaccines/*therapeutic use;Drug Development/methods;Genome, Viral/physiology;Humans;Molecular Targeted Therapy/*methods;SARSCoV2/drug effects/genetics/*immunology/pathogenicity;Viral Vaccines/therapeutic use;DA 2021/04/21 06:00		SARS-CoV-2: Targeted managements and vaccine development.	
37	32646061	Journal Article;Review	O  NNLM;COVID19;NETs;SARS;antioxidant;coronavirus;cytokine;ergothioneine;inflammation	DA 2020/07/11 06:01		Could Ergothioneine Aid in the Treatment of Coronavirus Patients?	NMRC/1264/2010/082/12/National Medical Research Council/;R183000321133/Tan Chin Tuan Centennial Foundation/
38	33301928	Comparative Study;Journal Article;Observational Study	O  NNLM;COVID19;Causal inference;Corticosteroids;Observational study;Therapeutic evaluation	Adolescent;Adrenal Cortex Hormones/*therapeutic use;Adult;Aged;Aged, 80 and over;CReactive Protein/analysis;COVID19/*drug therapy/mortality/therapy;Female;Humans;Male;Middle Aged;*Oxygen Inhalation Therapy;Prednisone/*therapeutic use;Respiration, Artificial;Severity of Illness Index;Young Adult;DA 2021/04/20 06:00		Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: 	
39	32485418	Journal Article;MetaAnalysis;Review	O  NNLM;*Anticoagulation;*COVID19;*Venous thromboembolism	Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/drug effects/*pathogenicity;*Blood Coagulation/drug effects;COVID19;Coronavirus Infections/blood/drug therapy/epidemiology/*virology;HostPathogen Interactions;Humans;Pandemics;Pneumonia, Viral/blood/drug therapy/epidemiology/*virology;Risk Assessment;Risk Factors;SARSCoV2;Treatment Outcome;Venous Thrombosis/blood/epidemiology/prevention & control/*virology;DA 2020/06/25 06:00		Thrombosis risk associated with COVID-19 infection. A scoping review.	
40	32937051	Case Reports;Clinical Conference;Journal Article		Aged;Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/complications/*diagnosis/therapy;Diagnosis, Differential;Dyspnea/*etiology;Fever/etiology;Humans;Immunocompromised Host;Immunosuppressive Agents/*therapeutic use;*Liver Transplantation;Male;Pandemics;Pneumonia, Viral/complications/*diagnosis/therapy;Respiration, Artificial;SARSCoV2;DA 2020/10/09 06:00		Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver 	
41	32674929	Journal Article;Review	O  NNLM;(Hydroxy)chloroquine;2019nCoV;Azithromycin;COVID19;SARSCoV2	Azithromycin/*administration & dosage/adverse effects/pharmacology;*Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Drug Therapy, Combination;Humans;Hydroxychloroquine/*administration & dosage/adverse effects/pharmacology;Outcome Assessment, Health Care;Pandemics;Pneumonia, Viral/*drug therapy;Research Design;SARSCoV2;DA 2020/08/05 06:00		Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: 	
42	33142431	Comparative Study;Journal Article;Review	O  NNLM;*3CL or Mpro Protease;*COVID19;*Clinical trials;*RNA dependent RNA polymerase;*SARSCoV2;*SARSCoV2 spike (S) protein	Amino Acid Sequence;Animals;Antiviral Agents/*metabolism/therapeutic use;Binding Sites;COVID19/drug therapy/epidemiology/virology;Drug Repositioning;Humans;Protein Binding;SARS Virus/*chemistry;SARSCoV2/*chemistry/drug effects;Viral Nonstructural Proteins/chemistry/*metabolism;Viral Structural Proteins/chemistry/*metabolism;DA 2020/12/15 06:00		A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for 	
43	33189888	Journal Article;Observational Study;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Cytokine release syndrome;*IL6R antagonist;*SARSCoV2;*Tocilizumab;*Treatment	Acute Lung Injury/*drug therapy/mortality;Aged;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/*drug therapy/mortality;Cohort Studies;Cytokine Release Syndrome/*drug therapy/mortality;Female;Ferritins/metabolism;Fibrin Fibrinogen Degradation Products/metabolism;Humans;Inflammation/*drug therapy/mortality;Male;Middle Aged;Receptors, Interleukin6/immunology;Respiratory Distress Syndrome/*drug therapy/mortality;SARSCoV2/*physiology;Survival Analysis;DA 2021/01/29 06:00		Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated 	
44	32623296	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Drug safety;Drugdrug interactions;Drugrelated problems;HerbDrug interactions;Immune depression	Antineoplastic Agents/administration & dosage/adverse effects;Betacoronavirus/isolation & purification;COVID19;Clinical Trials as Topic/methods/standards;Coronavirus Infections/*drug therapy/*immunology/virology;Humans;Medical Oncology/methods/*standards;Neoplasms/*drug therapy/*immunology/virology;Pandemics;Pharmacy/methods/*standards;Pneumonia, Viral/*drug therapy/*immunology/virology;Practice Guidelines as Topic;SARSCoV2;DA 2020/07/30 06:00		Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage 	
45	33521383	Journal Article	O  NNLM;COVID19;Clinical;Diagnosis;SARSCoV2;Transmission;Treatment	DA 2021/02/02 06:01		COVID-19: What you need to know.	
46	32428865	Journal Article;Review	O  NNLM;COVID19;Clinical outcome;Mortality;Remdesivir;SARSCoV2	Adenosine Monophosphate/*analogs & derivatives/pharmacology/therapeutic use;Alanine/*analogs & derivatives/pharmacology/therapeutic use;Antiviral Agents/*pharmacology/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy;Drug Evaluation, Preclinical;Humans;Pandemics;Pneumonia, Viral/*drug therapy;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;DA 2020/07/28 06:00		Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical 	
47	32346490	Journal Article	O  NNLM;COVID19 outbreak;CoVMpro;CoVNsp12 polymerase;CoVNsp13 helicase;SARSCoV2	DA 2020/04/30 06:01		Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal 	
48	33158787	Comment;Letter		Antibodies, Monoclonal, Humanized/therapeutic use;*COVID19;Humans;SARSCoV2;Severity of Illness Index;DA 2021/01/05 06:00		Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. 	
49	32222812	Journal Article;Practice Guideline	O  NNLM;*COVID19;*Clinical practice guidelines;*Coronavirus;*Critical illness;*SARS CoV2	COVID19;Coronavirus Infections/prevention & control/*therapy;Critical Care/*standards;Humans;Intensive Care Units/*standards;Pandemics/prevention & control;Pneumonia, Viral/prevention & control/*therapy;Sepsis/diagnosis/etiology/*therapy;Survivors;DA 2020/05/15 06:00		Surviving Sepsis Campaign: guidelines on the management of critically ill adults 	
50	32736007	Practice Guideline;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*SARSCoV2;*cellular therapy;*hematopoietic cell transplan	Adrenal Cortex Hormones/*therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*diagnosis/*drug therapy/immunology/therapy/virology;COVID19 Testing;Cell and TissueBased Therapy/methods;Clinical DecisionMaking;Disease Management;Disinfection/methods;Hematopoietic Stem Cell Transplantation/*methods;Humans;Immunization, Passive;Immunologic Factors/*therapeutic use;Neoplasms/immunology/*therapy/virology;Physical Distancing;Risk Assessment;SARSCoV2/drug effects/pathogenicity;Time Factors;DA 2020/12/18 06:00		Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and 	P30 CA016672/CA/NCI NIH HHS/United States;U01 AI132004/AI/NIAID NIH HHS/United States
51	32321540	Journal Article;Review	O  NNLM;2019nCoV;COVID19;Children;Italy;Respiratory syndrome;SARSCoV2	Adolescent;AntiInflammatory Agents, NonSteroidal/adverse effects/therapeutic use;Antirheumatic Agents/*therapeutic use;Arthritis, Juvenile/complications/virology;Betacoronavirus;COVID19;Child;Child, Preschool;Chloroquine/therapeutic use;Clinical Trials as Topic;Coronavirus Infections/*complications/*drug therapy/epidemiology;Cytokine Release Syndrome/drug therapy/virology;Humans;Hydroxychloroquine/therapeutic use;Infant;Interleukin6/antagonists & inhibitors;Italy/epidemiology;Pandemics;*Pediatricians;Pneumonia, Viral/*complications/*drug therapy/epidemiology;Rheumatic Diseases/*complications/*virology;*Rheumatologists;SARSCoV2;DA 2020/04/25 06:00		COVID-19 and what pediatric rheumatologists should know: a review from a highly 	
52	32514689	Journal Article;Systematic Review		AntiBacterial Agents/*pharmacology;AntiRetroviral Agents/*pharmacology;Antimalarials/*pharmacology;Antineoplastic Agents/*pharmacology;Antiviral Agents/pharmacology;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/prevention & control;*Drug Repositioning;Humans;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/prevention & control;SARSCoV2;DA 2020/07/21 06:00		The potential of drug repositioning as a short-term strategy for the control and 	
53	32605194	Journal Article;Review	O  NNLM;*COVID19;*Coronavirus;*SARSCoV2;*diagnosis;*pandemic;*pathobiology;*therapeutics;*vaccines	DA 2020/07/02 06:01		Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective.	
54	33435568	Journal Article;Review	O  NNLM;NETosis;NOXdependent and NOXindependent;chronic obstructive pulmonary disease (COPD);innate immunity neutrophils;neutrophil extracellular traps (NETs);pathogenesis	DA 2021/01/14 06:01		Orchestration of Neutrophil Extracellular Traps (Nets), a Unique Innate Immune 	
55	33152192	Journal Article;Systematic Review	O  NNLM;*chloroquine;*hydroxychloroquine;*coronavirus;*systematic review;*clinical trial;*pandemics;*SARSCoV2	Antiviral Agents/adverse effects/pharmacology/*therapeutic use;Betacoronavirus/*drug effects/physiology;COVID19;Chloroquine/adverse effects/pharmacology/*therapeutic use;Clinical Trials as Topic;Compassionate Use Trials;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/drug therapy;Drug Repositioning;Humans;Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use;Multicenter Studies as Topic;Pandemics;Pneumonia, Viral/*drug therapy;Randomized Controlled Trials as Topic;Registries;SARSCoV2;Treatment Outcome;Virus Replication/drug effects;DA 2020/11/20 06:00		Chloroquine and its derivatives in the management of COVID-19: A scoping review.	
56	33532594	Journal Article	O  NNLM;COVID‐19;SARS‐CoV‐2;artificial intelligence;combinatory treatment;digital medicine;drug development;drug interactions	DA 2021/02/04 06:01		IDentif.AI: Rapidly optimizing combination therapy design against severe Acute 	
57	32766679	Comment;Journal Article		*COVID19;*Coronavirus Infections/epidemiology;Humans;Hydroxychloroquine;Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/12/17 06:00		Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment 	
58	32982720	Journal Article;Review	O  NNLM;SARSCoV2;angiotensinconverting enzyme 2 receptors;endocytosis;immune response;mesenchymal stem cells;monoclonal antibodies;therapeutic targets;vaccine	DA 2020/09/29 06:01		SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile 	
59	33172592	Journal Article;Review	O  NNLM;ARDS;Acute respiratory failure;COVID19;Intensive care;Pneumonia;SARSCoV2	*COVID19/diagnosis/epidemiology/physiopathology/therapy;COVID19 Nucleic Acid Testing/methods;COVID19 Vaccines;*Congresses as Topic;Global Health/statistics & numerical data;Humans;Immunization, Passive/methods;Immunotherapy/methods;*Intensive Care Units;Pandemics;Phenotype;*SARSCoV2;Symptom Assessment;Thromboembolism/prevention & control;Videoconferencing;Virus Internalization;DA 2020/12/29 06:00		Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens 	
60	33519133	Journal Article	O  NNLM;Covid 19;Siddha strategy;accelerated recovery;synergistic effect	DA 2021/02/02 06:00		An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management 	
61	33310665	Controlled Clinical Trial;Journal Article	O  NNLM;COVID19;Oxygenozone therapy;Ozonated blood;Pneumonia;Time to clinical improvement	Aged;Aged, 80 and over;*Blood Transfusion, Autologous;COVID19/mortality/*therapy;Female;Humans;KaplanMeier Estimate;Male;Middle Aged;Ozone/*therapeutic use;*SARSCoV2;Treatment Outcome;DA 2021/01/23 06:00	ClinicalTrials.gov/NCT04444531	Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a 	
62	33558455	Journal Article;Review		DA 2021/02/10 06:00		Viral vector platforms within the gene therapy landscape.	R01NS07699101/U.S. Department of Health & Human Services | NIH | National Institute ;1P01AI10026301/Division of Intramural Research, National Institute of Allergy and ;4P01HL13147102/U.S. Department of Health & Human Services | NIH | National Heart, ;UG3 HL14736701/U.S. Department of Health & Human Services | NIH | National Heart, 
63	32840231	Journal Article;Review	O  NNLM;COVID19;Corona virus;Regenerative medicine;Severe infections;Treatment options	DA 2020/08/26 06:01		Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 	
64	32347144	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.;Review	O  NNLM;*COVID‐19;*SARS‐CoV‐2;*cardiovascular disease;*cardiovascular risk factors;*coronavirus disease 2019;*management;*treatment	*Betacoronavirus;COVID19;Cardiovascular Diseases/*epidemiology;Comorbidity;Coronavirus Infections/*epidemiology;Global Health;Humans;Incidence;*Pandemics;Pneumonia, Viral/*epidemiology;SARSCoV2;DA 2020/07/07 06:00		Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White 	K23 HL148528/HL/NHLBI NIH HHS/United States;PBPG121620028/Department of Health/United Kingdom;R01 HL108932/HL/NHLBI NIH HHS/United States;K12 CA133250/CA/NCI NIH HHS/United States
65	32979360	Journal Article;Review	O  NNLM;Cell therapy;Clinical trials;Coronavirus;Cytokine storm;Immunomodulatory effects	COVID19/*immunology/*therapy;Humans;Immunomodulation/*physiology;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/*immunology;SARSCoV2/*immunology;DA 2020/12/15 06:00		Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of 	
66	32862111	Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;Interferon β;Iran;SARSCOV2	Aged;Antiviral Agents/administration & dosage/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/immunology;Drug Administration Schedule;Drug Therapy, Combination;Female;Humans;Injections, Subcutaneous;Interferon beta1b/administration & dosage/adverse effects/*therapeutic use;KaplanMeier Estimate;Male;Methylprednisolone/administration & dosage/therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/immunology;SARSCoV2;Severity of Illness Index;Treatment Outcome;DA 2020/11/24 06:00		Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.	
67	32895254	Case Reports;Journal Article	O  NNLM;infection (neurology);infections	Adult;*Betacoronavirus;COVID19;Coronavirus Infections/*complications;Humans;Immunoglobulins, Intravenous/*therapeutic use;Immunologic Factors/*therapeutic use;Male;Meningoencephalitis/*drug therapy/*etiology;Pandemics;Pneumonia, Viral/*complications;SARSCoV2;Treatment Outcome;DA 2020/09/17 06:00		COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin.	
68	32499154	Journal Article;Review	O  NNLM;*Human coronavirus;*SARSCoV2;*Structure;*Therapy;*Treatments;*Virus	Animals;Betacoronavirus/drug effects/physiology;COVID19;Clinical Trials as Topic;Coronavirus Infections/drug therapy/*epidemiology/*therapy;Genome, Viral;Global Health;HostPathogen Interactions;Humans;Ligands;Pandemics;Pneumonia, Viral/*epidemiology/*therapy;Risk;SARSCoV2;Virus Replication;DA 2020/09/29 06:00		Covid-19 Pandemic and Current Medical Interventions.	
69	33334457	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*China;*acute kidney injury;*incidence;*management	Acute Kidney Injury/epidemiology/*virology;COVID19/*complications/epidemiology;China/epidemiology;Humans;Incidence;Pandemics;Prognosis;Risk Factors;SARSCoV2;DA 2020/12/31 06:00		Acute Kidney Injury in COVID-19: The Chinese Experience.	
70	32423024	Journal Article;Review	O  NNLM;ACE2;COVID19;SARSCoV2;TMPRSS2;baricitinib;chloroquine;favipiravir;interferons;lopinavir;remdesivir	DA 2020/05/20 06:01		The Rationale for Potential Pharmacotherapy of COVID-19.	
71	32433342	Journal Article;Review		Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;Cardiovascular Diseases/*etiology;Coronavirus Infections/*complications/*drug therapy;Humans;Hydroxychloroquine/therapeutic use;HydroxymethylglutarylCoA Reductase Inhibitors/therapeutic use;Pandemics;Pneumonia, Viral/*complications/*drug therapy;SARSCoV2;DA 2020/09/01 06:00		Cardiovascular manifestation and treatment in COVID-19.	
72	33389724	Journal Article;Review	O  NNLM;Antiviral;COVID19;Drug repurposing;SARSCoV2;Target proteins	DA 2021/01/04 06:00		SARS-CoV-2 therapeutics: how far do we stand from a remedy?	
73	33530467	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;clinical trials;drug repurposing;in silico;in vitro;in vivo;multitargeting;natural products	*Antiviral Agents/chemistry/therapeutic use;COVID19/*drug therapy/epidemiology/metabolism;*Drug Delivery Systems;Humans;Pandemics;*SARSCoV2/chemistry/metabolism;DA 2021/02/09 06:00		Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable 	
74	33412163	Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*gender;*sex;*transplantation	COVID19/diagnosis/immunology/*mortality/therapy;Clinical Trials as Topic/standards;Comorbidity;Female;Humans;Kidney Failure, Chronic/complications/*immunology/mortality/therapy;Kidney Transplantation/*adverse effects;Male;Observational Studies as Topic/standards;Practice Guidelines as Topic;Renal Dialysis/adverse effects;Research Design/standards;Risk Factors;SARSCoV2/*immunology/isolation & purification/pathogenicity;Severity of Illness Index;Survival Rate;DA 2021/03/09 06:00		Sex matters: COVID-19 in kidney transplantation.	
75	32459832	Journal Article	O  NNLM;*COVID19;*SARSCoV2;*clinical trial;*ethics;*pediatrics	Adolescent;*COVID19/drug therapy/therapy;Child;*Clinical Trials as Topic;*Coronavirus Infections;Humans;Immunization, Passive;SARSCoV2;United States;DA 2021/01/28 06:00		Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.	
76	32923119	Editorial		Ambulatory Care;COVID19/*prevention & control;*Delivery of Health Care;*Hospitalization;Humans;Neoplasms/*therapy;*Oncology Service, Hospital;*Telemedicine;Time Factors;TimetoTreatment;DA 2020/09/15 06:01		COVID-19: a challenge for oncology services.	
77	32363221	Journal Article;Review	O  NNLM;Betacoronavirus;COVID19;Coronavirus;SARSCoV1;SARSCoV2;Wuhan	DA 2020/05/05 06:01		An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, 	
78	33212828	Journal Article	O  NNLM;COVID19;SARSCoV2;child;neoplasm	DA 2020/11/21 06:01		Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report 	AAP flash Covid19/Agence Nationale de la Recherche/
79	32342676	Journal Article;Review	O  NNLM;Antiviral;COVID19;SARSCoV2;Treatment	DA 2020/04/29 06:01		Interim Guidelines on Antiviral Therapy for COVID-19.	
80	33457170	Journal Article;Review	O  NNLM;Antivirals;COVID19;Drugs and COVID19;Nanothenology against COVID19;Natural products against COVID19;Vaccines against COVID19	DA 2021/01/19 06:01		Recent biotechnological advances as potential intervention strategies against 	
81	32918656	Journal Article;Review	O  NNLM;*COVID19;*Cardiovascular therapy;*Drug interactions;*Lopinavirritonavir;*SARSCoV2	Anticoagulants/therapeutic use;COVID19/*drug therapy;Drug Interactions;Drug Therapy, Combination;Heart Diseases/*drug therapy;Humans;Hypolipidemic Agents/therapeutic use;Lopinavir/*administration & dosage;Platelet Aggregation Inhibitors/therapeutic use;Ritonavir/*administration & dosage;*SARSCoV2;DA 2021/05/18 06:00		Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with 	
82	33476760	Journal Article;Review	O  NNLM;Antivirals;COVID19;Clinical trials;Immunomodulators;Prevention;SARSCoV2;Vaccines	Antiviral Agents/therapeutic use;COVID19/*prevention & control;*Clinical Trials as Topic;*Drug Development;*Drug Repositioning;Humans;Immunologic Factors/therapeutic use;SARSCoV2;Vaccines/therapeutic use;DA 2021/04/24 06:00		Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early 	
83	33416095	Journal Article	O  NNLM;*SARS‑CoV2, COVID‑19, immune response, targeted drug delivery, prevention and 	DA 2021/01/09 06:00		An integrative look at SARS‑CoV‑2 (Review).	
84	32878641	Journal Article;Review	O  NNLM;COVID19;Immunotherapeutics;SARSCoV2;Therapeutics;Vaccines	Antiviral Agents/*therapeutic use;Betacoronavirus;China/epidemiology;Coronavirus/*immunology;Coronavirus Infections/*drug therapy/epidemiology/*prevention & control;Humans;Pandemics/*prevention & control;SARSCoV2;Severe Acute Respiratory Syndrome/*drug therapy/epidemiology;Vaccines/*therapeutic use;DA 2020/09/10 06:00		SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines 	
85	32492354	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural	O  NNLM;*ARDS;*COVID19;*ORCHID;*SARSCoV2;*hydroxychloroquine	Adult;Antimalarials/administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/epidemiology;DoseResponse Relationship, Drug;Hospitalization/trends;Humans;Hydroxychloroquine/*administration & dosage;*Pandemics;Pneumonia, Viral/*drug therapy/epidemiology;SARSCoV2;SingleBlind Method;Treatment Outcome;DA 2020/09/22 06:00	ClinicalTrials.gov/NCT04332991	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of 	U01 HL123018/HL/NHLBI NIH HHS/United States;U01 HL123031/HL/NHLBI NIH HHS/United States;K23 HL143053/HL/NHLBI NIH HHS/United States;U01 HL123020/HL/NHLBI NIH HHS/United States;U01 HL122989/HL/NHLBI NIH HHS/United States;U01 HL123009/HL/NHLBI NIH HHS/United States;U01 HL123004/HL/NHLBI NIH HHS/United States;U01 HL123008/HL/NHLBI NIH HHS/United States;U01 HL123022/HL/NHLBI NIH HHS/United States;U01 HL123023/HL/NHLBI NIH HHS/United States;U01 HL123027/HL/NHLBI NIH HHS/United States;K12 HL133117/HL/NHLBI NIH HHS/United States;U01 HL122998/HL/NHLBI NIH HHS/United States;UL1 TR002243/TR/NCATS NIH HHS/United States;U01 HL123033/HL/NHLBI NIH HHS/United States;U01 HL123010/HL/NHLBI NIH HHS/United States;R01 HL144624/HL/NHLBI NIH HHS/United States;K23 HL153584/HL/NHLBI NIH HHS/United States
86	32911430	Journal Article	O  NNLM;*COVID19;*IL6;*SARSCoV2;*Vitamin C;*drug discovery	Animals;Ascorbic Acid/pharmacology/*therapeutic use;COVID19/*drug therapy/*prevention & control;Coronavirus;Female;Humans;Interleukin6/metabolism;Male;Pandemics;SARSCoV2;Vitamins/pharmacology/*therapeutic use;DA 2020/12/15 06:00		Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?	
87	33549625	Comment;Letter		Amides;*COVID19;Humans;Imatinib Mesylate/therapeutic use;Pyrazines;SARSCoV2;Treatment Outcome;DA 2021/05/01 06:00		Early clinical experience with imatinib in COVID-19: Searching for a dual effect.	
88	33555378	Journal Article	O  NNLM;COVID19;Dexamethasone;Drug repositioning/repurposing;Favipiravir;Molecular targets;Remdesivir;Ribavarin	DA 2021/02/09 06:00		COVID-19: molecular pathophysiology, genetic evolution and prospective 	
89	32534189	Journal Article;Review	O  NNLM;Azithromycin;COVID19;Hydroxychloroquine;Macrolides	Antiviral Agents/administration & dosage/adverse effects/therapeutic use;Azithromycin/administration & dosage/adverse effects/*therapeutic use;Betacoronavirus/*isolation & purification;COVID19;Coronavirus Infections/*drug therapy/*pathology/virology;Drug Therapy, Combination;Humans;Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use;Immunologic Factors/administration & dosage/adverse effects/therapeutic use;Long QT Syndrome/chemically induced;Pandemics;Pneumonia, Viral/*drug therapy/*pathology/virology;SARSCoV2;DA 2020/08/22 06:00		Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.	
90	33014984	Journal Article;Review	O  NNLM;*COVID19;*Iran;*SARSCoV2;*antiviral therapy;*infection prevention and control;*public health	*COVID19;Clinical Protocols;Humans;Iran/epidemiology;Retrospective Studies;SARSCoV2;DA 2020/10/06 06:01		Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical 	
91	33545499	Journal Article;Observational Study	O  NNLM;*COVID19;*CPAP;*Mortality;*Pneumonia;*Respiratory failure;*Treatment	Adult;Aged;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;COVID19/complications/mortality/*therapy;Female;Hospital Mortality;*Hospitalization;Humans;Italy;Length of Stay;Male;Middle Aged;Prospective Studies;*Respiratory Therapy;Seasons;Survival Rate;DA 2021/03/11 06:00		Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 	
92	32397684	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;acute respiratory syndrome;anticytokine antibodies;human immunoglobulin for intravenous use;immune system targeting in COVID19;inflammation	Antiviral Agents/*therapeutic use;Betacoronavirus/physiology;COVID19;Coronavirus Infections/*immunology/pathology/*therapy;Cytokine Release Syndrome/immunology/pathology/therapy;Humans;*Immunotherapy;Inflammation/drug therapy/immunology/therapy;Pandemics;Pneumonia, Viral/*immunology/pathology/*therapy;SARSCoV2;DA 2020/05/15 06:00		SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological 	
93	32926272	Journal Article;Review	O  NNLM;*Angiotensinconverting enzyme 2;*COVID19;*Cardiovascular diseases;*SARSCoV2	AngiotensinConverting Enzyme 2/physiology;Antiviral Agents/adverse effects;COVID19/*complications/drug therapy/immunology;Cardiovascular Diseases/*complications;Cytokine Release Syndrome/etiology;Endothelial Cells/physiology;Humans;Hypertension/complications;Immunity, Innate;Myocardial Infarction/complications;*SARSCoV2;Sex Characteristics;Thrombophilia/etiology;DA 2021/05/18 06:00		Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports.	
94	33161150	Journal Article;MetaAnalysis;Systematic Review	O  NNLM;COVID19;Metaanalysis;Mortality;Tocilizumab;Toxicity	Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/*drug therapy/mortality/therapy;Cytokine Release Syndrome/drug therapy/mortality/therapy;Humans;Observational Studies as Topic;Odds Ratio;Randomized Controlled Trials as Topic;Receptors, Interleukin6/antagonists & inhibitors;Respiration, Artificial/statistics & numerical data;SARSCoV2;Safety;DA 2021/02/26 06:00		Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review 	
95	32501454	Journal Article		DA 2020/06/06 06:01	ClinicalTrials.gov/NCT04318366	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute 	
96	33040064	Journal Article;Review	O  NNLM;COVID19;Endoscopy;Gastrointestinal tract;Inflammatory bowel disease;Liver;Management;Pancreas;Pathophysiology;Review	COVID19/*complications/epidemiology/virology;*Gastroenterologists;Gastrointestinal Diseases/drug therapy/*virology;Humans;Inflammatory Bowel Diseases/virology;SARSCoV2/physiology;Virus Internalization;DA 2021/04/07 06:00		COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist.	
97	32947043	Journal Article;Review		DA 2020/09/19 06:00		Chloroquine against malaria, cancers and viral diseases.	
98	32293834	Journal Article;Review	O  NNLM;*Covid19;*SarsCoV2;*antiviral	Adenosine Monophosphate/analogs & derivatives;Alanine/analogs & derivatives;Amides;Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;Chloroquine;Coronavirus Infections/*drug therapy;Drug Combinations;Humans;Hydroxychloroquine;Ivermectin;Lopinavir;Pandemics;Pneumonia, Viral/*drug therapy;Pyrazines;Ritonavir;SARSCoV2;Thiazoles;DA 2020/04/23 06:00		Antiviral treatment of COVID-19.	
99	32577684	Preprint	O  NNLM;COVID19;SARSCoV2;interleukin6;tocilizumab	DA 2020/06/25 06:01		Tocilizumab for treatment of mechanically ventilated patients with COVID-19.	
100	33156812	Journal Article	O  NNLM;Brazil;COVID19;SARSCoV2;chronic disease;cohort;immunemediated rheumatic diseases;immunology;infection rate;inflammatory;morbidity;mortality;prospective study;registry	DA 2020/11/07 06:01		A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases 	
101	32391667	Journal Article;Randomized Controlled Trial		*Betacoronavirus/isolation & purification;COVID19;China;Coronavirus Infections/diagnostic imaging/drug therapy;Humans;*Hydroxychloroquine/therapeutic use;Pandemics;Pilot Projects;Pneumonia, Viral/diagnostic imaging/drug therapy;RNA, Viral/isolation & purification;SARSCoV2;Treatment Outcome;DA 2020/05/19 06:00	ClinicalTrials.gov/NCT04261517	[A pilot study of hydroxychloroquine in treatment of patients with moderate 	
102	33182073	Journal Article;Review	O  NNLM;COVID19;Cytokines;Immune response;Immunomodulation;SARSCoV2	Animals;*Betacoronavirus;COVID19;Coronavirus Infections/*immunology/pathology/therapy/virology;Humans;Immunologic Factors/*therapeutic use;Immunotherapy/*methods;Pandemics;Pneumonia, Viral/*immunology/pathology/therapy/virology;SARSCoV2;DA 2020/11/20 06:00		Understanding the complexities of SARS-CoV2 infection and its immunology: A road to 	
103	32397558	Journal Article;Review	O  NNLM;COVID19;cardiovascular disease;myocardial injury	DA 2020/05/14 06:01		Impact of COVID-19 on the Cardiovascular System: A Review.	
104	32784543	Journal Article;Review	O  NNLM;ACE2;Ang 17;Bartter’s syndrome;Gitelman’s syndrome;endosome pH;gene mutations;glycosylation;phenotype	AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/pharmacology/therapeutic use;Animals;Bartter Syndrome/*genetics/metabolism/pathology;COVID19;Coronavirus Infections/*drug therapy;Endosomes/drug effects/metabolism;Gitelman Syndrome/*genetics/metabolism/pathology;Humans;Hydroxychloroquine/pharmacology/therapeutic use;Pandemics;PeptidylDipeptidase A/*metabolism;*Phenotype;Pneumonia, Viral/*drug therapy;DA 2020/08/21 06:00		Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes 	
105	33075713	Clinical Trial;Journal Article;Multicenter Study	O  NNLM;COVID19;COVID19 pandemic;Coronavirus;Interleukin 6;Multicenter trial;Tocilizumab	Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects;COVID19/*drug therapy/mortality;Female;Humans;Injections, Subcutaneous;Male;Middle Aged;Prospective Studies;*SARSCoV2;DA 2020/12/16 06:00		Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective 	
106	32574237	Journal Article;Review	O  NNLM;2019nCoV;COVID19;acute lung injury;acute respiratory distress syndrome;cytokine release syndrome;systemic capillary leak	DA 2020/06/24 06:01		Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From 	
107	32754163	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*antimalarial agents;*cytokine storm;*immunoregulation;*tocilizumab;*treatment strategies	Adrenal Cortex Hormones/therapeutic use;Animals;Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use;Antimalarials/therapeutic use;Artesunate/therapeutic use;Betacoronavirus/*immunology;COVID19;Coronavirus Infections/*drug therapy/*immunology/virology;Hemoperfusion/methods;Humans;Hydroxychloroquine/therapeutic use;Immunoglobulins, Intravenous/therapeutic use;Interleukin6/antagonists & inhibitors/*metabolism;Mice;Pandemics;Pneumonia, Viral/*drug therapy/*immunology/virology;Programmed Cell Death 1 Receptor/antagonists & inhibitors;SARSCoV2;DA 2020/08/22 06:00		Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.	
108	33190086	Clinical Trial;Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Cytokine release syndrome;*Oxygenation;*Respiratory failure;*Therapeutic benefit;*Therapeutic plasma exchange	Adult;COVID19/*complications/epidemiology/metabolism/virology;Critical Illness/therapy;Cytokine Release Syndrome/classification/etiology/*therapy;Female;Humans;Male;Middle Aged;Oxygen Inhalation Therapy/methods;Pilot Projects;Plasma Exchange/*methods;Prospective Studies;Respiration, Artificial/methods/statistics & numerical data;Respiratory Insufficiency/therapy;SARSCoV2/*genetics;Severity of Illness Index;DA 2021/01/12 06:00	ClinicalTrials.gov/NCT04374149	Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 	
109	32512702	Journal Article	O  NNLM;COVID19;SARSCoV2;antiphospholipid syndrome;diseasemodifying treatment;multiple sclerosis;systemic lupus erythematosus	DA 2020/06/10 06:01		COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple 	
110	32629768	Journal Article;Review	O  NNLM;COVID19;MERS;SARS;guideline;lopinavir;recommendation;ritonavir	DA 2020/07/08 06:01		Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current 	
111	33256141	Journal Article	O  NNLM;COVID19;SARSCov2;drug treatment;hydroxychloroquine;machine learning;mortality;prediction	DA 2020/12/02 06:01		Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit 	
112	32840560	Journal Article;Review	O  NNLM;*COVID 19;*MERSCoV;*SARSCoV;*SARSCoV2;*spike protein and therapeutics	AngiotensinConverting Enzyme 2;Animals;Antiviral Agents/therapeutic use;Betacoronavirus/drug effects/genetics/immunology;COVID19;Coronavirus Infections/drug therapy/*epidemiology/*pathology;Disease Reservoirs/veterinary/virology;Humans;Middle East Respiratory Syndrome Coronavirus/drug effects/genetics/immunology;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/drug therapy/*epidemiology/*pathology;SARSCoV2;Severe Acute Respiratory Syndrome/drug therapy/*epidemiology/*pathology;Spike Glycoprotein, Coronavirus/immunology/metabolism;Zoonoses/virology;DA 2020/09/17 06:00		Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged 	
113	32227189	Editorial	O  NNLM;*Antimalarials;*Biomarkers;*COVID19;*Chloroquine;*Intensive care units;*Metastasis;*Polymerase chain reaction;*Postexposure prophylaxis;*Safety;*Viral load	Antiviral Agents/*therapeutic use;Azithromycin/therapeutic use;Betacoronavirus;COVID19;Clinical Trials as Topic/*standards;Confounding Factors, Epidemiologic;Coronavirus Infections/*drug therapy;Humans;Hydroxychloroquine/*therapeutic use;*Information Dissemination;*Mass Media;*Pandemics;Pneumonia, Viral/*drug therapy;Research Design/standards;SARSCoV2;DA 2020/07/01 06:00		A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its 	L30 AR072421/AR/NIAMS NIH HHS/United States;MR/P028071/1/MRC_/Medical Research Council/United Kingdom;P30 AR070253/AR/NIAMS NIH HHS/United States;P30 AR073752/AR/NIAMS NIH HHS/United States
114	32290293	Journal Article;Review	O  NNLM;ACE2;COVID19;SARSCoV2;clinical trials;immunotherapy;pneumonia;replicase;vaccine	Antiviral Agents/*therapeutic use;*Betacoronavirus/chemistry/genetics/immunology/physiology;COVID19;COVID19 Vaccines;Clinical Trials as Topic;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention & ;Genome, Viral;Humans;Immunization, Passive;Immunologic Factors/*therapeutic use;*Pandemics;*Pneumonia, Viral/diagnosis/epidemiology/therapy/virology;SARSCoV2;*Viral Vaccines;DA 2020/04/17 06:00		A Review of SARS-CoV-2 and the Ongoing Clinical Trials.	
115	33192503	Journal Article;Review	O  NNLM;COVID19;chloroquine;hydroxychloroquine;pharmacological considerations;piperaquine	DA 2020/11/17 06:01		Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs 	
116	32754003	Journal Article;Review	O  NNLM;Coronavirus;Drugs;Home remedies;Plasma;Therapeutic compounds;Vaccine	DA 2020/08/06 06:01		Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review.	
117	32896292	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Aged;Antiviral Agents/adverse effects/*therapeutic use;Azithromycin/adverse effects/*therapeutic use;Betacoronavirus;Brazil/epidemiology;COVID19;Coronavirus Infections/*drug therapy/epidemiology/mortality;Drug Therapy, Combination;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Length of Stay;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/mortality;Respiratory Therapy;SARSCoV2;Standard of Care;Treatment Outcome;DA 2020/10/21 06:00	ClinicalTrials.gov/NCT04321278	Azithromycin in addition to standard of care versus standard of care alone in the 	
118	32603991	Journal Article;Review	O  NNLM;*COVID19;*Immunotherapy;*Pregnancy;*Reproductive failure;*SARSCoV2	Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/*pathology;Female;Humans;Immunotherapy/*methods;Pandemics;Pneumonia, Viral/*drug therapy/*pathology;Pregnancy;Pregnancy Complications/*drug therapy;Reproductive Health;SARSCoV2;DA 2020/09/29 06:00		COVID-19 and immunomodulation treatment for women with reproductive failures.	
119	32368738	Journal Article		DA 2020/05/06 06:01		Excitement around hydroxychloroquine for treating COVID-19 causes challenges for 	
120	32598953	Journal Article;Review	O  NNLM;COVID19;China;Drug treatment;SARSCoV2	Antiviral Agents/*pharmacology;Betacoronavirus/drug effects;COVID19;China/epidemiology;*Coronavirus Infections/drug therapy/epidemiology;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/epidemiology;SARSCoV2;DA 2020/09/17 06:00		Drug treatment of coronavirus disease 2019 (COVID-19) in China.	
121	33116761	Journal Article;Review	O  NNLM;ADR;Covid19;SARSCoV2;drug effects;in silico;pharmacogenetics;pharmacogenomics	DA 2020/10/30 06:01		Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in 	
122	33117359	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*antiinflammation;*antioxidant;*food supplements;*immuneboosting;*pathogenesis	AntiInflammatory Agents/therapeutic use;Antioxidants/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*diet therapy/*drug therapy/pathology;Cytokine Release Syndrome/diet therapy/drug therapy/pathology;Cytokines/blood;Dietary Supplements;Drug Repositioning/*methods;Humans;Inflammation/drug therapy;Oxidative Stress/physiology;Pandemics;Phytochemicals/*therapeutic use;Pneumonia, Viral/*diet therapy/*drug therapy/pathology;Probiotics/therapeutic use;SARSCoV2;DA 2020/11/11 06:00		Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting 	
123	33272355	Comparative Study;Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*coronavirus;*death;*outcome;*risk factors	Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;COVID19;Comorbidity;Coronavirus/*isolation & purification;Coronavirus Infections/*diagnosis/mortality/therapy;Dyspnea/epidemiology;Female;France/epidemiology;Humans;Inflammation/epidemiology;Intensive Care Units/*statistics & numerical data;Male;Middle Aged;Obesity/epidemiology;Pandemics;Patient Admission/*statistics & numerical data;Pneumonia, Viral/*diagnosis/mortality/therapy;Prospective Studies;Risk Factors;Severity of Illness Index;Sex Factors;Survival Analysis;Young Adult;DA 2020/12/15 06:00		Clinical characteristics and risk factors associated with severe COVID-19: 	
124	33050924	Clinical Trial, Phase III;Letter;Randomized Controlled Trial		Aged;Aged, 80 and over;Amides/therapeutic use;Antihypertensive Agents/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/*genetics;COVID19;Coronavirus Infections/*drug therapy/epidemiology/virology;Drug Tolerance;Feasibility Studies;France/epidemiology;Hospitalization/trends;Humans;Hydroxychloroquine/therapeutic use;Imatinib Mesylate/therapeutic use;Luxembourg/epidemiology;Outpatients/*statistics & numerical data;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Protein Kinase Inhibitors/therapeutic use;Pyrazines/therapeutic use;Risk Reduction Behavior;SARSCoV2;Telmisartan/therapeutic use;Therapies, Investigational/*statistics & numerical data;Treatment Outcome;DA 2020/11/04 06:00	ClinicalTrials.gov/NCT04356495	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A 	NA/Université de Bordeaux/;NA/INSERM/;NA/Agence Nationale de la Recherche/;NA/Ministère de la Santé/;NA/EIT Health/
125	33130203	Journal Article;Review	O  NNLM;Antiviral;Clinical guidelines;In vitro;Pharmacokinetic;Viral clearance	Amides/*administration & dosage;Antiviral Agents/*administration & dosage/therapeutic use;COVID19/*drug therapy/epidemiology/virology;Humans;Pandemics;Pyrazines/*administration & dosage;SARSCoV2/*drug effects/physiology;DA 2021/01/20 06:00		Role of favipiravir in the treatment of COVID-19.	
126	33232817	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*Coronavirus;*Mesenchymal stem cells;*WHO	COVID19/*epidemiology/immunology/pathology/*therapy;Cytokine Release Syndrome/epidemiology/immunology/pathology/*therapy;Female;Humans;Male;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/*immunology/pathology;*Pandemics;SARSCoV2/*immunology;DA 2021/01/12 06:00		Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19.	R01 AG042178/AG/NIA NIH HHS/United States;R01 AG047812/AG/NIA NIH HHS/United States;R01 NS105473/NS/NINDS NIH HHS/United States;R56 AG060767/AG/NIA NIH HHS/United States;R01 AG069333/AG/NIA NIH HHS/United States;R56 AG066347/AG/NIA NIH HHS/United States
127	32631442	Journal Article;Systematic Review	O  NNLM;*2019nCoV;*COVID19;*Interventional trial;*New coronavirus pneumonia;*Observational study;*Registered clinical trial;*Systematic review	Betacoronavirus/*physiology;COVID19;*Clinical Trials as Topic;Coronavirus Infections/*virology;Humans;Observational Studies as Topic;Pandemics;Pneumonia, Viral/*virology;Publication Bias;Risk;SARSCoV2;Treatment Outcome;DA 2020/07/22 06:00		Systematic review of the registered clinical trials for coronavirus disease 2019 	
128	32922409	Journal Article	O  NNLM;*C1 esterase inhibitor;*COVID19;*SARSCoV2;*complement system;*contact activation system;*inflammation;*kallikreinkinin system	Aged;Aged, 80 and over;Betacoronavirus/*drug effects;COVID19;Complement C1/*antagonists & inhibitors;Complement C1 Inhibitor Protein/analysis/*therapeutic use;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/*drug therapy;Factor XIa/antagonists & inhibitors;Female;Humans;KallikreinKinin System/*drug effects;Kallikreins/antagonists & inhibitors;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy;Recombinant Proteins/therapeutic use;SARSCoV2;Viral Load/drug effects;DA 2020/09/29 06:00		Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact 	
129	33248473	Comment;Journal Article		Adenosine Monophosphate/analogs & derivatives;Adult;Alanine/analogs & derivatives;*COVID19/drug therapy;DoubleBlind Method;Humans;SARSCoV2;DA 2021/01/07 06:00	ClinicalTrials.gov/NCT03684044;ClinicalTrials.gov/NCT03376321	The place for remdesivir in COVID-19 treatment.	
130	32439389	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*asthma;*coronavirus disease 2019;*fetal death;*infection;*maternal morbidity;*obesity;*overweight;*pregnancy;*preterm birth;*respiratory insufficiency;*severe acute respiratory syndrome coronavirus 2;*stillbirth	Adult;COVID19/*epidemiology/physiopathology;Comorbidity;Female;Gestational Age;Hospitalization;Humans;Infant, Newborn;Obesity/epidemiology;Overweight/epidemiology;Pregnancy;Pregnancy Complications/epidemiology;Pregnancy Complications, Infectious/*epidemiology/physiopathology;Pregnancy Outcome;Premature Birth/epidemiology;Retrospective Studies;Risk Factors;*SARSCoV2;Washington/epidemiology;DA 2020/12/15 06:00		Clinical characteristics of 46 pregnant women with a severe acute respiratory 	R01 AI145890/AI/NIAID NIH HHS/United States;R01 HD098713/HD/NICHD NIH HHS/United States;T32 AI007044/AI/NIAID NIH HHS/United States;R01 AI133976/AI/NIAID NIH HHS/United States;K23 AI120793/AI/NIAID NIH HHS/United States;R21 AI144938/AI/NIAID NIH HHS/United States;T32 GM007266/GM/NIGMS NIH HHS/United States;R01 AI143265/AI/NIAID NIH HHS/United States;K12 HD001264/HD/NICHD NIH HHS/United States;UL1 TR002319/TR/NCATS NIH HHS/United States
131	33571544	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Lipid Metabolism;*SARSCoV2;*coronavirus;*dyslipidaemia	COVID19/epidemiology/*metabolism/virology;Humans;*Lipid Metabolism;Pandemics;SARSCoV2/classification/genetics/isolation & purification;DA 2021/05/27 06:00		Dissecting lipid metabolism alterations in SARS-CoV-2.	
132	32645632	Journal Article;Review	O  NNLM;Baricitinib;COVID19;Cytokine storm;JAKSTAT;Pharmaceutical care	AngiotensinConverting Enzyme 2;Azetidines/pharmacology/*therapeutic use;Betacoronavirus/*immunology/metabolism;COVID19;Clinical Trials as Topic;Coronavirus Infections/complications/diagnosis/*drug therapy/immunology;Cytokine Release Syndrome/diagnosis/*drug therapy/immunology/virology;Cytokines/immunology/metabolism;Humans;Janus Kinase 1/antagonists & inhibitors/metabolism;Janus Kinase 2/antagonists & inhibitors/metabolism;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/complications/diagnosis/*drug therapy/immunology;SARSCoV2;Severity of Illness Index;Signal Transduction/*drug effects/immunology;Sulfonamides/pharmacology/*therapeutic use;Treatment Outcome;Virus Assembly/drug effects;Virus Internalization/drug effects;DA 2020/08/25 06:00		Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target 	
133	32816059	Case Reports;Journal Article;Review	O  NNLM;*COVID19;*Cytokine storm;*Intensive care;*Lowdose radiotherapy;*Viral pneumonia	AntiBacterial Agents/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;COVID19/blood/diagnostic imaging/*drug therapy/*radiotherapy/therapy;Combined Modality Therapy;Compassionate Use Trials;Enoxaparin/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Male;Middle Aged;Oxygen Inhalation Therapy;Peru;Radiotherapy Planning, ComputerAssisted;Thrombophilia/drug therapy/etiology;Tomography, XRay Computed;DA 2020/12/15 06:00		Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and 	
134	32718020	Journal Article;Review	O  NNLM;ACE2;COVID19;SARSCoV2;TMPRSS2;coronavirus;endocytosis;spike protein;viral entry;viral fusion	Antibodies, Monoclonal/chemistry/pharmacology/therapeutic use;Antiviral Agents/chemistry/pharmacology/*therapeutic use;Betacoronavirus/drug effects/*physiology;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Humans;Pandemics;Peptides/chemistry/pharmacology/therapeutic use;Pneumonia, Viral/*drug therapy;Polysaccharides/chemistry/pharmacology/therapeutic use;SARSCoV2;Small Molecule Libraries/chemistry/pharmacology/therapeutic use;Virus Attachment/drug effects;Virus Internalization/drug effects;DA 2020/08/13 06:00		Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life 	SC3GM131986; P20GM103424/GM/NIGMS NIH HHS/United States
135	32895612	Editorial	O  NNLM;COVID19 pandemic;Clinical trials;Ethical considerations;Evidencebased medicine;Patient safety	DA 2020/09/09 06:01		An overview of current COVID-19 clinical trials and ethical considerations 	
136	32987060	Journal Article;Review	O  NNLM;COVID19;Mechanisms and treatment;Myocardial injury	AngiotensinConverting Enzyme 2/metabolism;AngiotensinConverting Enzyme Inhibitors/pharmacology/therapeutic use;COVID19/*complications/*drug therapy;Cardiomyopathies/*complications/*drug therapy;DownRegulation/drug effects;Humans;Pandemics;SARSCoV2/*drug effects;DA 2020/12/15 06:00		Mechanisms and treatments of myocardial injury in patients with corona virus disease 	
137	32838150	Journal Article	O  NNLM;Asian;Azithromycin;COVID19;Cardiac arrhythmia;Hydroxychloroquine;Ventricular arrhythmia	DA 2020/08/25 06:00		Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on 	
138	32387301	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Baricitinib;*Begelomab;*COVID19;*GVHD;*MAS;*Ruxolitinib;*TKIs;*Tocilizumab	Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*drug therapy;Graft vs Host Disease/drug therapy;Hematology/*methods;Humans;Macrophage Activation Syndrome/drug therapy;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/07/01 06:00		The CoV-2 outbreak: how hematologists could help to fight Covid-19.	
139	33311551	Clinical Trial;Journal Article;Multicenter Study;Research Support, NonU.S. Gov't		Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;*COVID19/drug therapy/mortality;DiseaseFree Survival;Female;*Hospitalization;Humans;Interleukin1beta/*antagonists & inhibitors;Male;Middle Aged;Oxygen/administration & dosage;Prospective Studies;*SARSCoV2;Survival Rate;DA 2020/12/22 06:00		Blockage of interleukin-1β with canakinumab in patients with Covid-19.	
140	32376392	Journal Article;Review	O  NNLM;Anakinra;COVID19;Cytokine storm;IL1;IL6;SarsCoV2;Tocilizumab;TypeI interferon	Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*immunology/*therapy;Cytokines/*antagonists & inhibitors/*therapeutic use;Humans;Interferons/therapeutic use;Interleukin1beta;Interleukin6;Pandemics;Pneumonia, Viral/*immunology/*therapy;SARSCoV2;DA 2020/06/11 06:00		Should we stimulate or suppress immune responses in COVID-19? Cytokine and 	
141	32471655	Comment;Letter;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*clinical trial;*prospective metaanalysis	*Betacoronavirus;COVID19;*Coronavirus Infections;Humans;*Pandemics;*Pneumonia, Viral;Prospective Studies;SARSCoV2;DA 2020/07/24 06:00		Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.	
142	32828171	Journal Article		COVID19;*Clinical Trials as Topic;Coronavirus Infections/drug therapy/*physiopathology;Data Interpretation, Statistical;Humans;Pandemics;Pneumonia, Viral/*physiopathology;Randomized Controlled Trials as Topic;Research Design;Treatment Outcome;DA 2020/10/02 06:00		Clinical trials of disease stages in COVID 19: complicated and often misinterpreted.	
143	32982184	Journal Article;Review	O  NNLM;COVID19;antiviral agents;clinical trials as topic;research design	Antiviral Agents/pharmacology/*therapeutic use;Betacoronavirus/drug effects;COVID19;*Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Data Collection;Data Interpretation, Statistical;Data Management;Drug Combinations;Humans;Pandemics;Pneumonia, Viral/*drug therapy;*Registries;Research Design;SARSCoV2;DA 2020/10/02 06:00		Study Design Characteristics and Pharmacological Mechanisms in International 	
144	32386744	Editorial		Antimalarials/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Global Health;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Treatment Outcome;DA 2020/07/25 06:00	ClinicalTrials.gov/NCT04321278	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?	
145	33051827	Journal Article	O  NNLM;COVID19;Clinical trials;Early treatment;Treatment as prevention	DA 2020/10/15 06:01		Early Treatment of COVID-19 Disease: A Missed Opportunity.	
146	33196555	Journal Article;Randomized Controlled Trial;Research Support, N.I.H., Extramural		Adult;African Americans/*psychology;AntiRetroviral Agents/therapeutic use;COVID19/drug therapy/ethnology/prevention & control/*psychology;*COVID19 Vaccines;Female;HIV Infections/*drug therapy/ethnology/psychology;Health Knowledge, Attitudes, Practice;Humans;Los Angeles;Male;Medication Adherence/*psychology/statistics & numerical data;Middle Aged;SARSCoV2;Sexual and Gender Minorities;Trust/*psychology;DA 2021/01/20 06:00		COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy 	R25 MH067127/MH/NIMH NIH HHS/United States;P30 MH058107/MH/NIMH NIH HHS/United States;R01 NR017334/NR/NINR NIH HHS/United States;R01 MD014722/MD/NIMHD NIH HHS/United States;P30 AI060354/AI/NIAID NIH HHS/United States
147	32766535	Journal Article	O  NNLM;Coronavirus disease 2019;Cytokine release syndrome;Tocilizumab	DA 2020/08/09 06:01		Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine 	
148	32205349	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*antiviral drugs;*treatment;*vaccines	*Betacoronavirus;COVID19;Coronavirus Infections/immunology/prevention & control/*therapy;Humans;Inflammation/prevention & control;Medicine, Chinese Traditional;Pandemics/prevention & control;Pneumonia, Viral/immunology/prevention & control/*therapy;SARSCoV2;Virus Internalization;Virus Replication;DA 2020/06/03 06:00		Updated Approaches against SARS-CoV-2.	
149	33117855	Journal Article	O  NNLM;COVID19;SARSCoV2;coronavirus	DA 2020/10/30 06:01		Symptoms of COVID-19 Outpatients in the United States.	R01 NS110519/NS/NINDS NIH HHS/United States;R01 NS086312/NS/NINDS NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;U01 AI125003/AI/NIAID NIH HHS/United States;T32 GM007347/GM/NIGMS NIH HHS/United States;T32 AI055433/AI/NIAID NIH HHS/United States;D43 TW009345/TW/FIC NIH HHS/United States;L30 TW011500/TW/FIC NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States
150	32291112	Journal Article;Review	O  NNLM;*2019nCoV;*COVID19;*SARSCoV2;*coronavirus;*pandemic	*Betacoronavirus;COVID19;*Clinical Trials as Topic;Coronavirus Infections/drug therapy/*therapy;Humans;Immunization, Passive;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;DA 2020/05/21 06:00		Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.	
151	32442528	Journal Article;Multicenter Study;Observational Study;Research Support, N.I.H., Extramural		Adult;Age Factors;Aged;Aged, 80 and over;Betacoronavirus;Biomarkers/blood;COVID19;Coronavirus Infections/*epidemiology/mortality/*therapy;Critical Illness/epidemiology;Female;Fibrin Fibrinogen Degradation Products/analysis;Hospital Mortality;Hospitalization;Humans;Interleukin6/blood;Male;Middle Aged;New York City/epidemiology;Pandemics;Pneumonia, Viral/*epidemiology/mortality/*therapy;Proportional Hazards Models;Prospective Studies;Respiration, Artificial;Respiratory Distress Syndrome/virology;Risk Factors;SARSCoV2;Young Adult;DA 2020/06/11 06:00		Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 	F32 AI147528/AI/NIAID NIH HHS/United States;UL1 TR001873/TR/NCATS NIH HHS/United States
152	32497913	Journal Article;Review		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus/immunology/pathogenicity;Biomarkers/blood;COVID19;Cardiovascular Diseases/*complications;Chloroquine/therapeutic use;Coronavirus Infections/*complications/drug therapy;Humans;Hydroxychloroquine/therapeutic use;Hypoxia/complications;Pandemics;Plasma/immunology;Pneumonia, Viral/*complications/drug therapy;Receptor, Angiotensin, Type 2/metabolism;Risk Factors;SARSCoV2;Takotsubo Cardiomyopathy/etiology;Virus Internalization;DA 2020/08/28 06:00		A current review of COVID-19 for the cardiovascular specialist.	
153	33055231	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*MERSCoV;*SARSCoV;*SARSCoV2;*antiviral;*coronavirus;*ebolavirus;*remdesivir	Adenosine Monophosphate/*analogs & derivatives/pharmacokinetics/pharmacology;Alanine/*analogs & derivatives/pharmacokinetics/pharmacology;Antiviral Agents/pharmacokinetics/*pharmacology;Betacoronavirus/drug effects/growth & development/pathogenicity;COVID19;Clinical Trials as Topic;Compassionate Use Trials/methods;Coronavirus Infections/*drug therapy/mortality/pathology/virology;Drug Administration Schedule;Ebolavirus/drug effects/growth & development/pathogenicity;Hemorrhagic Fever, Ebola/*drug therapy/mortality/pathology/virology;Humans;Middle East Respiratory Syndrome Coronavirus/drug effects/growth & ;Pandemics;Patient Safety;Pneumonia, Viral/*drug therapy/mortality/pathology/virology;SARS Virus/drug effects/growth & development/pathogenicity;SARSCoV2;Severe Acute Respiratory Syndrome/*drug therapy/mortality/pathology/virology;Survival Analysis;Treatment Outcome;DA 2020/10/30 06:00		Remdesivir against COVID-19 and Other Viral Diseases.	
154	32875809	Journal Article;Review	O  NNLM;*5’UTR;*COVID19;*GapmeRs;*RNAi;*SARSCoV;*SARSCoV2;*miRNAs	5' Untranslated Regions;Animals;COVID19;Coronavirus Infections/*therapy;Humans;Pandemics;Pneumonia, Viral/*therapy;RNA, Untranslated/*genetics/metabolism;RNAi Therapeutics/*methods;DA 2020/09/29 06:00		Potential use of noncoding RNAs and innovative therapeutic strategies to target the 	
155	32511599	Preprint		DA 2020/06/09 06:01		ICU and ventilator mortality among critically ill adults with COVID-19.	
156	32376901	Journal Article;Review		Animals;Betacoronavirus/immunology;COVID19;Coronavirus Infections/*complications/*immunology/pathology;Humans;Inflammation/*etiology/pathology;Macrophage Activation/drug effects;Macrophages/*immunology;Monocytes/immunology;Pandemics;Pneumonia, Viral/*complications/*immunology/pathology;SARSCoV2;DA 2020/06/17 06:00		Pathological inflammation in patients with COVID-19: a key role for monocytes and 	
157	33249060	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.	O  NNLM;*Antiviral;*COVID19;*Coronavirus;*Cytokine;*Cytokine storm;*DHODH;*PTC299;*SARSCoV2	Animals;Antiviral Agents/*pharmacology;COVID19/drug therapy;Carbamates/*pharmacology;Carbazoles/*pharmacology;Chlorocebus aethiops;Cytokine Release Syndrome/drug therapy;Cytokines/*antagonists & inhibitors/immunology;HeLa Cells;Humans;Inflammation/drug therapy/virology;Oxidoreductases Acting on CHCH Group Donors/*antagonists & inhibitors;SARSCoV2/*drug effects;Vero Cells;Virus Replication/*drug effects;DA 2021/01/05 06:00		The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction 	UL1 TR001430/TR/NCATS NIH HHS/United States;R01 AI148784/AI/NIAID NIH HHS/United States;R37 AI147868/AI/NIAID NIH HHS/United States;HL007035T32/NH/NIH HHS/United States;R35 GM122468/GM/NIGMS NIH HHS/United States;TL1 TR001440/TR/NCATS NIH HHS/United States
158	33329599	Case Reports	O  NNLM;*WiskottAldrich Syndrome;*gene therapy;*immune reconstitution;*primary immunodeficiencies;*severe acute respiratory syndrome Coronavirus 2 (2019nCoV)	*Antibodies, Neutralizing/blood/immunology;*Antibodies, Viral/blood/immunology;*COVID19/blood/immunology/therapy;*Genetic Therapy;Humans;Infant;Male;*SARSCoV2/immunology/metabolism;*WiskottAldrich Syndrome/blood/immunology/therapy;WiskottAldrich Syndrome Protein/biosynthesis/immunology;DA 2020/12/29 06:00		Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich 	
159	32660890	Journal Article;Research Support, N.I.H., Intramural;Review	O  NNLM;*ACE;*Androgens;*COVID19;*Coronavirus;*SARSCoV2;*TMPRSS2	Androgen Antagonists/therapeutic use;COVID19/*drug therapy/epidemiology/metabolism;Female;Gonadal Steroid Hormones/*metabolism;Humans;Male;Outcome Assessment, Health Care/methods/*statistics & numerical data;Pandemics;Protease Inhibitors/therapeutic use;Serine Endopeptidases/*metabolism;Sex Factors;DA 2020/12/15 06:00		Are sex discordant outcomes in COVID-19 related to sex hormones?	
160	33403142	Case Reports	O  NNLM;COVID19;heart transplantation;simmunocompromised	DA 2021/01/07 06:01		Heart transplant recipient survivor from COVID-19: The first case of Turkey.	
161	33495742	Journal Article;Review	O  NNLM;COVID19;Inflammation;Lung injury;Methylprednisolone;SARSCoV2;Tacrolimus	DA 2021/01/27 06:01	ClinicalTrials.gov/NCT04341038	Pragmatic, open-label, single-center, randomized, phase II clinical trial to 	
162	32571007	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*combination drug delivery;*coronavirus disease 2019;*immunopathology;*nanomedicine;*repurposed nanotechnology;*severe acute respiratory syndrome coronavirus 2 structure;*targeted therapeutics;*vaccine adjuvant nanoparticles;*vaccine nanocarriers	COVID19;COVID19 Vaccines;Coronavirus Infections/immunology/*prevention & control/therapy/virology;Humans;Mass Vaccination/adverse effects/*methods;Nanotechnology/*methods;Pandemics/*prevention & control;Pneumonia, Viral/immunology/*prevention & control/therapy/virology;Viral Vaccines/immunology/*therapeutic use;DA 2020/09/02 06:00		Nanotechnology for COVID-19: Therapeutics and Vaccine Research.	
163	32834950	Journal Article	O  NNLM;COVID19;Chloroquine phosphate;Dosing strategy;PBPK	DA 2020/08/25 06:01		Dose selection of chloroquine phosphate for treatment of COVID-19 based on a 	
164	32993173	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*EIDD2801;*RNAdependent RNA polymerase;*SARSCoV2;*dexamethasone;*dihydroorotate dehydrogenase;*favipiravir;*main protease;*papainlike protease;*remdesivir	Animals;AntiInflammatory Agents/therapeutic use;Antibodies, Monoclonal/therapeutic use;Antiviral Agents/chemistry/pharmacology/*therapeutic use;Betacoronavirus/*drug effects/physiology;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/virology;Drug Delivery Systems;Drug Development;Humans;Pandemics;Peptides/therapeutic use;Pneumonia, Viral/*drug therapy/virology;Protease Inhibitors/therapeutic use;SARSCoV2;DA 2020/11/03 06:00		Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the 	SC3GM131986/GM/NIGMS NIH HHS/United States;P20GM103424/GM/NIGMS NIH HHS/United States
165	32592716	Journal Article;Review	O  NNLM;*COVID19;*Cholesterol;*Coronavirus;*Glycyrrhizin;*HMGB1;*Natural product	Alarmins/drug effects;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/epidemiology;Drug Therapy, Combination;Glycyrrhizic Acid/*pharmacology/*therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Membrane Microdomains/drug effects;Molecular Docking Simulation;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology;SARSCoV2;Tenofovir/therapeutic use;DA 2020/10/02 06:00		Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the 	
166	32717282	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Cyclodextrins;Rings;SARSCoV2	Betacoronavirus/*drug effects/metabolism;Blood Coagulation/drug effects;COVID19;Coronavirus Infections/*drug therapy/prevention & control;Cyclodextrins/*chemistry/*pharmacology;Drug Carriers/chemistry/pharmacology;Drug Stability;Excipients/chemistry/pharmacology;*Nanostructures;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/prevention & control;SARSCoV2;Viral Vaccines/chemistry/pharmacology;DA 2020/10/21 06:00		The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2.	
167	32773165	Journal Article	O  NNLM;*COVID;*Hospitalizados;*Hospitalized;*Mortalidad;*Mortality;*SARSCoV2;*Tratamientos;*Treatments	Adrenal Cortex Hormones/therapeutic use;Angiotensin II Type 1 Receptor Blockers/therapeutic use;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;*Betacoronavirus/drug effects;COVID19;Comorbidity;Coronavirus Infections/*drug therapy/mortality;Drug Therapy, Combination;Female;Humans;Hydroxychloroquine/therapeutic use;Inpatients/statistics & numerical data;Lopinavir/therapeutic use;Male;Pandemics;Pneumonia, Viral/*drug therapy/mortality;Proportional Hazards Models;Retrospective Studies;Ritonavir/therapeutic use;SARSCoV2;Spain;Treatment Outcome;DA 2020/11/20 06:00		Therapeutic agents tested in 238 COVID-19 hospitalized patients and their 	
168	33065330	Journal Article;Review	O  NNLM;*Coronavirus	AntiInflammatory Agents/administration & dosage;Antioxidants/administration & dosage;Antiviral Agents/administration & dosage/adverse effects;Ascorbic Acid/*administration & dosage;COVID19/drug therapy/immunology/prevention & control/virology;Coronavirus Infections/*drug therapy/immunology/*prevention & control/virology;HostPathogen Interactions/drug effects/immunology;Humans;Oxidative Stress/drug effects;SARSCoV2/drug effects;DA 2021/01/20 06:00		Possible application of high-dose vitamin C in the prevention and therapy of 	
169	32688395	Clinical Trial;Journal Article;Multicenter Study		Adult;Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors;Aged;Aged, 80 and over;AntiInflammatory Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*complications/therapy;Female;Humans;Immunization, Passive;Leukemia, Lymphocytic, Chronic, BCell/*complications/therapy;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications/therapy;Protein Kinase Inhibitors/therapeutic use;SARSCoV2;Survival Analysis;Treatment Outcome;DA 2020/09/15 06:00		Outcomes of COVID-19 in patients with CLL: a multicenter international experience.	P30 CA008748/CA/NCI NIH HHS/United States
170	33292930	Editorial		Advisory Committees;*COVID19 Vaccines;Clinical Trials as Topic;Humans;Patient Selection;*Safety Management;United States;United States Food and Drug Administration;DA 2020/12/29 06:00		Ensuring Safety of Operation Warp Speed Vaccines for COVID-19.	
171	32661214	Journal Article;Review		Adrenal Cortex Hormones/*therapeutic use;AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/immunology/pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Disease Progression;Drug Discovery;*Drug Repositioning;Gene Expression Regulation;HostPathogen Interactions/drug effects/genetics/immunology;Humans;Hydroxychloroquine/therapeutic use;Immunologic Factors/*therapeutic use;Molecular Docking Simulation;Molecular Targeted Therapy/methods;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARSCoV2;Signal Transduction/genetics/immunology;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/genetics/immunology;DA 2020/07/22 06:00		Drug targets for COVID-19 therapeutics: Ongoing global efforts.	
172	32545799	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*antiviral drug combinations;*antivirals;*broadspectrum antivirals	Amodiaquine/pharmacology;Animals;Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects;COVID19;Caco2 Cells;Cell Line, Tumor;Chlorocebus aethiops;Coronavirus Infections/*drug therapy/therapy;Drug Therapy, Combination;Emetine/pharmacology;HEK293 Cells;HT29 Cells;Homoharringtonine/pharmacology;Humans;Immune Sera/immunology;Immunization, Passive/methods;Nelfinavir/pharmacology;Neutralization Tests/*methods;Pandemics;Pneumonia, Viral/*drug therapy;Pyrans/pharmacology;Pyrroles/pharmacology;SARSCoV2;Vero Cells;DA 2020/07/01 06:00		Potential Antiviral Options against SARS-CoV-2 Infection.	MOBTT39/Estonian Research Competency Council/International
173	32586885	Consensus Development Conference;Journal Article;Research Support, NonU.S. Gov't;Review		BCG Vaccine/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/diagnosis/drug therapy/epidemiology/immunology;Epidemics;HIV Infections/diagnosis/drug therapy/epidemiology/immunology;Humans;Influenza A Virus, H1N1 Subtype;Influenza, Human/diagnosis/drug therapy/epidemiology/immunology;Lung/immunology;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral/diagnosis/drug therapy/epidemiology/immunology;Public Health;Respiratory Tract Infections/diagnosis/drug therapy/*epidemiology/immunology;SARSCoV2;Severe Acute Respiratory Syndrome/diagnosis/drug therapy/epidemiology/immunology;Tuberculosis/diagnosis/*epidemiology/immunology/prevention & control;Virus Diseases/diagnosis/drug therapy/*epidemiology/immunology;DA 2020/10/10 06:00		Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A 	
174	33257213	Journal Article;Review		Animals;COVID19/*epidemiology/*surgery/virology;Clinical Trials as Topic;Comorbidity;Humans;Immunomodulation;Mesenchymal Stem Cell Transplantation/*methods;Mesenchymal Stem Cells/immunology;*Pandemics;Respiratory Distress Syndrome/*epidemiology/*surgery/virology;*SARSCoV2;Treatment Outcome;DA 2021/05/27 06:00		Stem cell therapy in coronavirus disease 2019: current evidence and future 	
175	32512873	Journal Article;Review	O  NNLM;COVID19;healthcare;postexposure;prophylaxis	Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Chemoprevention;Coronavirus Infections/*drug therapy/prevention & control;Humans;Pandemics/*prevention & control;Pneumonia, Viral/*drug therapy/prevention & control;*PostExposure Prophylaxis;Quarantine;SARSCoV2;Time Factors;DA 2020/07/01 06:00		COVID-19: Time for Post-Exposure Prophylaxis?	
176	32973818	Journal Article;Review	O  NNLM;*COVID19;*PI3K;*SARSCoV2;*inflammation;*therapy	AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;AntiInflammatory Agents/therapeutic use;Antirheumatic Agents/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus;Butyrophenones/pharmacology/therapeutic use;COVID19;Class I Phosphatidylinositol 3Kinases/*antagonists & inhibitors/metabolism;Coronavirus Infections/*drug therapy/virology;Drug Repositioning/*methods;Humans;Inflammation/drug therapy/immunology;Interleukin6/antagonists & inhibitors/blood;Molecular Targeted Therapy/*methods;Pandemics;PeptidylDipeptidase A/metabolism;Piperidines/pharmacology/therapeutic use;Pneumonia, Viral/*drug therapy/virology;Purines/pharmacology/therapeutic use;Quinazolinones/pharmacology/therapeutic use;SARSCoV2;DA 2020/10/21 06:00		PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.	
177	32304640	Journal Article		Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/virology;*Drug Repositioning;*EvidenceBased Medicine;Health Services Needs and Demand;Humans;Hydroxychloroquine/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/07/01 06:00	ClinicalTrials.gov/NCT04315948;EudraCT/202000098218	Hydroxychloroquine in the management of critically ill patients with COVID-19: the 	
178	32199468	Comment;Letter		*Antiviral Agents;Betacoronavirus;COVID19;Coronavirus Infections;Disease Outbreaks;Feasibility Studies;Pandemics;Pneumonia, Viral;SARSCoV2;DA 2020/05/06 06:00		Use of antiviral drugs to reduce COVID-19 transmission.	
179	32896649	Letter	O  NNLM;*COVID19;*Clinical trials;*Cytokine storm;*Dexamethasone;*SARSCoV2;*Therapeutics	DA 2020/09/09 06:01		Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary 	
180	33408016	Letter		AntiBacterial Agents/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/*therapeutic use;Azithromycin/*therapeutic use;COVID19/*drug therapy/virology;Clinical Trials as Topic;Drug Combinations;Drug Repositioning;Humans;Hydroxychloroquine/*therapeutic use;Indoles/therapeutic use;Interferonalpha/therapeutic use;Lopinavir/therapeutic use;Ritonavir/therapeutic use;SARSCoV2/*pathogenicity;Uncertainty;DA 2021/01/15 06:00		Can we use hydroxychloroquine to treat COVID-19 now?	
181	33094446	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Immunity;Zinc	DA 2020/10/24 06:00		Zinc and COVID-19: Basis of Current Clinical Trials.	
182	33158234	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Traditional Chinese Medicines;*angiotensinconverting enzyme2;*antiviral;*epidemiology	Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology/*therapy;Humans;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/*epidemiology/*therapy;SARSCoV2;DA 2020/11/21 06:00		COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional 	
183	32664810	Case Reports;Journal Article	O  NNLM;*ARDS;*Creactive protein;*COVID19;*IL6;*SARSCoV2;*cytokine storm syndrome;*hyperinflammation;*immunotherapy;*monoclonal antibodies;*severe pneumonia;*tocilizumab	Antibodies, Monoclonal, Humanized/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/pathology/*therapy;Critical Illness;Cytokine Release Syndrome/pathology/therapy;Female;Humans;Immunotherapy;Middle Aged;Pandemics;Pneumonia, Viral/pathology/*therapy;Receptors, Interleukin6/antagonists & inhibitors;Respiratory Distress Syndrome/pathology/*therapy;SARSCoV2;TimetoTreatment;Treatment Outcome;DA 2020/10/21 06:00		Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: 	
184	32311489	Editorial		Administration, Inhalation;Adrenal Cortex Hormones/adverse effects;Age Factors;AngiotensinConverting Enzyme Inhibitors/therapeutic use;AntiBacterial Agents/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;Bromhexine/therapeutic use;COVID19;Coronavirus Infections/complications/drug therapy/epidemiology/*immunology;Cytokines/*immunology;Expectorants/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Hypertension/epidemiology;Inflammation;Interferon beta1a/immunology;Interleukin1/immunology;Interleukin12/immunology;Interleukin6/immunology;Lymphohistiocytosis, Hemophagocytic/etiology/*immunology;Obesity/epidemiology;Pandemics;Pneumonia, Viral/complications/drug therapy/epidemiology/*immunology;Pulmonary Disease, Chronic Obstructive/drug therapy/epidemiology;Respiratory Distress Syndrome/etiology/*immunology;Risk Factors;Smoking/epidemiology;Tumor Necrosis Factoralpha/immunology;DA 2020/06/12 06:00		Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 	MR/T001151/1/MRC_/Medical Research Council/United Kingdom
185	33365326	Journal Article;Review	O  NNLM;COVID19;immunity;junctional complex;nutrients;vitamin C;vitamin D;zinc	DA 2020/12/29 06:01		Zinc, Vitamin D and Vitamin C: Perspectives for COVID-19 With a Focus on Physical 	
186	33072773	Journal Article	O  NNLM;ARDS;COVID  19;MERS (Middle East respiratory syndrome);SARS;SARS  CoV2;antifibrotics;fibrosis	DA 2020/10/20 06:01		Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.	K08 HL141623/HL/NHLBI NIH HHS/United States
187	32920514	Journal Article;Review	O  NNLM;COVID19;cytokine storm syndrome;interleukin 6	AntiInflammatory Agents/pharmacology;Betacoronavirus/immunology/isolation & purification;COVID19;Coronavirus Infections/complications/*drug therapy/immunology;Cytokine Release Syndrome/drug therapy/immunology/virology;Cytokines/immunology;Humans;Interleukin6/*antagonists & inhibitors/immunology;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology;Prognosis;SARSCoV2;Severity of Illness Index;DA 2020/11/11 06:00		The role of Interleukin 6 inhibitors in therapy of severe COVID-19.	
188	33194450	Journal Article	O  NNLM;COVID19;IL6;SARSCOV2;Tocilizumab	DA 2020/11/17 06:01		The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a 	
189	32407459	Journal Article;MetaAnalysis;Research Support, NonU.S. Gov't;Systematic Review	O  NNLM;*COVID19;*coronavirus;*risk factor;*severe;*treatment	Adrenal Cortex Hormones/adverse effects;COVID19/*drug therapy/mortality/*therapy;Clinical Trials as Topic;Coronavirus/drug effects;Hospitalization/statistics & numerical data;Humans;Intensive Care Units/statistics & numerical data;Regression Analysis;Respiratory Distress Syndrome/drug therapy/mortality/*virology;Risk Factors;Ritonavir/therapeutic use;SARSCoV2;Severity of Illness Index;Treatment Outcome;DA 2020/12/15 06:00		Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With 	
190	33072111	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*antibody;*convalescent plasma therapy;*coronavirus disease 2019;*immunotherapy;*severe acute respiratory syndrome coronavirus2	*Antibodies, Neutralizing/immunology/therapeutic use;*Antibodies, Viral/immunology/therapeutic use;Betacoronavirus/*immunology;COVID19;*Coronavirus Infections/epidemiology/immunology/therapy;Humans;Immunization, Passive;*Pandemics;Plasma/immunology;*Pneumonia, Viral/epidemiology/immunology/therapy;Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/10/27 06:00		Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 	CIHR/Canada
191	32562486	Journal Article;Multicenter Study;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Italy;*Outofhospital cardiac arrest;*SARSCoV2	Aged;Aged, 80 and over;*Betacoronavirus;COVID19;Cardiopulmonary Resuscitation/*methods;Coronavirus Infections/*complications/epidemiology;Emergency Medical Services/*statistics & numerical data;Female;FollowUp Studies;Humans;Incidence;Italy/epidemiology;Male;OutofHospital Cardiac Arrest/*epidemiology/etiology/therapy;*Pandemics;Pneumonia, Viral/*complications/epidemiology;Prospective Studies;SARSCoV2;DA 2020/09/22 06:00		COVID-19 kills at home: the close relationship between the epidemic and the increase 	
192	32292848	Journal Article;Review	O  NNLM;ACE2, angiotensinconverting enzyme 2;ARDS, acute respiratory distress syndrome;CFR, case fatality rate;COVID19;COVID19, coronavirus disease2019;CoV, coronavirus;DIC, disseminated intravascular coagulation;ER, endoplasmic reticulum;ICU, intensive care unit;SARSCoV, severe acute respiratory syndromecoronavirus;SARSCoV2;SOFA, sequential organ failure assessment;TMPRSS2, transmembrane serine protease 2;cardiovascular;hsCRP, highsensitivity Creactive protein;treatments;virology	DA 2020/04/16 06:01		COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, 	
193	32821381	Journal Article;Review	O  NNLM;COVID19;chloroquine;evidence;hydroxychloroquine;review	DA 2020/08/22 06:01		Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a 	
194	32870481	Journal Article;Review		Adenosine Monophosphate/*analogs & derivatives/pharmacology;Alanine/*analogs & derivatives/pharmacology;Antiviral Agents/pharmacology;Betacoronavirus/drug effects;COVID19;*Coronavirus Infections/drug therapy/epidemiology;*Drug Development;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/epidemiology;SARSCoV2;DA 2020/09/17 06:00		Remdesivir: First Approval.	
195	33082342	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Aged;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/mortality;Female;Humans;Hydroxychloroquine/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/mortality;SARSCoV2;Treatment Outcome;Viral Load/drug effects;DA 2020/11/03 06:00	ClinicalTrials.gov/NCT04316377	A pragmatic randomized controlled trial reports lack of efficacy of 	
196	33358502	Journal Article;Observational Study	O  NNLM;*COVID19;*IL6;*Outcomes;*Treatment	Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/diagnosis/*drug therapy/mortality;*Disease Management;Female;Humans;Male;Middle Aged;Mortality/trends;Retrospective Studies;DA 2021/02/10 06:00		Tocilizumab in the Management of COVID-19: A Preliminary Report.	
197	33225308	Journal Article	O  NNLM;Sepsisrelated Organ Failure Assessment;camostat mesylate;coronavirus disease 2019;sepsis	DA 2020/11/24 06:01		Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First 	
198	33521749	Journal Article	O  NNLM;COVID19;SARSCoV2;cellfree DNA;disease severity;liquid biopsy;methylation;tissue injury	DA 2021/02/02 06:01		Cell-free DNA tissues of origin by methylation profiling reveals significant cell, 	DP2 AI138242/AI/NIAID NIH HHS/United States;R01 AI151059/AI/NIAID NIH HHS/United States;K08 CA230156/CA/NCI NIH HHS/United States;WT_/Wellcome Trust/United Kingdom;R01 HL105704/HL/NHLBI NIH HHS/United States;R21 AI129455/AI/NIAID NIH HHS/United States;R01 MH117406/MH/NIMH NIH HHS/United States;R01 AI146165/AI/NIAID NIH HHS/United States;R61 HD105618/HD/NICHD NIH HHS/United States
199	33511518	Journal Article;Review	O  NNLM;*COVID19;*Cellbased therapy;*Personalized medicine;*Stem cell	COVID19/*drug therapy/immunology/*therapy/virology;*Cell and TissueBased Therapy;Humans;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/immunology;SARSCoV2/pathogenicity;DA 2021/03/03 06:00		Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.	
200	33285283	Journal Article;Multicenter Study	O  NNLM;COVID19;Clinical improvement;Convalescent plasma;Mortality;Pneumonia;SARSCoV2	Adult;COVID19/*therapy;Female;Humans;Immunization, Passive/methods;Male;Middle Aged;Prospective Studies;*SARSCoV2;DA 2021/02/17 06:00		COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 	
201	33365358	Journal Article	O  NNLM;ARDS;COVID19;SARSCoV2;lowmolecular weight;mortality	DA 2020/12/29 06:01		Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute 	
202	32535732	Journal Article		Animals;Antibodies, Monoclonal/administration & dosage/immunology;Betacoronavirus/immunology/isolation & purification;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/immunology/physiopathology;Cytokines/immunology;Humans;Interleukin6/*antagonists & inhibitors/immunology;Pandemics;Pneumonia, Viral/*drug therapy/immunology/physiopathology;SARSCoV2;DA 2020/08/25 06:00		IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?	
203	33408529	Journal Article	O  NNLM;ARDS;COVID19;mechanical ventilation;mortality;multidisciplinary team approach;noninvasive ventilation	DA 2021/01/08 06:01		Sixty-Day Mortality Among 520 Italian Hospitalized COVID-19 Patients According to 	
204	32423580	Comment;Journal Article		Adenosine Monophosphate/analogs & derivatives;Alanine/analogs & derivatives;*Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;*Coronavirus Infections;DoubleBlind Method;Pandemics;Pneumonia, Viral;Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/05/30 06:00		Remdesivir for COVID-19: challenges of underpowered studies.	
205	33063092	Journal Article;Review	O  NNLM;*Aryl hydrocarbon receptor;*Indoleamine 2,3dioxygenase;*Kynurenine pathway;*Nicotinamide;*Poly (ADPribose) polymerase;*glucocorticoids	Basic HelixLoopHelix Transcription Factors/metabolism;Betacoronavirus/drug effects;COVID19;Cell Line;Coronavirus Infections/*drug therapy/pathology;Cytokines/blood;Humans;Immunotherapy/methods;IndoleaminePyrrole 2,3,Dioxygenase/metabolism;Kynurenine/metabolism;Niacinamide/*pharmacology;Pandemics;Pneumonia, Viral/*drug therapy/pathology;Poly (ADPRibose) Polymerase1/*antagonists & inhibitors/metabolism;Poly(ADPribose) Polymerase Inhibitors/*pharmacology;Receptors, Aryl Hydrocarbon/metabolism;SARSCoV2;DA 2020/11/18 06:00		Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting 	
206	32670071	Journal Article	O  NNLM;COVID19 (severe);convalescent plasma;drugs analysis;guideline;therapeutic strategy	DA 2020/07/17 06:01		Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 	
207	32804279	Journal Article;Review	O  NNLM;COVID19;Diseasemodifying therapies;Neuromuscular disorder centres;Neuromuscular disorders;Pandemic;Telemedicine;Vaccine;Ventilatory support	COVID19/drug therapy/*epidemiology;Humans;Neuromuscular Diseases/epidemiology/*therapy;*Pandemics;SARSCoV2/drug effects;*Telemedicine;DA 2021/05/18 06:00		Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 	
208	32721928	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*age;*critical patient;*liver abnormality;*severe	Adult;Age Factors;Aged;Betacoronavirus;COVID19;China/epidemiology;Coronavirus Infections/*complications;Female;Humans;Incidence;Liver Diseases/epidemiology/*virology;Liver Function Tests;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications;SARSCoV2;DA 2020/08/14 06:00		COVID-19 induced liver function abnormality associates with age.	R01 AI155140/AI/NIAID NIH HHS/United States
209	33003134	Journal Article		Adult;COVID19/*epidemiology/*metabolism;COVID19 Testing/*statistics & numerical data;CaseControl Studies;Female;Gonadal Steroid Hormones/*metabolism;Humans;Male;Republic of Korea;Retrospective Studies;Risk Factors;SARSCoV2/metabolism;Young Adult;DA 2020/12/15 06:00		Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061 	
210	32681497	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*Adultonset Still’s disease;*Antiviral;*COVID19;*Catastrophic antiphospholipid syndrome;*Deferoxamine;*Hemophagocytic lymphohistiocytosis;*Hyperferritinemic;*Iron;*Iron depletion therapy;*Macrophage activation syndrome;*SARSCoV2	Betacoronavirus/*metabolism;COVID19;*Coronavirus Infections/blood/drug therapy/epidemiology;Ferritins/*blood;Humans;Iron/*blood;Iron Chelating Agents/*therapeutic use;*Iron Overload/blood/drug therapy/epidemiology;*Pandemics;*Pneumonia, Viral/blood/drug therapy/epidemiology;SARSCoV2;DA 2020/08/04 06:00		COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion 	
211	32984792	Journal Article;Research Support, N.I.H., Extramural;Research Support, N.I.H., Intramural;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.;Review		Algorithms;Antiviral Agents/therapeutic use;*Artificial Intelligence;COVID19/*drug therapy;Drug Discovery/methods;Drug Repositioning/*methods;Drug Therapy, Combination;Humans;SARSCoV2/drug effects;Treatment Outcome;DA 2020/09/29 06:01		Artificial intelligence in COVID-19 drug repurposing.	HHSN261200800001C/RC/CCR NIH HHS/United States;HHSN261200800001E/CA/NCI NIH HHS/United States;R00 HL138272/HL/NHLBI NIH HHS/United States;R01 AG066707/AG/NIA NIH HHS/United States
212	32788101	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*coagulopathy;*inflammation;*thrombosis	Animals;AntiInflammatory Agents/therapeutic use;Anticoagulants/therapeutic use;*Blood Coagulation/drug effects;*COVID19/blood/drug therapy/epidemiology/physiopathology;Humans;Incidence;Inflammation/blood/*drug therapy/epidemiology/physiopathology;*Thrombophilia/blood/epidemiology/physiopathology/prevention & control;*Thrombosis/blood/epidemiology/physiopathology/therapy;*Venous Thromboembolism/blood/epidemiology/physiopathology/therapy;DA 2020/12/15 06:00		The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.	K08 HL121131/HL/NHLBI NIH HHS/United States;R01 HL142647/HL/NHLBI NIH HHS/United States;U01 HL143402/HL/NHLBI NIH HHS/United States
213	32988772	Journal Article;Review	O  NNLM;*SARSCoV2;*convalescent plasma therapy;*immunotherapy;*monoclonal antibodies;*nanobodies	Antibodies, Viral/blood/*immunology;COVID19/immunology/therapy;Humans;Immunization, Passive;Immunomodulation;Pandemics/prevention & control;SARSCoV2/*immunology;DA 2021/02/03 06:00		Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2.	
214	32410758	Letter		Betacoronavirus;COVID19;COVID19 Vaccines;*Clinical Trials as Topic;Coronavirus Infections/*drug therapy/*prevention & control;Female;Humans;Pandemics/*prevention & control;*Patient Selection;Pneumonia, Viral/*drug therapy/*prevention & control;Pregnancy;*Pregnant Women;SARSCoV2;Viral Vaccines;DA 2020/05/30 06:00		Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.	
215	32385672	Journal Article;Review	O  NNLM;*ACE2;*ARDS;*COVID19;*Cancer;*Coronavirus;*Immune response;*Pandemic;*Pneumonia;*SARS;*SARSCoV2	Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*epidemiology/transmission;Hospital Mortality;Humans;*Immunocompromised Host;Neoplasms/*epidemiology/*immunology;Pandemics;Pneumonia, Viral/drug therapy/*epidemiology/transmission;Risk Factors;SARSCoV2;DA 2020/05/13 06:00		COVID-19 and Cancer: a Comprehensive Review.	
216	33080900	Journal Article	O  NNLM;ACE2 human receptors;antiCOVID19;nicotine and caffeine	DA 2020/10/22 06:01		In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the 	
217	32880032	Journal Article;Review	O  NNLM;*Cardiovascular risk;*Colchicine;*Fibrosis;*Hydroxychloroquine;*Methotrexate;*Thrombosis	Antirheumatic Agents/*therapeutic use;*Betacoronavirus;COVID19;Colchicine/adverse effects/*therapeutic use;Coronavirus Infections/*drug therapy;*Drug Repositioning;Hydroxychloroquine/adverse effects/*therapeutic use;Methotrexate/adverse effects/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/10/07 06:00		Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: 	
218	32661375	Journal Article;Research Support, NonU.S. Gov't;Review		Betacoronavirus/*immunology/pathogenicity;COVID19;COVID19 Vaccines;Coronavirus Infections/epidemiology/immunology/*prevention & control/virology;Humans;Pandemics/*prevention & control;Pneumonia, Viral/epidemiology/immunology/*prevention & control/virology;SARSCoV2;Viral Vaccines/immunology/*therapeutic use;DA 2020/08/29 06:00		Immune-mediated approaches against COVID-19.	"835227/EC | EU Framework Programme for Research and Innovation H2020 | H2020 ;862580/EC | EU Framework Programme for Research and Innovation H2020 | H2020 ;615808/Melanoma Research Alliance (MRA)/International;51/2016/EC | ERALEARN 2020 (ERA LEARN 2020)/International;52160021/""la Caixa"" Foundation (Caixa Foundation)/International;CF0100014/""la Caixa"" Foundation (Caixa Foundation)/International;1969/18/Israel Science Foundation (ISF)/International;PROF18602/Israel Cancer Research Fund (Israel Cancer Research Fund, "
219	32574236	Journal Article;Review	O  NNLM;COVID19;GS5734;RdRp;SARSCoV2;remdesivir	DA 2020/06/24 06:01		Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a 	
220	32710969	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Antiviral agents;*COVID19;*Coronavirus;*Cytokine storm;*Drug repositioning;*SARSCoV2	Animals;Antiviral Agents/*pharmacology/therapeutic use;Betacoronavirus/*drug effects;COVID19;Cardiovascular Diseases/drug therapy/virology;*Clinical Trials as Topic;Coronavirus Infections/complications/*drug therapy;Cytokines/metabolism;*Drug Repositioning;Humans;Outcome and Process Assessment, Health Care;Pandemics;Pneumonia, Viral/complications/*drug therapy;SARSCoV2;DA 2020/11/18 06:00		Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with 	
221	33028400	Journal Article;Review	O  NNLM;COVID19;Health worker;Healthcare worker;Management;Risk assessment;Surveillance	Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*diagnosis/epidemiology/*therapy/transmission;Databases, Factual;Disease Management;Epidemiological Monitoring;Health Personnel/*statistics & numerical data;Hospitals;Humans;Infectious Disease Transmission, PatienttoProfessional;Pandemics;Pneumonia, Viral/*diagnosis/epidemiology/*therapy/transmission;PostExposure Prophylaxis;Public Health Surveillance;Risk Assessment/methods;Risk Factors;SARSCoV2;DA 2020/10/21 06:00		Burden, risk assessment, surveillance and management of SARS-CoV-2 infection in 	
222	33025463	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Anticancer agents;*Atrial fibrillation;*COVID19;*Direct oral anticoagulants;*Drugdrug interactions;*QT prolongation	Antineoplastic Agents/*adverse effects;Arrhythmias, Cardiac/*chemically induced;Atrial Fibrillation/complications/*drug therapy;COVID19/complications/*drug therapy;Cytochrome P450 Enzyme Inhibitors/adverse effects;Cytochrome P450 Enzyme System;Drug Interactions;Factor Xa Inhibitors/*adverse effects;Hemorrhage/*chemically induced;Humans;Long QT Syndrome/chemically induced;Neoplasms/complications/*drug therapy;Thromboembolism/etiology/*prevention & control;DA 2020/12/15 06:00		The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug 	
223	32792417	Journal Article;Review	O  NNLM;*Ebola virus disease;*Middle East respiratory syndrome;*SARS;*antibodydependent enhancement;*convalescent blood product;*convalescent plasma;*convalescent whole blood;*coronavirus disease 2019;*enzymelinked immunosorbent assay;*intravenous immunoglobulins;*plaque reduction neutralization test	Antibodies, Neutralizing/analysis;Biological Specimen Banks/standards;COVID19;Coronavirus Infections/*therapy;Donor Selection/methods/standards;EnzymeLinked Immunosorbent Assay;Humans;Immunization, Passive/adverse effects/standards;Neutralization Tests/standards;Pandemics;Pneumonia, Viral/*therapy;Severe Acute Respiratory Syndrome/therapy;DA 2020/08/21 06:00		Convalescent Plasma Therapy for COVID-19: State of the Art.	
224	33341233	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Antiviral;*COVID19;*Dengue virus;*Ivermectin;*SARSCoV2;*Zika virus	Antiparasitic Agents/*pharmacology/therapeutic use;Antiviral Agents/*pharmacology/therapeutic use;COVID19/*drug therapy;Humans;Ivermectin/*pharmacology/therapeutic use;SARSCoV2/*drug effects;alpha Karyopherins/antagonists & inhibitors;DA 2021/03/09 06:00		The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?	
225	32709482	Comparative Study;Journal Article;Multicenter Study	O  NNLM;*COVID19;*Northern Italy;*coronavirus;*epidemiology;*heart transplantation	Aged;COVID19;Cohort Studies;Coronavirus Infections/*epidemiology/prevention & control;Female;Graft Rejection/prevention & control;Graft Survival;Heart Transplantation/methods/*statistics & numerical data;Hospital Mortality/*trends;Humans;Immunosuppression;Incidence;Infection Control/methods;Italy/epidemiology;Male;Middle Aged;Pandemics/prevention & control/*statistics & numerical data;Pneumonia, Viral/*epidemiology/prevention & control;Prognosis;Retrospective Studies;Risk Assessment;Severe Acute Respiratory Syndrome/diagnosis/*epidemiology;Survival Analysis;DA 2020/10/07 06:00		A case series of novel coronavirus infection in heart transplantation from 2 centers 	
226	32972277	Journal Article;Review	O  NNLM;Severe Acute Respiratory Syndromerelated Virus 2;cytokine storm;immunoregulation;mesenchymal stem cells;neovascularization;tissue repair	Betacoronavirus/*isolation & purification;COVID19;Coronavirus Infections/*therapy/virology;Humans;Mesenchymal Stem Cell Transplantation/*methods;Mesenchymal Stem Cells/*cytology;Pandemics;Pneumonia, Viral/*therapy/virology;Prognosis;SARSCoV2;DA 2020/10/06 06:00		Mesenchymal stem cell research progress for the treatment of COVID-19.	
227	32820478	Journal Article;Review		AntiInflammatory Agents/pharmacokinetics/therapeutic use;Anticoagulants/adverse effects/pharmacokinetics/*therapeutic use;Antiviral Agents/pharmacokinetics/therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*blood/complications/drug therapy;Drug Administration Routes;Drug Interactions;Fibrinolytic Agents/adverse effects/pharmacokinetics/*therapeutic use;Hemostasis/drug effects;Humans;*Pandemics;Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use;Pneumonia, Viral/*blood/complications/drug therapy;SARSCoV2;Thrombophilia/*drug therapy/etiology;Thrombosis/drug therapy/etiology/*prevention & control;Venous Thromboembolism/drug therapy/etiology/prevention & control;DA 2020/10/31 06:00		Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.	T32 HL007854/HL/NHLBI NIH HHS/United States
228	32579195	Journal Article;Randomized Controlled Trial		Aged;Aged, 80 and over;Betacoronavirus;CReactive Protein/*metabolism;COVID19;Cause of Death;Colchicine/*therapeutic use;Coronavirus Infections/*drug therapy/metabolism;Diarrhea/chemically induced;Disease Progression;Female;Fibrin Fibrinogen Degradation Products/*metabolism;Greece;Hospitalization;Humans;Inflammation/metabolism;KaplanMeier Estimate;Male;Middle Aged;Mortality;Pandemics;Pneumonia, Viral/*drug therapy/metabolism;Respiration, Artificial/statistics & numerical data;SARSCoV2;Time Factors;Treatment Outcome;Troponin/*metabolism;Tubulin Modulators/*therapeutic use;DA 2020/07/03 06:00	ClinicalTrials.gov/NCT04326790	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and 	
229	32784899	Journal Article;Review	O  NNLM;COVID19;SARSCoV2 entry inhibitors;TMPRSS2;cathepsins;coronavirus;peptides inhibitors;small molecules inhibitors;spike	AngiotensinConverting Enzyme Inhibitors/*pharmacology;Animals;Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects/metabolism/physiology;Humans;SARSCoV2;Serine Proteinase Inhibitors/*pharmacology;Spike Glycoprotein, Coronavirus/metabolism;Virus Internalization/*drug effects;DA 2020/08/21 06:00		SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host 	101003551/Horizon 2020/
230	33072589	Case Reports	O  NNLM;COVID19;SARSCoV2;aplastic anemia;cytokine storm;tocilizumab	DA 2020/10/20 06:01		Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With 	
231	33040483	Journal Article	O  NNLM;*clinical research/practice;*infection and infectious agents;*infection and infectious agents  viral;*infectious disease;*organ transplantation in general	COVID19/*diagnosis;*COVID19 Nucleic Acid Testing;Child;Dexamethasone/therapeutic use;Humans;*Organ Transplantation;*Tissue Donors;*Tissue and Organ Procurement;DA 2021/05/14 06:00		C4 article: Implications of COVID-19 in transplantation.	K08 DK120868/DK/NIDDK NIH HHS/United States
232	33432303	Journal Article	O  NNLM;COVID19;Diarrhea;GI;Metaanalysis;Nausea;Vomiting	DA 2021/01/13 06:00		Diarrhea Is Associated with Increased Severity of Disease in COVID-19: Systemic 	
233	33120812	Journal Article		*Betacoronavirus;COVID19;COVID19 Vaccines;Clinical Trials as Topic/*methods/standards/statistics & numerical data;Coronavirus Infections/prevention & control/*therapy;Humans;Pandemics;Pneumonia, Viral/*therapy;Quality Improvement;*Registries;*Research Design/standards/statistics & numerical data;SARSCoV2;Viral Vaccines;*World Health Organization;DA 2020/11/11 06:00		Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations.	
234	32904897	Journal Article;Review		DA 2020/09/10 06:01		Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.	
235	32838232	Journal Article	O  NNLM;COVID19;Case series;Cellular therapy;Mechanical ventilation;Mesenchymal stromal cells;Pneumonia;SARSCoV2	DA 2020/08/25 06:01		Adipose-derived mesenchymal stromal cells for the treatment of patients with severe 	
236	33014380	Journal Article;Review	O  NNLM;2019nCoV;Coronavirus 2019;WHO;drugs;global tally;severe acute respiratory syndrome coronavirus 2	DA 2020/10/06 06:01		Diagnostic approaches and potential therapeutic options for coronavirus disease 	
237	32892293	Journal Article;MetaAnalysis;Systematic Review	O  NNLM;*COVID19;*Hydroxychloroquine;*Metaanalysis	Adult;Antiviral Agents/adverse effects/*therapeutic use;COVID19/diagnosis/*drug therapy/mortality/virology;Disease Progression;EvidenceBased Medicine;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Male;Middle Aged;Treatment Outcome;DA 2021/04/10 06:00		Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review 	
238	32585913	Journal Article;Review	O  NNLM;2019nCoV;COVID19;SARSCoV;SARSCoV2;antibodies;antivirals	DA 2020/06/27 06:01		SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug 	
239	33177829	Journal Article;Review	O  NNLM;COVID19;Nacetylcysteine;SARSCov2	DA 2020/11/13 06:01		N-Acetylcysteine to Combat COVID-19: An Evidence Review.	
240	32569708	Journal Article;Review	O  NNLM;*Baricitinib;*COVID19;*Coagulation;*Coronavirus;*Dexamethasone;*Drugs;*Eculizumab;*Emapalumab;*Inflammation;*Remdesivir;*Ruxolitinib;*SARSCoV1;*SARSCoV2;*Therapies;*Tocilizumab;*Treatment	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;AntiInflammatory Agents/*therapeutic use;Antibodies, Monoclonal/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antibodies, Neutralizing/therapeutic use;Anticoagulants/*therapeutic use;Antiviral Agents/*therapeutic use;Azetidines/therapeutic use;Betacoronavirus/*drug effects/immunology;COVID19;Coronavirus Infections/*drug therapy/virology;Cytokine Release Syndrome/*drug therapy/virology;Disseminated Intravascular Coagulation/*drug therapy/virology;Drug Combinations;Heparin/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Inflammation;Interleukin 1 Receptor Antagonist Protein/therapeutic use;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/virology;Ritonavir/therapeutic use;SARSCoV2;Sulfonamides/therapeutic use;DA 2020/09/09 06:00		COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. 	
241	32425051	Clinical Trial Protocol;Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*clinical trial;*hydroxychloroquine	Adult;AntiInfective Agents/administration & dosage/adverse effects;*Azithromycin/administration & dosage/adverse effects;Betacoronavirus/drug effects/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/drug therapy/epidemiology;Drug Monitoring/methods;Female;Humans;*Hydroxychloroquine/administration & dosage/adverse effects;Male;*Pandemics;*Pneumonia, Viral/diagnosis/drug therapy/epidemiology;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;Utah;DA 2020/08/14 06:00	ClinicalTrials.gov/NCT04329832	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or 	K23 GM129661/GM/NIGMS NIH HHS/United States;R01 HL144624/HL/NHLBI NIH HHS/United States
242	32785162	Journal Article;Review	O  NNLM;AntiPD1 monoclonal antibody;COVID19;SARSCoV2;cancer;immunecheckpoint inhibitors;immunotherapy	DA 2020/08/14 06:01		Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based 	
243	33380340	Journal Article;Review	O  NNLM;ACE2;COVID19;Coronavirus;SARSCoV2	DA 2021/01/01 06:01		ACE2: the molecular doorway to SARS-CoV-2.	Scholarship number 969754 to JACE/Consejo Nacional de Ciencia y Tecnología, Mexico/
244	33515390	Journal Article	O  NNLM;COVID19;Global longitudinal strain;Heart failure;Myocardial injury;Threedimensional echocardiography	Aged;COVID19/complications/diagnostic imaging/pathology/*physiopathology;Echocardiography, ThreeDimensional;Female;FollowUp Studies;Heart Ventricles/diagnostic imaging/pathology/physiopathology;Hospitalization;Humans;Male;Middle Aged;Prospective Studies;SARSCoV2;Stroke Volume;Troponin T/blood;Ventricular Dysfunction/diagnostic imaging/etiology/pathology/*physiopathology;DA 2021/06/08 06:00		Left and right ventricular dysfunction in patients with COVID-19-associated 	SFB914/Deutsche Forschungsgemeinschaft/
245	32565030	Journal Article	O  NNLM;Biological agents;Biológicos;COVID19;Coronavirus;Pandemia;Pandemic;Resident;Residente;Reumatólogos;Rheumatologists	DA 2020/06/23 06:00		COVID-19: Overview of Rheumatology Fellows.	
246	32569797	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;autoimmune disease;dermatologyrheumatology;immunosuppression;immunosuppressive therapy;medical dermatology	Advisory Committees/standards;Betacoronavirus/immunology/pathogenicity;COVID19;Clinical DecisionMaking;Coronavirus Infections/epidemiology/immunology/*prevention & control/virology;Decision Making, Shared;Dermatologists/standards;Dermatology/methods/*standards;Disease Susceptibility/immunology;Hospitalists/standards;Humans;Immunosuppression/adverse effects/methods/*standards;Interdisciplinary Communication;Pandemics/*prevention & control;Pneumonia, Viral/epidemiology/immunology/*prevention & control/virology;*Practice Guidelines as Topic;SARSCoV2;Skin Diseases/immunology/*therapy;Societies, Medical/standards;Symptom Flare Up;DA 2020/09/23 06:00		Navigating immunosuppression in a pandemic: A guide for the dermatologist from the 	
247	33521689	Journal Article	O  NNLM;AYUSH;COVID19;COVID19 vaccines;Clinical management;India	DA 2021/02/02 06:01		The current situation of COVID-19 in India.	
248	32654006	Journal Article	O  NNLM;*Acute respiratory distress syndrome;*Acute respiratory failure;*Coronavirus;*Mesenchymal stromal cells;*Pharmacologic therapy	Antioxidants/therapeutic use;Ascorbic Acid/therapeutic use;COVID19/*drug therapy;Citrulline/therapeutic use;Drug Therapy/*trends;Glycoproteins/therapeutic use;Humans;Mesenchymal Stem Cells;Pandemics;Peptides, Cyclic/therapeutic use;Pyridones/therapeutic use;Pyrimidines/therapeutic use;Receptors, Tumor Necrosis Factor, Type I/antagonists & inhibitors/therapeutic use;Respiratory Distress Syndrome/*drug therapy;Steroids/therapeutic use;Trypsin Inhibitors/therapeutic use;DA 2020/12/29 06:00		Emerging pharmacological therapies for ARDS: COVID-19 and beyond.	MC_G1002460/MRC_/Medical Research Council/United Kingdom;MR/M009149/1/MRC_/Medical Research Council/United Kingdom
249	32441741	Comment;Journal Article		Betacoronavirus;COVID19;Coronavirus Infections;Edetic Acid;Expert Testimony;Humans;Immunosuppression;*Kidney Transplantation;Pandemics;Pneumonia, Viral;SARSCoV2;Transplant Recipients;DA 2020/06/18 06:00		How should I manage immunosuppression in a kidney transplant patient with COVID-19? 	
250	32619764	Case Reports	O  NNLM;Antiviral therapy;Case reports;Remdesivir;SARSCoV2 viral load;Viral pneumonia	Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use;Adult;Aged;Aged, 80 and over;Alanine/adverse effects/*analogs & derivatives/therapeutic use;Antiviral Agents/adverse effects/therapeutic use;Betacoronavirus/drug effects/physiology;COVID19;Coronavirus Infections/*drug therapy/virology;Female;France;Hospitalization;Humans;Male;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;Viral Load/drug effects;Withholding Treatment;DA 2020/09/22 06:00		Case report study of the first five COVID-19 patients treated with remdesivir in 	
251	32272857	Journal Article	O  NNLM;*biomaterials;*coronavirus;*pandemic;*tissue engineering;*viral	*Betacoronavirus;COVID19;COVID19 Testing;COVID19 Vaccines;Clinical Laboratory Techniques/methods;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention & ;Drug Delivery Systems;Humans;In Vitro Techniques;*Pandemics/prevention & control;*Pneumonia, Viral/diagnosis/epidemiology/prevention & control/therapy;SARSCoV2;*Tissue Engineering;Viral Vaccines;DA 2020/05/23 06:00		Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks.	
252	32765502	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*IL11;*IL6;*JAK;*STAT;*cytokine;*drug development;*interleukin;*structural biology	Animals;Humans;*Interleukin11/chemistry/immunology/metabolism;*Interleukin6/chemistry/immunology/metabolism;Signal Transduction/*immunology;StructureActivity Relationship;DA 2021/04/07 06:00		Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted 	
253	32505908	Case Reports;Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Fingolimod;*Multiple sclerosis	Betacoronavirus;COVID19;Coronavirus Infections/*complications/*immunology;Female;Fingolimod Hydrochloride/therapeutic use;Humans;*Immunocompromised Host;Immunosuppressive Agents/therapeutic use;Middle Aged;Multiple Sclerosis, RelapsingRemitting/drug therapy/*immunology/*virology;Pandemics;Pneumonia, Viral/*complications/*immunology;SARSCoV2;DA 2020/07/10 06:00		Immunologic characterization of a immunosuppressed multiple sclerosis patient that 	
254	33110677	Journal Article;Review	O  NNLM;COVID19;Coronavirus 2019 disease;SARSCoV2;children;newborn	DA 2020/10/29 06:01		Coronavirus-2019 Disease (COVID-19) in Children.	
255	32727613	Clinical Trial Protocol;Letter;Multicenter Study	O  NNLM;COVID19;Randomised controlled trial;Spain;doubleblinded;healthcare workers;hydroxychloroquine;preexposure;prophylaxis;protocol	*Betacoronavirus;COVID19;Coronavirus Infections/*prevention & control;DoubleBlind Method;*Health Personnel;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control;*PreExposure Prophylaxis;*Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/08/19 06:00	ClinicalTrials.gov/NCT04331834	Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers 	
256	32568376	Case Reports;Letter		Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Humans;Injections, Subcutaneous;Interleukin 1 Receptor Antagonist Protein/administration & dosage/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Treatment Outcome;DA 2020/08/11 06:00		Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole 	
257	33240265	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*coronavirus disease 2019;*critical illness;*immunomodulation;*pneumonia;*severe acute respiratory syndrome coronavirus 2	COVID19/*immunology/physiopathology/*therapy;Critical Illness/therapy;Cytokines/immunology;Humans;*Immunomodulation;Patient Acuity;DA 2020/12/29 06:00		Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.	
258	32612666	Journal Article;Review	O  NNLM;ACE2;COVID19;Diabetes mellitus (DM);SARSCoV2	DA 2020/07/03 06:01		SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?	
259	32957112	Journal Article;Review	O  NNLM;COVID19;Extracellular vesicles;Pulmonary disease;SARSCoV2	Antiviral Agents/administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/complications/metabolism/*therapy;Extracellular Vesicles/metabolism/*virology;Genetic Therapy/trends;Humans;Lung Diseases/metabolism/*therapy/virology;Pandemics;Pneumonia, Viral/complications/metabolism/*therapy;SARSCoV2;Virus Shedding/drug effects/physiology;DA 2020/10/23 06:00		COVID-19 and Extracellular Vesicles: An Intriguing Interplay.	
260	33290397	Journal Article;Research Support, NonU.S. Gov't		Animals;COVID19/drug therapy;Cathepsin B/*chemistry;Cathepsin L/*chemistry;Chlorocebus aethiops;Drug Repositioning;Humans;Models, Theoretical;Protein Binding;SARSCoV2/*physiology;Serine Endopeptidases/*chemistry;Spike Glycoprotein, Coronavirus/genetics;Vero Cells;Virion;Virus Internalization/*drug effects;DA 2021/01/05 06:00		Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 	WT_/Wellcome Trust/United Kingdom;IA/S/14/1/501307/WTDBT_/DBTWellcome Trust India Alliance/India
261	33103068	Journal Article	O  NNLM;Bioinformatics;Systems Biology;Virology	DA 2020/10/27 06:01		Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal.	
262	32344177	Journal Article	O  NNLM;2019nCoV;Azithromycin;COVID19;Hydroxychloroquine;SARSCoV2;Vero E6	Animals;Antiviral Agents/*pharmacology;Azithromycin/*pharmacology;Betacoronavirus/*drug effects;COVID19;Cell Line;Chlorocebus aethiops;Coronavirus Infections/*drug therapy;Drug Repositioning;Drug Synergism;Drug Therapy, Combination/methods;Humans;Hydroxychloroquine/*pharmacology;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Vero Cells;Virus Replication/drug effects;DA 2020/06/19 06:00		In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows 	
263	32403217	Journal Article;Review	O  NNLM;ACE2, acute kidney injury;COVID;Kawasaki disease;blood pressure;catepsin;coronavirus;cytokine storm;endothelium;heparin	DA 2020/05/15 06:01		Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial 	R01 DK123259/DK/NIDDK NIH HHS/United States;P30 DK020541/DK/NIDDK NIH HHS/United States;R01HL146691/NH/NIH HHS/United States;P60 DK020541/DK/NIDDK NIH HHS/United States;R01 HL146691/HL/NHLBI NIH HHS/United States
264	32693298	Journal Article;Review	O  NNLM;Antiviral drugs;Bioactivity scores;COVID19;In silico ADMET properties;Lipinski’s parameters;SARSCoV2	Animals;Antiviral Agents/pharmacokinetics/*therapeutic use;Betacoronavirus/*drug effects;Biological Availability;COVID19;COVID19 Vaccines;Coronavirus Infections/*drug therapy/prevention & control;Drug Combinations;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Viral Vaccines;DA 2020/09/25 06:00		COVID-19 treatment: Much research and testing, but far, few magic bullets against 	
265	32817953	Preprint		DA 2020/08/21 06:01		Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in 	R35 GM119617/GM/NIGMS NIH HHS/United States
266	32533062	Journal Article;Research Support, NonU.S. Gov't;Review		AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/genetics/immunology/pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Cytokines/antagonists & inhibitors/genetics/immunology;Gene Expression Regulation;HostPathogen Interactions/*drug effects/genetics/immunology;Humans;Middle East Respiratory Syndrome Coronavirus/drug ;Molecular Targeted Therapy/methods;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARS Virus/drug effects/genetics/immunology/pathogenicity;SARSCoV2;Severe Acute Respiratory Syndrome/drug therapy/epidemiology/immunology/virology;Signal Transduction/*drug effects/genetics/immunology;Spike Glycoprotein, Coronavirus/genetics/immunology;TLymphocytes/drug effects/immunology/virology;DA 2020/07/01 06:00		Overview of lethal human coronaviruses.	
267	32719687	Systematic Review	O  NNLM;*COVID19;*SARS  CoV2;*adaptive immunity;*coronavirus;*innate immunity	Betacoronavirus/*immunology;COVID19;*Coronavirus Infections/epidemiology/immunology/therapy;*Epidemics;Humans;*Immunity, Cellular;*Immunotherapy;*Pandemics;*Pneumonia, Viral/epidemiology/immunology/therapy;SARSCoV2;DA 2020/08/04 06:00		Cell-Mediated Immune Responses to COVID-19 Infection.	
268	32801640	Journal Article;Review	O  NNLM;antiviral therapy;coronavirus disease 2019;severe acute respiratory syndrome coronavirus 2;special population	Aged;Antiviral Agents/adverse effects/pharmacokinetics/*pharmacology;Betacoronavirus/drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/epidemiology/virology;Critical Illness;Female;Humans;Kidney Diseases/complications;Liver Diseases/complications;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Pregnancy;SARSCoV2;DA 2020/08/25 06:00		Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.	
269	32633327	Journal Article;Review	O  NNLM;*Middle East respiratory syndrome coronavirus;*acute hepatic injury;*acute kidney injury;*acute neurologic syndrome;*acute respiratory distress syndrome;*central neurogenic respiratory failure;*coronavirus disease 2019;*cytokine release syndrome;*heart failure;*pneumonia;*severe acute respiratory syndrome coronavirus 1;*severe acute respiratory syndrome coronavirus 2	Acute Kidney Injury/virology;COVID19;Coronavirus Infections/diagnosis/*pathology;Cytokine Release Syndrome/virology;Gastrointestinal Diseases/virology;Heart Failure/virology;Humans;Liver Failure, Acute/virology;Nervous System Diseases/virology;Pandemics;Pneumonia, Viral/diagnosis/*pathology;Respiratory Insufficiency/virology;Severe Acute Respiratory Syndrome/diagnosis/*pathology;DA 2020/08/04 06:00		SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a 	
270	32499303	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*COVID19;*COVID19 symptoms;*Famotidine;*PROMs;*SARSCoV2;*coronavirus;*outpatients	Adult;Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/drug therapy/physiopathology;DoseResponse Relationship, Drug;Drug Monitoring/*methods;Famotidine/*administration & dosage;Female;Histamine H2 Antagonists/administration & dosage;Humans;Male;Middle Aged;Oximetry/methods;*Pandemics;Patient Reported Outcome Measures;*Pneumonia, Viral/diagnosis/drug therapy/physiopathology;Retrospective Studies;SARSCoV2;Self Administration;Symptom Assessment/*methods;Treatment Outcome;DA 2020/08/25 06:00		Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised 	P30 CA045508/CA/NCI NIH HHS/United States;R35 GM118182/GM/NIGMS NIH HHS/United States
271	33041830	Journal Article;Review	O  NNLM;antiinflammatory;antiviral;coronavirus disease 2019;drug repurposing;immunotherapy;pathophysiology;severe acute respiratory syndrome coronavirus 2	DA 2020/10/13 06:01		Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly 	
272	32727107	Case Reports	O  NNLM;COVID19;acute respiratory distress syndrome (ARDS);case report;cytokines;immunotherapy;inflammation	Administration, Intravenous;Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Combined Modality Therapy;Coronavirus Infections/*complications;Dyspnea/diagnosis;Humans;Hypoxia/diagnosis;Male;Middle Aged;Noninvasive Ventilation/methods;Pandemics;Pneumonia, Viral/*complications;Respiratory Distress Syndrome/diagnostic imaging/*etiology/therapy;SARSCoV2;Tomography, XRay Computed/methods;Treatment Outcome;DA 2020/08/07 06:00		Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab 	
273	32527763	Journal Article;Research Support, NonU.S. Gov't		Antiviral Agents/*therapeutic use;COVID19;*Coronavirus Infections;Drug Repositioning;Humans;Interferons/*therapeutic use;Multiple Sclerosis/*drug therapy;*Pandemics;*Pneumonia, Viral;DA 2020/09/10 06:00		Should interferons take front stage as an essential MS disease-modifying therapy in 	
274	32433345	Journal Article;Review		Active Transport, Cell Nucleus/drug effects;Antibodies, Monoclonal/therapeutic use;Antiviral Agents/*therapeutic use;*Betacoronavirus/genetics;COVID19;Coronavirus Infections/*drug therapy;*Drug Development;Genome, Viral;Humans;Killer Cells, Natural/immunology;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/09/01 06:00		The pharmacological development of direct acting agents for emerging needed therapy 	
275	33351817	Journal Article;Observational Study;Research Support, N.I.H., Extramural		Aged;CReactive Protein;COVID19/blood/complications/*epidemiology/virology;Cohort Studies;Female;Ferritins/blood;Hospital Mortality;Humans;Intensive Care Units;Interleukin6/blood;LLactate Dehydrogenase/blood;Lymphocyte Count;Male;Middle Aged;Obesity/blood/complications/*epidemiology/virology;Procalcitonin/blood;*Respiration, Artificial;Respiratory Insufficiency/blood/complications/*epidemiology/virology;Retrospective Studies;Risk Factors;SARSCoV2/pathogenicity;Smoking/adverse effects;DA 2021/01/09 06:00		Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: 	UL1 TR001881/TR/NCATS NIH HHS/United States;T32 5T32HL0727521/NH/NIH HHS/United States;K08 DA048163/DA/NIDA NIH HHS/United States;T32 HL072752/HL/NHLBI NIH HHS/United States;KL2 TR001882/TR/NCATS NIH HHS/United States;TL1 TR001883/TR/NCATS NIH HHS/United States
276	32739134	Journal Article;Systematic Review	O  NNLM;Atención Primaria;COVID19;Chloroquine;Cloroquina;Hidroxicloroquina;Hydroxychloroquine;Primary Care	COVID19/drug therapy;Chloroquine/*therapeutic use;Coronavirus Infections/drug therapy;Humans;Hydroxychloroquine/therapeutic use;Uncertainty;DA 2020/08/28 06:00		[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use 	
277	32544867	Clinical Trial;Journal Article	O  NNLM;COVID19;Coronavirus;Interferon Beta1a;Pulmonary infection	Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents/administration & dosage/pharmacology/*therapeutic use;*Betacoronavirus/drug effects;COVID19;Coronavirus Infections/diagnostic imaging/*drug therapy;Drug Combinations;Drug Therapy, Combination;Female;Humans;Hydroxychloroquine/administration & dosage/therapeutic use;Injections, Subcutaneous;Interferon beta1a/administration & dosage/pharmacology/*therapeutic use;Lopinavir/administration & dosage/therapeutic use;Lung/diagnostic imaging;Male;Middle Aged;*Pandemics;Pneumonia, Viral/diagnostic imaging/*drug therapy;Prospective Studies;Ritonavir/administration & dosage/therapeutic use;SARSCoV2;Tomography, XRay Computed;Treatment Outcome;Young Adult;DA 2020/07/18 06:00		Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled 	
278	32203970	Journal Article;Review	O  NNLM;*Angiotensin receptor blockers;*Angiotensinconverting enzyme inhibitors;*COVID19;*Renal and cardiac side effects;*SARSCoV2;*Severe acute respiratory syndrome coronavirus	Angiotensin Receptor Antagonists;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors;Angiotensins/*antagonists & inhibitors;Betacoronavirus/physiology;COVID19;Coronavirus Infections/*complications;Humans;Kidney/virology;Kidney Diseases/*complications/*drug therapy;Kidney Transplantation;Nephrologists;Pandemics;PeptidylDipeptidase A;Pneumonia, Viral/*complications;Renal Dialysis;SARSCoV2;Virus Replication;DA 2020/05/28 06:00		Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse 	
279	32582574	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*COVID19;*alveolar;*angiotensin;*coagulopathy;*lung	Alveolar Epithelial Cells/*metabolism;AngiotensinConverting Enzyme 2;Betacoronavirus/*metabolism;COVID19;Coronavirus Infections/pathology;HostPathogen Interactions/physiology;Humans;Lung/pathology/virology;Pandemics;PeptidylDipeptidase A/*metabolism;Pneumonia, Viral/pathology;Receptors, Virus/*metabolism;ReninAngiotensin System/*physiology;SARSCoV2;Virus Internalization;DA 2020/07/07 06:00		ACE2, Much More Than Just a Receptor for SARS-COV-2.	R01 HL150474/HL/NHLBI NIH HHS/United States
280	32687696	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*antiinflammatory drugs;*antiviral drugs;*direct acting antivirals;*hosttargeted approaches;*repurposing;*small molecule inhibitors	Animals;AntiInflammatory Agents/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/immunology/virology;*Drug Repositioning;Humans;Inflammation/immunology/prevention & control/virology;Pandemics;Pneumonia, Viral/*drug therapy/immunology/virology;SARSCoV2;Virus Replication/drug effects;DA 2020/09/24 06:00		Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.	
281	33206207	Journal Article;Systematic Review	O  NNLM;COVID19;Histamine;Histamine receptor;Immunomodulation;Mast cells;SARSCoV2	COVID19/*drug therapy/metabolism;Histamine Antagonists/*therapeutic use;Histamine H2 Antagonists/therapeutic use;Humans;Receptors, Histamine/*drug effects/metabolism;SARSCoV2/drug effects/metabolism;DA 2021/01/22 06:00		Histamine receptors and COVID-19.	
282	32500409	Journal Article;Review	O  NNLM;*COVID19;*COVID19 virus;*Familial Mediterranean fever;*Rheumatic disease;*SARSCoV2;*Systemic lupus erythematosus	BCG Vaccine/immunology;*Betacoronavirus;COVID19;Child;Coronavirus Infections/*drug therapy/prevention & control;Female;Humans;Male;MeaslesMumpsRubella Vaccine/immunology;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/prevention & control;Rheumatic Diseases/*drug therapy;SARSCoV2;DA 2020/07/15 06:00		Implications of COVID-19 in pediatric rheumatology.	
283	32493514	Clinical Trial Protocol;Letter	O  NNLM;COVID19;IL6Rezeptor blockade;Inflammation;Pneumonia;Randomised controlled trial;SARSCoV2;Tocilizumab;Ventilator free days;protocol	AntiInflammatory Agents/adverse effects/*therapeutic use;Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use;Betacoronavirus/*drug effects/pathogenicity;COVID19;Coronavirus Infections/diagnosis/*drug therapy/physiopathology/virology;DoubleBlind Method;Germany;HostPathogen Interactions;Humans;Lung/*drug effects/physiopathology/virology;Multicenter Studies as Topic;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/physiopathology/virology;Prospective Studies;Randomized Controlled Trials as Topic;Recovery of Function;Respiration, Artificial;Risk Assessment;SARSCoV2;Severity of Illness Index;Time Factors;Treatment Outcome;DA 2020/06/11 06:00		A prospective, randomised, double blind placebo-controlled trial to evaluate the 	
284	32562159	Comparative Study;Journal Article;Observational Study	O  NNLM;Combination therapy;Coronavirus disease 2019;Length of stay in hospitals (ALOS)	Adult;Aged;Azithromycin/administration & dosage;COVID19/complications/*drug therapy;Drug Combinations;Drug Therapy, Combination;Female;Hospitalization/*statistics & numerical data;Humans;Hydroxychloroquine/administration & dosage;Iran;Length of Stay;Levofloxacin/administration & dosage;Lopinavir/administration & dosage;Male;Meropenem/administration & dosage;Middle Aged;Naproxen/administration & dosage;Oseltamivir/administration & dosage;Pneumonia, Viral/*drug therapy/virology;Prednisolone/administration & dosage;Retrospective Studies;Ritonavir/administration & dosage;Treatment Outcome;Vancomycin/administration & dosage;DA 2020/12/15 06:00		The clinical value of two combination regimens in the Management of Patients 	
285	32435882	Journal Article	O  NNLM;*Clinical dose;*Indomethacin;*Modelbased;*SARSCoV2;*Translational model	Animals;Antiviral Agents/*administration & dosage/pharmacokinetics/*therapeutic use;Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*drug therapy/virology;DelayedAction Preparations/administration & dosage/pharmacokinetics/therapeutic use;Dogs;*Drug Dosage Calculations;Humans;Indomethacin/*administration & dosage/pharmacokinetics/*therapeutic use;*Models, Biological;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;Viral Load/drug effects;DA 2020/07/01 06:00		Model based approach for estimating the dosage regimen of indomethacin a potential 	
286	32793615	Journal Article;Review	O  NNLM;AKI;COVID19;acute kidney injury;dialysis;transplant	DA 2020/08/15 06:01		COVID-19 and the Kidneys: An Update.	
287	32986137	Journal Article;Review	O  NNLM;*Antiviral therapy;*COVID19 treatment;*Chronic kidney disease;*Nephrology	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Adrenal Cortex Hormones/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Amides/therapeutic use;Antibodies, Monoclonal/therapeutic use;COVID19;Cobicistat/therapeutic use;Coronavirus Infections/*complications/drug therapy;Darunavir/therapeutic use;Drug Combinations;Humans;Kidney/drug effects/injuries/physiopathology;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*complications/drug therapy;Pyrazines/therapeutic use;Renal Insufficiency, Chronic/complications/*drug therapy;Renal Replacement Therapy/methods;Ritonavir/therapeutic use;DA 2020/11/25 06:00		Current treatment of COVID-19 in renal patients: hope or hype?	
288	33041391	Journal Article;Review	O  NNLM;COVID19;Human respiratory infection;Natural inhibitors	DA 2020/10/13 06:00		Coronaviruses and Nature's Pharmacy for the Relief of Coronavirus Disease 2019.	
289	32720223	Journal Article;Review	O  NNLM;COVID19;Cardiovascular;Gastrointestinal;Lungs;Neurological;SARSCoV2	AngiotensinConverting Enzyme 2;Betacoronavirus;COVID19;Coronavirus Infections/*pathology;Gastrointestinal Tract/*pathology/virology;Heart/*virology;Humans;Lung/*pathology/virology;Myocardium/*pathology;Nervous System/*pathology/virology;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*pathology;SARSCoV2;Virus Attachment;DA 2020/10/27 06:00		Organ-specific manifestations of COVID-19 infection.	
290	32533292	Comment;Letter	O  NNLM;*Anticoagulation;*COVID19;*Immune therapy;*Strategy	Betacoronavirus;COVID19;*Coronavirus;*Coronavirus Infections;Humans;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/07/10 06:00		Targeting the immunology of coronavirus disease-19: synchronization creates 	
291	33038418	Journal Article;Review	O  NNLM;COVID19;Cytokines;Inflammatory pathways;Interleukin;JAK/STAT;TLR	AntiInflammatory Agents/*therapeutic use;COVID19/*drug therapy/immunology;Humans;Inflammation/drug therapy/immunology;*SARSCoV2;DA 2020/12/29 06:00		Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review.	
292	33428995	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*COVID19 vaccine;*Nanovaccine;*SARSCoV2;*mRNA vaccine	Animals;COVID19/immunology/*prevention & control;COVID19 Vaccines/*administration & dosage/immunology;Drug Carriers/*administration & dosage;Drug Delivery Systems/methods/trends;Humans;Nanocapsules/*administration & dosage;SARSCoV2/*drug effects/immunology;Viral Vaccines/administration & dosage/immunology;DA 2021/05/26 06:00		Nanocarrier vaccines for SARS-CoV-2.	R01 NS036126/NS/NINDS NIH HHS/United States;R01 MH115860/MH/NIMH NIH HHS/United States;P01 DA028555/DA/NIDA NIH HHS/United States;P30 MH062261/MH/NIMH NIH HHS/United States;R01 MH121402/MH/NIMH NIH HHS/United States;R01 AG043540/AG/NIA NIH HHS/United States;R01 AG043530/AG/NIA NIH HHS/United States;F31 NS042419/NS/NINDS NIH HHS/United States
293	33132570	Journal Article;Review	O  NNLM;Coronavirus;Coronavirus disease2019;Heparin;Hydroxychloroquine;Remdesvir;SARSCoV2;Tocilizumab	DA 2020/11/03 06:01		Current Approaches to COVID-19: Therapy and Prevention.	
294	32550705	Journal Article;Review	O  NNLM;*COVID19 diagnostic testing [Supplementary Concept];*Patients;*Therapeutics	Betacoronavirus;Biomedical Research/*trends;COVID19;Coronavirus Infections/*therapy;Humans;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;DA 2020/07/24 06:00		Treatment and research lines for the patient with COVID-19. What do we have and 	
295	33317695	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*TFEB;*autophagy;*human;*human T cells;*immunology;*inflammation;*spermidine;*vaccine	Adjuvants, Immunologic/pharmacology;Adult;Aged;Aging/*immunology;Animals;Autophagy/*immunology;Basic HelixLoopHelix Leucine Zipper Transcription Factors/metabolism;CD8Positive TLymphocytes/*immunology;Cell Line, Tumor;Humans;Immunologic Memory/immunology;Interferongamma/blood;Jurkat Cells;Mice;Mice, Inbred C57BL;Mice, Knockout;Middle Aged;Peptide Initiation Factors/metabolism;RNABinding Proteins/metabolism;Respiratory Syncytial Virus Vaccines/*immunology;Respiratory Syncytial Viruses/immunology;Spermidine/blood/*pharmacology;Vaccination;Young Adult;DA 2021/03/17 06:00	ClinicalTrials.gov/NCT01070407;ClinicalTrials.gov/NCT01296451	Autophagy in T cells from aged donors is maintained by spermidine and correlates 	WT_/Wellcome Trust/United Kingdom;WT109665MA/Wellcome/International
296	33510041	Journal Article;Multicenter Study;Observational Study;Research Support, NonU.S. Gov't	O  NNLM;*autoimmune diseases;*epidemiology;*health care;*outcome and process assessment;*outcome assessment;*therapeutics	Adult;Brazil/epidemiology;COVID19/*immunology/*mortality/therapy;Critical Care/statistics & numerical data;Emergency Medical Services/statistics & numerical data;Female;Hospitalization/statistics & numerical data;Humans;Immunosuppression/*adverse effects;Male;Middle Aged;Prospective Studies;*Registries;Respiration, Artificial/statistics & numerical data;Rheumatic Diseases/*complications/immunology;DA 2021/02/07 06:00		High levels of immunosuppression are related to unfavourable outcomes in 	
297	33412395	Journal Article	O  NNLM;Covid19;IFNβ1a;Intensive care;Mortality;Outcome;Survival	Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;CaseControl Studies;Drug Combinations;Female;HIV Protease Inhibitors/*therapeutic use;Humans;Interferonbeta/administration & dosage/*therapeutic use;Lopinavir/administration & dosage/*therapeutic use;Male;Middle Aged;Retrospective Studies;Ritonavir/administration & dosage/*therapeutic use;Young Adult;DA 2021/02/23 06:00		Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, 	
298	32472461	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Rheumatoid arthritis;Treatment	Antirheumatic Agents/*pharmacology;Betacoronavirus/isolation & purification;COVID19;Comorbidity;*Coronavirus Infections/drug therapy/epidemiology/immunology;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/epidemiology/immunology;*Rheumatic Diseases/drug therapy/epidemiology/immunology;SARSCoV2;DA 2020/06/25 06:00		COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.	
299	32753153	Letter		Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy;Famotidine/*therapeutic use;Histamine H2 Antagonists/*therapeutic use;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Treatment Outcome;DA 2020/11/06 06:00		Famotidine Against SARS-CoV2: A Hope or Hype?	
300	32278766	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Hospital pharmacy;*Pharmacy service;*Rational use of medicine;*Telehealth	COVID19/epidemiology/*therapy;Humans;Pharmacists/*organization & administration;Pharmacy Service, Hospital/*organization & administration;Professional Role;Telemedicine/organization & administration;DA 2020/12/23 06:00		Fighting against COVID-19: Innovative strategies for clinical pharmacists.	
301	33358260	Journal Article	O  NNLM;ARDS;Blood purification;Critically ill COVID19;Cytokine storm;Plasmapheresis	DA 2020/12/29 06:00		Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with 	
302	32950749	Journal Article	O  NNLM;Alcohol;COVID19;Cirrhosis;Mortality	DA 2020/09/21 06:00	ClinicalTrials.gov/NCT04439084	Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US 	R01 AA024762/AA/NIAAA NIH HHS/United States;UL1 TR002384/TR/NCATS NIH HHS/United States
303	32835246	Journal Article;Review		DA 2020/08/25 06:01		The immunology of COVID-19: is immune modulation an option for treatment?	
304	32838164	Journal Article;Review	O  NNLM;ACE2;COVID19;Cardiovascular complications;Furin;SARSCoV2;Spike protein	DA 2020/08/25 06:00		Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular 	
305	33329400	Journal Article	O  NNLM;*COVID19;*SARSCOV2;*hypernatremia;*hyponatremia;*mortality;*sepsis	Aged;COVID19/epidemiology/*mortality/virology;Female;FollowUp Studies;Global Health;Hospital Mortality/*trends;Hospitalization/statistics & numerical data;Humans;Hypernatremia/*physiopathology;Hyponatremia/*physiopathology;Male;Middle Aged;Outcome Assessment, Health Care;Prognosis;Registries/*statistics & numerical data;Retrospective Studies;SARSCoV2/*isolation & purification;Survival Rate;DA 2021/01/05 06:00	ClinicalTrials.gov/NCT04334291	Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A 	
306	32616381	Journal Article;Review	O  NNLM;*ARDS;*COVID19;*Glucocorticoids;*Immune response;*SARSCoV2	AntiInflammatory Agents/*therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*drug therapy/pathology;Cytokine Release Syndrome/*drug therapy;Dexamethasone/*therapeutic use;Glucocorticoids/*therapeutic use;Humans;Pandemics;Pneumonia, Viral/*drug therapy/pathology;Pulmonary Alveoli/pathology;SARSCoV2;DA 2020/09/29 06:00		A critical evaluation of glucocorticoids in the management of severe COVID-19.	
307	32811798	Comment;Letter		Betacoronavirus;COVID19;*Coronavirus Infections/drug therapy;Health Personnel;Humans;Hydroxychloroquine;India;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/09/24 06:00		Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen.	
308	32320516	Journal Article;Research Support, NonU.S. Gov't;Review		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Amides/therapeutic use;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/immunology/pathogenicity;COVID19;COVID19 Testing;COVID19 Vaccines;Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/*drug therapy/*epidemiology/immunology/prevention & ;Disease Progression;Gene Expression Regulation;HostPathogen Interactions/genetics/immunology;Humans;Immunization, Passive/methods;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/diagnosis/*drug therapy/*epidemiology/immunology;Pyrazines/therapeutic use;SARSCoV2;Severity of Illness Index;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/*genetics/immunology;Viral Vaccines/biosynthesis;DA 2020/07/01 06:00		Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.	81521001, 81870182/National Natural Science Foundation of China/International;2016YFC1301204, 2020YFC1316701/National Key Basic Research Programme/International
309	32758659	Journal Article;Observational Study	O  NNLM;COVID19;Coronavirus;Pneumonia;Respiratory distress syndrome;SARSCoV2	Aged;Aged, 80 and over;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Cause of Death;Coronavirus Infections/diagnosis/drug therapy/*mortality/therapy;Female;Hospital Mortality;Hospitalization;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/diagnosis/*mortality/therapy;Retrospective Studies;Risk Factors;SARSCoV2;Spain/epidemiology;DA 2020/11/21 06:00		Characteristics and predictors of death among 4035 consecutively hospitalized 	
310	33014532	Journal Article;Review	O  NNLM;Adipose Stem Cells;COVID19;Coronavirus therapy;Mesenchymal Stem Cells;SARSCoV2;Stem Cell Therapy	DA 2020/10/06 06:01		Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem 	
311	32470568	Journal Article;Review;Systematic Review	O  NNLM;Antivirals;COVID19;Chikungunya;Chloroquine;Dengue;Hydroxychloroquine;Pneumonia	Adult;Antiviral Agents/pharmacology/*therapeutic use;Betacoronavirus/drug effects/physiology;COVID19;Child;Chloroquine/pharmacology/*therapeutic use;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/virology;Drug Repositioning;Humans;Hydroxychloroquine/pharmacology/*therapeutic use;Observational Studies as Topic;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;Treatment Outcome;Viral Load/drug effects;DA 2020/08/12 06:00		Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral 	
312	32461141	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*C5 inhibition;*COVID19;*complement activation;*complement terminal pathway;*kidney injury;*vascular injury	Animals;*Betacoronavirus;COVID19;*Complement Activation;Complement C5a/physiology;Coronavirus Infections/complications/*immunology;Endothelial Cells/physiology;Humans;Inflammation/etiology;MannoseBinding Lectin/physiology;Mice;Pandemics;Pneumonia, Viral/complications/*immunology;SARSCoV2;Thrombosis/etiology;Vascular Diseases/etiology;DA 2020/08/05 06:00		The case of complement activation in COVID-19 multiorgan impact.	
313	33126054	Clinical Trial;Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Biomarker;*COVID19;*Inflammation;*Micronutrient;*Trace element	Adult;Age Factors;Aged;Aged, 80 and over;COVID19/*blood/diagnosis/*mortality;CrossSectional Studies;DiseaseFree Survival;Female;Humans;Male;Middle Aged;PSelectin/*blood;Predictive Value of Tests;SARSCoV2/*metabolism;Survival Rate;Zinc/*blood;DA 2021/01/13 06:00		Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as 	
314	32445440	Clinical Trial, Phase III;Journal Article;Randomized Controlled Trial;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & ;Administration, Intravenous;Adult;Aged;Alanine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic ;Antiviral Agents/administration & dosage/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/mortality/therapy;DoubleBlind Method;Extracorporeal Membrane Oxygenation;Female;Humans;KaplanMeier Estimate;Male;Middle Aged;Oxygen Inhalation Therapy;Pandemics;Pneumonia, Viral/*drug therapy/mortality/therapy;Respiration, Artificial;SARSCoV2;Time Factors;Young Adult;DA 2020/12/02 06:00	ClinicalTrials.gov/NCT04280705	Remdesivir for the Treatment of Covid-19 - Final Report.	UM1AI148576/US/United States/United States;UM1AI148573/US/United States/United States;UM1AI148685/US/United States/United States;UM1AI148452/US/United States/United States;UM1 AI148685/AI/NIAID NIH HHS/United States;UM1AI148575/US/United States/United States;UM1AI148684/US/United States/United States;UM1 AI148573/AI/NIAID NIH HHS/United States;UM1 AI148684/AI/NIAID NIH HHS/United States;MC_UU_12023/22/MRC_/Medical Research Council/United Kingdom;HHSN261200800001E/US/United States/United States;R38 AI140299/AI/NIAID NIH HHS/United States;UM1 AI148689/AI/NIAID NIH HHS/United States;UM1 AI148450/AI/NIAID NIH HHS/United States;UM1 AI148575/AI/NIAID NIH HHS/United States;UM1 AI148576/AI/NIAID NIH HHS/United States;UM1AI148689/US/United States/United States;UM1 AI148452/AI/NIAID NIH HHS/United States;HHSN261201500003I/US/United States/United States;UM1AI148450/US/United States/United States
315	33398609	Journal Article;Review	O  NNLM;*Antiviral drugs;*Lowmolecularweight heparin;*Remdesivir;*SARSCoV2;*Therapy;*Tocilizumab	Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology;Drugs, Investigational/therapeutic use;Heparin, LowMolecularWeight/*therapeutic use;Humans;Immunologic Factors/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;SARSCoV2;Steroids/*therapeutic use;DA 2021/03/19 06:00		COVID-19 treatment options: a difficult journey between failed attempts and 	
316	32512611	Journal Article;Review		COVID19;Coronavirus Infections/*complications/epidemiology/therapy;Endocrine System Diseases/*complications/epidemiology/therapy;Humans;Pandemics;Pneumonia, Viral/*complications/epidemiology/therapy;DA 2020/07/24 06:00		Endocrine Conditions and COVID-19.	
317	33214093	Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;Coronavirus;IVIg;Intravenous Immunoglobulin;Pulmonary infection	Adult;Aged;Antiviral Agents/therapeutic use;COVID19/*drug therapy;Drug Therapy, Combination;Female;Humans;Hydroxychloroquine/therapeutic use;Immunoglobulins, Intravenous/*therapeutic use;Immunologic Factors/*therapeutic use;Length of Stay;Lopinavir/therapeutic use;Male;Middle Aged;Ritonavir/therapeutic use;*SARSCoV2;Treatment Outcome;DA 2021/01/23 06:00		Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of 	
318	33120785	Journal Article;Observational Study		Adult;Aged;Aged, 80 and over;Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;China/epidemiology;Coronavirus Infections/complications/*diagnosis/drug therapy/mortality;Female;FollowUp Studies;Hospital Mortality;Humans;Male;Middle Aged;Overweight/*complications;Pandemics;Pneumonia, Viral/complications/*diagnosis/drug therapy/mortality;Prognosis;Retrospective Studies;Risk Factors;SARSCoV2;Severity of Illness Index;Survival Analysis;DA 2020/11/11 06:00		The importance of overweight in COVID-19: A retrospective analysis in a single 	
319	32857301	Comparative Study;Journal Article	O  NNLM;Atazanavir/ritonavir;COVID19;Hydroxychloroquine;Outcomes	Adult;Aged;Antiviral Agents/administration & dosage/adverse effects;Atazanavir Sulfate/*administration & dosage/adverse effects;COVID19/*drug therapy/mortality/virology;Drug Therapy, Combination;Female;Hospitalization/statistics & numerical data;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;Intensive Care Units/statistics & numerical data;Length of Stay;Male;Middle Aged;Prospective Studies;Ritonavir/*administration & dosage/adverse effects;Severity of Illness Index;Time Factors;Treatment Outcome;DA 2020/12/15 06:00		Comparing outcomes of hospitalized patients with moderate and severe COVID-19 	
320	32870433	Journal Article;Review	O  NNLM;Argatroban;COVID19;Coagulopathy;Inflammation;SARSCoV2	Antithrombins/pharmacology;Arginine/*analogs & derivatives/pharmacology;Blood Coagulation/drug effects;*COVID19/blood/drug therapy/immunology;Drug Development;Humans;Inflammation/drug therapy;Pipecolic Acids/*pharmacology;SARSCoV2/*drug effects;Sulfonamides/*pharmacology;DA 2021/04/07 06:00		Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.	SC3GM131986/GM/NIGMS NIH HHS/United States;SC3GM131986/GM/NIGMS NIH HHS/United States
321	32670917	Editorial	O  NNLM;COVID19; CoronaVirus;Epidemiology;Pandemic Disease	DA 2020/07/17 06:01		Current perspective on pandemic of COVID-19 in the United States.	
322	32267771	Adaptive Clinical Trial;Clinical Trial Protocol;Journal Article;Randomized Controlled Trial	O  NNLM;*Bayesian adaptive;*communityacquired pneumonia;*coronavirus disease 2019;*master protocol;*platform trial;*randomized clinical trial	AntiBacterial Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;COVID19;CommunityAcquired Infections/*therapy;Coronavirus Infections/*therapy;EvidenceBased Medicine;Humans;Influenza, Human/*therapy;Pandemics;Pneumonia/*therapy;Pneumonia, Viral/*therapy;PointofCare Systems;SARSCoV2;DA 2020/09/12 06:00	ClinicalTrials.gov/NCT02735707	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for 	RP201506018/DH_/Department of Health/United Kingdom
323	33341481	Journal Article;Review	O  NNLM;COVID19;Chloroquine;Diagnosis;Drug toxicities;Favipiravir;Hydroxychloroquine;Lopinavir;Precautionary measures;Remdesivir;Ritonavir;SARSCoV2;Umifenovir	Antiviral Agents/*therapeutic use;COVID19/*drug therapy;*Drug Repositioning;Humans;Hydroxychloroquine/*therapeutic use;*SARSCoV2;DA 2021/02/07 06:00		Impact of repurposed drugs on the symptomatic COVID-19 patients.	
324	33212256	Clinical Trial, Phase III;Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial	O  NNLM;Antiviral;COVID19;Coronavirus;Favipiravir;Randomized clinical trial;SARSCoV2	Adolescent;Adult;Aged;Amides/adverse effects/*therapeutic use;COVID19/*drug therapy;Female;Humans;Male;Middle Aged;Pyrazines/adverse effects/*therapeutic use;RNADependent RNA Polymerase/*antagonists & inhibitors;*SARSCoV2;Young Adult;DA 2021/02/17 06:00		Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, 	
325	32602006	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Acute kidney injury;*COVID19;*Chronic kidney failure;*Mortality;*Prognosis;*Registry	Acute Kidney Injury/epidemiology;Aged;Aged, 80 and over;AngiotensinConverting Enzyme 2;*Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology/mortality/physiopathology/therapy;Female;Glomerular Filtration Rate/*physiology;Humans;Male;Middle Aged;Pandemics;PeptidylDipeptidase A/physiology;Pneumonia, Viral/*epidemiology/mortality/physiopathology/therapy;*Registries;Risk Assessment;SARSCoV2;DA 2020/08/11 06:00	ClinicalTrials.gov/NCT04334291	Impact of renal function on admission in COVID-19 patients: an analysis of the 	
326	32923397	Journal Article;Review	O  NNLM;CAR Tcell;COVID19;SARSCoV2;hematologic malignancies;leukemia;lymphoma;myeloma;telehealth	DA 2020/09/15 06:01		Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: 	
327	33291455	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*IMU838;*SARSCoV2;*antiviral therapy;*dihydroorotate dehydrogenase (DHODH) inhibitors;*hostdirected antivirals (HDAs);*vidofludimus	Adenosine Monophosphate/analogs & derivatives/pharmacology;Alanine/analogs & derivatives/pharmacology;Animals;Antiviral Agents/chemistry/*pharmacology;COVID19/drug therapy;Chlorocebus aethiops;Clinical Trials, Phase II as Topic;Drug Discovery;*Drug Repositioning;Drug Synergism;Humans;Oxidoreductases Acting on CHCH Group Donors/*antagonists & inhibitors;SARSCoV2/*drug effects;Vero Cells;Virus Replication/drug effects;DA 2020/12/30 06:00		IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows 	
328	32868092	Journal Article;Review		AngiotensinConverting Enzyme Inhibitors/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/immunology/*therapy/virology;*COVID19 Vaccines;Combined Modality Therapy;Humans;Respiratory Therapy/*methods;*SARSCoV2/immunology/pathogenicity;DA 2020/12/15 06:00		COVID-19: Therapeutics and interventions currently under consideration.	
329	33203141	Journal Article;Review	O  NNLM;COVID19;adrenomedullin;angiotensin II;apelin;bradykinin;natriuretic peptide;neprilysin;sacubitril/valsartan;substance P	Aminobutyrates/administration & dosage/therapeutic use;Angiotensin Receptor Antagonists/administration & dosage/*therapeutic use;Animals;COVID19;Coronavirus Infections/*drug therapy/metabolism;Drug Combinations;Humans;Neprilysin/*antagonists & inhibitors/metabolism;Pandemics;Pneumonia, Viral/*drug therapy/metabolism;Tetrazoles/administration & dosage/therapeutic use;Valsartan/administration & dosage/therapeutic use;DA 2020/11/28 06:00		The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted 	
330	32838187	Journal Article;Review	O  NNLM;Diagnosis;Lopinavir/ritonavir;Novel coronavirus pneumonia;Treatment	DA 2020/08/25 06:00		Protease Inhibitor Use in COVID-19.	
331	32322397	Journal Article;Review	O  NNLM;Azithromycin;COVID19;coronavirus;hydroxychloroquine;ivermectin	DA 2020/04/24 06:01		Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting 	
332	32748244	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;diagnosis;pandemic;public health;treatment strategies	Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*diagnosis/*therapy;Humans;Immunization, Passive/trends;Nucleic Acid Amplification Techniques/methods/trends;Pandemics/*prevention & control;Pneumonia, Viral/*diagnosis/*therapy;RealTime Polymerase Chain Reaction/methods/trends;SARSCoV2;DA 2020/08/11 06:00		Diagnostic and Treatment Strategies for COVID-19.	
333	33432269	Journal Article	O  NNLM;COVID19;SARSCoV;SARSCoV2;TMC310911;drug repurposing;ritonavir	DA 2021/01/13 06:01		Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main 	
334	33385581	Journal Article;Observational Study	O  NNLM;COVID19;Canakinumab;Pneumonia;SARSCoV2	Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/*complications;CaseControl Studies;Cohort Studies;Female;Hospitalization/statistics & numerical data;Humans;Male;Middle Aged;Pneumonia, Viral/*complications/*drug therapy;Prospective Studies;SARSCoV2/immunology;Treatment Outcome;DA 2021/04/24 06:00		Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control 	P30 CA008748/CA/NCI NIH HHS/United States
335	33397429	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Clinical symptoms;Hospitalization Mechanical ventilation;Ivermectin;Protocol;Randomized controlled trial	Administration, Oral;Adult;Antiviral Agents/*administration & dosage/adverse effects;COVID19/diagnosis/*drug therapy/virology;Clinical Trials, Phase III as Topic;Drug Therapy, Combination/adverse effects/methods;Female;Humans;Hydroxychloroquine/administration & dosage/adverse effects;Intensive Care Units/statistics & numerical data;Interferon beta1a/administration & dosage/adverse effects;Iran;Ivermectin/*administration & dosage/adverse effects;Length of Stay/statistics & numerical data;Lopinavir/administration & dosage/adverse effects;Male;Randomized Controlled Trials as Topic;Ritonavir/administration & dosage/adverse effects;SARSCoV2/drug effects/*isolation & purification;Severity of Illness Index;DA 2021/01/13 06:00		The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A 	990238/Hormozgan University of Medical Sciences/
336	33058394	Journal Article	O  NNLM;COVID19;SARSCoV2;antiviral drugs;therapeutic targets	Antiviral Agents/*pharmacology/therapeutic use;COVID19/*drug therapy/immunology/virology;Humans;Immune System Phenomena/*drug effects;SARSCoV2/*drug effects/immunology/metabolism/pathogenicity;DA 2020/12/19 06:00		SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.	Finance Code 001./Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/
337	32655013	Journal Article;MetaAnalysis;Systematic Review	O  NNLM;*acute kidney injury;*death;*kidney;*kidney diseases	Acute Kidney Injury/diagnosis/*epidemiology/virology;*Betacoronavirus;COVID19;Coronavirus Infections/*complications/*mortality;Humans;Incidence;Pandemics;Pneumonia, Viral/*complications/*mortality;SARSCoV2;DA 2020/10/10 06:00		Incidence of acute kidney injury and its association with mortality in patients with 	
338	32344449	Journal Article;Research Support, N.I.H., Extramural		Antimalarials/*administration & dosage/blood;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/blood/*prevention & control;Humans;Hydroxychloroquine/*administration & dosage/blood;Malaria/blood/*drug therapy;Models, Biological;Pandemics/*prevention & control;Pneumonia, Viral/blood/*prevention & control;PreExposure Prophylaxis/*methods;SARSCoV2;Treatment Outcome;DA 2020/09/30 06:00		Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate 	K08 AI134262/AI/NIAID NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;U01AI125003/National Institute of Allergy and Infectious Diseases/International;R01AI140303/National Institute of Allergy and Infectious Diseases/International
339	32699031	Journal Article;Observational Study;Research Support, NonU.S. Gov't		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Age Factors;Aged;Alanine/analogs & derivatives/therapeutic use;Betacoronavirus/pathogenicity;COVID19;Clinical DecisionMaking;Coronavirus Infections/complications/diagnosis/*drug therapy/mortality;Drug Therapy, Combination/methods/statistics & numerical data;Drug Utilization/*statistics & numerical data;FollowUp Studies;Glucocorticoids/therapeutic use;Healthcare Disparities/*statistics & numerical data;Hospital Mortality;Humans;Hydroxychloroquine/therapeutic use;Male;Middle Aged;Neoplasms/complications/*mortality;Pandemics;Pneumonia, Viral/complications/diagnosis/*drug therapy/mortality;Risk Factors;SARSCoV2;Severity of Illness Index;Sex Factors;Treatment Outcome;United States/epidemiology;DA 2020/10/21 06:00		Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: 	UL1 TR000445/TR/NCATS NIH HHS/United States;T32 HG008341/HG/NHI NIH HHS/United States;U01 CA231840/CA/NCI NIH HHS/United States;UG1 CA189974/CA/NCI NIH HHS/United States;UG1 CA189828/CA/NCI NIH HHS/United States;P30 CA013696/CA/NCI NIH HHS/United States;P30 CA068485/CA/NCI NIH HHS/United States;P30 CA054174/CA/NCI NIH HHS/United States;T32 CA203703/CA/NCI NIH HHS/United States;T32 CA009515/CA/NCI NIH HHS/United States;U10 CA180888/CA/NCI NIH HHS/United States;P30 CA196521/CA/NCI NIH HHS/United States
340	32420936	Journal Article;Review		Anticoagulants/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy;Humans;Inflammation/drug therapy;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/05/27 06:00		Treatments for COVID-19: emerging drugs against the coronavirus.	
341	33093056	Clinical Trial, Phase II;Journal Article;Multicenter Study;Randomized Controlled Trial		Adult;Antibodies, Neutralizing/blood;Antibodies, Viral/blood;Betacoronavirus;COVID19;Coronavirus Infections/mortality/*therapy;Disease Progression;Female;Humans;Immunization, Passive;India;Male;Middle Aged;Pandemics;Pneumonia, Viral/mortality/*therapy;SARSCoV2;Treatment Failure;DA 2020/11/06 06:00	CTRI/CTRI/2020/04/024775	Convalescent plasma in the management of moderate covid-19 in adults in India: open 	
342	33115543	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Randomised controlled trial;SARSCoV;TKI;TKIinduced attenuation of vascular leak;TKIinduced prevention and treatment lung inflammation;imatinib;lysosomal sequestration;protocol;tyrosine kinase inhibitor;viral ABL1 signalling	Administration, Oral;Adult;*Betacoronavirus/drug effects/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/drug therapy;Critical Care/methods;DoseResponse Relationship, Drug;DoubleBlind Method;Drug Monitoring;Female;Humans;*Imatinib Mesylate/administration & dosage/adverse effects;Male;*Pandemics;*Pneumonia, Viral/diagnosis/drug therapy;Protein Kinase Inhibitors/administration & dosage/adverse effects;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;DA 2020/11/06 06:00	ClinicalTrials.gov/NCT04394416	Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured 	P30CA134274/CA/NCI NIH HHS/United States
343	33486200	Journal Article;Review	O  NNLM;3CL protease;ACE2 receptor;COVID19;Cathepsin L proteinase;Coronavirus;Inhibitors. contents;RdRp;SARSCoV2;Spike glycoprotein;TMPRSS2	Animals;Antiviral Agents/chemistry/*therapeutic use;COVID19/*drug therapy/epidemiology;Drug Discovery;Humans;Pandemics;Protease Inhibitors/chemistry/therapeutic use;SARSCoV2/*drug effects/physiology;Spike Glycoprotein, Coronavirus/antagonists & inhibitors;DA 2021/03/10 06:00		The race to treat COVID-19: Potential therapeutic agents for the prevention and 	
344	33166179	Journal Article		DA 2020/11/10 06:00	ClinicalTrials.gov/NCT04329832	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): 	U01 HL123018/HL/NHLBI NIH HHS/United States;UL1 RR025764/RR/NCRR NIH HHS/United States;U01 HL123009/HL/NHLBI NIH HHS/United States;UL1 TR002538/TR/NCATS NIH HHS/United States;K23 GM129661/GM/NIGMS NIH HHS/United States;UL1 TR000105/TR/NCATS NIH HHS/United States;U01 HL143505/HL/NHLBI NIH HHS/United States;UL1 TR001067/TR/NCATS NIH HHS/United States
345	33524462	Journal Article;Observational Study	O  NNLM;*Artificial intelligence;*COVID19;*Hydroxychloroquineazythromycine;*QTc interval;*Smartwatch	Adult;Arrhythmias, Cardiac/chemically induced/*diagnosis;*Artificial Intelligence;Azithromycin/adverse effects/therapeutic use;COVID19/*drug therapy;*Electrocardiography;Female;Humans;Hydroxychloroquine/adverse effects/therapeutic use;*Long QT Syndrome/epidemiology;Male;Middle Aged;Pandemics;DA 2021/04/24 06:00	ClinicalTrials.gov/NCT04371744	Smartwatch Electrocardiogram and Artificial Intelligence for Assessing 	
346	32702077	Preprint		DA 2020/07/24 06:01		Identification of new drug treatments to combat COVID19: A signature-based approach 	R01 MH107487/MH/NIMH NIH HHS/United States;R01 MH121102/MH/NIMH NIH HHS/United States
347	32637086	Journal Article	O  NNLM;COVID19;Convalescent plasma;Coronavirus;SARSCoV2	DA 2020/07/09 06:01		A severe refractory COVID-19 patient responding to convalescent plasma; A case 	
348	32442023	Letter	O  NNLM;azithromycin;cardiotoxicity;hydroxychloroquine;phamacovigilance	DA 2020/05/23 06:00		Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An 	P50 GM115305/GM/NIGMS NIH HHS/United States
349	32739642	Journal Article	O  NNLM;*ACE2;*COVID19;*Drug repositioning;*Entry inhibitor;*SARSCoV2	Amino Acid Motifs;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/*chemistry;Antiviral Agents/*chemistry;Betacoronavirus/*chemistry/enzymology;COVID19;Carbazoles/chemistry;Catalytic Domain;Coronavirus Infections/drug therapy/virology;Drug Repositioning;Dyphylline/analogs & derivatives/chemistry;HostPathogen Interactions;Humans;Hydroxamic Acids/chemistry;Ligands;Molecular Docking Simulation;Pandemics;Paromomycin/analogs & derivatives/chemistry;Pemetrexed/chemistry;PeptidylDipeptidase A/*chemistry/metabolism;Pneumonia, Viral/drug therapy/virology;Protein Binding;Protein Interaction Domains and Motifs;Protein Structure, Secondary;SARSCoV2;Small Molecule Libraries/*chemistry;StructureActivity Relationship;Thermodynamics;DA 2020/09/24 06:00		Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a 	
350	32793246	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*cytokine treatment;*immune therapy;*monoclonal antibody;*respiratory distress	AntiInflammatory Agents/therapeutic use;Antibodies, Viral/therapeutic use;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/drug effects/immunology;COVID19;Coronavirus Infections/*drug therapy/*prevention & control/transmission;Cytokine Release Syndrome/*drug therapy;Humans;Pandemics/*prevention & control;Pneumonia, Viral/*drug therapy/*prevention & control/transmission;Quarantine/methods;Respiratory Insufficiency/*therapy;SARSCoV2;DA 2020/08/25 06:00		Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.	
351	32738306	Journal Article	O  NNLM;Azithromycin;COVID19;Chloroquine;Coronavirus;Hydroxychloroquine;Molecular docking	Amino Acid Motifs;AngiotensinConverting Enzyme 2;Antiviral Agents/chemistry/*pharmacology;Azithromycin/*chemistry/pharmacology;Betacoronavirus/*chemistry/metabolism;Binding Sites;COVID19;Cathepsin L/antagonists & inhibitors/*chemistry/metabolism;Chloroquine/*chemistry/pharmacology;Coronavirus 3C Proteases;Coronavirus Infections/drug therapy/virology;Cysteine Endopeptidases/*chemistry/metabolism;HostPathogen Interactions/drug effects/genetics;Humans;Hydroxychloroquine/*chemistry/pharmacology;Molecular Docking Simulation;Pandemics;PeptidylDipeptidase A/*chemistry/genetics/metabolism;Pneumonia, Viral/drug therapy/virology;Protein Binding;Protein Interaction Domains and Motifs;Protein Structure, Secondary;SARSCoV2;Spike Glycoprotein, Coronavirus/antagonists & ;Thermodynamics;Viral Nonstructural Proteins/antagonists & inhibitors/*chemistry/metabolism;Virus Attachment/drug effects;DA 2020/09/12 06:00		In silico study of azithromycin, chloroquine and hydroxychloroquine and their 	
352	32147496	Journal Article;Review	O  NNLM;*2019nCoV;*Antiviral;*COVID19;*Chloroquine;*SARSCoV2	Antiviral Agents/adverse effects/pharmacology/standards/*therapeutic use;Betacoronavirus/drug effects;COVID19;China;Chloroquine/adverse effects/pharmacology/standards/*therapeutic use;Clinical Trials as Topic/standards;Coronavirus Infections/*drug therapy;Humans;Hydroxychloroquine/adverse effects/pharmacology/standards/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/04/24 06:00		Of chloroquine and COVID-19.	
353	32982336	Journal Article;Review	O  NNLM;ACEIs;ARBs;COVID19;coronavirus	DA 2020/09/29 06:01		ACEIs and ARBs and Their Correlation with COVID-19: A Review.	
354	32737471	Journal Article	O  NNLM;3CL protease;SARSCoV2;Shuanghuanglian oral liquid;baicalein;baicalin;traditional Chinese medicines	Administration, Oral;Animals;Antiviral Agents/chemistry/pharmacology;Betacoronavirus/*drug effects/physiology;COVID19;Chlorocebus aethiops;*Coronavirus Infections/drug therapy/virology;*Drugs, Chinese Herbal/chemistry/pharmacology;Enzyme Assays;*Flavanones/chemistry/pharmacokinetics;*Flavonoids/chemistry/pharmacokinetics;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/virology;SARSCoV2;Vero Cells;Virus Replication/*drug effects/physiology;DA 2020/09/09 06:00		Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive 	
355	32562483	Journal Article;Review	O  NNLM;COVID19;IVIG;SARSCoV2;convalescent plasma;cytokine storm syndrome;cytokines;hyperimmune globulin;immunotherapy;inflammation;monoclonal antibody;passive immunotherapy	DA 2020/06/21 06:01		Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.	
356	32376402	Journal Article;Review	O  NNLM;Bioinformatics;COVID19;Coronavirus;Pathogenesis;SARS;SARSCoV2	Betacoronavirus;COVID19;Cells, Cultured;Coronavirus Infections/*genetics/*mortality/pathology;Drug Discovery;Epithelial Cells/virology;Female;Humans;Lung/cytology;Male;Pandemics;Pneumonia, Viral/*genetics/*mortality/pathology;SARSCoV2;Severe Acute Respiratory Syndrome;*Sex Factors;TOR SerineThreonine Kinases;Transcriptome;DA 2020/06/11 06:00		Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways 	
357	32438620	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;antiinflammatory;coronavirus;infection;inflammation;noncommunicable diseases;nutrition;vitamin C;vitamin D;zinc	AntiInflammatory Agents/*administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/blood/immunology/*therapy/virology;Cytokines/blood;Diet/methods;Humans;Inflammation/immunology/*therapy;Nutrition Therapy/*methods;*Nutritional Status/immunology;Pandemics;Pneumonia, Viral/blood/immunology/*therapy/virology;SARSCoV2;DA 2020/05/30 06:00		COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.	
358	32427279	Journal Article	O  NNLM;*COVID19;*Corticosteroids;*SARSCOV2;*coronavirus;*outcomes	Adrenal Cortex Hormones/administration & dosage/*therapeutic use;COVID19/*drug therapy;Female;Hospitalization/statistics & numerical data;Humans;Male;Methylprednisolone/administration & dosage/therapeutic use;Middle Aged;Multicenter Studies as Topic;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04374071	Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19.	
359	33130005	Journal Article	O  NNLM;*COVID19;*Connectivity map;*Drug repurposing;*SARSCoV2;*Transcriptomic profiling	A549 Cells;*Antiviral Agents;*COVID19/genetics/metabolism/virology;Cell Line, Tumor;Drug Repositioning/*methods;Humans;Pandemics;Protein Interaction Maps/*genetics;*SARSCoV2;Transcriptome/*genetics;DA 2020/12/22 06:00		A connectivity map-based drug repurposing study and integrative analysis of 	
360	32296817	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*COVID19;*pregnancy;*treatment;*trial	Antiviral Agents/therapeutic use;Betacoronavirus/*drug effects;Breast Feeding;COVID19;Coronavirus Infections/*drug therapy/virology;Drug Administration Schedule;Female;Humans;Hydroxychloroquine/therapeutic use;OffLabel Use;Outpatients;Pandemics;Pneumonia, Viral/*drug therapy/virology;PostExposure Prophylaxis/methods;Pregnancy;Pregnancy Complications, Infectious/drug therapy/virology;SARSCoV2;Time Factors;DA 2020/08/11 06:00		Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic 	K23 AI120793/AI/NIAID NIH HHS/United States
361	33447537	Editorial		DA 2021/01/16 06:01		COVID-19 in Qatar: Ways forward in public health and treatment.	
362	33535156	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*ACE2;*BSG;*CD147;*COVID19;*Coronavirus;*Eye;*RAS;*SARSCoV2	AngiotensinConverting Enzyme 2/chemistry/metabolism;Animals;Antirheumatic Agents/therapeutic use;Basigin/metabolism;COVID19/drug therapy/*pathology/transmission/virology;Dexamethasone/therapeutic use;Eye/cytology/metabolism/*virology;Eye Diseases/pathology/virology;Glucocorticoids/therapeutic use;Humans;ReninAngiotensin System/physiology;SARSCoV2/isolation & purification;DA 2021/03/26 06:00		Eyes on coronavirus.	
363	32882823	Journal Article	O  NNLM;Bioinformatics;COVID19;IFN response;SARSCoV;SARSCoV2;SARSMERS;fatty acid synthesis;gene expressions;immune response;influenza A;influenza B;pathway analysis;rhinovirus	DA 2020/09/05 06:01		Computational and Transcriptome Analyses Revealed Preferential Induction of 	QB13/Qatar Biomedical Research institute/
364	33278358	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*SARSCoV2;*baricitinib;*immune activation;*immunology;*inflammation;*nonhuman primate;*pathogenesis	Animals;AntiInflammatory Agents/*administration & dosage;Azetidines/*administration & dosage;COVID19/*drug therapy/*immunology/physiopathology;Cell Death/drug effects;Cell Degranulation/drug effects;Disease Models, Animal;Inflammation/drug therapy/genetics/immunology;Janus Kinases/antagonists & inhibitors;Lung/drug effects/immunology/pathology;Lymphocyte Activation/drug effects;*Macaca mulatta;Macrophages, Alveolar/immunology;Neutrophil Infiltration/*drug effects;Purines/*administration & dosage;Pyrazoles/*administration & dosage;SARSCoV2/physiology;Severity of Illness Index;Sulfonamides/*administration & dosage;TLymphocytes/immunology;Virus Replication/drug effects;DA 2021/01/30 06:00		Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil 	R01 AI116379/AI/NIAID NIH HHS/United States;U24 AI120134/AI/NIAID NIH HHS/United States;R01 AI143411/AI/NIAID NIH HHS/United States;S10 OD025002/OD/NIH HHS/United States;S10 OD026799/OD/NIH HHS/United States;R01 HL140223/HL/NHLBI NIH HHS/United States;R01 AI149672/AI/NIAID NIH HHS/United States;R01 MH116695/MH/NIMH NIH HHS/United States;P51 OD011092/OD/NIH HHS/United States;P30 AI050409/AI/NIAID NIH HHS/United States;R37 AI141258/AI/NIAID NIH HHS/United States;P51 OD011132/OD/NIH HHS/United States
365	33145698	Journal Article;Review		Age Factors;AntiInflammatory Agents, NonSteroidal/pharmacology;Anticoagulants/administration & dosage/classification/*pharmacology/*therapeutic use;Antiviral Agents/pharmacology;Atrial Fibrillation/drug therapy;COVID19/*complications;Chemoprevention/adverse effects/methods;Disseminated Intravascular Coagulation/drug therapy;Drug Interactions;Humans;Italy;Pandemics;Risk Factors;Risk Management;SARSCoV2;Severity of Illness Index;Sex Factors;Thrombosis/drug therapy/*etiology/physiopathology/*prevention & control;DA 2020/12/22 06:00		Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A 	
366	33070079	Journal Article;Review	O  NNLM;Antiviral drugs;COVID19;Clinical trials;Drug repurposing;Monoclonal antibodies;SARSCoV2;Small molecule drugs;Vaccines	Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology/prevention & control/*therapy;COVID19 Vaccines/*therapeutic use;Clinical Trials as Topic;Drug Repositioning;Humans;Pandemics/prevention & control;SARSCoV2;DA 2020/12/31 06:00		Primed for global coronavirus pandemic: Emerging research and clinical outcome.	
367	33239864	Journal Article;Review	O  NNLM;COVID19;anticancer drugs;drugrepurposing	Antineoplastic Agents/*therapeutic use;Antiviral Agents/therapeutic use;COVID19/*drug therapy;Clinical Trials as Topic;*Drug Repositioning;Humans;DA 2020/12/15 06:00		Repurposing Anti-Cancer Drugs for COVID-19 Treatment.	P30 CA086862/CA/NCI NIH HHS/United States;T32 GM007337/GM/NIGMS NIH HHS/United States
368	33152450	Controlled Clinical Trial;Journal Article	O  NNLM;Antimalarial;Artemisinin;COVID19;Piperaquine;SARSCoV2	Adult;Antiviral Agents/*adverse effects/*therapeutic use;Artemisinins/adverse effects/*therapeutic use;COVID19/*drug therapy;Drug Therapy, Combination;Female;Humans;Long QT Syndrome/chemically induced;Lung Diseases/diagnostic imaging/drug therapy/virology;Male;Middle Aged;Quinolines/adverse effects/*therapeutic use;RNA, Viral/blood;SARSCoV2/genetics;Viral Load;DA 2021/01/23 06:00		Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an 	
369	32837854	Journal Article;Review	O  NNLM;A recent update;COVID19;Pharmacological therapy;Pipeline drugs;SARSCoV2	DA 2020/08/25 06:00		Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent 	
370	33046268	Journal Article;Review	O  NNLM;COVID19;HLAE;HLAG;NKG2A;SARSCoV2	Antiviral Agents/pharmacology/therapeutic use;COVID19/drug therapy/*epidemiology/*immunology/virology;HLAG Antigens/*immunology/metabolism;Histocompatibility Antigens Class I/*immunology/metabolism;HostPathogen Interactions/drug effects/immunology;Humans;Immune Tolerance;Immunization, Passive;Molecular Targeted Therapy;SARSCoV2/*physiology;Signal Transduction/drug effects;Virus Internalization;Virus Replication;DA 2020/12/15 06:00		Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.	
371	33145472	Journal Article;Review	O  NNLM;COVID19;adrenal;diabetes mellitus;gonads;thyroid diseases	DA 2020/11/05 06:01		SARS-CoV-2 (COVID-19) and the Endocrine System.	
372	33193418	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*coronavirus infection;*immune response;*systemic lupus erythematosus;*therapeutics	Animals;COVID19/drug therapy/genetics/*immunology/virology;Humans;Lupus Erythematosus, Systemic/drug therapy/genetics/*immunology;SARSCoV2/genetics/immunology/*physiology;DA 2020/12/15 06:00		COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and 	
373	32848774	Journal Article;Review	O  NNLM;COVID19;chloroquine;coronavirus;hydroxychloroquine;potential risk	DA 2020/08/28 06:01		Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their 	
374	32814839	Clinical Trial;Comparative Study;Journal Article;Research Support, NonU.S. Gov't		Aged;Aged, 80 and over;Biomarkers;COVID19/diagnosis/*drug therapy/metabolism/*virology;Combined Modality Therapy;Comorbidity;*Compassionate Use Trials;Female;Humans;Janus Kinase 1/*antagonists & inhibitors;Janus Kinase 2/*antagonists & inhibitors;Janus Kinase Inhibitors/pharmacology/*therapeutic use;Male;Middle Aged;Prospective Studies;Pyrazoles/pharmacology/therapeutic use;SARSCoV2/*drug effects;Severity of Illness Index;Treatment Outcome;Viral Load;DA 2021/04/23 06:00		Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective 	
375	32423584	Journal Article;Multicenter Study;Randomized Controlled Trial		Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use;Aged;Alanine/adverse effects/*analogs & derivatives/therapeutic use;Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus;COVID19;China;Coronavirus Infections/*drug therapy;DoubleBlind Method;Female;Humans;Infusions, Intravenous;Male;Middle Aged;Negative Results;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/05/30 06:00	ClinicalTrials.gov/NCT04257656	Remdesivir in adults with severe COVID-19: a randomised, double-blind, 	WT_/Wellcome Trust/United Kingdom
376	33262798	Journal Article	O  NNLM;COVID19;Hospital Information System (HIS);Treatment Strategies	DA 2020/12/03 06:01		Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two 	
377	33234866	Journal Article;Review		COVID19/*epidemiology/*physiopathology/*therapy;Contact Tracing/*methods;Global Health/*statistics & numerical data;Humans;Pandemics/*prevention & control;Preventive Medicine/*methods;SARSCoV2;United States/epidemiology;DA 2020/12/15 06:00		COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic 	
378	32595947	Journal Article;Review	O  NNLM;*COVID19;*Pandemic;*Public health;*SARSCoV2;*Virus	Betacoronavirus/*genetics;COVID19;Coronavirus Infections/*epidemiology/*physiopathology/*therapy;Humans;Pandemics;Pneumonia, Viral/*epidemiology/*physiopathology/*therapy;SARSCoV2;DA 2020/07/03 06:00		The COVID-19 pandemic: catching up with the cataclysm.	
379	32678040	Journal Article;Multicenter Study	O  NNLM;*COVID19;*Mortality;*Prediction system;*Risk factor	Adult;Aged;Aged, 80 and over;COVID19;Coronavirus Infections/*mortality/*therapy;Female;Humans;Male;Middle Aged;*Models, Statistical;Pandemics;Pneumonia, Viral/*mortality/*therapy;Prognosis;Reproducibility of Results;Retrospective Studies;Risk Factors;Survival Analysis;DA 2020/07/23 06:00		Development and validation of a risk factor-based system to predict short-term 	82041018/National Natural Science Foundation of China/International;81770096/National Natural Science Foundation of China/International;81700091/National Natural Science Foundation of China/International;2020kfyXGYJ/Independent Innovation Research Fund for Huazhong University of Science ;2019ZX09301001/State Project for Essential Drug Research and 
380	33167852	Journal Article;Research Support, N.I.H., Extramural;Review		Animals;Betacoronavirus/*immunology;Bradykinin/metabolism;COVID19;Coronavirus Infections/*immunology;Humans;*Immunity, Innate;Kallikreins/metabolism;Models, Immunological;Pandemics;Pneumonia, Viral/*immunology;ReninAngiotensin System;SARSCoV2;DA 2020/11/24 06:00		SARS-CoV-2 and interferon blockade.	1P01 AI07369306/NH/NIH HHS/United States
381	33477477	Journal Article;Review	O  NNLM;Ebola virus;SARSCoV2;antibodies;antivirals;endocytosis;vaccines	DA 2021/01/23 06:01		SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from 	NA/joemcorono crowfunding initiative/
382	32655577	Journal Article;Review	O  NNLM;*ARDS;*COVID19;*JAK inhibitors;*coagulation;*hydroxychloroquine;*interleukin1;*interleukin6	Adaptive Immunity/drug effects;Adult;Anticoagulants/therapeutic use;Antirheumatic Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/immunology/*metabolism;COVID19;Cardiovascular Diseases/*drug therapy/*etiology;Coronavirus Infections/*complications/*drug therapy/immunology/virology;Humans;Hydroxychloroquine/therapeutic use;Immunity, Innate/drug effects;Interleukin1/antagonists & inhibitors;Interleukin6/antagonists & inhibitors;Janus Kinase Inhibitors/therapeutic use;Pandemics;Pneumonia, Viral/*complications/*drug therapy/immunology/virology;Respiratory Distress Syndrome/drug therapy/etiology;SARSCoV2;DA 2020/08/04 06:00		Targeting the Immune System for Pulmonary Inflammation and Cardiovascular 	
383	32367857	Letter		DA 2020/05/06 06:01		Safety of an immunomodulator Mycobacterium w in COVID-19.	
384	32891146	Journal Article;Review	O  NNLM;Coronavirus;Nanovaccines;Nanoparticles;Nanosensors;Nanotechnology;SARSCoV2	Antiviral Agents/administration & dosage;*Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;COVID19 Vaccines;Clinical Laboratory Techniques/methods;*Coronavirus Infections/diagnosis/epidemiology/prevention & control/therapy;Disinfection/methods;Drug Carriers;Drug Delivery Systems;Humans;Nanostructures/administration & dosage;Nanotechnology/*methods;*Pandemics;Personal Protective Equipment;*Pneumonia, Viral/diagnosis/epidemiology/therapy;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/09/12 06:00		How can nanotechnology help to combat COVID-19? Opportunities and urgent need.	2019/051001/Fundação de Amparo à Pesquisa do Estado de São Paulo/;2017/244021/Fundação de Amparo à Pesquisa do Estado de São Paulo/;2018/211421/Fundação de Amparo à Pesquisa do Estado de São Paulo/;2018/236088/Fundação de Amparo à Pesquisa do Estado de São Paulo/;2017/210045/Fundação de Amparo à Pesquisa do Estado de São Paulo/;CAPESCOFECUB 88887.363975/201900/Coordenação de Aperfeiçoamento de Pessoal de 
385	32564212	Comment;Letter		*Betacoronavirus;COVID19;Colchicine;*Coronavirus Infections;Humans;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/07/10 06:00		"Comment on ""Colchicine may not be effective in COVID-19 infection; it may even be "	
386	32290348	Journal Article	O  NNLM;COVID19;SARSCoV2;chloroquine;hydroxychloroquine;lopinavir/ritonavir;remdesivir;repurposing	DA 2020/04/16 06:01		COVID-19: A Brief Overview of the Discovery Clinical Trial.	
387	32454187	Journal Article;Review;Systematic Review	O  NNLM;Antiinflammatory;Antivirals;COVID19;Clinical trials;Immunomodulators;Novel coronavirus;Pneumonia;Prevention;SARSCoV2;Treatment	Antiviral Agents/pharmacology/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Cell and TissueBased Therapy/*methods;Clinical Trials as Topic;Coronavirus Infections/*therapy/virology;Humans;Pandemics;Pneumonia, Viral/*therapy/virology;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;DA 2020/08/12 06:00		Review of trials currently testing treatment and prevention of COVID-19.	
388	32574274	Journal Article	O  NNLM;COVID19;antiinflammatory drug;cytokine storm;lung injury;thalidomide	Animals;AntiInflammatory Agents, NonSteroidal/therapeutic use;Antiviral Agents/*therapeutic use;COVID19;Coronavirus Infections/complications/*drug therapy/immunology;Disease Progression;*Drug Repositioning;Humans;Inflammation/drug therapy/etiology;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology;Thalidomide/*therapeutic use;DA 2020/07/11 06:00		Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet 	
389	33338232	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Ambulatory Care/*methods/trends;Antimalarials/administration & dosage;Antiviral Agents/*administration & dosage;COVID19/*diagnosis/*drug therapy;Carbamates/*administration & dosage;DoubleBlind Method;Drug Therapy, Combination;Female;FollowUp Studies;Humans;Hydroxychloroquine/administration & dosage;Imidazoles/*administration & dosage;Male;Middle Aged;Pyrrolidines/*administration & dosage;Sofosbuvir/*administration & dosage;Treatment Outcome;Valine/administration & dosage/*analogs & derivatives;DA 2021/02/24 06:00		Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a 	
390	33149899	Journal Article	O  NNLM;COVID19;FAME;IPD;MAMS;SARSCoV2;adaptive;conduct;efficient;epidemic;metaanalysis;multiarm;multistage;pandemic;platform;trials	*Adaptive Clinical Trials as Topic;*COVID19;Humans;Pandemics;Prospective Studies;Research Design;DA 2020/12/15 06:00		Adaptive platform trials using multi-arm, multi-stage protocols: getting fast 	MC_UU_12023/22/Medical Research Council/United Kingdom
391	32468014	Journal Article;Review		Angiotensin II Type 1 Receptor Blockers/classification/therapeutic use;AngiotensinConverting Enzyme 2;Betacoronavirus/*drug effects/pathogenicity/physiology;Bromhexine/pharmacology/therapeutic use;COVID19;Chlorpromazine/pharmacology/therapeutic use;Clinical Trials as Topic/methods;Coronavirus Infections/*drug therapy/epidemiology/mortality;Diminazene/pharmacology/therapeutic use;*Drug Repositioning/methods/standards/trends;Gabexate/analogs & derivatives/pharmacology/therapeutic use;Humans;Pandemics;PeptidylDipeptidase A/chemistry/metabolism/therapeutic use;Pneumonia, Viral/*drug therapy/epidemiology/mortality;Receptor, Angiotensin, Type 1/metabolism;Recombinant Proteins/chemistry/therapeutic use;SARSCoV2;Signal Transduction/drug effects;Virus Internalization/*drug effects;DA 2020/07/02 06:00		Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights 	
392	32849833	Journal Article	O  NNLM;COVID19;Indian population;SARSCoV2;angiotensin converting enzyme 2;killer cell immunoglobulinlike receptors;microRNA	DA 2020/08/28 06:01		The Enigma of Low COVID-19 Fatality Rate in India.	
393	32835666	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*ACE2;*Arrhythmia;*COVID19;*Cardiovascular;*Sex differences;*Thrombosis	AngiotensinConverting Enzyme 2/genetics;Arrhythmias, Cardiac/complications/epidemiology;COVID19/complications/*epidemiology/genetics;Cardiovascular Diseases/complications/*epidemiology;Disease Progression;Disease Susceptibility;Endothelium, Vascular/pathology;Female;Humans;Inflammation;Male;Microcirculation;Obesity/complications;Risk Factors;*Sex Factors;Smoking;Thrombosis/complications/epidemiology;DA 2021/01/05 06:00		Sex differences underlying preexisting cardiovascular disease and cardiovascular 	R01 HL131182/HL/NHLBI NIH HHS/United States;R01 HL147586/HL/NHLBI NIH HHS/United States
394	32372435	Journal Article	O  NNLM;*COVID19;*Drug industry;*Drugs, generic;*Infectious diseases;*Medicine, traditional;*Policy, drugs and alcohol;*Respiratory tract infections;*Virology	Australia;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/virology;Drug Repositioning/*economics/methods;*Financing, Government;Humans;Investments;Leadership;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/06/13 06:00		Drug repurposing in the era of COVID-19: a call for leadership and government 	
395	32450906	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Gender;*Immune system;*Renin angiotensin aldosterone system;*Sex	AngiotensinConverting Enzyme 2;*Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology/immunology/metabolism/therapy;Europe;Female;Humans;Male;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*epidemiology/immunology/metabolism/therapy;Risk Factors;SARSCoV2;Serine Endopeptidases/metabolism;Sex Characteristics;Treatment Outcome;DA 2020/05/30 06:00		Impact of sex and gender on COVID-19 outcomes in Europe.	Research grant/Olga Mayenfisch Foundation, Switzerland/International;Research grant/Schweizerische Herzstiftung/International;Research grant/University Hospital Zurich Foundation, Switzerland/International;Research grant/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ;Research grant/EMDO Foundation, Switzerland/International;Research grant/Helmut Horten Foundation, Switzerland/International;Research grant/Novartis Stiftung für MedizinischBiologische Forschung/International;Research grant/ItenKohaut Foundation, Switzerland/International;U54 AG062333/AG/NIA NIH HHS/United States;Research grant/OPO Foundation, Switzerland/International
396	33180830	Journal Article;Observational Study;Research Support, NonU.S. Gov't		Aged;Aged, 80 and over;Betacoronavirus;COVID19;Coronavirus Infections/*mortality;Extracorporeal Membrane Oxygenation;Female;Germany/epidemiology;*Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Models, Statistical;Pandemics;Pneumonia, Viral/*mortality;Respiration, Artificial;Retrospective Studies;SARSCoV2;Tertiary Healthcare;DA 2020/11/24 06:00		COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted 	
397	32474885	Journal Article;Review	O  NNLM;COVID19;Cytokine storm syndrome;Hemophagocytic lymphohistiocytosis;Macrophage activation syndrome	*Antirheumatic Agents/classification/immunology/pharmacology;Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/complications/drug therapy/immunology;*Cytokine Release Syndrome/etiology/immunology/therapy;Humans;*Lymphohistiocytosis, Hemophagocytic/etiology/immunology/therapy;*Macrophage Activation Syndrome/etiology/immunology/therapy;*Pandemics;Patient Selection;*Pneumonia, Viral/complications/drug therapy/immunology;SARSCoV2;TimetoTreatment;DA 2020/06/25 06:00		Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents 	
398	32458206	Journal Article;Review	O  NNLM;Bromhexine;COVID19;Prophylactic;Protease inhibitor;SARSCoV2;Treatment	Betacoronavirus;Bromhexine/*therapeutic use;COVID19;Coronavirus Infections/*drug therapy;Expectorants/*therapeutic use;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Serine Endopeptidases/*drug effects;Virus Internalization/drug effects;DA 2020/08/29 06:00		Potential new treatment strategies for COVID-19: is there a role for bromhexine as 	
399	32521760	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;nutraceuticals;probiotics;supplementation	Ascorbic Acid/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*diet therapy/*prevention & control;*Diet;*Dietary Supplements;Humans;Pandemics/*prevention & control;Pneumonia, Viral/*diet therapy/*prevention & control;Probiotics/*therapeutic use;SARSCoV2;Vitamin D/therapeutic use;DA 2020/06/17 06:00		Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A 	
400	32871342	Journal Article;Review	O  NNLM;Azithromycin;Broadspectrum therapeutic;COVID19	Animals;AntiInflammatory Agents/adverse effects/*therapeutic use;Antiviral Agents/adverse effects/*therapeutic use;Azithromycin/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Cell Line, Tumor;Coronavirus Infections/*drug therapy;Humans;Immunologic Factors/adverse effects/therapeutic use;Macrophages/metabolism;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/11/18 06:00		Azithromycin: The First Broad-spectrum Therapeutic.	
401	32383125	Clinical Trial Protocol;Journal Article;Multicenter Study;Randomized Controlled Trial	O  NNLM;*COVID19;*Hydroxychloroquine;*SARSCoV2;*clinical trials;*coronavirus;*healthcare worker;*postexposure prophylaxis;*preemptive therapy	Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*prevention & control/transmission;DoubleBlind Method;Humans;Hydroxychloroquine/*administration & dosage;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control/transmission;PostExposure Prophylaxis/*methods;SARSCoV2;Severity of Illness Index;DA 2020/08/25 06:00	ClinicalTrials.gov/NCT04308668	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory 	K23 AI138851/AI/NIAID NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States
402	33125946	Journal Article;Review	O  NNLM;*Anticancer drugs;*COVID19;*Repurposing;*SARSCoV2	Antineoplastic Agents/*administration & dosage;Antiviral Agents/administration & dosage;COVID19/*drug therapy/virology;*Drug Repositioning;Humans;Pandemics;SARSCoV2/*drug effects;DA 2021/01/05 06:00		Repurposing anticancer drugs for the management of COVID-19.	
403	32662571	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*antivirals;*biomaterials;*diagnostics;*filtration	*Betacoronavirus/genetics/pathogenicity/physiology;*Biocompatible Materials;Biosensing Techniques;COVID19;COVID19 Testing;COVID19 Vaccines;Clinical Laboratory Techniques;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention & ;Disinfection/methods;Drug Delivery Systems;Extracorporeal Circulation;Filtration;Humans;Immunologic Tests/instrumentation/methods;Metals;Nanostructures;Nucleic Acid Amplification Techniques/instrumentation/methods;*Pandemics/prevention & control;*Pneumonia, Viral/diagnosis/prevention & control/therapy/transmission;Protective Devices;RNA, Viral/analysis;SARSCoV2;Severe Acute Respiratory Syndrome/epidemiology/transmission;SurfaceActive Agents;Tissue Engineering;Viral Vaccines;DA 2020/08/29 06:00		Opportunities for biomaterials to address the challenges of COVID-19.	T32 EB005583/EB/NIBIB NIH HHS/United States;T32EB005583/EB/NIBIB NIH HHS/United States
404	32890967	Journal Article;Review	O  NNLM;Antiinflammatory;Antiviral;COVID19;PAK1 blocker;Propolis;SARSCoV2	Animals;Antiviral Agents/administration & dosage/*pharmacology;Betacoronavirus/drug effects/isolation & purification;COVID19;Coronavirus Infections/complications/*drug therapy/virology;Dietary Supplements;Functional Food;Humans;Macrophages/drug effects/immunology;Monocytes/drug effects/immunology;Pandemics;Pneumonia, Viral/complications/*drug therapy/virology;Propolis/administration & dosage/*pharmacology;SARSCoV2;DA 2020/11/11 06:00		Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 	
405	33549263	Journal Article;Review		*Biological Variation, Population;*COVID19/diagnosis/therapy;COVID19 Testing;Genetic Predisposition to Disease;Humans;*Precision Medicine;Severity of Illness Index;Treatment Outcome;DA 2021/02/26 06:00		COVID-19: Understanding Inter-Individual Variability and Implications for Precision 	K23 HL143161/HL/NHLBI NIH HHS/United States
406	33040020	Journal Article;Multicenter Study;Observational Study	O  NNLM;*COVID19;*respiratory infections;*respiratory medicine (see thoracic medicine);*respiratory physiology;*virology	Aged;Betacoronavirus;Blood Gas Analysis;COVID19;Coronavirus Infections/metabolism/mortality/*pathology/virology;Female;*Hospital Mortality;*Hospitalization;Hospitals;Humans;Hypoxia;Intensive Care Units;Italy/epidemiology;Lung/metabolism/pathology/virology;Male;Middle Aged;Oxygen/*blood;Pandemics;Partial Pressure;Pneumonia, Viral/metabolism/mortality/*pathology/virology;Prospective Studies;Respiratory Distress Syndrome/*etiology/mortality/therapy/virology;Respiratory Insufficiency/etiology/mortality/therapy/virology;Risk Factors;SARSCoV2;Severe Acute Respiratory Syndrome/*etiology/mortality/therapy/virology;*Severity of Illness Index;DA 2020/10/30 06:00	ClinicalTrials.gov/NCT04307459	Severity of respiratory failure at admission and in-hospital mortality in patients 	
407	33156843	Journal Article;Observational Study;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Angiotensin Receptor Antagonists/administration & dosage;AngiotensinConverting Enzyme Inhibitors/administration & dosage;COVID19/*drug therapy;Datasets as Topic;*Drug Repositioning;HostPathogen Interactions/genetics;Humans;Melatonin/*administration & dosage;Pandemics;Transcriptome;DA 2020/12/19 06:00		A network medicine approach to investigation and population-based validation of 	R00 HL138272/HL/NHLBI NIH HHS/United States;R01 AG066707/AG/NIA NIH HHS/United States;3R01AG06670701S1/NH/NIH HHS/United States;K08 HL133381/HL/NHLBI NIH HHS/United States;R35 CA200422/CA/NCI NIH HHS/United States
408	32943404	Journal Article;Randomized Controlled Trial		Adult;Aged;AntiInflammatory Agents/*administration & dosage;COVID19/*drug therapy;Female;Hospitalization;Humans;Injections, Intravenous;Male;Methylprednisolone/*administration & dosage;Middle Aged;Pulse Therapy, Drug;Severity of Illness Index;SingleBlind Method;DA 2021/02/09 06:00		Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 	
409	32307653	Journal Article;Review	O  NNLM;*Antiviral responses;*Asthma;*Basigin;*Cellular therapy;*Coronavirus;*Diabetes mellitus;*EMMPRIN;*Invasion;*Lung stem cells;*SARSCoV2	AngiotensinConverting Enzyme 2;AntiBacterial Agents/*therapeutic use;Azithromycin/*therapeutic use;BLymphocytes/drug effects/immunology/virology;Basigin/antagonists & inhibitors/*genetics/immunology;Betacoronavirus/*drug effects/metabolism/pathogenicity;COVID19;Clinical Trials as Topic;Coronavirus Infections/epidemiology/immunology/*therapy/virology;Gene Expression;HostPathogen Interactions/drug effects/immunology;Humans;Lung/immunology/virology;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/epidemiology/immunology/*therapy/virology;Protein Binding/drug effects;SARSCoV2;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/*genetics/immunology;*Stem Cell Transplantation;Stem Cells/drug effects/immunology/virology;TLymphocytes/drug effects/immunology/virology;Viral Load/drug effects;DA 2020/06/03 06:00		CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem 	No. 2018/084260/Fundação de Amparo à Pesquisa do Estado de São Paulo/International
410	33347311	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*SARSCoV2;*drug;*replication process;*target	AngiotensinConverting Enzyme 2/metabolism;Animals;Antiviral Agents/chemistry/*pharmacology;Basigin/metabolism;Coronavirus 3C Proteases/antagonists & inhibitors/metabolism;Coronavirus Nucleocapsid Proteins/chemistry/metabolism;Coronavirus RNADependent RNA Polymerase/metabolism;Dipeptidyl Peptidase 4/metabolism;Furin/antagonists & inhibitors/metabolism;HostPathogen Interactions/drug effects;Humans;SARSCoV2/*drug effects/pathogenicity/physiology;Serine Endopeptidases/metabolism;Small Molecule Libraries/pharmacology;Spike Glycoprotein, Coronavirus/chemistry/metabolism;Virus Replication/*drug effects;DA 2021/01/20 06:00		Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral 	
411	33519463	Journal Article	O  NNLM;biomarker;coronavirus disease 2019;drug target identification;immunology;mitochondrial DNA;pathophysiology;severe acute respiratory syndrome coronavirus 2;tolllike receptor 9	DA 2021/02/02 06:01		TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.	
412	32563584	Case Reports;Journal Article		Antibodies, Monoclonal/therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/*immunology;Humans;*Immunocompromised Host;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/*immunology;Receptors, Interleukin6/antagonists & inhibitors;SARSCoV2;DA 2020/11/06 06:00		Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart 	
413	32283243	Letter		Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/complications/*drug therapy;Humans;Pandemics;Pemphigus/*complications;Pneumonia, Viral/complications/*drug therapy;Rituximab/adverse effects/*therapeutic use;SARSCoV2;DA 2020/05/27 06:00		Treatment considerations for patients with pemphigus during the COVID-19 pandemic.	
414	33245898	Journal Article;Review	O  NNLM;COVID19;Platforms;SARSCoV2;Targets;Vaccine designing	Animals;Biological Products/therapeutic use;COVID19/immunology/prevention & control;*COVID19 Vaccines;Coronavirus/chemistry/genetics;Drug Design;Drug Development;Humans;Immunologic Factors/therapeutic use;Viral Structures;DA 2021/01/23 06:00		COVID-19 vaccine: A recent update in pipeline vaccines, their design and development 	
415	32511724	Case Reports;Journal Article	O  NNLM;*COVID19;*Coronavirus;*Prevention;*Prognosis;*Risk factors;*Treatment	*Betacoronavirus/pathogenicity/physiology;COVID19;Coronavirus Infections/diagnosis/*epidemiology/*therapy/transmission;Endocarditis/surgery;Humans;Male;Middle Aged;*Pandemics;Pneumonia, Viral/diagnosis/*epidemiology/*therapy/transmission;ProsthesisRelated Infections/surgery;SARSCoV2;DA 2020/06/24 06:00		COVID-19: from epidemiology to treatment.	R01 AI132178/AI/NIAID NIH HHS/United States
416	33061471	Journal Article;Review	O  NNLM;COVID19;NK cells;multiple sclerosis	DA 2020/10/17 06:01		Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against 	
417	32605278	Journal Article;Review	O  NNLM;COVID19;SGLT2;canagliflozin;cardiovascular;chronic kidney disease;dapagliflozin;diabetes;empagliflozin	DA 2020/07/02 06:01		Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in 	
418	33123014	Journal Article;Review	O  NNLM;antimicrobial therapy;coronavirus disease 2019;drug;severe acute respiratory syndrome coronavirus 2;supportive therapy;vaccine	DA 2020/10/31 06:01		Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial 	
419	32256547	Journal Article	O  NNLM;Drug repositioning;clinical trials as topic;coronavirus infection;pandemics;pneumonia, viral;virus diseases	DA 2020/04/08 06:01		Clinical trials on drug repositioning for COVID-19 treatment.	
420	32665039	Clinical Trial Protocol;Letter;Multicenter Study	O  NNLM;COVID19;Randomised placebo controlled trial;hydroxychloroquine;protocol;psychological distress;serology;viral PCR	Adolescent;Adult;*Betacoronavirus;COVID19;Coronavirus Infections/*prevention & control;*Health Personnel;Humans;Hydroxychloroquine/*therapeutic use;Outcome Assessment, Health Care;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control;*PreExposure Prophylaxis;*Randomized Controlled Trials as Topic;SARSCoV2;Young Adult;DA 2020/08/19 06:00		Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine 	NRC IRAP #947684/National Research Council of Canada/
421	32708112	Journal Article;Review	O  NNLM;SARSCoV2 infection;immune system;outbreak;prevention;treatment	A549 Cells;AngiotensinConverting Enzyme 2;Animals;AntiInflammatory Agents/therapeutic use;Antibodies, Neutralizing/immunology/*therapeutic use;Antibodies, Viral/immunology/*therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/immunology;CD4Positive TLymphocytes/immunology;CD8Positive TLymphocytes/immunology;COVID19;Cell Line;Chlorocebus aethiops;*Coronavirus Infections/diagnosis/drug therapy/prevention & control;Humans;Immunization, Passive/*methods;Lymphocyte Count;*Pandemics/prevention & control;PeptidylDipeptidase A/metabolism;*Pneumonia, Viral/diagnosis/drug therapy/prevention & control;SARSCoV2;Spike Glycoprotein, Coronavirus/metabolism;Vero Cells;DA 2020/08/04 06:00		COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.	
422	32562029	Journal Article;Review	O  NNLM;*Anakinra;*AntiIL1 drugs;*Inflammatory refractory pericarditis;*Recurrent pericarditis	Adult;Biomarkers;Child;Humans;Interleukin 1 Receptor Antagonist Protein;Interleukin1;*Pericarditis;Recurrence;DA 2021/01/28 06:00		Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.	
423	32492298	Comment;Editorial		*Betacoronavirus;COVID19;*Coronavirus Infections/prevention & control;Humans;Hydroxychloroquine;*Pandemics;*Pneumonia, Viral/prevention & control;SARSCoV2;DA 2020/08/08 06:00		Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.	
424	32493478	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Randomised controlled trial;health care worker;household contact;hydroxychloroquine;postexposure prophylaxis;protocol	Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents/*administration & dosage/adverse effects;Ascorbic Acid/administration & dosage;Betacoronavirus/*drug effects/pathogenicity;COVID19;Contact Tracing;Coronavirus Infections/diagnosis/epidemiology/transmission/virology;Drug Administration Schedule;Female;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;Incidence;Male;Middle Aged;Multicenter Studies as Topic;Occupational Exposure/*adverse effects;Occupational Health;Pandemics;Pneumonia, Viral/diagnosis/epidemiology/transmission/virology;*PostExposure Prophylaxis;Randomized Controlled Trials as Topic;Risk Assessment;Risk Factors;SARSCoV2;Time Factors;Treatment Outcome;United States/epidemiology;Virus Shedding/drug effects;Young Adult;DA 2020/06/11 06:00	ClinicalTrials.gov/NCT04328961	Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute 	INV016204/Bill and Melinda Gates Foundation/
425	32522282	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Randomised controlled trial;azithromycin;hydroxychloroquine;protocol;respiratory infections	Antiviral Agents/*administration & dosage/adverse effects;Azithromycin/*administration & dosage/adverse effects;Betacoronavirus/*drug effects/pathogenicity;COVID19;Coronavirus Infections/diagnosis/*drug therapy/mortality/virology;Critical Care;Denmark;DoubleBlind Method;Drug Administration Schedule;Hospital Mortality;HostPathogen Interactions;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;*Inpatients;Length of Stay;Multicenter Studies as Topic;Noninvasive Ventilation;Pandemics;*Patient Admission;Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology;Randomized Controlled Trials as Topic;SARSCoV2;Severity of Illness Index;Time Factors;Treatment Outcome;DA 2020/06/18 06:00	ClinicalTrials.gov/NCT04322396	Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised 	NNF20SA0062834/Novo Nordisk Fonden/
426	33251522	Journal Article	O  NNLM;coronavirus;corticosteroids;critical care;mortality;outcome;ventilation	DA 2020/12/01 06:01		Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated 	
427	33550043	Journal Article;Review	O  NNLM;COVID19;Favipiravir;Remdesivir;SARSCoV2;Vaccines	*Antiviral Agents/classification/pharmacology;*COVID19/drug therapy/prevention & control;*COVID19 Vaccines/classification/pharmacology;Humans;SARSCoV2/drug effects/physiology;Treatment Outcome;DA 2021/04/07 06:00		Effective drugs used to combat SARS-CoV-2 infection and the current status of 	
428	32374874	Editorial		Adalimumab/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antirheumatic Agents/*therapeutic use;Azetidines/therapeutic use;Betacoronavirus;COVID19;Chloroquine/therapeutic use;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/virology;Drug Repositioning;Humans;Hydroxychloroquine/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Sulfonamides/therapeutic use;DA 2020/05/30 06:00		COVID-19: an unexpected indication for anti-rheumatic therapies?	
429	33031652	Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial		Aged;Aged, 80 and over;Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/mortality;Female;Hospitalization;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/mortality;Respiration, Artificial;SARSCoV2;Treatment Failure;DA 2020/12/02 06:00	ISRCTN/ISRCTN50189673;ClinicalTrials.gov/NCT04381936	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.	MC_UU_00002/14/MRC_/Medical Research Council/United Kingdom;RP201405019/DH_/Department of Health/United Kingdom;MC_U137686861/MRC_/Medical Research Council/United Kingdom;MC_PC_18033/MRC_/Medical Research Council/United Kingdom;MC_PC_19056/National Institute for Health Research/;MC_UU_00017/3/MRC_/Medical Research Council/United Kingdom;MC_U137686860/MRC_/Medical Research Council/United Kingdom;WT_/Wellcome Trust/United Kingdom;MC_UU_12026/4/MRC_/Medical Research Council/United Kingdom;RP201607012/DH_/Department of Health/United Kingdom;MC_PC_19056/UK Research and Innovation/;SRF201508001/DH_/Department of Health/United Kingdom;MC_PC_19056/MRC_/Medical Research Council/United Kingdom
430	32973535	Systematic Review	O  NNLM;2019 Novel Coronavirus;coronavirus disease 2019;crosssectional analysis;randomized controlled trial protocol;therapies	DA 2020/09/26 06:01		Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for 	
431	32707147	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Drug delivery devices;*Micro and nanocarriers;*Micro and nanoscale technologies;*Oral drug delivery;*Tissue models	DA 2020/07/25 06:00		Micro and nanoscale technologies in oral drug delivery.	MR/R015651/1/MRC_/Medical Research Council/United Kingdom;RE/18/4/34215/BHF_/British Heart Foundation/United Kingdom
432	33187978	Journal Article;Multicenter Study;Observational Study;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.		Adult;Aged;Aged, 80 and over;Antiviral Agents/*pharmacology;Azetidines/*pharmacology;COVID19/drug therapy/metabolism/*mortality/virology;Cytokine Release Syndrome;Cytokines/metabolism;Drug Evaluation, Preclinical;Enzyme Inhibitors/*pharmacology;Female;Gene Expression Profiling;Humans;Interferon alpha2/metabolism;Italy;Janus Kinases/*antagonists & inhibitors/metabolism;Liver/drug effects/*virology;Male;Middle Aged;Patient Safety;Platelet Activation;Proportional Hazards Models;Purines/*pharmacology;Pyrazoles/*pharmacology;RNASeq;SARSCoV2/*pathogenicity;Spain;Sulfonamides/*pharmacology;Virus Internalization/drug effects;DA 2021/02/17 06:00		JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory 	NIHRRP011053/DH_/Department of Health/United Kingdom;R01 GM133198/GM/NIGMS NIH HHS/United States
433	32854751	Clinical Trial Protocol;Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;HCQ;Hydroxychloroquine;Postexposure;Prophylaxis;Randomized controlled trial;SARSCoV2;Sri Lanka	Betacoronavirus;COVID19;Coronavirus Infections/*prevention & control;DoubleBlind Method;Enzyme Inhibitors/*therapeutic use;Humans;Hydroxychloroquine/*therapeutic use;*Military Personnel;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control;PostExposure Prophylaxis/*methods;SARSCoV2;Sri Lanka;DA 2020/09/04 06:00		Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel 	
434	33485122	Journal Article;Review	O  NNLM;*Anticoagulantrefractory;*Clinical practice points;*Direct oral anticoagulants;*Recurrent thrombosis;*Thrombotic antiphospholipid syndrome;*Vitamin K antagonists	DA 2021/01/24 06:00		Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management.	
435	33158051	Journal Article;Review	O  NNLM;SARSCoV2;coinfection;comorbidity;drugs;host response;integrative genomics;therapeutics;vaccines	DA 2020/11/08 06:01		Threading the Pieces Together: Integrative Perspective on SARS-CoV-2.	MLP2005,2020/Council of Scientific and Industrial Research/
436	32450344	Clinical Trial, Phase II;Controlled Clinical Trial;Journal Article	O  NNLM;*Antiplatelet;*Coagulation;*Coronavirus;*Covid19;*Ddimer;*Respiratory failure	Aged;Aspirin/therapeutic use;*Betacoronavirus;COVID19;Clopidogrel/therapeutic use;Compassionate Use Trials;Coronavirus Infections/complications/*drug therapy;Female;Fibrin Fibrinogen Degradation Products/metabolism;Humans;Hypoxia/complications/*drug therapy;Male;Middle Aged;Pandemics;Platelet Aggregation Inhibitors/*therapeutic use;Pneumonia, Viral/complications/*drug therapy;Proof of Concept Study;SARSCoV2;Thrombophilia/blood/complications/*drug therapy;Tirofiban/therapeutic use;DA 2020/07/21 06:00		Enhanced platelet inhibition treatment improves hypoxemia in patients with severe 	
437	32678530	Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial		Administration, Oral;Aged;Aged, 80 and over;AntiInfective Agents/therapeutic use;COVID19/*drug therapy/mortality/therapy;Dexamethasone/administration & dosage/adverse effects/*therapeutic use;Drug Therapy, Combination;Female;Glucocorticoids/administration & dosage/adverse effects/*therapeutic use;Hospitalization;Humans;Injections, Intravenous;KaplanMeier Estimate;Length of Stay;Male;Odds Ratio;*Oxygen Inhalation Therapy;*Respiration, Artificial;United Kingdom;DA 2021/03/02 06:00	ClinicalTrials.gov/NCT04381936	Dexamethasone in Hospitalized Patients with Covid-19.	MC_PC_19056/UK Research and Innovation/;MC_UU_00002/14/MRC_/Medical Research Council/United Kingdom;RP201405019/DH_/Department of Health/United Kingdom;MC_U137686861/MRC_/Medical Research Council/United Kingdom;MC_PC_18033/MRC_/Medical Research Council/United Kingdom;MC_PC_19056/National Institute for Health Research/;MC_UU_00017/3/MRC_/Medical Research Council/United Kingdom;MC_U137686860/MRC_/Medical Research Council/United Kingdom;WT_/Wellcome Trust/United Kingdom;MC_UU_12026/4/MRC_/Medical Research Council/United Kingdom
438	33279656	Journal Article;Systematic Review	O  NNLM;*Coronavirus;*Novel coronavirus 2019;*Randomized controlled trials;*Systematic literature review	*COVID19/epidemiology/prevention & control/therapy;Data Management/organization & administration/standards;Humans;Quality Improvement;*Randomized Controlled Trials as Topic/methods/standards/statistics & numerical data;Research Design/standards/statistics & numerical data;SARSCoV2;DA 2021/03/23 06:00		Reporting and design of randomized controlled trials for COVID-19: A systematic 	
439	32354651	Practice Guideline	O  NNLM;COVID19;Guidelines;Management;Neuromuscular;Treatment	Angiotensin Receptor Antagonists/therapeutic use;AngiotensinConverting Enzyme Inhibitors/therapeutic use;AntiBacterial Agents/therapeutic use;Antimalarials/therapeutic use;Azithromycin/therapeutic use;*Betacoronavirus;COVID19;Cardiorespiratory Fitness;Coronavirus Infections/drug therapy/*epidemiology;Emergency Treatment;France/epidemiology;Glycogen Storage Disease Type II/therapy;Hospitalization;Humans;Hydroxychloroquine/therapeutic use;Immune System Diseases/therapy;Immunoglobulins, Intravenous/therapeutic use;Immunosuppressive Agents/therapeutic use;Muscular Atrophy, Spinal/drug therapy;Neuromuscular Diseases/*therapy;Oligonucleotides/therapeutic use;*Pandemics;Physical Therapy Modalities;Pneumonia, Viral/drug therapy/*epidemiology;Prognosis;RNA, Small Interfering/therapeutic use;SARSCoV2;Steroids/therapeutic use;Withholding Treatment;alphaGlucosidases/therapeutic use;DA 2020/06/12 06:00		Guidance for the care of neuromuscular patients during the COVID-19 pandemic 	
440	32816200	Journal Article;Review	O  NNLM;COVID19;Pharmacology;Pneumonia;SARSCoV2	Animals;COVID19/*drug therapy/virology;Clinical Trials as Topic;Humans;SARSCoV2/*isolation & purification;DA 2020/12/15 06:00		Pharmacological treatments of COVID-19.	
441	32895645	Journal Article	O  NNLM;(ALC), Absolute Lymphocyte Count;(ARDS), Acute respiratory distress syndrome;(BMI), Body mass index;(CRP), Creactive protein;(CRS), Cytokine release syndrome;(DNR/DNI), Do not resuscitate/do not intubate;(ECMO), Extracorporeal membrane oxygenation;(ESR), Erythrocyte sedimentation rate;(IRB), Institutional review board;(LDH), Lactate dehydrogenase;(NIV), Noninvasive ventilation;(PaO2/FiO2), Arterial oxygen partial pressure/fraction of inspired oxygen;(RTPCR), Reversetranscriptase polymerasechainreaction;(RWMC), Roger Williams Medical Center;(SITC), Society for Immunotherapy of Cancer;(SpO2), Peripheral capillary oxygen saturation;(antiIL6/IL6R), AntiIL6/IL6Receptor;Creactive protein;IL6;Infectious disease;SARSCoV2	DA 2020/09/09 06:01		Tocilizumab for severe COVID-19 related illness - A community academic medical 	
442	32982062	Journal Article;Review	O  NNLM;Antiviral compoundsnatural products;MERS;SARS;Viral fight;Web based resource	DA 2020/09/29 06:01		anti-HCoV: A web resource to collect natural compounds against human coronaviruses.	
443	32388976	Journal Article		Animals;Betacoronavirus/chemistry/*physiology;COVID19;Coronavirus Infections/*epidemiology/physiopathology/*prevention & control/virology;Cysteine Proteinase Inhibitors/chemistry/therapeutic use;Drug Repositioning;Humans;Mice;Neglected Diseases/*prevention & control;Pandemics/*prevention & control;Pneumonia, Viral/*epidemiology/physiopathology/*prevention & control/virology;RNA, Viral/immunology;SARSCoV2;Spike Glycoprotein, Coronavirus/immunology;Vaccination;Viral Vaccines/immunology/therapeutic use;Virus Replication/drug effects;DA 2020/08/04 06:00		COVID-19: Living through Another Pandemic.	
444	33264337	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;COVID19/*drug therapy;Female;Humans;Hydroxychloroquine/*adverse effects/*therapeutic use;Male;Middle Aged;Retrospective Studies;*Safety;Standard of Care;Treatment Outcome;Young Adult;DA 2020/12/15 06:00		A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and 	
445	32995780	Preprint		DA 2020/10/01 06:01		Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment 	R01 AI116379/AI/NIAID NIH HHS/United States;U24 AI120134/AI/NIAID NIH HHS/United States;R01 AI143411/AI/NIAID NIH HHS/United States;S10 OD025002/OD/NIH HHS/United States;S10 OD026799/OD/NIH HHS/United States;R01 AI149672/AI/NIAID NIH HHS/United States;R01 MH116695/MH/NIMH NIH HHS/United States;P51 OD011092/OD/NIH HHS/United States;P30 AI050409/AI/NIAID NIH HHS/United States;R37 AI141258/AI/NIAID NIH HHS/United States;P51 OD011132/OD/NIH HHS/United States
446	32921314	Congress		DA 2020/09/15 06:01		40th International Symposium on Intensive Care & Emergency Medicine 2020 - Part 2 : 	
447	32426001	English Abstract;Journal Article	O  NNLM;ARDS;COVID19;Colchicine;Inflammasome;SARSCoV2	DA 2020/05/20 06:00		[Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 	
448	32790733	Journal Article;Multicenter Study;Observational Study		Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use;Antimalarials/*therapeutic use;Azithromycin/therapeutic use;*Betacoronavirus;COVID19;Child;Child, Preschool;Coronavirus Infections/*drug therapy/mortality/virology;Drug Therapy, Combination;Female;FollowUp Studies;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Infant;Infant, Newborn;Intensive Care Units;Interleukin6/antagonists & inhibitors;KaplanMeier Estimate;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/mortality/virology;Retrospective Studies;SARSCoV2;Treatment Outcome;Young Adult;DA 2020/08/29 06:00	ClinicalTrials.gov/NCT04347993	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational 	P30 CA016672/CA/NCI NIH HHS/United States;UL1 TR003167/TR/NCATS NIH HHS/United States
449	33227285	Journal Article;Review	O  NNLM;Antiviral;COVID19;Clinical trials;Immunomodulation;Nitazoxanide;SARSCoV2	Antiprotozoal Agents/pharmacology;*COVID19/drug therapy/immunology;Clinical Trials as Topic;*Drug Repositioning;Humans;Immunity, Innate/drug effects;*SARSCoV2/drug effects/physiology;Thiazoles/*pharmacology;DA 2021/01/06 06:00		A review on possible mechanistic insights of Nitazoxanide for repurposing in 	
450	33075088	Journal Article;Observational Study		Aged;Aged, 80 and over;Betacoronavirus/*genetics;COVID19;Coronavirus Infections/*epidemiology/mortality/virology;Female;Forecasting/*methods;Hospital Mortality/*trends;*Hospitalization;Humans;*Intensive Care Units;Male;Middle Aged;Pandemics;Paris/epidemiology;Patient Discharge;Patient Transfer/*trends;Pneumonia, Viral/*epidemiology/mortality/virology;Prognosis;Prospective Studies;RealTime Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;SARSCoV2;DA 2020/11/03 06:00		Development of a multivariate prediction model of intensive care unit transfer or 	
451	32470515	Journal Article;Multicenter Study	O  NNLM;*COVID19;*SARSCoV2;*reninangiotensin;*transcatheter aortic valve replacement	Aged;Aged, 80 and over;AngiotensinConverting Enzyme Inhibitors/*adverse effects;Betacoronavirus;COVID19;Coronavirus Infections/chemically induced/*mortality;Female;Humans;Male;Pandemics;Pneumonia, Viral/chemically induced/*mortality;Ramipril/*adverse effects;Randomized Controlled Trials as Topic;Risk Factors;SARSCoV2;Spain/epidemiology;DA 2020/07/25 06:00	ClinicalTrials.gov/NCT03201185	Ramipril in High-Risk Patients With COVID-19.	
452	32623038	Journal Article	O  NNLM;Angiotensinconverting enzyme 2;Coronavirus disease2019 (COVID19);Diabetes mellitus;Severe acute respiratory syndrome coronavirus2	Betacoronavirus/*isolation & purification;COVID19;Comorbidity;Coronavirus Infections/complications/*epidemiology/virology;Diabetes Mellitus/epidemiology/*physiopathology/virology;Global Health;Humans;Pandemics;Pneumonia, Viral/complications/*epidemiology/virology;Republic of Korea/epidemiology;SARSCoV2;DA 2020/09/22 06:00		Diabetes and COVID-19: Global and regional perspectives.	
453	33492523	Clinical Trial, Phase II;Clinical Trial, Phase III;Journal Article;Multicenter Study;Randomized Controlled Trial		Adult;Amides/*therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Chloroquine/therapeutic use;Female;Humans;Length of Stay;Male;Pyrazines/*therapeutic use;Respiration, Artificial/statistics & numerical data;SARSCoV2/*drug effects;Treatment Outcome;DA 2021/02/23 06:00	ClinicalTrials.gov/NCT04351295	Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.	
454	32838211	Journal Article		DA 2020/08/25 06:00		Perspective: Cell therapy, SARS-CoV-2, COVID-19, and James Lind.	
455	32473657	Journal Article;Observational Study		Adult;Age Distribution;Aged;Aged, 80 and over;AntiHIV Agents/therapeutic use;Body Mass Index;CD4 Lymphocyte Count;COVID19;Comorbidity;Coronavirus Infections/*complications/drug therapy/*epidemiology;Female;HIV Infections/*complications/drug therapy;Humans;Incidence;Logistic Models;Male;Middle Aged;Multivariate Analysis;Pandemics;Pneumonia, Viral/*complications/drug therapy/*epidemiology;Prospective Studies;Spain/epidemiology;Tenofovir/therapeutic use;Young Adult;DA 2020/08/22 06:00		Description of COVID-19 in HIV-infected individuals: a single-centre, prospective 	
456	32685022	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*antiviral therapy;*diagnostics	Antiviral Agents/isolation & purification/therapeutic use;*Betacoronavirus/genetics/immunology/isolation & purification;COVID19;COVID19 Testing;COVID19 Vaccines;*Clinical Laboratory Techniques/trends;*Coronavirus Infections/diagnosis/drug therapy/prevention & control/therapy;Drug Development/trends;Humans;Immunization, Passive/trends;*Pandemics/prevention & control;*Pneumonia, Viral/diagnosis/prevention & control/therapy;SARSCoV2;Theranostic Nanomedicine/trends;*Viral Vaccines/isolation & purification/pharmacology;DA 2020/08/07 06:00		COVID-19: Progress in diagnostics, therapy and vaccination.	
457	33049215	Journal Article;Review	O  NNLM;*COVID19;*cancer;*cancer research;*pandemic	Betacoronavirus/*isolation & purification;COVID19;Coronavirus Infections/*complications/transmission/virology;Delivery of Health Care/*standards;Humans;Neoplasms/epidemiology/*therapy/virology;Pandemics;Pneumonia, Viral/*complications/transmission/virology;SARSCoV2;DA 2020/12/01 06:00		COVID-19 and Cancer: Current Challenges and Perspectives.	P30 CA068485/CA/NCI NIH HHS/United States
458	33072093	Journal Article;Review	O  NNLM;*COVID19;*NSMIs;*SARSCoV;*SARSCoV2;*natural Nrf2 modulators	AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*immunology;COVID19;*Coronavirus Infections/drug therapy/immunology/mortality;*Drug Delivery Systems;Humans;*Pandemics;PeptidylDipeptidase A/immunology;*Pneumonia, Viral/drug therapy/immunology/mortality;SARSCoV2;Serine Endopeptidases/immunology;Serine Proteinase Inhibitors/therapeutic use;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/immunology;Th2 Cells/immunology;Viral Vaccines/immunology/therapeutic use;Virus Internalization/*drug effects;DA 2020/10/27 06:00		Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.	
459	32557332	Journal Article;Review	O  NNLM;COVID19 Elderly patients;Coronavirus;Nursing homes;Palliation;SarsCov2	Aged;Aged, 80 and over;Aging;*Betacoronavirus;COVID19;*Clinical DecisionMaking;*Coronavirus Infections;Cytokines/immunology;Humans;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/09/04 06:00		COVID-19 and the elderly: insights into pathogenesis and clinical decision-making.	
460	33121920	Journal Article;Review		Animals;COVID19/*drug therapy/epidemiology/etiology/therapy;Humans;Pandemics;SARSCoV2/drug effects;DA 2020/12/15 06:00		Race to arsenal COVID-19 therapeutics: Current alarming status and future 	
461	33243284	Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;Herb;M. communis;Myrtle;Persian medicine	Adult;Aged;COVID19/complications/epidemiology/*therapy/virology;CaseControl Studies;Female;Humans;Iran/epidemiology;Male;Middle Aged;Mortality;Myrtus/*adverse effects/chemistry;Pandemics;Phytotherapy/*methods;Prognosis;Respiratory Distress Syndrome/etiology/therapy/virology;SARSCoV2/*genetics;Safety;Treatment Outcome;DA 2020/12/15 06:00		Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and 	
462	32535870	Journal Article		Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/*complications/virology;Humans;Infection Control;Neoplasms/complications/epidemiology/*surgery;Pandemics;Patient Education as Topic;Pneumonia, Viral/*complications/virology;Population Health;Practice Guidelines as Topic/*standards;SARSCoV2;Surgical Oncology/*standards;DA 2020/07/23 06:00		Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively 	P30 CA023108/CA/NCI NIH HHS/United States
463	33192506	Journal Article	O  NNLM;COVID19;SARSCoV2;antivirals drugs;clinical trial;hydroxychloroquine	DA 2020/11/17 06:01		Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New 	
464	33471683	Journal Article;Review		Aged;Angiotensin Receptor Antagonists;AngiotensinConverting Enzyme Inhibitors;*COVID19;COVID19 Vaccines;Female;Humans;Male;Pandemics;*Pituitary Diseases/epidemiology;SARSCoV2;DA 2021/01/23 06:00		Important Management Considerations In Patients With Pituitary Disorders During The 	
465	32929403	Journal Article	O  NNLM;COVID19;SARSCoV2;breastfeeding;coronavirus;pregnancy	DA 2020/09/16 06:01		A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19-A Call 	K08 AI134262/AI/NIAID NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States
466	32934758	Journal Article;Research Support, NonU.S. Gov't;Review		BCG Vaccine/therapeutic use;Betacoronavirus;COVID19;COVID19 Testing;Clinical Laboratory Techniques;Coinfection/*epidemiology/immunology/physiopathology;Coronavirus Infections/diagnosis/*epidemiology/immunology/physiopathology;Cytokines/immunology;Diagnostic Errors;Disease Outbreaks;Humans;Influenza, Human/epidemiology/physiopathology;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral/diagnosis/*epidemiology/immunology/physiopathology;SARS Virus;SARSCoV2;Severe Acute Respiratory Syndrome/epidemiology/physiopathology;Severity of Illness Index;Tuberculosis/*epidemiology/immunology/physiopathology/prevention & control;DA 2020/09/25 06:00	ClinicalTrials.gov/NCT04327206;ClinicalTrials.gov/NCT04121494;ClinicalTrials.gov/NCT01829490	Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future 	
467	32771797	Journal Article;Review	O  NNLM;Chemical drugs;Coronavirus;Target protein;Traditional Chinese medicine (TCM);Vaccines	Antiviral Agents/*therapeutic use;COVID19;Coronavirus Infections/*drug therapy/therapy;Humans;Immunization, Passive;Immunotherapy/methods;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/*drug therapy;DA 2020/10/09 06:00		Potential treatment methods targeting 2019-nCoV infection.	
468	33014780	Journal Article	O  NNLM;CML;COVID19;NanoString;TKIs;TTV;imatinib;immunity;nilotinib	DA 2020/10/06 06:01		Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic 	
469	33157292	Case Reports	O  NNLM;COVID19;Disseminated intravascular coagulation;Nafamostat;Serine proteinase inhibitor	Aged;Anticoagulants/*administration & dosage;Blood Coagulation/drug effects;COVID19/blood/*complications/virology;Disseminated Intravascular Coagulation/blood/*drug therapy/etiology/virology;Guanidines/*administration & dosage;Humans;Male;SARSCoV2/physiology;DA 2021/01/20 06:00		Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with 	
470	32638628	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*clinical trials;*repositioning antiviral drugs;*specific antiviral drugs	Antiviral Agents/therapeutic use;Betacoronavirus/chemistry/drug effects;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;*Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Viral Proteins/chemistry/drug effects;DA 2020/10/02 06:00		Research progress on repositioning drugs and specific therapeutic drugs for 	
471	33268442	Journal Article	O  NNLM;autoimmune diseases;biological therapy;communicable diseases;glucocorticoids;imported;tumor necrosis factors	DA 2020/12/04 06:00	ClinicalTrials.gov/NCT04353609	Severity of COVID-19 and survival in patients with rheumatic and inflammatory 	
472	33408023	Letter		DA 2021/01/08 06:00		Hydroxychloroquine (HCQ): real treatment or false hope?	
473	32766608	Preprint		DA 2020/08/09 06:01		Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury 	R21 AI129455/AI/NIAID NIH HHS/United States;DP2 AI138242/AI/NIAID NIH HHS/United States;R01 AI151059/AI/NIAID NIH HHS/United States;K08 CA230156/CA/NCI NIH HHS/United States;WT_/Wellcome Trust/United Kingdom;R01 AI146165/AI/NIAID NIH HHS/United States
474	32563283	Journal Article;Review		Adult;Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/*complications/transmission/virology;Disease Management;Expert Testimony;Humans;Infection Control/*standards;Leukemia/*therapy/virology;Myeloproliferative Disorders/*therapy/virology;Pandemics;Pneumonia, Viral/*complications/transmission/virology;Practice Guidelines as Topic/*standards;Resource Allocation;SARSCoV2;DA 2020/08/11 06:00		Special considerations in the management of adult patients with acute leukaemias and 	MC_UU_00016/11/MRC_/Medical Research Council/United Kingdom;MR/L008963/1/MRC_/Medical Research Council/United Kingdom;P30 CA016086/CA/NCI NIH HHS/United States;MC_UU_12009/11/MRC_/Medical Research Council/United Kingdom;MC_U137961146/MRC_/Medical Research Council/United Kingdom;K12 CA087723/CA/NCI NIH HHS/United States;P30 CA016359/CA/NCI NIH HHS/United States;G1000729/MRC_/Medical Research Council/United Kingdom
475	33001138	Journal Article;Multicenter Study;Randomized Controlled Trial		Adult;COVID19/*drug therapy/epidemiology/*prevention & control;Cross Infection/*prevention & control/*virology;DoubleBlind Method;Female;Hospitals, Urban;Humans;Hydroxychloroquine/*administration & dosage;Incidence;Male;Pennsylvania/epidemiology;*Personnel, Hospital;*PreExposure Prophylaxis;SARSCoV2;DA 2021/02/07 06:00	ClinicalTrials.gov/NCT04329923	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 	
476	33096223	Journal Article	O  NNLM;*COVID19;*Clinical trial;*Living mapping;*Metaanalysis;*Prevention;*Systematic review;*Treatment	COVID19/*drug therapy/prevention & control;Epidemiologic Research Design;Female;Geographic Mapping;Humans;Hydroxychloroquine/*therapeutic use;Internet;Italy;Male;Pandemics/*prevention & control;Randomized Controlled Trials as Topic;Sample Size;United States;DA 2021/01/28 06:00		Research response to coronavirus disease 2019 needed better coordination and 	
477	32565914	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;cerebrovascular diseases;healthcare impact;neurological manifestations	DA 2020/06/23 06:01		Neurological manifestations and implications of COVID-19 pandemic.	
478	32835091	Journal Article		DA 2020/08/25 06:01		Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?	
479	33041620	Journal Article;Review	O  NNLM;AntiHMGCR;HIV myositis;Immune checkpoint inhibitors;Immunosuppression;Inflammatory myopathy;Malignancyassociated myositis;Overlap myositis;SARSCoV2	DA 2020/10/13 06:01		Secondary Causes of Myositis.	
480	33027420	Journal Article		Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;*Drug Discovery;*Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/10/10 06:00		COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.	
481	33022293	Journal Article;Review	O  NNLM;*COVID19;*Prophylaxis;*Repurposed chemotherapy;*SARSCoV2	COVID19/*prevention & control;Clinical Protocols;*Clinical Trials as Topic;Humans;*PostExposure Prophylaxis;*PreExposure Prophylaxis;SARSCoV2;DA 2021/05/25 06:00		Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.	
482	32291137	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Coronavirus disease 2019;*Cytokine release syndrome;*Interleukin6;*Tocilizumab	AntiInflammatory Agents/therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;Betacoronavirus/pathogenicity;COVID19;Coronavirus Infections/*pathology;Cytokine Release Syndrome/*therapy;Humans;Immunomodulation/drug effects;Interleukin6/*antagonists & inhibitors/blood;Pandemics;Pneumonia, Viral/*pathology;SARSCoV2;Severe Acute Respiratory Syndrome/pathology;DA 2020/06/12 06:00		Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 	
483	32764417	Journal Article;Review	O  NNLM;*ACE2;*COVID19;*SARSCoV2;*diagnosis;*epidemiology;*inhibitors;*pneumonia;*temperature and humidity;*therapeutics strategies;*transmission	Animals;Betacoronavirus;COVID19;China/epidemiology;Coronavirus Infections/*epidemiology/physiopathology/therapy;Disease Outbreaks;Emergency Service, Hospital;Humans;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral/*epidemiology/physiopathology/therapy;Public Health;SARSCoV2;Zoonoses;DA 2020/09/04 06:00		The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current 	
484	33129363	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Favipiravir;Hydroxychloroquine;Randomised controlled trial;Saudi Arabia;protocol	Amides/adverse effects/*therapeutic use;Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/diagnosis/*drug therapy/virology;Drug Therapy, Combination;Female;HostPathogen Interactions;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Inpatients;Male;Multicenter Studies as Topic;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/virology;Pyrazines/adverse effects/*therapeutic use;Randomized Controlled Trials as Topic;SARSCoV2;Saudi Arabia;Time Factors;Treatment Outcome;DA 2020/11/05 06:00	ClinicalTrials.gov/NCT04392973	A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized 	
485	32827661	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Computational drug discovery;Coronavirus;Drug repurposing;SARSCoV2;Target proteins	Antiviral Agents/pharmacology/*therapeutic use;COVID19;*Computational Biology;Computer Simulation;Coronavirus Infections/*drug therapy;Drug Delivery Systems;Drug Development/*methods;Drug Discovery;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;DA 2020/11/06 06:00		Emerging strategies on in silico drug development against COVID-19: challenges and 	
486	33521333	Case Reports	O  NNLM;Cirrhosis;Covid19;Peritoneal tuberculosis;SARSCoV2;Tuberculosis	DA 2021/02/02 06:01		Coronavirus disease 2019 and extra-pulmonary tuberculosis co-infection - A case 	
487	32607505	Journal Article	O  NNLM;BCG;COVID19;Convalescent plasma;Cytokine storm;Immunomodulatory;Immunosuppression;SARSCoV2;Vaccines	DA 2020/07/02 06:01		COVID-19 Clinical Research.	UG1 CA189850/CA/NCI NIH HHS/United States
488	33133697	Journal Article;Review		DA 2020/11/03 06:01		Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, 	
489	32629280	Journal Article;Review	O  NNLM;*ACEIs/ARBs inhibitors;*COVID19;*Ethanolamine;*Hydroxychloroquine;*SARSCoV2	Angiotensin Receptor Antagonists/therapeutic use;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Animals;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/08/07 06:00		COVID19 inhibitors: A prospective therapeutics.	
490	33067112	Journal Article;Review	O  NNLM;Antiviral;COVID19;Clinical trials;Natural products;Patent;Protection	Antiviral Agents/*pharmacology;Biological Products/*pharmacology;COVID19/*drug therapy;COVID19 Vaccines;Clinical Trials as Topic;Drug Evaluation, Preclinical;Humans;Molecular Structure;Pandemics;Plant Preparations/pharmacology;SARSCoV2/*drug effects;DA 2021/04/29 06:00		Screening for natural and derived bio-active compounds in preclinical and clinical 	
491	33213035	Journal Article	O  NNLM;coronavirus disease 2019 (COVID19);current therapies;methodology;symptomatic treatment;trimethylxanthine	DA 2020/11/21 06:01	ClinicalTrials.gov/NCT04395742	Why Methodology Is Important: Coffee as a Candidate Treatment for COVID-19?	
492	33348292	Journal Article;Review	O  NNLM;Antiviral;COVID19;Immune system;Interferon;Pandemic;Severe acute respiratory syndrome coronavirus 2	Animals;Antiviral Agents/*pharmacology/*therapeutic use;COVID19/*drug therapy/virology;Humans;Interferon Type I/*pharmacology/*therapeutic use;Pandemics/prevention & control;SARSCoV2/*drug effects;DA 2021/02/03 06:00		Interferon-inducer antivirals: Potential candidates to combat COVID-19.	
493	32812051	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Aged;Antiviral Agents/*administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/mortality;Drug Therapy, Combination;Female;Humans;Imidazoles/*administration & dosage;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/mortality;Ribavirin/*administration & dosage;SARSCoV2;Sofosbuvir/*administration & dosage;Treatment Outcome;DA 2020/10/30 06:00		The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.	
494	32581514	Journal Article;Review	O  NNLM;COVID19;blinding;clinical trial;interventional;randomized	Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus/*drug effects/pathogenicity;COVID19;China/epidemiology;*Clinical Trials as Topic;Coronavirus Infections/diagnosis/*drug therapy/mortality/virology;HostPathogen Interactions;Humans;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology;Remission Induction;Research Design/*trends;SARSCoV2;Time Factors;Treatment Outcome;Viral Load/trends;DA 2020/07/02 06:00		Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data 	
495	33495763	Journal Article	O  NNLM;Computed tomography;Covid19;Elderly patients;Prognostic factors;SarsCoV2	DA 2021/01/27 06:00		Clinical, biological and radiological features, 4-week outcomes and prognostic 	
496	32699615	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;cardiovascular disease;chronic kidney disease;immunity;therapy	DA 2020/07/24 06:01		Coronavirus disease 2019 in chronic kidney disease.	
497	32565126	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Fusion inhibitors;*Molecular dynamics;*SARSCoV2;*Sequence alignment;*Spike glycoprotein;*Virtual screening	Antiviral Agents/*chemistry/pharmacology;Betacoronavirus/*chemistry/pathogenicity;Binding Sites;COVID19;Coronavirus Infections/drug therapy/virology;Gene Expression;Heterocyclic Compounds, 4 or More Rings/*chemistry/pharmacology;HighThroughput Screening Assays;Humans;Indoles/*chemistry/pharmacology;Molecular Docking Simulation;Molecular Dynamics Simulation;Pandemics;Perylene/*analogs & derivatives/chemistry/pharmacology;Pneumonia, Viral/drug therapy/virology;Protein Binding;Protein Conformation, alphaHelical;Protein Conformation, betaStrand;Protein Interaction Domains and Motifs;Protein Multimerization;SARSCoV2;Small Molecule Libraries/chemistry/pharmacology;Spike Glycoprotein, Coronavirus/antagonists & ;Sulfonamides/*chemistry/pharmacology;Thermodynamics;UserComputer Interface;Virus Internalization/drug effects;DA 2020/09/09 06:00		Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual 	
498	33531826	Journal Article;Review	O  NNLM;COVID19;NLRP3;SARSCoV2;cGASSTING;coronavirus;immune evasion;innate immune system;nucleic acid sensing	DA 2021/02/04 06:01		Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus 	
499	32739342	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Clinical trials;*Coronavirus;*Drugs;*SARSCoV2;*Vaccines	Adjuvants, Pharmaceutic;Animals;Antiviral Agents/*therapeutic use;*Betacoronavirus/drug effects/immunology/physiology;COVID19;COVID19 Vaccines;*Clinical Trials as Topic;Coronavirus Infections/physiopathology/prevention & ;Drug Repositioning;Humans;Immunization, Passive;Immunotherapy;Pandemics;Pneumonia, Viral/physiopathology/*therapy/transmission/virology;SARSCoV2;*Viral Vaccines/therapeutic use;DA 2020/11/18 06:00		COVID-19: An overview of the current pharmacological interventions, vaccines, and 	
500	32880807	Comment;Letter		*Betacoronavirus;COVID19;*Coronavirus Infections;Humans;Immunomodulation;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/10/02 06:00		"Comment on: ""Pharmaco-Immunomodulatory Therapy in COVID-19""."	
501	32920232	Journal Article;Observational Study	O  NNLM;COVID19;Invasive ventilation;Italy;Multidisciplinary;Noninvasive ventilation;Risk factors	Adult;Aged;Aged, 80 and over;COVID19/*therapy;Cohort Studies;Critical Illness;Diabetes Mellitus, Type 2/complications;Female;Hospital Mortality;Hospitalization;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;*Respiration, Artificial;Retrospective Studies;Risk Factors;SARSCoV2;DA 2020/12/15 06:00		Risk factors for non-invasive/invasive ventilatory support in patients with COVID-19 	
502	32387332	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Diagnostic approaches;*SARSCoV2;*Therapeutics;*Vaccines	Animals;Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;COVID19 Vaccines;China;Clinical Trials as Topic;Coronavirus Infections/*diagnosis/drug therapy/immunology/*prevention & control;Humans;Pandemics/*prevention & control;Pneumonia, Viral/*diagnosis/drug therapy/*prevention & control;SARSCoV2;Viral Vaccines/*immunology;World Health Organization;DA 2020/08/15 06:00		Current development of COVID-19 diagnostics, vaccines and therapeutics.	
503	32825816	Journal Article;Research Support, NonU.S. Gov't;Systematic Review	O  NNLM;*Clinical trial;*H1N1;*Influenza;*Pandemic;*Systematic review	Antiviral Agents/*therapeutic use;Betacoronavirus;Bibliometrics;COVID19;*Compassionate Use Trials;Coronavirus Infections/drug therapy/epidemiology;CostBenefit Analysis;Global Health;Humans;Inappropriate Prescribing/*prevention & control;*Influenza A Virus, H1N1 Subtype;Influenza, Human/*drug therapy/epidemiology;*OffLabel Use;Pandemics;Pneumonia, Viral/drug therapy/epidemiology;Research Design;SARSCoV2;Treatment Outcome;DA 2020/09/04 06:00		Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009.	107834/Z/15/Z/WT_/Wellcome Trust/United Kingdom;106491/Z/14/Z/WT_/Wellcome Trust/United Kingdom
504	32929317	Journal Article;Review	O  NNLM;Antiviral;COVID19;Cellular therapy;Drug;Immunotherapy;Pandemic	DA 2020/09/16 06:00		What are the drugs having potential against COVID-19?	
505	33349815	Journal Article		DA 2020/12/23 06:01		Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a 	WT_/Wellcome Trust/United Kingdom;MR/V015737/1/MRC_/Medical Research Council/United Kingdom
506	33360831	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Drug repurposing;*Free energy calculations;*Molecular dynamics;*SARSCoV2;*Virtual screening	COVID19/*drug therapy/*enzymology;Cephalosporins/*chemistry/therapeutic use;*Coronavirus 3C Proteases/antagonists & inhibitors/chemistry;*Drug Repositioning;Hepacivirus/*enzymology;Hepatitis C/*drug therapy/enzymology;Humans;*Molecular Dynamics Simulation;Oligopeptides/*chemistry/therapeutic use;*SARSCoV2/chemistry/enzymology;DA 2021/03/03 06:00		A computational drug repurposing approach in identifying the cephalosporin 	
507	33370645	Journal Article;Practice Guideline;Review	O  NNLM;*COVID19;*Carcinoid tumours;*Gastroenteropancreatic neuroendocrine tumour;*Lung neuroendocrine tumours;*Neuroendocrine tumours	*COVID19;Carcinoid Tumor/diagnosis/*therapy;Consensus;Gastrointestinal Neoplasms/diagnosis/*therapy;Humans;Medical Oncology/*standards;Pancreatic Neoplasms/diagnosis/*therapy;Thoracic Neoplasms/diagnosis/*therapy;DA 2021/01/28 06:00		Practical recommendations for the management of patients with gastroenteropancreatic 	
508	32952855	Journal Article;Review	O  NNLM;COVID19;Cytokine storm;Dendritic cells;Immunoregulation;Lungs;Mesenchymal stromal cells;Natural killer cells;Respiratory syndrome;SARSCoV2;Th2 response	DA 2020/09/22 06:01		Mesenchymal stromal cells as potential immunomodulatory players in severe acute 	
509	32668165	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*ACE2;*COVID19;*SARSCoV2;*TMPRSS2;*cystic fibrosis	Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/*etiology;Cystic Fibrosis/metabolism/*virology;Epithelial Cells/virology;Humans;Inflammation/metabolism/*virology;Lung/metabolism/virology;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*etiology;SARSCoV2;DA 2020/09/02 06:00		SARS-CoV-2 (COVID-19) and cystic fibrosis.	R01 HL074175/HL/NHLBI NIH HHS/United States;STANTO20PO/Cystic Fibrosis Foundation (CFF)/International;R01 HL151385/HHS | NIH | National Heart, Lung, and Blood Institute ;P30 DK117469/DK/NIDDK NIH HHS/United States;R01 HL122372/HL/NHLBI NIH HHS/United States;STANTO19R0/Cystic Fibrosis Foundation (CFF)/International;STANTO16GO/Cystic Fibrosis Foundation (CFF)/International
510	32837750	Journal Article	O  NNLM;Coronavirus disease 2019;Efficacy;Pneumonia;SARSCoV2;Safety;Triazavirin	DA 2020/08/25 06:01		The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol.	
511	32654489	Journal Article	O  NNLM;*COVID19;*SARSCoV2;*deep learning;*drug repurposing;*knowledge graph;*representation learning	Antiviral Agents;*Betacoronavirus;COVID19;*Coronavirus Infections/drug therapy/virology;*Deep Learning;Drug Repositioning/*methods;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/virology;Proteome;SARSCoV2;Transcriptome;DA 2020/12/01 06:00		Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning.	
512	33019592	Journal Article;Review	O  NNLM;COVID19;SARSCoV2 infection;gut microbiota dysbiosis;immune hyperresponse;inflammation;pharmacological and nutraceutical approaches	DA 2020/10/07 06:01		Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus 	This work was supported by the European Regional Development Fund (FEDER), through 
513	33249292	Letter		DA 2020/11/30 06:00		Repurposing medications.	
514	33319649	Journal Article	O  NNLM;*BGBDXP593;*COVID19;*CTP59;*GSK4182136;*LYCoV016;*LYCoV555;*REGNCOV2;*SARSCoV2;*VIR7831;*bamlanivimab;*monoclonal antibody	Antibodies, Monoclonal/genetics/*metabolism;Antibodies, Neutralizing/genetics/*metabolism;Antibodies, Viral/genetics/*metabolism;COVID19/*immunology/*therapy;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Humans;Immunization, Passive/methods;SARSCoV2/*physiology;DA 2020/12/29 06:00		Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.	
515	32380316	Journal Article;Review	O  NNLM;ACE2 receptor;COVID19;Convalescent plasma;Coronavirus;Cytokines;Intravenous immunoglobulins;Neutralizing antibodies;SARSCov2	Antibodies, Neutralizing/*therapeutic use;Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/immunology/*therapy;Humans;Immunization, Passive;Lymphocytes/immunology;Pandemics;Pneumonia, Viral/immunology/*therapy;Retrospective Studies;SARSCoV2;DA 2020/06/11 06:00		Convalescent plasma in Covid-19: Possible mechanisms of action.	
516	33081817	Journal Article;Multicenter Study;Randomized Controlled Trial	O  NNLM;Azithromycin;Detailed statistical analysis plan;Hydroxychloroquine;Infectious diseases;Intervention;Randomized controlled trial;Safety	Aged;AntiBacterial Agents/adverse effects/*therapeutic use;Antibiotic Prophylaxis/methods;Antimalarials/adverse effects/*therapeutic use;Azithromycin/adverse effects/*therapeutic use;Betacoronavirus/*drug effects/genetics;COVID19;CaseControl Studies;Coronavirus Infections/epidemiology/*prevention & control/transmission/virology;Denmark/epidemiology;DoubleBlind Method;Drug Therapy, Combination;Female;Hospital Mortality/trends;Hospitalization/statistics & numerical data;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Intensive Care Units/statistics & numerical data;Intention to Treat Analysis/methods;Male;Noninvasive Ventilation/adverse effects;Pandemics/*prevention & control;Placebos/administration & dosage;Pneumonia, Viral/epidemiology/*prevention & control/transmission/virology;Risk Reduction Behavior;SARSCoV2;DA 2020/11/04 06:00	ClinicalTrials.gov/NCT04322396	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized 	
517	33371905	Journal Article;Multicenter Study;Randomized Controlled Trial	O  NNLM;Antiinflammatory;Antiviral;COVID19;Mortality;Older adults;Prognosis;Randomized controlled trial;SARSCoV2;Vitamin D	Aged;COVID19/epidemiology/*therapy;*Dietary Supplements;DoseResponse Relationship, Drug;Female;Humans;Male;Nutrition Therapy/*methods;*Pandemics;Risk Factors;SARSCoV2;Time Factors;Treatment Outcome;Vitamin D/*administration & dosage;Vitamins/administration & dosage;DA 2021/01/07 06:00	ClinicalTrials.gov/NCT04344041	COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients 	202000160234/Patronage division of Angers University Hospital/
518	33486202	Journal Article;Review	O  NNLM;Angiotensinconverting enzyme 2;COVID19;Main and papainlike proteases;RNAdependentRNApolymerase;Repurposing and de novo strategies;Spike protein	Antiviral Agents/*pharmacology;*COVID19/drug therapy/epidemiology;Drug Development/methods;Drug Repositioning/methods;Humans;*SARSCoV2/drug effects/physiology;Treatment Outcome;Viral Proteins/antagonists & inhibitors/genetics;Virus Internalization/drug effects;DA 2021/04/07 06:00		Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the 	
519	32916297	Journal Article	O  NNLM;*Antimalarial drugs;*Antiviral;*COVID19;*In vitro;*SARSCoV2	Animals;Antimalarials/*pharmacology;Betacoronavirus/*drug effects;Cell Survival/drug effects;Chlorocebus aethiops;SARSCoV2;Vero Cells;Virus Replication/*drug effects;DA 2020/10/30 06:00		Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.	
520	32691699	Journal Article;Review	O  NNLM;COVID19;cardiovascular burden;chloroquine;hydroxychloroquine;remdesivir;review	Adenosine Monophosphate/*analogs & derivatives/pharmacology;Alanine/*analogs & derivatives/pharmacology;Antiviral Agents/pharmacology;Azithromycin/*pharmacology;COVID19/*drug therapy/epidemiology;*Cardiovascular Diseases/chemically induced/prevention & control;*ChemicallyInduced Disorders/etiology/prevention & control;Chloroquine/*pharmacology;Drug Therapy, Combination/adverse effects/methods;Humans;SARSCoV2;DA 2021/04/13 06:00		Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: 	
521	32665040	Clinical Trial Protocol;Comparative Study;Letter;Multicenter Study	O  NNLM;COVID19;Randomised controlled trial;hydroxychloroquine;lopinavir;protocol;ritonavir	*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Therapy, Combination;Hospitalization;Humans;Hydroxychloroquine/*administration & dosage;Lopinavir/*administration & dosage;Pandemics;Pneumonia, Viral/*drug therapy;*Randomized Controlled Trials as Topic;Ritonavir/*administration & dosage;SARSCoV2;*Standard of Care;DA 2020/08/19 06:00		The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised 	
522	32773471	Journal Article;Observational Study		Adult;AntiHIV Agents/therapeutic use;Betacoronavirus;CD4 Lymphocyte Count;COVID19;Coronavirus Infections/*mortality/*physiopathology;Female;HIV Infections/*complications/drug therapy;Humans;Incidence;Male;Middle Aged;Pandemics;Pneumonia, Viral/*mortality/*physiopathology;Prospective Studies;Risk Factors;SARSCoV2;Spain/epidemiology;DA 2020/09/17 06:00		Clinical characteristics, risk factors, and incidence of symptomatic coronavirus 	
523	32473418	Journal Article	O  NNLM;*COVID19;*Health system;*Inflammatory rheumatic diseases;*Treatment	Antirheumatic Agents/*therapeutic use;COVID19;Coronavirus Infections/*epidemiology/prevention & control;Delphi Technique;Disease Management;Female;France/epidemiology;Humans;Infection Control/methods;Male;Pandemics/prevention & control/*statistics & numerical data;Pneumonia, Viral/*epidemiology/prevention & control;Prognosis;Retrospective Studies;Rheumatic Diseases/diagnosis/*drug therapy/*epidemiology;Rheumatology;Societies, Medical;*Surveys and Questionnaires;Treatment Outcome;DA 2020/10/21 06:00		Managing patients with rheumatic diseases during the COVID-19 pandemic: The French 	
524	32641163	Clinical Trial Protocol;Journal Article;Multicenter Study	O  NNLM;Azithromycin;COVID19;Hydroxychloroquine;Novel coronavirus;Respiratory failure;SARSCoV2	Azithromycin/*administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/mortality;DoubleBlind Method;Drug Therapy, Combination;Humans;Hydroxychloroquine/*administration & dosage;Intensive Care Units;Pandemics;Pneumonia, Viral/*drug therapy/mortality;Prospective Studies;*Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/07/15 06:00	ClinicalTrials.gov/NCT04339816	Azithromycin added to hydroxychloroquine for patients admitted to intensive care due 	DI2040001A/Donatio Intensivistam Endowment Fund (CZ)/;COVID19GAMA2 via Charles University/Technologická Agentura České Republiky/
525	33371468	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;drug repositioning;public health crisis;vaccine	Antimalarials/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*prevention & control;COVID19 Vaccines/*therapeutic use;Chloroquine/therapeutic use;*Drug Repositioning;Humans;Hydroxychloroquine/therapeutic use;Nucleosides/analogs & derivatives/therapeutic use;Pandemics/prevention & control;Protease Inhibitors/therapeutic use;Public Health;SARSCoV2/drug effects/physiology;DA 2021/01/06 06:00		The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 	5120200513755/National Research Foundation of Korea (NRF)/
526	33165621	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural		Adult;Aged;COVID19/*drug therapy;Female;Humans;Hydroxychloroquine/administration & dosage/*therapeutic use;Male;Middle Aged;Treatment Failure;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04332991	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients 	U01 HL123010/HL/NHLBI NIH HHS/United States;U01 HL123018/HL/NHLBI NIH HHS/United States;U01 HL123023/HL/NHLBI NIH HHS/United States;UL1 TR001102/TR/NCATS NIH HHS/United States;UL1 TR002541/TR/NCATS NIH HHS/United States;U01 HL122989/HL/NHLBI NIH HHS/United States;U01 HL123008/HL/NHLBI NIH HHS/United States;U01 HL123027/HL/NHLBI NIH HHS/United States;U01 HL123033/HL/NHLBI NIH HHS/United States;U01 HL123022/HL/NHLBI NIH HHS/United States;K23 HL153584/HL/NHLBI NIH HHS/United States;U01 HL123009/HL/NHLBI NIH HHS/United States;U01 HL123031/HL/NHLBI NIH HHS/United States;U01 HL123020/HL/NHLBI NIH HHS/United States;U01 HL123004/HL/NHLBI NIH HHS/United States;UL1 TR002243/TR/NCATS NIH HHS/United States
527	32081774	Journal Article;Review	O  NNLM;Antiviral drug;BSAAs;Broadspectrum antiviral agents;Drug discovery and development;Virus	Animals;*Antiviral Agents/therapeutic use;*Drug Development;*Drug Discovery;Humans;Virus Diseases/drug therapy;DA 2020/07/25 06:00		Discovery and development of safe-in-man broad-spectrum antiviral agents.	
528	32303365	Journal Article	O  NNLM;*COVID19;*Ozone;*Ozono;*SARSCoV2;*Vitamin C;*Vitamina C	Antioxidants/therapeutic use;Ascorbic Acid/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/epidemiology;Critical Illness;Humans;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology;SARSCoV2;DA 2020/05/22 06:00		Two known therapies could be useful as adjuvant therapy in critical patients 	
529	33206053	Journal Article	O  NNLM;COVID19;SARSCoV2;drug;intervention;proposed therapy;protocol;randomized controlled trial;therapy;treatment	DA 2020/11/19 06:01		Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or 	
530	32539627	Journal Article;Review	O  NNLM;*ARDS;*COVID19;*SARSCoV2;*cytokine storm;*immunomodulatory drugs;*pneumonia	Antibodies, Monoclonal, Humanized/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*immunology/metabolism;Cytokines/*immunology/metabolism;Endothelial Cells/metabolism;Humans;*Immunity, Innate;Lung/*metabolism;Pandemics;Pneumonia, Viral/drug therapy/*immunology/metabolism;SARSCoV2;DA 2020/07/01 06:00		Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and 	
531	32982349	Journal Article;Review	O  NNLM;ACE;ACE2;atypical ARDS;myocarditis;silent hypoxia;stroke	DA 2020/09/29 06:01		COVID's Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected 	
532	33364957	Journal Article;Review	O  NNLM;COVID19;ER stress;SARSCoV2;antiviral;drug repurposing;repurposed drugs;sigma1 receptor;viral replication	DA 2020/12/29 06:01		Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?	
533	33340603	Clinical Trial, Phase I;Journal Article		Adult;Aged;Aged, 80 and over;COVID19/blood/diagnostic imaging/*immunology/*radiotherapy;Female;Hospitalization;Humans;Immunomodulation/*radiation effects;Lung/diagnostic imaging/immunology/*radiation effects;Male;Middle Aged;*Radiation Dosage;Radiotherapy Dosage;Safety;Tomography, XRay Computed;Treatment Outcome;DA 2021/03/05 06:00		Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 	TL1 TR002382/TR/NCATS NIH HHS/United States;UL1 TR002378/TR/NCATS NIH HHS/United States
534	32399655	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Cell therapy;*Coronavirus;*Cytokine storm;*Hyperinflammation	Aged;Betacoronavirus;Biomarkers/blood;COVID19;*Cell and TissueBased Therapy;*Compassionate Use Trials;Coronavirus Infections/*therapy;Critical Illness/therapy;Female;Ferritins/blood;Humans;Infusions, Intravenous;Los Angeles;Lymphocyte Count;Male;Middle Aged;Myocardium/*cytology;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;Stem Cells/*cytology;Young Adult;DA 2020/05/15 06:00		Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 	R01 HL137076/HL/NHLBI NIH HHS/United States;T32 HL116273/HL/NHLBI NIH HHS/United States
535	32472459	Journal Article;Review	O  NNLM;Algorithm;COVID19;Management;SarsCoV2	Algorithms;*Antiviral Agents/immunology/pharmacology;Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;Clinical Laboratory Techniques/*methods;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/immunology/therapy;Critical Pathways;*Cytokine Release Syndrome/diagnosis/drug therapy/etiology;Humans;*Pandemics;Patient Care Team/*organization & administration;*Pneumonia, Viral/epidemiology/immunology/therapy;SARSCoV2;DA 2020/06/25 06:00		Treatment algorithm for COVID-19: a multidisciplinary point of view.	
536	32863636	Journal Article	O  NNLM;Acute respiratory distress syndrome;COVID19;Coronavirus;Cytokine storm;Immunosuppressants	DA 2020/08/31 06:01		Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management 	
537	32615569	Journal Article;Review	O  NNLM;Antibiotic resistance;Blood purification;Extracorporeal therapy	Anticoagulants/*chemistry;Bacteria/isolation & purification;Bacterial Infections/blood/*therapy;Binding Sites;COVID19/blood/*therapy;Hemoperfusion/*methods;Heparin/*chemistry;Humans;SARSCoV2/*isolation & purification;DA 2021/02/09 06:00		Heparin 2.0: A New Approach to the Infection Crisis.	
538	33191206	Journal Article;Review		Adenosine Monophosphate/analogs & derivatives/chemistry/pharmacology/therapeutic use;Alanine/analogs & derivatives/chemistry/pharmacology/therapeutic use;AntiInflammatory Agents/chemistry/pharmacology/*therapeutic use;Antioxidants/chemistry/pharmacology/*therapeutic use;Antiviral Agents/chemistry/pharmacology/*therapeutic use;COVID19/*drug therapy;Drug Repositioning/*methods/trends;Humans;SARSCoV2/*drug effects;Treatment Outcome;Virus Internalization/drug effects;DA 2021/01/14 06:00		Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A 	
539	32987852	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;immune response;inflammation	DA 2020/09/30 06:01		SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic 	13SOL/Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, 
540	32323577	Editorial	O  NNLM;COVID19;chemotherapy;coronavirus;immune checkpoint inhibitors;oncologist;oncology;review	Antineoplastic Agents/therapeutic use;Antiviral Agents/therapeutic use;COVID19;Clinical DecisionMaking;Coronavirus Infections/diagnosis/drug therapy/*epidemiology/transmission;Disease Progression;Humans;Medical Oncology/*trends;Neoplasms/drug therapy/*epidemiology;Oncologists;Pandemics;Pneumonia, Viral/diagnosis/drug therapy/*epidemiology/transmission;Vulnerable Populations;DA 2020/06/18 06:00		What the oncologist needs to know about COVID-19 infection in cancer patients.	
541	32353634	Journal Article;Review		AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Azithromycin/therapeutic use;Betacoronavirus/drug effects/immunology/*pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Cytokines/genetics/immunology;Disease Management;Gene Expression Regulation;Humans;Hydroxychloroquine/therapeutic use;Immune Evasion/genetics/immunology;Immunologic Factors/*therapeutic use;*Pandemics;PeptidylDipeptidase A/*genetics/immunology;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARSCoV2;Spike Glycoprotein, Coronavirus/*genetics/immunology;TollLike Receptors/genetics/immunology;Tumor Necrosis Factor ReceptorAssociated Peptides and Proteins/genetics/immunology;DA 2020/06/24 06:00		COVID-19: Immunology and treatment options.	
542	33260370	Journal Article	O  NNLM;COVID19;FDAapproved drugs;SARSCoV2;docking studies;spike glycoprotein	Antiviral Agents/chemistry/*pharmacology;Computer Simulation;Drug Repositioning/*methods;Ligands;Membrane Fusion/drug effects;Models, Molecular;Molecular Docking Simulation;Protein Conformation;Spike Glycoprotein, Coronavirus/*chemistry/metabolism;Varenicline/chemistry/metabolism/pharmacology;DA 2020/12/19 06:00		Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for 	PAACTI 312807/CONACYT/
543	33197879	Clinical Trial;Journal Article	O  NNLM;*COVID19;*SARSCoV2;*antihypertensives;*hydroxymethylglutarylcoenzyme A reductase inhibitors;*online survey;*statins;*surveillance	Aged;Antihypertensive Agents/*adverse effects/therapeutic use;COVID19/diagnosis/*drug therapy/transmission/virology;CrossSectional Studies;Epidemiological Monitoring;Female;Germany/epidemiology;Humans;HydroxymethylglutarylCoA Reductase Inhibitors/*adverse effects/therapeutic use;Male;Middle Aged;Mobile Applications/supply & distribution;Prospective Studies;SARSCoV2/*drug effects/genetics;Self Report;Surveys and Questionnaires;DA 2021/01/12 06:00	DRKS/DRKS00022185	Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: 	
544	32572842	Journal Article		Attitude to Health;Betacoronavirus;COVID19;*Coronavirus Infections/classification/drug therapy/epidemiology/psychology;Drug Utilization/*trends;Humans;*Information Dissemination/ethics/methods;Medication Therapy Management/ethics/standards;*Pandemics;Pharmacovigilance;*Pneumonia, Viral/drug therapy/epidemiology/psychology;*Public Health/methods/standards;SARSCoV2;Social Media/ethics/standards;Social Medicine/ethics/standards;DA 2020/08/12 06:00		"The Impact of the COVID-19 ""Infodemic"" on Drug-Utilization Behaviors: Implications "	
545	33020111	Journal Article;Observational Study;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*clinical trials;*infectious diseases	Betacoronavirus/isolation & purification;*Biomedical Research/organization & administration/statistics & numerical data;COVID19;*Coronavirus Infections/epidemiology/therapy;Eligibility Determination;Female;Health Services Accessibility/statistics & numerical data;Hospitalization/statistics & numerical data;Humans;Male;Middle Aged;*Pandemics;*Patient Selection;*Pneumonia, Viral/epidemiology/therapy;Prospective Studies;*Randomized Controlled Trials as Topic/methods/statistics & numerical data;Registries/statistics & numerical data;SARSCoV2;United Kingdom;DA 2020/10/21 06:00		How achievable are COVID-19 clinical trial recruitment targets? A UK observational 	MC_UU_00002/15/MRC_/Medical Research Council/United Kingdom;MR/P008801/1/MRC_/Medical Research Council/United Kingdom
546	33040075	Comment;Journal Article;Research Support, NonU.S. Gov't		Azides;Betacoronavirus;COVID19;*Coronavirus Infections/drug therapy;Deoxycytidine/analogs & derivatives;Humans;*Pandemics;Pilot Projects;*Pneumonia, Viral;SARSCoV2;Tablets;DA 2020/10/21 06:00		Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.	U1804283/National Natural Science Foundation of China (National Science Foundation 
547	32402186	Journal Article;Review	O  NNLM;*3CLpro;*COVID19;*SARSCoV;*SARSCoV2;*broadspectrum antiviral agents;*coronavirus;*dimerization;*homodimer;*main protease (Mpro);*mutation	Antiviral Agents/pharmacology;Betacoronavirus/chemistry/drug effects/*enzymology/genetics;COVID19;Coronavirus 3C Proteases;Coronavirus Infections/*drug therapy/virology;Cysteine Endopeptidases/chemistry/genetics/*metabolism;Drug Discovery;Humans;Models, Molecular;Molecular Targeted Therapy;Mutation/drug effects;Pandemics;Peptides/pharmacology;Pneumonia, Viral/*drug therapy/virology;Protease Inhibitors/*pharmacology;Protein Conformation/drug effects;Protein Multimerization/*drug effects;SARSCoV2;Viral Nonstructural Proteins/antagonists & inhibitors/chemistry/genetics/*metabolism;DA 2020/06/17 06:00		Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential 	
548	32284951	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;hydroxychloroquine;lopinavir/ritonavir;remdesivir	DA 2020/04/15 06:01		Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.	
549	32814759	Journal Article;Research Support, NonU.S. Gov't		Animals;Antiviral Agents/pharmacology;Betacoronavirus/*physiology;COVID19;Cell Death/drug effects;Chlorocebus aethiops;Coronavirus Infections/*metabolism/virology;Drug Evaluation, Preclinical/*methods;Hydroxychloroquine/pharmacology;Imatinib Mesylate/pharmacology;Lysosomes/drug effects;Pandemics;Pneumonia, Viral/*metabolism/virology;Protein Kinase Inhibitors/pharmacology;RNA, Viral/drug effects;SARSCoV2;Vero Cells;Viral Load/drug effects;Virus Replication/*drug effects;DA 2020/09/02 06:00		On-target versus off-target effects of drugs inhibiting the replication of 	
550	32620597	Journal Article;Observational Study	O  NNLM;*antiinflammatory agents, nonsteroidal;*inflammation;*therapeutics	Administration, Intravenous;AntiBacterial Agents/therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;Bacteremia/epidemiology;Betacoronavirus;CReactive Protein/*immunology;COVID19;Cohort Studies;Coinfection/epidemiology;Coronavirus Infections/diagnostic imaging/*drug therapy/immunology/mortality;Drug Combinations;Enzyme Inhibitors/therapeutic use;Female;Humans;Hydroxychloroquine/therapeutic use;Inflammation/*immunology;Interleukin6/*immunology;Italy;Lopinavir/therapeutic use;Lung/diagnostic imaging;Male;Middle Aged;Noninvasive Ventilation;Oxygen Inhalation Therapy;Pandemics;Pneumonia, Viral/diagnostic imaging/*drug therapy/immunology/mortality;Proportional Hazards Models;Receptors, Interleukin6/antagonists & inhibitors;Ritonavir/therapeutic use;SARSCoV2;Severity of Illness Index;Time Factors;Tomography, XRay Computed;Treatment Outcome;DA 2020/09/25 06:00		Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic 	
551	32376399	Journal Article;Review	O  NNLM;*COVID19;*DMARDs;*Flowchart;*Infection;*Inflammatory bowel disease;*Prevention;*Rheumatic disease;*Small molecules;*Treatment;*bDMARDs	Antirheumatic Agents/therapeutic use;Autoimmune Diseases/complications/*drug therapy;Betacoronavirus;COVID19;Coronavirus Infections/*complications;Humans;Immunosuppressive Agents/*therapeutic use;Inflammatory Bowel Diseases/complications/*drug therapy;Pandemics;Pneumonia, Viral/*complications;Rheumatic Diseases/*drug therapy;Risk Factors;SARSCoV2;DA 2020/06/11 06:00		How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in 	
552	32717568	Journal Article;Review	O  NNLM;*Chloroquine;*Coronavirus;*Lopinavir;*Remdesivir;*Ribavirin;*Ritonavir;*SARSCoV2	Animals;AntiBacterial Agents/administration & dosage/metabolism;Antibodies, Monoclonal, Humanized/administration & dosage/metabolism;Antimalarials/administration & dosage/metabolism;Antiviral Agents/*administration & dosage/metabolism;COVID19/*drug therapy/metabolism;Clinical Trials as Topic/methods;Cytochrome P450 CYP3A Inhibitors/administration & dosage/metabolism;Drug Approval/*methods;Drug Therapy, Combination;Humans;Hydroxychloroquine/administration & dosage/metabolism;SARSCoV2/*drug effects/metabolism;United States/epidemiology;DA 2020/12/29 06:00		FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) 	
553	32850989	Journal Article;Review	O  NNLM;COVID19;RAS inhibitors;SARSCOV2;heart damage;pulmonary damage;reninangiotensin system	DA 2020/08/28 06:01		Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review.	
554	32685221	Case Reports		DA 2020/07/21 06:01		Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 	
555	33324210	Journal Article	O  NNLM;COVID19;coronavirus;cytokine storm;fibrosis;macrophage	DA 2020/12/17 06:01		Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019.	
556	32946870	Journal Article;Review	O  NNLM;COVID19;Methylxanthines;Pentoxifylline and caffeine	AntiInflammatory Agents, NonSteroidal/pharmacology/therapeutic use;COVID19;Caffeine/pharmacology/therapeutic use;Coronavirus Infections/complications/*drug therapy;Humans;Infant, Newborn;Infant, Premature;Inflammation/drug therapy/etiology;*Pandemics;Pentoxifylline/pharmacology/*therapeutic use;Pneumonia, Viral/complications/*drug therapy;Xanthines/*pharmacology/*therapeutic use;DA 2020/11/06 06:00		Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 	
557	33497876	Journal Article	O  NNLM;Acute respiratory distress syndrome;Coronavirus;Mortality;SARSCoV2;Viral pneumonia	Adult;Aged;Aged, 80 and over;COVID19/*epidemiology/physiopathology;Comorbidity;Female;Humans;Italy/epidemiology;Male;Middle Aged;Pandemics;Retrospective Studies;Young Adult;DA 2021/03/03 06:00		Severe COVID-19 pneumonia in Piacenza, Italy - A cohort study of the first pandemic 	
558	33391502	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*cancer;*comorbidity;*coronaviruses;*inflammation	Antineoplastic Agents/pharmacology/*therapeutic use;COVID19/*drug therapy/epidemiology/immunology/virology;Comorbidity;Drug Repositioning;Genome, Viral/genetics;Humans;Neoplasms/*drug therapy/epidemiology;Pandemics/prevention & control;SARSCoV2/*genetics/immunology;Signal Transduction/drug effects/genetics/immunology;DA 2021/01/13 06:00		COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.	K22 CA197074/CA/NCI NIH HHS/United States;P30 CA036727/CA/NCI NIH HHS/United States;1K22CA197074/CA/NCI NIH HHS/United States
559	33411222	Congress		DA 2021/01/08 06:01		Irish Thoracic Society Annual Scientific Meeting 2020.	
560	33398233	Journal Article;Review		DA 2021/01/06 06:01		Novel coronavirus disease (COVID-19) pandemic: A recent mini review.	
561	32788120	Journal Article	O  NNLM;*COVID19;*Continuous renal replacement therapy;*Mortality;*Thromboprophylaxis;*Venous thromboembolism	Aged;Anticoagulants/*administration & dosage;Biomarkers/blood;COVID19/complications/diagnostic imaging/*drug therapy/mortality;*Clinical Protocols;Critical Illness;Databases, Factual;Drug Monitoring;Factor Xa/analysis;Female;Heparin, LowMolecularWeight/*administration & dosage;Humans;*Intensive Care Units;Longitudinal Studies;Male;Middle Aged;Retrospective Studies;Risk Factors;Treatment Outcome;Venous Thromboembolism/diagnosis/etiology/mortality/*prevention & control;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04394000	Impact of implementation of an individualised thromboprophylaxis protocol in 	
562	32268381	Journal Article		Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/epidemiology/prevention & control;Female;Humans;Infant, Newborn;*Infection Control/methods/organization & administration;Infectious Disease Transmission, Vertical/prevention & control;Intensive Care, Neonatal/methods/organization & administration;*Pandemics/prevention & control;*Pneumonia, Viral/diagnosis/epidemiology/prevention & control;Pregnancy;*Pregnancy Complications, Infectious/epidemiology/prevention & control/virology;*Resuscitation/methods/trends;Risk Management/*methods;SARSCoV2;DA 2020/07/08 06:00		Neonatal Resuscitation and Postresuscitation Care of Infants Born to Mothers with 	
563	32711111	Journal Article;Review	O  NNLM;*ACE2;*Ang (17);*Covid19;*Immunomodulators;*Remdesivir;*SARSCoV2	AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Betacoronavirus/chemistry/*metabolism;COVID19;Coronavirus Infections/*drug therapy/prevention & control/virology;Drug Repositioning/*methods;Humans;Life Cycle Stages/*drug effects;Molecular Targeted Therapy/*methods;Pandemics/prevention & control;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*drug therapy/prevention & control/virology;ReninAngiotensin System/drug effects;SARSCoV2;Spike Glycoprotein, Coronavirus/immunology/metabolism;Viral Vaccines/immunology;Virus Internalization/drug effects;Virus Replication/drug effects;DA 2020/09/10 06:00		Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising 	
564	32903199	Journal Article	O  NNLM;COVID19;SARSCoV2;antibodies;convalescent plasma;coronaviruses;efficacy;feasibility;immunology;infectious disease;safety;treatment	DA 2020/09/10 06:01	ClinicalTrials.gov/NCT04347681	Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for 	
565	32375142	Editorial		Adrenal Cortex Hormones/adverse effects;Bone Marrow Transplantation;COVID19/*complications/drug therapy/epidemiology;China/epidemiology;Cohort Studies;EvidenceBased Medicine;Hematologic Neoplasms/*complications/therapy;Hematology;Humans;Immunotherapy, Adoptive;Pandemics;Risk Factors;*SARSCoV2;DA 2021/04/02 06:00		Perspective: SARS-CoV-2, COVID-19 and Haematologists.	
566	33354381	Case Reports	O  NNLM;COVID19;SARSCoV2;chemotherapy;immunodeficiency;rituximab	DA 2020/12/24 06:01		Clinical Observation of COVID-19 in a Patient With an Acquired Humoral Deficiency 	
567	32758635	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Pharmacology;*SARSCoV2;*Viral clearance kinetics	Antiviral Agents/pharmacology/*therapeutic use;COVID19/*drug therapy/*virology;Humans;*SARSCoV2;Viral Load;DA 2021/01/01 06:00		COVID-19: Pharmacology and kinetics of viral clearance.	
568	32592163	Journal Article;Review	O  NNLM;*COVID19;*Coronavirus;*Immunomodulation;*MSC priming;*Mesenchymal stem cells;*SARSCoV2	COVID19/immunology/*therapy/virology;Humans;Immunomodulation/*immunology;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/immunology;*Pandemics;SARSCoV2/pathogenicity;DA 2021/03/03 06:00		'Primed' Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.	
569	32778962	Journal Article;Review	O  NNLM;COVID19;Coronavirus;MERSCoV;SARSCoV;SARSCoV2;antiviral therapy;kinase inhibitors;pharmacokinetics	Animals;Antiviral Agents/*therapeutic use;COVID19;Coronavirus Infections/*drug therapy;*Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;Protein Kinase Inhibitors/*therapeutic use;DA 2020/08/14 06:00		Repurposing of Kinase Inhibitors for Treatment of COVID-19.	Project Program Grant, NIH PO1CA66996/NH/NIH HHS/United States
570	32768971	Journal Article;Review	O  NNLM;Anakinra;Convalescent plasma;Corticosteroids;Hydroxychloroquine;SARSCoV2;Vaccine	Animals;Antiviral Agents/*pharmacology;Betacoronavirus/drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/epidemiology/virology;Drug Design;Humans;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Public Health;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/09/08 06:00		Natural history of COVID-19 and current knowledge on treatment therapeutic options.	
571	32519200	Case Reports;Letter		Adult;COVID19;Coronavirus Infections/*complications/therapy;Critical Care;Female;Genetic Predisposition to Disease;Hormone Replacement Therapy;Humans;Italy;Pandemics;Pneumonia/*complications/therapy;Pneumonia, Viral/*complications/therapy;Polyendocrinopathies, Autoimmune/*complications/drug therapy/genetics;Respiration, Artificial;DA 2020/07/24 06:00		A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in 	
572	32903349	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;antivirals;coronaviruses;treatment	DA 2020/09/10 06:01		Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?	
573	33052920	Journal Article;Observational Study		Aftercare/statistics & numerical data;Aged;COVID19;Cognitive Dysfunction/*epidemiology;Coronavirus Infections/complications/*epidemiology/rehabilitation;Dyspnea/*epidemiology;Female;FollowUp Studies;Humans;Male;Malnutrition/*epidemiology;Middle Aged;Pandemics;Pneumonia, Viral/complications/*epidemiology/rehabilitation;Stress Disorders, PostTraumatic/*epidemiology;DA 2020/10/31 06:00		Residual clinical damage after COVID-19: A retrospective and prospective 	
574	32492293	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Adult;Betacoronavirus;COVID19;Canada;Coronavirus Infections/*prevention & control;DoubleBlind Method;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Inhalation Exposure;Male;Middle Aged;Occupational Exposure;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control;*PostExposure Prophylaxis;SARSCoV2;Treatment Failure;United States;DA 2020/08/13 06:00	ClinicalTrials.gov/NCT04308668	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.	R01 NS110519/NS/NINDS NIH HHS/United States;R01 NS086312/NS/NINDS NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;U01 AI125003/AI/NIAID NIH HHS/United States;T32 GM007347/GM/NIGMS NIH HHS/United States;T32 AI055433/AI/NIAID NIH HHS/United States;D43 TW009345/TW/FIC NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States;K08 AI134262/AI/NIAID NIH HHS/United States
575	32907357	Clinical Trial, Phase II;Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*heart block;*hydroxychloroquine;*incidence;*pregnancy	Antiviral Agents/*administration & dosage/adverse effects/blood;Cardiotoxicity;Drug Administration Schedule;Drug Monitoring;*Electrocardiography;Female;Fetal Blood/metabolism;Fetal Heart/*drug effects/physiopathology;Gestational Age;Heart Block/*congenital/diagnosis/physiopathology/prevention & control;Heart Rate/*drug effects;Humans;Hydroxychloroquine/*administration & dosage/adverse effects/blood;Infant;Infant, Newborn;Male;Predictive Value of Tests;Pregnancy;Risk Assessment;Risk Factors;Time Factors;Treatment Outcome;DA 2020/10/29 06:00	ClinicalTrials.gov/NCT01379573	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine 	R01 HD079951/HD/NICHD NIH HHS/United States;R03 HD069986/HD/NICHD NIH HHS/United States
576	33093945	Journal Article;Review	O  NNLM;*ACE2;*Hypokalaemia;*SARSCoV2;*alkalosis;*transtubular potassium gradient	Aldosterone;Betacoronavirus;COVID19;Coronavirus Infections/*complications;Electrolytes;Humans;Hypokalemia/*virology;Pandemics;Pneumonia, Viral/*complications;Potassium;ReninAngiotensin System;SARSCoV2;DA 2020/10/29 06:00		Electrolyte Disturbances in SARS-CoV-2 Infection.	
577	32352535	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*ACE2;*Acute coronary syndrome;*COVID19;*Cardiac;*Endothelium;*Microvascular;*Myocardial infarction;*Myocarditis;*Vascular;*Virus	AngiotensinConverting Enzyme Inhibitors/*pharmacology;Betacoronavirus/*pathogenicity;COVID19;*Coronavirus Infections/diagnosis/drug therapy;Humans;*Myocarditis/diagnosis/drug therapy/virology;*Pandemics;*Pneumonia, Viral/diagnosis/drug therapy;ReninAngiotensin System/drug effects;Risk Assessment;SARSCoV2;DA 2020/08/18 06:00		COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, 	RG/14/2/30616/BHF_/British Heart Foundation/United Kingdom;MC_UU_12014/1/MRC_/Medical Research Council/United Kingdom;MC_UU_12014/6/MRC_/Medical Research Council/United Kingdom;K08 HL121671/HL/NHLBI NIH HHS/United States;MC_UU_12014/7/MRC_/Medical Research Council/United Kingdom;DP2 HL137166/HL/NHLBI NIH HHS/United States;MC_PC_19026/MRC_/Medical Research Council/United Kingdom
578	32278065	Journal Article;Systematic Review	O  NNLM;*ACE2;*AngiotensinConverting Enzyme 2;*COVID19;*Diarrhea;*Epidemiology;*SARSCoV2;*TMPRSS2	AngiotensinConverting Enzyme 2;Betacoronavirus/*isolation & purification;COVID19;Child;Coronavirus Infections/*complications;Diarrhea/*epidemiology/pathology/*physiopathology/therapy;*Disease Management;Disease Transmission, Infectious/prevention & control;Feces/*virology;Humans;Incidence;Infection Control/methods;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*complications;SARSCoV2;Serine Endopeptidases/metabolism;Spike Glycoprotein, Coronavirus/metabolism;Virus Attachment;Virus Internalization;DA 2020/07/01 06:00		Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and 	
579	32861340	Journal Article		AngiotensinConverting Enzyme 2;Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology;Female;Gene Expression;Gene Frequency;Humans;Lung;Male;Pandemics;PeptidylDipeptidase A/genetics;Pneumonia, Viral/*epidemiology;SARSCoV2;Serine Endopeptidases/*genetics;*Sex Factors;DA 2020/09/04 06:00		Targeting TMPRSS2 in SARS-CoV-2 Infection.	
580	33317461	Journal Article;Randomized Controlled Trial	O  NNLM;Arbidol;COVID19;Corona virus;Efficacy	Adult;Aged;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Drug Combinations;Female;Humans;Hydroxychloroquine/therapeutic use;Indoles/*therapeutic use;Lopinavir/therapeutic use;Male;Middle Aged;Pandemics;Ritonavir/therapeutic use;SARSCoV2;DA 2020/12/19 06:00		Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.	17640/Iran University of Medical Sciences/
581	33247380	Journal Article	O  NNLM;Antioxidants;COVID 19;Chloroquine;Treatment;Zinc	DA 2020/11/29 06:00	ClinicalTrials.gov/NCT04447534	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a 	
582	33227700	Journal Article;Review	O  NNLM;Chloroquine;Heparin;Noscapine;Remedesivir;Severe acute respiratory syndrome (SARSCoV2);Vitamin C	Antiviral Agents/*therapeutic use;COVID19/*drug therapy/transmission;Chloroquine/pharmacology;*Drug Repositioning;Humans;Hydroxychloroquine/pharmacology;Immunotherapy;SARSCoV2/drug effects;DA 2020/12/31 06:00		Decoding the silent walk of COVID-19: Halting its spread using old bullets.	
583	32987757	Journal Article;Review	O  NNLM;COVID19;drugs;hemostasis;immunity;immunomodulators;peptides	Acute Disease;AntiInflammatory Agents/chemical synthesis/*therapeutic use;Antiviral Agents/chemical synthesis/*therapeutic use;Betacoronavirus/drug effects/growth & development;COVID19;Coronavirus Infections/complications/diagnosis/*drug therapy/virology;Cytokine Release Syndrome/complications/diagnosis/drug therapy/virology;Disseminated Intravascular Coagulation/complications/diagnosis/drug therapy/virology;HostPathogen Interactions/drug effects;Humans;Immunologic Factors/chemical synthesis/*therapeutic use;Lung/blood supply/drug effects/pathology/virology;Pandemics;Peptides/chemical synthesis/*therapeutic use;Pneumonia, Viral/complications/diagnosis/*drug therapy/virology;Respiratory Insufficiency/complications/diagnosis/prevention & control/virology;Respiratory System Agents/chemical synthesis/*therapeutic use;SARSCoV2;StructureActivity Relationship;DA 2020/10/08 06:00		Peptides: Prospects for Use in the Treatment of COVID-19.	
584	32750438	Journal Article;MetaAnalysis;Systematic Review	O  NNLM;COVID19;Coronavirus;Immune system;Immunotherapy;SARSCOV2	Antibodies, Monoclonal/therapeutic use;Betacoronavirus/*immunology;COVID19;Coronavirus Infections/immunology/*therapy;Humans;Immunization, Passive/methods;Immunoglobulins, Intravenous/therapeutic use;Immunotherapy/*methods;Interferons/therapeutic use;Mesenchymal Stem Cell Transplantation;Pandemics;Pneumonia, Viral/immunology/*therapy;SARSCoV2;Treatment Outcome;DA 2020/09/30 06:00		The immune system as a target for therapy of SARS-CoV-2: A systematic review of the 	
585	33053024	Clinical Trial Protocol;Journal Article;Multicenter Study;Randomized Controlled Trial		Adult;COVID19;Coronavirus Infections/*drug therapy/physiopathology;Dexamethasone/*administration & dosage;Glucocorticoids/*administration & dosage;Humans;Intensive Care Units;Organ Dysfunction Scores;Pandemics;Pneumonia, Viral/*drug therapy/physiopathology;Prospective Studies;Respiration, Artificial;Respiratory Distress Syndrome/*drug therapy/virology;Time Factors;DA 2020/10/27 06:00		COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and 	
586	33329000	Journal Article	O  NNLM;COVID19;SARSCoV2;inflammation;interferonβ1b;nebulization	DA 2020/12/18 06:01		Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and 	
587	33041814	Journal Article;Review	O  NNLM;COVID19 proposed therapy;Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2);convalescent plasma;pandemic;therapeutic challenges	DA 2020/10/13 06:01		Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future 	
588	32801840	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;coronavirus;treatment;vaccine	DA 2020/08/18 06:01		A Review on Currently Available Potential Therapeutic Options for COVID-19.	
589	32979572	Journal Article;Multicenter Study	O  NNLM;Creactive protein;COVID19;Mortality;SARSCoV2;Tocilizumab	Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*therapeutic use;CReactive Protein/metabolism;COVID19/*drug therapy/mortality/pathology;Cohort Studies;Female;Hospital Mortality;Hospitalization/*statistics & numerical data;Humans;Intensive Care Units/statistics & numerical data;Male;Middle Aged;SARSCoV2;Spain/epidemiology;Treatment Outcome;DA 2021/02/26 06:00		Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a 	
590	32997657	Journal Article		Aged;Aged, 80 and over;Betacoronavirus;COVID19;Cohort Studies;Comorbidity;Connecticut;Coronavirus Infections/*epidemiology/*mortality;Delivery of Health Care, Integrated;Female;Heart Failure/*epidemiology/mortality;Hospitalization/statistics & numerical data;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*epidemiology/*mortality;*Registries;Retrospective Studies;SARSCoV2;DA 2020/10/08 06:00		COVID-19 infections and outcomes in a live registry of heart failure patients across 	
591	33364961	Journal Article;Review	O  NNLM;PB28;SARSCoV2;sigma1 receptor;sigma2 receptor;structureaffinity relationships	DA 2020/12/29 06:01		PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 	
592	32611687	Journal Article;Review	O  NNLM;*Tlymphocytes;*immune evation;*review;*tumor escape;*vaccination	Betacoronavirus;COVID19;Coronavirus Infections/complications/drug therapy/immunology/therapy;Hepatitis B/complications/drug therapy/immunology/therapy;Hepatitis C/complications/drug therapy/immunology/therapy;Humans;Immunosuppressive Agents/*therapeutic use;Influenza, Human/complications/drug therapy/immunology/therapy;Neoplasms/*complications;Pandemics;Pneumonia, Viral/complications/drug therapy/immunology/therapy;SARSCoV2;Virus Diseases/complications/drug therapy/immunology/*therapy;DA 2020/07/21 06:00		On the use of immune checkpoint inhibitors in patients with viral infections 	
593	32792167	Journal Article;Review	O  NNLM;*COVID19;*Clinical trials;*Corona pandemic;*Therapeutic;*Vaccination	COVID19/*drug therapy/virology;*Clinical Trials as Topic;Europe;Humans;SARSCoV2/*drug effects/pathogenicity;World Health Organization;DA 2020/12/30 06:00		Current updates on the European and WHO registered clinical trials of coronavirus 	
594	32409782	Journal Article		*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*immunology;Glomerulonephritis/*drug therapy/immunology;Humans;Immunosuppressive Agents/*therapeutic use;*Kidney Transplantation;Pandemics;Pneumonia, Viral/drug therapy/*immunology;SARSCoV2;DA 2020/07/01 06:00		COVID-19: implications for immunosuppression in kidney disease and transplantation.	
595	33373681	Journal Article;Review		COVID19/*complications/*physiopathology;*Cellular Senescence;Humans;Iron/metabolism/physiology;Iron Metabolism Disorders/*etiology/*physiopathology;Neurodegenerative Diseases/*etiology/*physiopathology;DA 2021/06/04 06:00		COVID-19, ferrosenescence and neurodegeneration, a mini-review.	
596	32533443	Journal Article	O  NNLM;ARDS;COVID19;Chronic lung disease;Community acquired pneumonia;SARSCoV‑2	Adolescent;Adult;Austria;Betacoronavirus;COVID19;Child;Chronic Disease;*Coronavirus;*Coronavirus Infections/complications/diagnosis/therapy;Humans;Lung Diseases/*complications/therapy;*Pandemics;*Pneumonia, Viral/complications/diagnosis/therapy;Practice Guidelines as Topic;*Pulmonary Medicine;SARSCoV2;DA 2020/07/29 06:00		Management of patients with SARS-CoV-2 infections and of patients with chronic lung 	
597	32309679	Journal Article;Review	O  NNLM;ACE, angiotensinconverting enzyme;ACE2;AT1R, angiotensin II type 1 receptor;CI, confidence interval;COVID19;COVID19, coronavirus disease2019;CoV, coronavirus;FDA, Food and Drug Administration;IFN, interferon;IL, interleukin;IQR, interquartile range;MERS, Middle East respiratory syndrome;RAS, reninangiotensin system;RNA, ribonucleic acid;SARSCoV2;SARSCoV2, severe acute respiratory syndromecoronavirus2;TMPRSS2, transmembrane protease serine 2;clinical trials;renin angiotensin system;sACE2, soluble angiotensinconverting enzyme 2	DA 2020/04/21 06:01		COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology 	R01 HL107594/HL/NHLBI NIH HHS/United States;R21 HL141802/HL/NHLBI NIH HHS/United States;U10 HL110309/HL/NHLBI NIH HHS/United States;R01 HL118018/HL/NHLBI NIH HHS/United States;R34 HL146927/HL/NHLBI NIH HHS/United States
598	32360423	Letter		COVID19/*epidemiology/prevention & control;Chloroquine/therapeutic use;Drug Resistance;Humans;Hydroxychloroquine/therapeutic use;Malaria/drug therapy/*prevention & control;PreExposure Prophylaxis;*SARSCoV2;DA 2021/01/06 06:00		Malaria prophylaxis approach during COVID-19 pandemic.	
599	32800760	Consensus Development Conference;Journal Article;Practice Guideline;Review	O  NNLM;Immunomodulation;Immunosuppression;Inmunomodulación;Inmunosupresión;SARSCoV2/COVID19;Tratamiento;Treatment	Adult;AntiInflammatory Agents, NonSteroidal/adverse effects/therapeutic use;Antibodies, Monoclonal/adverse effects/therapeutic use;Antimalarials/adverse effects/therapeutic use;Antirheumatic Agents/adverse effects/*therapeutic use;*Betacoronavirus;Biological Products/adverse effects/therapeutic use;COVID19;Clinical Trials as Topic;Colombia;Coronavirus Infections/*complications/drug therapy;Delphi Technique;Drug Interactions;Drug Repositioning;Glucocorticoids/adverse effects/therapeutic use;Humans;Immunoglobulins, Intravenous/therapeutic use;Immunologic Factors/adverse effects/therapeutic use;Immunosuppressive Agents/adverse effects/therapeutic use;Multicenter Studies as Topic;*Pandemics;Pneumonia, Viral/*complications/drug therapy;Rheumatic Diseases/*complications/drug therapy;SARSCoV2;DA 2020/11/11 06:00		Recommendations on the management of adult patients with rheumatic diseases in the 	
600	32276453	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*SASP inhibitors;*cellular senescence;*extracellular vesicles;*inflammation;*mitochondria;*senolytics;*senoptotics;*viral infection	Aging/*immunology;AntiInfective Agents/standards/therapeutic use;Azithromycin/therapeutic use;COVID19;Cellular Senescence/immunology;Coronavirus Infections/*drug therapy/*immunology;Global Health/*trends;Humans;Interleukin6/immunology;Pandemics;Pneumonia, Viral/*drug therapy/*immunology;Pyrazoles/therapeutic use;DA 2020/04/16 06:00		Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and 	Ricerca Corrente/Ministero della Salute/International
601	32882216	Journal Article;Review	O  NNLM;Adjuvant therapy;COVID19;Coronavirus;Supplements;Vitamins	Animals;Antioxidants/therapeutic use;COVID19;Coronavirus Infections/prevention & control/*therapy;*Dietary Supplements;Humans;Pandemics/prevention & control;Pneumonia, Viral/prevention & control/*therapy;Vitamins/therapeutic use;DA 2020/11/06 06:00		The prophylaxis and treatment potential of supplements for COVID-19.	
602	32913297	Journal Article;Review		DA 2020/09/12 06:00		Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa.	WT_/Wellcome Trust/United Kingdom
603	32760407	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*intravenous immunoglobulin;*mechanism of action;*therapeutic inference;*viral pneumonia	Adult;Animals;Antibodies, Neutralizing/administration & dosage/*therapeutic use;AntibodyDependent Enhancement;Betacoronavirus/*immunology;COVID19;Child;Coronavirus Infections/*drug therapy/*immunology/virology;Cytokines/metabolism;Humans;Immunoglobulin Fab Fragments/metabolism;Immunoglobulin Fc Fragments/metabolism;Immunoglobulin G/administration & dosage/*therapeutic use;Immunoglobulins, Intravenous/administration & dosage/*therapeutic use;Immunologic Factors/administration & dosage/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/*immunology/virology;SARSCoV2;DA 2020/08/22 06:00		High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral 	
604	33105142	Clinical Trial;Journal Article;Multicenter Study	O  NNLM;*COVID19;*Elderly;*Immunomodulatory drugs;*Itolizumab;*SARSCoV2	Aged;Aged, 80 and over;Antibodies, Monoclonal/*therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/*drug therapy;Cuba;Female;Humans;Male;Middle Aged;SARSCoV2/drug effects;DA 2020/12/29 06:00		Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients 	
605	32880078	Journal Article;Review	O  NNLM;COVID19;Computational;Coronavirus;Drug;SARSCoV2;Vaccine	Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/virology;Computational Biology/methods;Drug Discovery/methods;Drug Repositioning/methods;Humans;Pandemics/prevention & control;SARSCoV2/*drug effects;DA 2021/02/18 06:00		Therapeutics for COVID-19: from computation to practices-where we are, where we are 	
606	32698249	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*ACE;*ACE2;*androgens;*cardiovascular comorbidities;*coronavirus;*oestrogens	COVID19/genetics/*mortality;Cardiovascular Diseases/complications/epidemiology;Comorbidity;Female;Humans;Male;Pandemics;PeptidylDipeptidase A/genetics;Sex Characteristics;Sex Factors;DA 2020/12/18 06:00		Sex-related differences in COVID-19 lethality.	SIC/MSD/International;PENC_FFABR_17_01/MIUR/International;PAGP_FFABR_17_01/MIUR/International;PAGP_RILO_16_01/University of Torino/International
607	33188624	Journal Article	O  NNLM;*COVID19;*cytokine storm;*intensive care unit;*interleukin6;*tocilizumab	Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/administration & dosage/adverse ;COVID19/diagnosis/*drug therapy/*virology;Combined Modality Therapy;Disease Progression;Female;Humans;KaplanMeier Estimate;Male;Middle Aged;Propensity Score;Receptors, Interleukin6/antagonists & inhibitors;SARSCoV2/*drug effects;Severity of Illness Index;Treatment Outcome;DA 2021/02/12 06:00		Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.	
608	32995820	Preprint		DA 2020/10/01 06:01		Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a 	R01 NS110519/NS/NINDS NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;F30 CA236157/CA/NCI NIH HHS/United States;T32 GM007347/GM/NIGMS NIH HHS/United States;T32 AI055433/AI/NIAID NIH HHS/United States;D43 TW009345/TW/FIC NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States;K08 AI134262/AI/NIAID NIH HHS/United States
609	33017904	Letter		Administration, Inhalation;Adolescent;Adult;Aged;Asthma/drug therapy;Betacoronavirus;COVID19;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Coronavirus Infections/*drug therapy;Female;Humans;Hydroxychloroquine/*administration & dosage;Lung/*drug effects;Male;Middle Aged;Pandemics;Patient Safety;Pneumonia, Viral/*drug therapy;SARSCoV2;Treatment Outcome;Young Adult;DA 2020/10/21 06:00		Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of 	
610	32789802	Historical Article;Journal Article;Review	O  NNLM;*1918 Influenza Pandemic;*Antiviral Drugs;*COVID19;*Coronavirus;*Pandemics;*SARS Virus;*Stem Cells;*Vaccines	COVID19/pathology/prevention & control/*therapy/virology;*Cell and TissueBased Therapy;History, 20th Century;Humans;Immunization, Passive;Influenza Pandemic, 19181919/history;Pandemics/history;Regenerative Medicine/history;SARSCoV2/pathogenicity;DA 2021/03/03 06:00		Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons 	R01 NS090962/NS/NINDS NIH HHS/United States;R01 NS102395/NS/NINDS NIH HHS/United States;R21 NS109575/NS/NINDS NIH HHS/United States;R01NS090962, R01NS102395, and R21NS109575/National Institutes of Health (US)/
611	33013067	Journal Article		DA 2020/10/06 06:01		Anti-corona Drugs: Current Scenario.	
612	32817959	Preprint		DA 2020/08/21 06:01		Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: 	T32 HL072752/HL/NHLBI NIH HHS/United States
613	32854988	Journal Article;Review	O  NNLM;*ARDSCoV2;*COVID19;*ICU;*SARSCoV2;*Tratamiento;*Treatment;*UCI	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Adrenal Cortex Hormones/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Antibodies, Monoclonal/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;COVID19/*drug therapy/therapy;Disease Progression;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive;Immunoglobulins, Intravenous/therapeutic use;Immunomodulation;Interferonbeta/therapeutic use;Interleukin 1 Receptor Antagonist Protein/therapeutic use;Lopinavir/therapeutic use;Protein Kinase Inhibitors/therapeutic use;Pyrazoles/therapeutic use;Ritonavir/therapeutic use;*SARSCoV2;DA 2021/03/11 06:00		Pharmacological treatment of COVID-19: Narrative review of the Working Group in 	
614	32496872	Journal Article;Review	O  NNLM;*COVID19;*SARS;*SARSCoV2;*coronavirus	Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*pathology/*virology;Global Health;Humans;Immunologic Factors/therapeutic use;Pandemics;Pneumonia, Viral/drug therapy/*pathology/*virology;SARSCoV2;DA 2020/07/17 06:00		SARS-CoV-2 and COVID-19: From the Bench to the Bedside.	
615	33498725	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;dendritic cells;immunopathology;therapy	Adaptive Immunity;Animals;COVID19/*immunology/pathology/therapy;Dendritic Cells/*immunology/pathology;Humans;Immunity, Innate;SARSCoV2/*immunology;TLymphocytes/immunology;DA 2021/02/07 06:00		A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 	RGPIN201504144/Natural Sciences and Engineering Research Council of Canada/
616	32889088	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Prevention;Treatment;Vaccine	Animals;Antiviral Agents/adverse effects/*therapeutic use;COVID19/*drug therapy/*prevention & control/virology;COVID19 Vaccines/adverse effects/*therapeutic use;*Drug Development;*Drug Discovery;HostPathogen Interactions;Humans;Molecular Targeted Therapy;SARSCoV2/*drug effects/immunology/pathogenicity;DA 2020/12/17 06:00		Current state of vaccine development and targeted therapies for COVID-19: impact of 	R01 HL132401/HL/NHLBI NIH HHS/United States;R01 HL151737/HL/NHLBI NIH HHS/United States;S10 OD018135/OD/NIH HHS/United States
617	32374264	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*crisis;*drug costs;*drug repositioning;*drugs, generic;*offlabel use;*pandemic;*public health;*severe acute respiratory syndrome coronavirus 2	Antiviral Agents/therapeutic use;Betacoronavirus;COVID19;*Coronavirus/drug effects/isolation & purification;Coronavirus Infections/*drug therapy/epidemiology/virology;*Drug Costs;*Drug Repositioning;*Drugs, Generic;Humans;*OffLabel Use;*Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Public Health;SARSCoV2;DA 2020/05/27 06:00		Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The 	
618	33087172	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Aging;*Chronic disease;*Coronaviruses;*Epigenetics;*Metabolism;*Nucleic acids	Antiviral Agents/*pharmacology;Betacoronavirus/*physiology;COVID19;Coronavirus Infections/*drug therapy/*genetics/immunology;Cytokines/genetics/immunology;*Epigenesis, Genetic;*Gene Expression Regulation, Viral/drug effects;HostPathogen Interactions;Humans;Inflammation/immunology;Pandemics;Pneumonia, Viral/*drug therapy/*genetics/immunology;RNA Processing, PostTranscriptional;SARSCoV2;DA 2020/10/29 06:00		The epigenetic implication in coronavirus infection and therapy.	GGP19035A/Fondazione Telethon/International;SG201812366446/Ministero della Salute/International;CA17129/Horizon 2020 Framework Programme/International;ID 1165235/Regione Lombardia/International;PRIN2017S55RXB/Ministero dell'Istruzione, dell'Università e della 
619	32642005	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*ACE2;*COVID19;*and animal model;*pathogenesis;*spike protein	Angiotensin II Type 1 Receptor Blockers/therapeutic use;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Animals;Antibodies, Neutralizing/therapeutic use;Antibodies, Viral/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus/chemistry/pathogenicity/physiology;COVID19;COVID19 Vaccines;Coronavirus Infections/*metabolism/prevention & control/therapy/*virology;Disease Models, Animal;Host Microbial Interactions/physiology;Humans;Mice;Models, Biological;Pandemics;PeptidylDipeptidase A/*metabolism;Pneumonia, Viral/*metabolism/therapy/*virology;Receptors, Virus/*metabolism;ReninAngiotensin System/physiology;SARSCoV2;Spike Glycoprotein, Coronavirus/chemistry/genetics/metabolism;Theranostic Nanomedicine;Viral Vaccines/isolation & purification;Virus Internalization;DA 2020/07/17 06:00		SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the 	P51 OD011104/OD/NIH HHS/United States;5 P51OD01110458/NH/NIH HHS/United States
620	33423874	Journal Article	O  NNLM;*30Day mortality;*COPD;*COVID19;*EPOC;*Enfermedades respiratorias;*Mortalidad a 30 días;*Prognosis;*Pronóstico;*Respiratory diseases	DA 2021/01/12 06:00		Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior 	
621	33478953	Journal Article	O  NNLM;COVID19;arthritis;epidemiology;osteoarthritis;rheumatoid	DA 2021/01/23 06:00		Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an 	MR/V015737/1/MRC_/Medical Research Council/United Kingdom
622	32574699	Journal Article;Research Support, N.I.H., Extramural;Review		Animals;Antiviral Agents/pharmacology/*therapeutic use;Betacoronavirus/drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/virology;Drug Discovery;Humans;OffLabel Use;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/09/01 06:00		Discovering small-molecule therapeutics against SARS-CoV-2.	P01 HL107152/HL/NHLBI NIH HHS/United States;R01 HL090586/HL/NHLBI NIH HHS/United States;U01 CA241951/CA/NCI NIH HHS/United States;S10 RR027411/RR/NCRR NIH HHS/United States
623	32754570	Journal Article;Review	O  NNLM;*2019nCoV;*COVID19;*SARSCoV2;*clinical trials;*coronavirus;*diagnosis;*drug repurposing;*vaccines	COVID19/*diagnosis/*drug therapy/*prevention & control;COVID19 Testing;China/epidemiology;Humans;DA 2020/08/06 06:01		Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of 	
624	32849448	Journal Article	O  NNLM;COVID19;antivirals;pandemic;rapid review;systematic review	DA 2020/08/28 06:01		Directly Acting Antivirals for COVID-19: Where Do We Stand?	
625	32848795	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;adjunctive therapy;antivirals;therapeutics	DA 2020/08/28 06:01		COVID-19 Therapeutic Options Under Investigation.	
626	33281063	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*IFNα/β;*SARSCoV2;*antiviral molecules;*cytokine storm;*immunomodulators	AngiotensinConverting Enzyme 2/immunology/metabolism;Antiviral Agents/*immunology/metabolism/therapeutic use;COVID19/drug therapy/*immunology/virology;Cytokines/immunology/metabolism;Humans;Immunologic Factors/*immunology/metabolism/therapeutic use;Interferon Type I/*immunology/metabolism;SARSCoV2/drug effects/*immunology/metabolism;Serine Endopeptidases/immunology/metabolism;Virus Replication/drug effects/immunology;DA 2021/01/26 06:00		Combining Antivirals and Immunomodulators to Fight COVID-19.	
627	32319200	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*type 2 diabetes	Aged;COVID19/*complications/epidemiology/*therapy;Cardiovascular Diseases/complications/epidemiology/*therapy;Chloroquine/therapeutic use;Clinical Trials as Topic/methods/standards;Delivery of Health Care/methods/standards;Female;Glucocorticoids/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Hypoglycemic Agents/therapeutic use;Male;Metabolic Diseases/complications/epidemiology/*therapy;Middle Aged;Pandemics;SARSCoV2/physiology;*Uncertainty;DA 2020/12/23 06:00		Therapeutic uncertainties in people with cardiometabolic diseases and severe acute 	K.K. and S.S. are supported by the National Institute for Health Research (NIHR) 
628	32568620	Journal Article	O  NNLM;2019nCOV;COVID19;Remdesivir;dynamics simulations;molecular docking;phylogeny;sequence analysis	DA 2020/06/23 06:00		Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico 	
629	32983936	Journal Article	O  NNLM;Bromhexine hydrochloride;COVID19 disease;COVID19 pneumonia;COVID19 treatment;SARSCoV2;TMPRSS2	DA 2020/09/29 06:01		Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A 	
630	33240091	Journal Article;Review	O  NNLM;COVID19;coronavirus;drug repositioning;drug repurposing;pandemic	DA 2020/11/27 06:01	ClinicalTrials.gov/NCT04244591;ClinicalTrials.gov/NCT04280705;ClinicalTrials.gov/NCT04304313;ClinicalTrials.gov/NCT04348695;ClinicalTrials.gov/NCT04359329;ClinicalTrials.gov/NCT04342663;ClinicalTrials.gov/NCT04321174	Challenges for Drug Repurposing in the COVID-19 Pandemic Era.	
631	33482181	Journal Article;Review	O  NNLM;2019nCoV;COVID19;Drug repositioning;Outbreak;Review;SARSCoV2	Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/virology;Humans;Pandemics/prevention & control;SARSCoV2/*drug effects;DA 2021/02/23 06:00		A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.	
632	33232783	Journal Article;Review	O  NNLM;*Acute respiratory distress syndrome (ARDS);*COVID19;*Coronavirus;*Cytokine storm;*Dexamethasone;*Immune response;*SARSCoV2;*Treatment;*Vitamin D	Adaptive Immunity;Animals;COVID19/*immunology/*physiopathology;Clinical Trials as Topic;Cytokine Release Syndrome/immunology/prevention & control;Disease Management;Humans;Immunity, Innate;Immunologic Factors;Inflammation/immunology/prevention & control;SARSCoV2;Vitamin D/*immunology/therapeutic use;Zoonoses/immunology;DA 2021/01/05 06:00		Putative roles of vitamin D in modulating immune response and immunopathology 	
633	32923151	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*SARSCoV2;*cancer;*hydroxychloroquine;*immune checkpoint;*immunotherapy	Animals;Antineoplastic Combined Chemotherapy Protocols/*administration & ;Azithromycin/*administration & dosage/pharmacokinetics;COVID19/*drug therapy/immunology/virology;Cell Line, Tumor;Cisplatin/administration & dosage/pharmacokinetics;Clinical Trials, Phase II as Topic;Crizotinib/administration & dosage/pharmacokinetics;Disease Models, Animal;Drug Evaluation, Preclinical;Drug Interactions;Drug Therapy, Combination/methods;Female;France;Humans;Hydroxychloroquine/*administration & dosage/pharmacokinetics;Mice;Neoplasms/*drug therapy/immunology;Oxaliplatin/administration & dosage/pharmacokinetics;Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology;SARSCoV2/immunology/isolation & purification;DA 2020/09/15 06:01		Combination treatments with hydroxychloroquine and azithromycin are compatible with 	
634	32535188	Clinical Trial;Journal Article	O  NNLM;*ARDS;*COVID19;*Infection;*RALE score	Age Factors;Aged;Betacoronavirus/immunology/pathogenicity;COVID19;Comorbidity;Coronary Disease/*diagnosis/epidemiology/immunology/mortality;Coronavirus Infections/*diagnosis/epidemiology/immunology/mortality;Diabetes Mellitus/*diagnosis/epidemiology/immunology/mortality;Female;Hospitalization;Humans;Hypertension/*diagnosis/epidemiology/immunology/mortality;Infectious Disease Incubation Period;Italy/epidemiology;Kidney Failure, Chronic/*diagnosis/epidemiology/immunology/mortality;Lymphocyte Count;Lymphocytes/immunology/pathology/virology;Male;Middle Aged;Pandemics;Pneumonia, Viral/*diagnosis/epidemiology/immunology/mortality;Pulmonary Edema/*diagnosis/epidemiology/immunology/mortality;Risk Factors;SARSCoV2;Severe Acute Respiratory Syndrome/*diagnosis/epidemiology/immunology/mortality;Severity of Illness Index;Survival Analysis;DA 2020/07/22 06:00		Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy.	
635	33363416	Journal Article;Review	O  NNLM;COVID19;SARSCoV;SARSCoV2;chloroquine;corona virus	DA 2020/12/29 06:01		An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease.	
636	32926918	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Pathophysiology;Pharmacotherapy;SARSCov2	COVID19;Clinical Trials as Topic;Coronavirus Infections/*complications/*drug therapy;Humans;Molecular Targeted Therapy/*methods;Pandemics;Pneumonia, Viral/*complications/*drug therapy;DA 2020/10/27 06:00		COVID-19 associated complications and potential therapeutic targets.	
637	32564908	Journal Article	O  NNLM;Angiotensin converting enzyme inhibitors;Angiotensin receptor blockers;COVID 19;Neprilysin;Renin angiotensin system;Vitamin D	AngiotensinConverting Enzyme 2;Betacoronavirus/*physiology;COVID19;*Coronavirus Infections/metabolism/mortality/virology;Humans;Mortality;*Pandemics;*PeptidylDipeptidase A/genetics/metabolism;*Pneumonia, Viral/metabolism/mortality/virology;ReninAngiotensin System/*physiology;*Risk Factors;SARSCoV2;Virus Internalization;DA 2020/08/19 06:00		COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System 	
638	32641343	Clinical Trial Protocol;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't	O  NNLM;*adult intensive & critical care;*clinical trials;*infectious diseases;*respiratory infections	Administration, Intravenous;Ascorbic Acid/*administration & dosage;Betacoronavirus;COVID19;China;Coronavirus Infections/complications/*drug therapy/immunology;Cytokine Release Syndrome/*drug therapy/etiology/immunology;Hospital Mortality;Humans;Intensive Care Units;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology;Respiration, Artificial;SARSCoV2;Severity of Illness Index;Treatment Outcome;Vitamins/*administration & dosage;DA 2020/07/18 06:00	ClinicalTrials.gov/NCT04264533	Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol 	
639	32889701	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Repurposing;SARSCoV2	Animals;Antiviral Agents/pharmacology/*therapeutic use;COVID19/*drug therapy/virology;Computer Simulation;Drug Discovery/methods;*Drug Repositioning;Humans;SARSCoV2/drug effects/pathogenicity;DA 2020/12/15 06:00		Drug repurposing approach to fight COVID-19.	
640	33157081	Letter	O  NNLM;*COVID19;*Cytokine;*Hypoglycemia;*SARSCoV2;*Type 2 diabetes	Aged;Biomarkers/metabolism;COVID19/complications/epidemiology/*metabolism/virology;CaseControl Studies;Cytokines/metabolism;Diabetes Mellitus, Type 2/complications/*metabolism;Female;Humans;Hypoglycemia;Male;Middle Aged;Pandemics;SARSCoV2;Severity of Illness Index;DA 2021/01/07 06:00	ClinicalTrials.gov/NCT03102801	Do biomarkers of COVID-19 severity simply reflect a stress response in type 2 	
641	33428981	Journal Article;Review	O  NNLM;*ABACAS;*CRISPRCas system;*DETECTR;*Diagnosis;*PACMAN;*SARSCoV2;*SHERLOCK;*Singlestranded RNA viruses	Antiviral Agents/therapeutic use;COVID19/diagnosis/*drug therapy/therapy;COVID19 Nucleic Acid Testing;CRISPRAssociated Proteins/therapeutic use;*CRISPRCas Systems;Clustered Regularly Interspaced Short Palindromic Repeats/genetics;Humans;RNA, Guide/genetics/metabolism;RNA, Viral/genetics/metabolism;SARSCoV2/*drug effects/genetics/*isolation & purification;DA 2021/02/12 06:00		CRISPR systems: Novel approaches for detection and combating COVID-19.	
642	32405780	Journal Article;Review	O  NNLM;drug therapy;novel coronavirus (2019nCoV);pneumonia;research progress	Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;Biological Factors/therapeutic use;Biomedical Research/trends;COVID19;Coronavirus Infections/*drug therapy/therapy;Glucocorticoids/therapeutic use;Humans;Immunization, Passive;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/05/20 06:00		Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.	
643	32933039	Journal Article	O  NNLM;COVID19;aldosterone;angiotensinconverting enzyme2;canrenone;mineralcorticoid receptor antagonist;renin–angiotensin–aldosterone system	DA 2020/09/17 06:01		The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 	
644	33502567	Case Reports;Clinical Trial;Journal Article	O  NNLM;*COVID19 pneumonitis;*Cytokine storm;*Inflamatory response;*Radiation;*SARSCoV2	Aged;Aged, 80 and over;COVID19/pathology/*radiotherapy;Female;Humans;Male;Preliminary Data;Prospective Studies;Radiotherapy/methods;Radiotherapy Dosage;SARSCoV2/*radiation effects;Treatment Outcome;DA 2021/05/04 06:00	ClinicalTrials.gov/NCT04394182	COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): 	
645	32565132	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*CRS;*HLH;*IRIS;*SARSCoV2;*cellular therapy;*cytokine release;*hyperimmune response;*immunotherapy	Adrenal Cortex Hormones/therapeutic use;COVID19;Coronavirus Infections/drug therapy/*etiology/physiopathology;Cytokine Release Syndrome/etiology/therapy;Humans;Immune Reconstitution Inflammatory Syndrome/etiology/therapy;Immunization, Passive;Interleukin1/antagonists & inhibitors;Interleukin6/antagonists & inhibitors;Killer Cells, Natural/immunology;Lymphohistiocytosis, Hemophagocytic/etiology/therapy;Pandemics;Plasmapheresis;Pneumonia, Viral/*etiology/physiopathology;STAT Transcription Factors/antagonists & inhibitors;DA 2020/09/08 06:00		Emerging trends in COVID-19 treatment: learning from inflammatory conditions 	P30 CA008748/CA/NCI NIH HHS/United States
646	32275914	Journal Article	O  NNLM;*COVID19;*Interferon;*SARSCoV2	Antiviral Agents/*therapeutic use;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/virology;Humans;Interferon Type I/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/07/07 06:00		Type 1 interferons as a potential treatment against COVID-19.	
647	32696108	Journal Article;Review		Betacoronavirus/physiology;COVID19;*Coronavirus Infections/drug therapy/immunology;Humans;*Immunologic Factors/classification/pharmacology;Immunomodulation/*immunology;*Pandemics;*Pneumonia, Viral/drug therapy/immunology;SARSCoV2;Treatment Outcome;DA 2020/09/17 06:00		Pharmaco-Immunomodulatory Therapy in COVID-19.	
648	32734518	Journal Article;Review	O  NNLM;COVID19;Coronaviruses;Drug classification;Pandemic;Pharmaceutical agents;Possible treatments;SARSCoV2	Animals;COVID19/*drug therapy/physiopathology/virology;Humans;Inflammation/drug therapy/physiopathology/virology;SARSCoV2/*drug effects/pathogenicity;DA 2020/12/15 06:00		Classification of the present pharmaceutical agents based on the possible effective 	
649	33570583	Journal Article;Systematic Review	O  NNLM;*COVID19;*SARSCoV2;*immune system;*influenza;*micronutrients;*nutrition	COVID19/immunology/*prevention & control/*therapy;*Diet;Dietary Supplements;Humans;Immune System;Iron;*Micronutrients;Nutrition Therapy/*methods;*Nutritional Status;Selenium;Trace Elements;Vitamin A;Zinc;DA 2021/03/02 06:00	ClinicalTrials.gov/NCT04304053;ClinicalTrials.gov/NCT04318444;ClinicalTrials.gov/NCT04251871;ClinicalTrials.gov/NCT04303507;ClinicalTrials.gov/NCT04321174;ClinicalTrials.gov/NCT04312243;ClinicalTrials.gov/NCT04308668	Nutritional perspectives for the prevention and mitigation of COVID-19.	
650	32852338	Comparative Study;Journal Article;Observational Study		Aged;Aged, 80 and over;Betacoronavirus/isolation & purification/pathogenicity;COVID19;Coronavirus Infections/diagnosis/drug therapy/mortality/*therapy/virology;Famotidine/*therapeutic use;Female;Humans;Intubation, Intratracheal/*statistics & numerical data;Male;Middle Aged;Pandemics;Pneumonia, Viral/diagnosis/mortality/*therapy/virology;Propensity Score;Retrospective Studies;SARSCoV2;Severity of Illness Index;Tertiary Care Centers/statistics & numerical data;Treatment Outcome;DA 2020/10/21 06:00		Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With 	
651	33085857	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*therapeutic use;Boston;COVID19/*drug therapy/mortality;Disease Progression;DoubleBlind Method;Female;Humans;Intubation/statistics & numerical data;Male;Middle Aged;Receptors, Interleukin6/*antagonists & inhibitors;Respiratory Therapy;Treatment Failure;Young Adult;DA 2020/12/18 06:00	ClinicalTrials.gov/NCT04356937	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.	T32 AI007387/AI/NIAID NIH HHS/United States;T32 HL094301/HL/NHLBI NIH HHS/United States;ML42488/Genentech/International
652	33126772	Journal Article	O  NNLM;COVID19;fibrinolysis;heparin;pulmonary thromboembolism;sepsis;thrombin generation	DA 2020/11/01 06:01		Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis 	
653	33232303	Journal Article;Research Support, N.I.H., Intramural	O  NNLM;*COVID19;*Chemokines;*Cytokines;*Immunology	Adrenal Cortex Hormones/therapeutic use;Adult;Aged;AntiBacterial Agents/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;Biomarkers;COVID19/genetics/*immunology/*mortality/therapy;Calgranulin B/genetics/immunology;CaseControl Studies;Chemokine CCL2/genetics/immunology;Chemokine CXCL9/genetics/immunology;Enzyme Inhibitors/therapeutic use;Female;Ferritins/genetics/immunology;Gene Expression Profiling;Humans;Hydroxychloroquine/therapeutic use;Immunologic Factors/therapeutic use;Interferon Type I/genetics/immunology;Interferongamma/genetics/immunology;Interleukin1 ReceptorLike 1 Protein/genetics/immunology;Interleukin10/genetics/immunology;Interleukin15/genetics/immunology;Interleukin2/genetics/immunology;Interleukin6/genetics/immunology;Lactoferrin/genetics/immunology;Lipocalin2/genetics/immunology;Male;Matrix Metalloproteinase 9/genetics/immunology;Middle Aged;Multivariate Analysis;NFkappa B/genetics/immunology;Prognosis;Receptors, Tumor Necrosis Factor, Type I/genetics/immunology;SARSCoV2;Severity of Illness Index;Vascular Endothelial Growth Factor Receptor1/genetics/immunology;DA 2021/01/20 06:00		An immune-based biomarker signature is associated with mortality in COVID-19 	HHSN261200800001C/RC/CCR NIH HHS/United States;HHSN261200800001E/CA/NCI NIH HHS/United States
654	33416933	Journal Article;Review	O  NNLM;*COVID19 inflammasomes;*Chloroquine;*Hydroxychloroquine	AntiInflammatory Agents/*therapeutic use;COVID19/*drug therapy;Chloroquine/*therapeutic use;Cytokine Release Syndrome;Humans;Hydroxychloroquine/*therapeutic use;Inflammasomes/*drug effects;NLR Family, Pyrin DomainContaining 3 Protein/*drug effects/genetics;DA 2021/05/14 06:00		Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?	
655	33101604	Journal Article	O  NNLM;COVID19;Drug repositioning;Offtarget sites;SARSCoV2;Side chain similarity	DA 2020/10/27 06:01		Side chain similarity comparisons for integrated drug repositioning and potential 	
656	32947927	Journal Article;Review	O  NNLM;COVID19;cardiovascular diseases;treatment strategies	AngiotensinConverting Enzyme 2;Antiviral Agents/pharmacology/therapeutic use;Betacoronavirus/genetics/isolation & purification/physiology;COVID19;Cardiovascular Diseases/*diagnosis/etiology;Coronavirus Infections/complications/drug therapy/*pathology/virology;Genome, Viral;Humans;Lung Diseases/diagnosis/etiology/mortality;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/complications/drug therapy/*pathology/virology;ReninAngiotensin System;SARSCoV2;Virus Replication/drug effects;DA 2020/09/24 06:00		Cardiovascular Complications Associated with COVID-19 and Potential 	NIH RO1HL134366/NH/NIH HHS/United States;VETAR/Value and Efficiency Teaching and Research Project) sponsored by of Virginia 
657	32661006	Journal Article;Randomized Controlled Trial	O  NNLM;*COVID19;*clinical response;*interferon;*mortality	Adult;Aged;Antiviral Agents/*therapeutic use;Atazanavir Sulfate/*therapeutic use;Betacoronavirus/*drug effects/immunology/pathogenicity;COVID19;Cardiovascular Diseases/drug therapy/immunology/mortality/virology;Comorbidity;Coronavirus Infections/*drug therapy/immunology/mortality/virology;Diabetes Mellitus/drug therapy/immunology/mortality/virology;Drug Administration Schedule;Drug Combinations;Drug Therapy, Combination;Dyslipidemias/drug therapy/immunology/mortality/virology;Female;Humans;Hydroxychloroquine/therapeutic use;Intensive Care Units;Interferon beta1a/*therapeutic use;Length of Stay;Lopinavir/*therapeutic use;Male;Middle Aged;Neoplasms/drug therapy/immunology/mortality/virology;Pandemics;Patient Safety;Pneumonia, Viral/*drug therapy/immunology/mortality/virology;Ritonavir/*therapeutic use;SARSCoV2;Survival Analysis;Treatment Outcome;DA 2020/09/04 06:00		A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in 	
658	33112981	Journal Article	O  NNLM;Cytokine storm;Macrophage activation syndrome like sepsis;Ruxolitinib;Telemedicine;Viral pneumonia	Aged;*COVID19;Critical Care;Humans;Inflammation;Retrospective Studies;*SARSCoV2;DA 2021/03/11 06:00		[Interdisciplinary COVID board for patients with SARS-CoV-2-triggered 	
659	32565599	Journal Article;Review	O  NNLM;*Coronavirus disease19;*drug repurposing;*pandemic;*severe acute respiratory syndromecoronavirus2	Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;COVID19 Vaccines;*Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention & ;Developing Countries;Disease Outbreaks;Drug Repositioning;Drug Therapy, Combination;Humans;India/epidemiology;Pandemics;Pneumonia, Viral/diagnosis/epidemiology/*therapy;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/07/01 06:00		COVID-19 pandemic: A review based on current evidence.	
660	32485610	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Adverse drug reactions;*COVID19;*Dietary supplements;*Duchenne muscular dystrophy;*SARSCoV2;*Safety	*Betacoronavirus;COVID19;Coronavirus Infections/complications/*diet therapy;Dietary Supplements/*adverse effects;*Drug Interactions;Humans;Muscular Dystrophy, Duchenne/complications/*diet therapy;Pandemics;Pneumonia, Viral/complications/*diet therapy;SARSCoV2;*Standard of Care;DA 2020/07/21 06:00		Safety issues and harmful pharmacological interactions of nutritional supplements in 	
661	32758625	Journal Article;Review	O  NNLM;COVID19;Comorbidities;Coronavirus;Diabetes;Epidemiology;Management;SARSCoV2;Treatment	AngiotensinConverting Enzyme 2;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Comorbidity;Coronavirus Infections/drug therapy/*epidemiology/genetics;Diabetes Mellitus/drug therapy/*epidemiology/genetics;Disease Management;Humans;Hypoglycemic Agents/therapeutic use;Pandemics;PeptidylDipeptidase A/genetics;Pneumonia, Viral/drug therapy/*epidemiology/genetics;Polymorphism, Genetic;SARSCoV2;DA 2020/09/30 06:00		Role of comorbidities like diabetes on severe acute respiratory syndrome 	
662	32699149	Journal Article	O  NNLM;*COVID19;*anakinra;*interleukin1;*pneumonia	Aged;AntiInflammatory Agents/administration & dosage/*therapeutic use;COVID19;CaseControl Studies;Coronavirus Infections/complications/*drug therapy;Female;Humans;Immunologic Factors/administration & dosage/*therapeutic use;Injections, Intravenous;Interleukin 1 Receptor Antagonist Protein/administration & dosage/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy/etiology;Respiratory Insufficiency/*drug therapy/etiology;DA 2020/08/29 06:00		Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating 	
663	33527003	Journal Article	O  NNLM;Ageratina adenophora;Angiotensinconverting enzyme;COVID19;Main protease;Molecular docking	DA 2021/02/03 06:01		Molecular dynamics analysis of phytochemicals from Ageratina adenophora against 	
664	32493447	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Randomised controlled trial;healthcare professionals;hydroxychloroquine;prevention;protocol	Antiviral Agents/*administration & dosage/adverse effects;Betacoronavirus/*drug effects/pathogenicity;COVID19;Chemoprevention;Coronavirus Infections/diagnosis/*prevention & control/virology;DoubleBlind Method;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;Infectious Disease Transmission, PatienttoProfessional/*prevention & control;Iran;Occupational Exposure/*adverse effects;*Occupational Health;Pandemics/*prevention & control;Pneumonia, Viral/diagnosis/*prevention & control/virology;Randomized Controlled Trials as Topic;Risk Assessment;Risk Factors;SARSCoV2;Time Factors;Treatment Outcome;DA 2020/06/11 06:00		Effect of hydroxychloroquine on prevention of COVID-19 virus infection among 	
665	32828741	Case Reports;Journal Article	O  NNLM;COVID19;Coronavirus;Methylene blue;Nacetyl cysteine;Treatment;Vitamin C	Acetylcysteine/*therapeutic use;Ascorbic Acid/*therapeutic use;COVID19;*Clinical Trials, Phase I as Topic;Compassionate Use Trials;Coronavirus Infections/complications/*drug therapy;*Critical Illness;Female;Humans;Hypoxia/complications;Male;Methylene Blue/*therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy;DA 2020/10/21 06:00	ClinicalTrials.gov/NCT04370288	Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of 	
666	32947136	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Coronavirus;*RNA virus;*Respiratory disease;*SARSCoV2;*SARSCoV2 inhibitors	Amino Acid Sequence;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology;*Drug Discovery;Drug Repositioning;Humans;Pandemics;Protease Inhibitors/*therapeutic use;SARSCoV2/*drug effects;DA 2020/12/15 06:00		Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.	U19 AI142759/AI/NIAID NIH HHS/United States
667	32700055	Journal Article;Review	O  NNLM;*Adrenaline;*Autonomic;*COVID19;*Catecholamines;*Dyshomeostasis;*Homeostasis;*Stress;*Sympathetic	Autonomic Nervous System/*physiology;*Betacoronavirus;COVID19;Coronavirus Infections/diagnosis/*physiopathology;Homeostasis/*physiology;Humans;Pandemics;Pneumonia, Viral/diagnosis/*physiopathology;SARSCoV2;Stress, Physiological/*physiology;DA 2020/08/13 06:00		The extended autonomic system, dyshomeostasis, and COVID-19.	
668	33403528	Journal Article;Review	O  NNLM;*COVID19;*Clinical trials;*Outcomes;*Prevalence;*Telemedicine	Antirheumatic Agents/therapeutic use;COVID19/*complications/*therapy;Humans;Rheumatic Diseases/*complications/*therapy;*Rheumatology;Telemedicine;DA 2021/01/16 06:00		COVID-19: What Do Rheumatologists Need to Know?	
669	33442304	Journal Article;Review	O  NNLM;ARDS;SARSCoV2;chloroquine;heparin;remdesivir;steroids	DA 2021/01/15 06:01		Experimental Pharmacotherapy for COVID-19: The Latest Advances.	
670	32364011	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*3CL main protease;*COVID19;*SARSCoV2;*disulfiram;*thiolreacting drugs	DA 2020/05/05 06:00		FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main 	
671	32473596	Journal Article;Review		Animals;AntiInflammatory Agents/therapeutic use;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/complications/drug therapy/*immunology;Fibrinolytic Agents/*therapeutic use;Glycosaminoglycans/therapeutic use;Hemostasis;Humans;Inflammation/complications/*drug therapy/immunology;Pandemics;Platelet Aggregation Inhibitors/therapeutic use;Pneumonia, Viral/complications/drug therapy/*immunology;SARSCoV2;Thrombosis/complications/*drug therapy/immunology;DA 2020/07/21 06:00		Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and 	K23 HL148528/HL/NHLBI NIH HHS/United States
672	33134417	Journal Article	O  NNLM;COVID19;SARSCoV2;hydroxychloroquine;randomized controlled trial	DA 2020/11/03 06:01		Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind 	UL1 TR001445/TR/NCATS NIH HHS/United States
673	32942671	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*Zika virus;*antiviral;*dengue virus;*flavivirus;*ivermectin	Animals;Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects;COVID19;Cell Line;Chlorocebus aethiops;Coronavirus Infections/*drug therapy;Dengue/drug therapy;Dengue Virus/drug effects;HIV Infections/drug therapy;HIV Integrase/drug effects;HIV Integrase Inhibitors/pharmacology;HIV1/*drug effects;Humans;Ivermectin/*pharmacology;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Vero Cells;Zika Virus/drug effects;Zika Virus Infection/drug therapy;DA 2020/09/29 06:00		Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?	Senior Principal Research Fellowship APP1002486/APP1103050/National Health and 
674	32355446	Comment;Editorial		DA 2020/05/02 06:01		[Not Available].	
675	32684351	Journal Article;Systematic Review	O  NNLM;Antiviral research;COVID19;Clinical efficacy;SARSCoV2;Safety	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Amides/therapeutic use;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus;Biomedical Research;COVID19;Coronavirus Infections/*drug therapy/therapy;Drug Combinations;Drug Development;Drugs, Chinese Herbal/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive;Indoles/therapeutic use;Interferons/therapeutic use;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/therapy;Pyrazines/therapeutic use;Ribavirin/therapeutic use;Ritonavir/therapeutic use;SARSCoV2;DA 2020/10/21 06:00		An overview of the safety, clinical application and antiviral research of the 	
676	33388129	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Adenosine analogues;*Antiviral therapy;*RNA dependent RNA polymerase;*Remdesivir;*SARSCoV2	Adenosine Monophosphate/*analogs & derivatives/chemistry/isolation & ;Alanine/*analogs & derivatives/chemistry/isolation & purification/therapeutic use;*Antiviral Agents/chemistry/isolation & purification/therapeutic use;COVID19/*drug therapy;*Drug Discovery;Hemorrhagic Fever, Ebola/*drug therapy;Humans;DA 2021/03/09 06:00		Remdesivir: From Ebola to COVID-19.	
677	33086029	Journal Article;Review	O  NNLM;ACE2;ACEIs;ARBs and COVID19;RAS;SARSCoV2	Angiotensin Receptor Antagonists/*therapeutic use;AngiotensinConverting Enzyme 2/metabolism;AngiotensinConverting Enzyme Inhibitors/*therapeutic use;Animals;COVID19/*drug therapy/metabolism;Humans;ProtoOncogene Proteins/metabolism;Receptors, GProteinCoupled/metabolism;*ReninAngiotensin System;SARS Virus;*SARSCoV2/physiology;Severe Acute Respiratory Syndrome;DA 2020/12/30 06:00		Renin-angiotensin system at the interface of COVID-19 infection.	
678	32623632	Journal Article	O  NNLM;Acute liver injury;COVID19;Chronic liver disease;SARS CoV2	*AcuteOnChronic Liver Failure/diagnosis/virology;Asia/epidemiology;Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/epidemiology/physiopathology/therapy;Disease Progression;Female;Humans;*Liver Cirrhosis/diagnosis/epidemiology/etiology;Liver Function Tests/methods/statistics & numerical data;Male;Middle Aged;*Pandemics;Patient Acuity;*Pneumonia, Viral/epidemiology/physiopathology/therapy;Prognosis;Risk Assessment;Risk Factors;SARSCoV2;DA 2020/10/31 06:00		Pre-existing liver disease is associated with poor outcome in patients with SARS 	
679	32849425	Journal Article;Review	O  NNLM;SARSCoV2;autophagy;coronavirus;drugs;lipid rafts	DA 2020/08/28 06:01		Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic 	
680	32613089	Journal Article	O  NNLM;COVID;Pneumonia;Radiotherapy	DA 2020/07/03 06:01	ClinicalTrials.gov/NCT04380818	Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: 	
681	32838238	Journal Article	O  NNLM;Aerosol inhalation;COVID19;Clinical trial;IFNκ;SARSCoV2;Safety and efficacy;TFF2	DA 2020/08/25 06:01		A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of 	
682	33033884	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Mesenchymal stem cells;Umbilical cord;Wharton’s jelly	COVID19/*therapy;Clinical Trials as Topic;Humans;Immunomodulation;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells;Pandemics;Respiratory Distress Syndrome/virology;Umbilical Cord/*cytology;Wharton Jelly/*cytology;DA 2021/01/16 06:00		Umbilical cord: an allogenic tissue for potential treatment of COVID-19.	
683	32930657	Comparative Study;Journal Article;Observational Study	O  NNLM;coronavirus;covid 19;hydroxychloroquine;ionophore;mortality;zinc	Azithromycin/*therapeutic use;Betacoronavirus/drug effects;COVID19;Cell Membrane Permeability/drug effects;Coronavirus Infections/*drug therapy;Drug Therapy, Combination;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Ionophores/therapeutic use;Length of Stay;Pandemics;Pneumonia, Viral/*drug therapy;Retrospective Studies;SARSCoV2;Zinc Sulfate/*therapeutic use;DA 2020/11/03 06:00		Zinc sulfate in combination with a zinc ionophore may improve outcomes in 	
684	33193314	Journal Article;Multicenter Study;Research Support, NonU.S. Gov't	O  NNLM;*cerebral hypoperfusion;*coagulation;*complement;*infection;*multiple sclerosis;*platelets;*relapse	Biomarkers;Blood Coagulation/*immunology;Blood Coagulation Factors/metabolism;*Cerebrovascular Circulation;*Clinical Protocols;Complement Activation/*immunology;Complement System Proteins/immunology/metabolism;Disease Susceptibility;Gene Expression Profiling;Humans;Magnetic Resonance Imaging/methods;Multiple Sclerosis, RelapsingRemitting/*blood/*diagnosis/etiology;DA 2021/05/15 06:00	ClinicalTrials.gov/NCT04380220	Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting 	
685	32708755	Journal Article;Review	O  NNLM;*IL10;*Mas receptor;*asthma;*cardiac dysfunction;*eosinophil;*hypertension;*hypoxia;*lung fibrosis;*reninangiotensin system;*severe acute respiratory syndrome coronavirus2	AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/*pharmacology/therapeutic use;Angiotensins/metabolism;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/metabolism/*physiopathology;Feedback, Physiological/drug effects;Humans;Pandemics;PeptidylDipeptidase A/adverse effects/genetics/*metabolism;Pneumonia, Viral/*drug therapy/metabolism/*physiopathology;ReninAngiotensin System/*drug effects/genetics/physiology;Risk Factors;SARSCoV2;DA 2020/08/12 06:00		The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of 	
686	33279860	Journal Article	O  NNLM;Breath analysis;COVID19;Intensive care;Mechanical ventilation;Metabolomics	Aged;Area Under Curve;Breath Tests;COVID19/*pathology/virology;Critical Illness;Discriminant Analysis;Female;Humans;LeastSquares Analysis;Male;Metabolomics/*methods;Middle Aged;Pilot Projects;Principal Component Analysis;Prospective Studies;ROC Curve;Respiration, Artificial;Respiratory Distress Syndrome/pathology;SARSCoV2/isolation & purification;Volatile Organic Compounds/*analysis/metabolism;DA 2021/01/29 06:00		Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study.	
687	32430627	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Acute myocardial injury;*Aging;*COVID19;*Cardiovascular system;*Frailty;*SARSCoV2	Age Factors;Aged;*Betacoronavirus;COVID19;Cardiovascular Diseases/epidemiology/*virology;Coronavirus Infections/*complications/epidemiology;Female;Humans;Italy;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications/epidemiology;Risk Factors;SARSCoV2;DA 2020/08/18 06:00		COVID-19-associated cardiovascular morbidity in older adults: a position paper from 	828984/Horizon 2020 Framework Programme/International;ETHERNA 161/16/Fondazione Cassa di Risparmio di Pisa (IT)/International;Dipartimenti di Eccellenza Program (20182022)/Ministero dell'Istruzione, ;2018/FIL/International
688	33385710	Journal Article;Review	O  NNLM;COVID19;Cytokines;Inflammation;SARSCoV2;Tcells;Type2 asthma	Animals;Asthma/metabolism/*pathology/*virology;COVID19/metabolism/*pathology;Cytokines;Disease Progression;Humans;Pandemics/prevention & control;Risk Factors;SARSCoV2/pathogenicity;DA 2021/02/03 06:00		A review on the effect of COVID-19 in type 2 asthma and its management.	
689	32593339	Journal Article;Multicenter Study;Research Support, NonU.S. Gov't		*Betacoronavirus;COVID19;Child;Child, Preschool;Coronavirus Infections/*epidemiology/therapy;Delivery of Health Care/*organization & administration;Europe/epidemiology;Female;FollowUp Studies;Humans;Infant;Infant, Newborn;Intensive Care Units/*organization & administration;Male;*Pandemics;Patient Admission/trends;Pneumonia, Viral/*epidemiology/therapy;Risk Factors;SARSCoV2;DA 2020/09/02 06:00		COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort 	
690	32516704	Journal Article;Review	O  NNLM;Cancer;Covid19;Immunotherapy;Mortality;NSCLC	Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/drug therapy/immunology/mortality/*physiopathology/*therapy;Humans;Neoplasms/diagnosis/mortality/*therapy/*virology;Pandemics;Pneumonia, Viral/immunology/mortality/*physiopathology/*therapy;Respiratory Distress Syndrome/mortality/physiopathology/virology;SARSCoV2;DA 2020/07/30 06:00		Cancer and COVID-19: Unmasking their ties.	
691	32727701	Case Reports;Journal Article	O  NNLM;*Allogeneic stem cell transplantation;*COVID19;*Graftversushost disease;*Immunocompromised;*JAK inhibitor	Betacoronavirus/*immunology/isolation & purification;COVID19;Coronavirus Infections/*diagnosis/drug therapy/immunology/virology;Graft vs Host Disease/*drug therapy/etiology/immunology;Hematopoietic Stem Cell Transplantation/*adverse effects;Humans;Immunocompromised Host;Lymphoma, TCell/immunology/therapy;Male;Middle Aged;Pandemics;Pneumonia, Viral/*diagnosis/drug therapy/immunology/virology;Pyrazoles/*therapeutic use;SARSCoV2;Severity of Illness Index;Transplantation, Homologous/adverse effects;Treatment Outcome;DA 2020/11/18 06:00		Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem 	
692	32641750	Journal Article;Research Support, NonU.S. Gov't;Review		AngiotensinConverting Enzyme 2;Antineoplastic Agents, Hormonal/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus/physiology/ultrastructure;COVID19;Comorbidity;Coronavirus Infections/drug therapy/*epidemiology/immunology;Disease Susceptibility;Drug Repositioning;Female;Forecasting;Gonadal Steroid Hormones/physiology;Humans;Male;Neoplasm Proteins/antagonists & inhibitors/biosynthesis/physiology;*Pandemics;PeptidylDipeptidase A/physiology;Pneumonia, Viral/drug therapy/*epidemiology/immunology;Prostatic Neoplasms/drug therapy/*epidemiology/metabolism;Protease Inhibitors/therapeutic use;Receptors, Virus/drug effects/physiology;Risk Factors;SARSCoV2;Serine Endopeptidases/biosynthesis/physiology;*Sex Distribution;United States/epidemiology;Virus Internalization;DA 2020/07/17 06:00		Sex differences in SARS-CoV-2 infection rates and the potential link to prostate 	
693	33490839	Journal Article	O  NNLM;Complex regional pain syndrome;Hydroxychloroquine;Microglia;Neuroinflammation;Translational research	DA 2021/01/26 06:01		Of mice, microglia, and (wo)men: a case series and mechanistic investigation of 	
694	32878881	Journal Article	O  NNLM;*Angiotensin converting enzyme 2;*De novo designing;*Hybrid antiviral molecule;*Molecular dynamics simulation;*Retrosynthetic analysis;*SARSCoV2 spike glycoprotein	AngiotensinConverting Enzyme 2;Antiviral Agents/chemistry/*pharmacology;Betacoronavirus/*metabolism;Cell Death/drug effects;*Combinatorial Chemistry Techniques;Humans;Molecular Docking Simulation;PeptidylDipeptidase A/chemistry/*metabolism;Protein Binding/drug effects;Protein Domains;SARSCoV2;Spike Glycoprotein, Coronavirus/*metabolism;Thermodynamics;DA 2020/10/28 06:00		De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid 	
695	33353549	Historical Article;Journal Article;Review	O  NNLM;*Antiviral therapy;*Biologics;*COVID19;*Immune response;*JAKinhibitors;*Monoclonal antibodies;*Passive antibody administration;*SARSCoV2;*Spanish influenza;*Vaccines	COVID19/drug therapy/*epidemiology/virology;COVID19 Vaccines;History, 20th Century;History, 21st Century;Host Microbial Interactions;Humans;Influenza A Virus, H1N1 Subtype;Influenza Pandemic, 19181919/*history/statistics & numerical data;Influenza, Human/epidemiology/*history/virology;*Pandemics/statistics & numerical data;Physical Distancing;*SARSCoV2;Spain/epidemiology;Translational Medical Research;DA 2021/01/15 06:00		May the analysis of 1918 influenza pandemic give hints to imagine the possible 	
696	32838231	Journal Article	O  NNLM;Acute respiratory distress syndrome;COVID19;Coronavirus;Pandemic;Public health	DA 2020/08/25 06:01		Prognostic factors associated with mortality risk and disease progression in 639 	
697	32713677	Journal Article	O  NNLM;*Interstitial pneumonia;*Intubation;*SARSCov2	Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;Betacoronavirus/immunology;COVID19;CaseControl Studies;Coronavirus Infections/complications/*drug therapy/immunology/mortality;Female;Hospital Mortality;Humans;Infusions, Intravenous;Interleukin6/immunology/metabolism;Male;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology/mortality;Receptors, Interleukin6/*antagonists & inhibitors/metabolism;Respiratory Distress Syndrome/diagnosis/*drug therapy/immunology/mortality;Retrospective Studies;SARSCoV2;Severity of Illness Index;Survival Analysis;Treatment Outcome;DA 2020/10/28 06:00		Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe 	
698	32405269	Letter		Betacoronavirus/drug effects/immunology/pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Cytokine Release Syndrome/etiology/immunology/pathology/*prevention & control;Cytokines/*antagonists & inhibitors/genetics/immunology;Disease Progression;Gene Expression Regulation;Humans;Immunity, Innate/drug effects;Immunologic Factors/*therapeutic use;Molecular Targeted Therapy/methods;*Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARSCoV2;Sirolimus/*therapeutic use;TLymphocytes/drug effects/immunology/virology;DA 2020/07/14 06:00		Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe 	
699	33264556	Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Aged;Alanine/*analogs & derivatives/therapeutic use;Antiviral Agents/administration & dosage/adverse effects/*therapeutic use;COVID19/*drug therapy/mortality;Drug Therapy, Combination;Female;Hospital Mortality;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Intention to Treat Analysis;Interferon beta1a/*therapeutic use;KaplanMeier Estimate;Length of Stay;Lopinavir/*therapeutic use;Male;Middle Aged;Respiration, Artificial;Treatment Failure;DA 2021/02/13 06:00	ISRCTN/ISRCTN83971151;ClinicalTrials.gov/NCT04315948	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.	001/WHO_/World Health Organization/International
700	32513566	Journal Article;Review	O  NNLM;*COVID19;*Chemokines;*Cytokine storm;*Growth factors;*SARSCoV2	Betacoronavirus/*immunology;COVID19;Coronavirus Infections/immunology/mortality/*pathology;Cytokine Release Syndrome/immunology/*pathology;Cytokines/*metabolism;Humans;Pandemics;Pneumonia, Viral/immunology/mortality/*pathology;SARSCoV2;Signal Transduction/immunology;DA 2020/09/29 06:00		SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.	
701	32409561	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Antiviral Agents/*therapeutic use;COVID19;China;Coronavirus Infections/*drug therapy;Female;Humans;Hydroxychloroquine/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy;Treatment Outcome;DA 2020/05/20 06:00		Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 	
702	33400058	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*ARDS;*antiSARSCoV2 antibody;*antiviral drugs;*antiviral vaccines;*convalescent plasma therapy;*immunotherapy;*nanotherapeutics	Animals;Antiviral Agents/adverse effects/*therapeutic use;COVID19/*diagnosis/*drug therapy/*therapy/virology;*COVID19 Testing;COVID19 Vaccines/adverse effects/*therapeutic use;HostPathogen Interactions;Humans;Immunization, Passive/adverse effects;Predictive Value of Tests;SARSCoV2/*drug effects/pathogenicity;Treatment Outcome;DA 2021/01/14 06:00		Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.	R01 CA238871/CA/NCI NIH HHS/United States;R01 CA209818/CA/NCI NIH HHS/United States
703	32577649	Preprint		DA 2020/06/25 06:01		Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing 	R01 HL119215/HL/NHLBI NIH HHS/United States;R01 DK120623/DK/NIDDK NIH HHS/United States;UL1 TR002240/TR/NCATS NIH HHS/United States;T32 DE007057/DE/NIDCR NIH HHS/United States;U19 AI116482/AI/NIAID NIH HHS/United States;KL2 TR000434/TR/NCATS NIH HHS/United States
704	32898838	Journal Article	O  NNLM;COVID19;Hypothiocyanite;Lactoferrin;Lactoperoxidase;Nasal disinfection;SARSCoV2	DA 2020/09/09 06:00		Nasal disinfection for the prevention and control of COVID-19: A scoping review on 	
705	32411313	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Anakinra;*COVID19;*HScore;*SARSCoV2;*ferritin;*hemophagocytic lymphohistocytosis;*pneumonia;*respiratory function	Aged;Aged, 80 and over;*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/*complications/*drug therapy;Female;Humans;Interleukin 1 Receptor Antagonist Protein/*therapeutic use;Lymphohistiocytosis, Hemophagocytic/*drug therapy/etiology;Male;Middle Aged;OffLabel Use;Oxygen/blood;Pandemics;Pneumonia, Viral/*complications/*drug therapy;Respiratory Insufficiency/prevention & control;SARSCoV2;DA 2020/07/18 06:00		Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary 	
706	32482250	Journal Article;Systematic Review	O  NNLM;*COVID19;*Novel coronavirus;*pregnancy;*reproduction;*review	Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/complications/diagnosis/*virology;Female;Fertility;HostPathogen Interactions;Humans;Infertility, Female/diagnosis/physiopathology/*virology;Infertility, Male/diagnosis/physiopathology/*virology;Male;Orchitis/diagnosis/physiopathology/*virology;Pandemics;Pneumonia, Viral/complications/diagnosis/*virology;Pregnancy;Pregnancy Complications, Infectious/physiopathology/virology;Pregnancy Outcome;*Reproduction;Risk Assessment;Risk Factors;SARSCoV2;Sperm Count;Sperm Motility;DA 2020/06/11 06:00		Prior and novel coronaviruses, Coronavirus Disease 2019 (COVID-19), and human 	
707	32467561	Journal Article;Research Support, NonU.S. Gov't;Review		Adaptive Immunity/drug effects;AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/immunology/pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Cytokines/antagonists & inhibitors/genetics/immunology;Disease Progression;Gastrointestinal Microbiome/immunology;Gene Expression Regulation;HostPathogen Interactions/*drug effects/genetics/immunology;Humans;Immunity, Innate/drug effects;Molecular Targeted Therapy;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARSCoV2;Signal Transduction/*drug effects/genetics/immunology;Spike Glycoprotein, Coronavirus/genetics/immunology;TLymphocytes/drug effects/immunology/virology;TollLike Receptors/genetics/immunology;DA 2020/06/13 06:00		Immune response in COVID-19: addressing a pharmacological challenge by targeting 	
708	32785135	Journal Article	O  NNLM;COVID19;adverse drug events;older adults;polypharmacy;simulation	DA 2020/08/14 06:01		Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed 	
709	33092737	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;arrhythmia;myocardial injury;thrombosis	Betacoronavirus;COVID19;Cardiovascular Diseases/*virology;Coronavirus Infections/*complications;Humans;Pandemics;Pneumonia, Viral/*complications;SARSCoV2;DA 2020/10/30 06:00		Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: 	T32 HL007843/HL/NHLBI NIH HHS/United States
710	32743601	Preprint		DA 2020/08/04 06:01		Population Data-Driven Formulation of a COVID-19 Therapeutic.	
711	32958495	Adaptive Clinical Trial;Clinical Trial Protocol;Clinical Trial, Phase III;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't	O  NNLM;*clinical trials;*infectious diseases;*intensive & critical care;*public health;*respiratory infections	Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Adult;Alanine/*analogs & derivatives/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/therapy;Drug Combinations;Drug Therapy, Combination;Early Warning Score;Extracorporeal Membrane Oxygenation;Hospital Mortality;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Interferon beta1a/*therapeutic use;Length of Stay;Lopinavir/*therapeutic use;Oxygen Inhalation Therapy;Pandemics;Pneumonia, Viral/*drug therapy/therapy;Respiration, Artificial;Ritonavir/*therapeutic use;SARSCoV2;Standard of Care;Treatment Outcome;DA 2020/10/06 06:00	ClinicalTrials.gov/NCT04315948;EudraCT/EudraCT 202000093623	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the 	
712	33359141	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Coronavirus disease 2019 (COVID19);*Immune response;*Neutralizing antibodies;*Severe acute respiratory syndrome coronavirus 2 (SARSCoV2);*Vaccine delivery	Animals;Antiviral Agents/*administration & dosage/immunology;COVID19/*epidemiology/immunology/*prevention & control;COVID19 Vaccines/*administration & dosage/chemical synthesis/immunology;Drug Development/*methods/trends;Humans;Immunization Programs/methods/trends;SARSCoV2/*drug effects/immunology;DA 2021/04/01 06:00		COVID-19 vaccines: The status and perspectives in delivery points of view.	
713	33029696	Journal Article;Review	O  NNLM;ARDS;Cytokine storm syndrome;Herd immunity;Rheumatoid arthritis;Vaccine nationalism;Vertical transmission	AngiotensinConverting Enzyme 2/*genetics;COVID19/*drug therapy/genetics/therapy/virology;China;Chloroquine/therapeutic use;Drug Repositioning/methods;Humans;Immunization, Passive/methods;*Pandemics;SARSCoV2/*genetics/pathogenicity;DA 2021/02/13 06:00		Role of ACE2 receptor and the landscape of treatment options from convalescent 	TAR/2018/001054/Science and Engineering Research Board/
714	32833695	Case Reports;Journal Article;Research Support, NonU.S. Gov't		COVID19/*complications/*therapy;Critical Illness;Cytokines/biosynthesis;Humans;Inflammation Mediators/metabolism;Macrophages/metabolism;Male;Middle Aged;Multiple Organ Failure/*etiology;Plasma Exchange/*methods;SARSCoV2;Severity of Illness Index;DA 2020/12/22 06:00		Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With 	
715	33072781	Systematic Review	O  NNLM;COVID19;SARSCoV2;antivirals;clinical trials;drug development;immunomodulators;research protocols	DA 2020/10/20 06:01		The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 	
716	33291603	Journal Article;Review	O  NNLM;Patients Derived Tumor Organoids (PDTOs);anticancer care;drug repurposing;living biobank;translational oncology	DA 2020/12/10 06:01		Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising 	
717	33519271	Journal Article;Review	O  NNLM;Acute respiratory distress syndrome (ARDS);COVID19;Cytokine storm;Immunomodulators;Immunotherapeutics;MERSCoV;SARSCoV;SARSCoV2	DA 2021/02/02 06:01		Immune system response during viral Infections: Immunomodulators, cytokine storm 	
718	32224769	Journal Article		Betacoronavirus;COVID19;Coronavirus Infections/*therapy;Critical Illness;Diagnostic Techniques and Procedures/standards;Humans;Infection Control/methods/standards;Intensive Care Units/*organization & administration/standards;Pandemics;Pneumonia, Viral/*therapy;Practice Guidelines as Topic/*standards;Respiration, Artificial/methods/standards;SARSCoV2;Shock/therapy;DA 2020/06/05 06:00		Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults 	
719	32663575	Journal Article;Review	O  NNLM;COVID19;Cytokine storm;Dexamethasone;Hydroxychloroquine;IL1 inhibitors;IL6 inhibitors;JAK inhibitors;Mast cell stabilizers	Adrenal Cortex Hormones/pharmacology;AntiInflammatory Agents/pharmacology;Betacoronavirus/immunology/pathogenicity;COVID19;Coronavirus/immunology/pathogenicity;Coronavirus Infections/*drug therapy/*immunology/pathology/virology;Cytokines/immunology;Dexamethasone/*pharmacology;Humans;Pandemics;Pneumonia, Viral/*drug therapy/*immunology/pathology/virology;Respiratory Distress Syndrome/drug therapy;SARSCoV2;DA 2020/09/30 06:00		Tackling the cytokine storm in COVID-19, challenges and hopes.	
720	33053381	Journal Article;Review	O  NNLM;Antirheumatic drugs;Antiviral agents;COVID19;Inflammation inhibitors;Low molecular weight heparins;SARSCoV2	COVID19/diagnosis/*drug therapy;Humans;Pandemics;SARSCoV2/drug effects;DA 2020/12/22 06:00		Treatment for COVID-19: An overview.	
721	32750442	Journal Article	O  NNLM;*COVID19;*Calcineurin inhibitors;*Epidemiology;*Everolimus;*Immunosuppression;*Mycophenolate;*Pneumonia;*SARSCoV2;*Standardised incidence;*Standardised mortality;*Tacrolimus;*Transplantation	Aged;COVID19/*epidemiology/mortality;Calcineurin Inhibitors/therapeutic use;Female;Hospitalization;Humans;Immunosuppression;Immunosuppressive Agents/therapeutic use;Incidence;*Liver Transplantation;Male;Middle Aged;Mycophenolic Acid/therapeutic use;Prospective Studies;Spain/epidemiology;*Transplant Recipients;DA 2020/12/30 06:00		Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant 	
722	33251500	Journal Article	O  NNLM;Azithromycin;Covid19;Hyodroxychloroquine	DA 2020/12/01 06:01	ClinicalTrials.gov/NCT04349592	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or 	
723	32665090	Journal Article;Review	O  NNLM;Dexamethasone;Hydroxychloroquine;Pharmacology;Rheumatoid arthritis;Rheumatology	AntiInflammatory Agents, NonSteroidal/administration & dosage;Antirheumatic Agents/administration & dosage;Autoimmune Diseases/drug therapy/*epidemiology;COVID19;Chloroquine/administration & dosage;Coronavirus Infections/*epidemiology/mortality;Humans;Hydroxychloroquine/administration & dosage;Incidence;Pandemics;Pneumonia, Viral/*epidemiology/mortality;Rheumatic Diseases/drug therapy/*epidemiology;DA 2020/09/02 06:00		Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A 	
724	32982751	Journal Article	O  NNLM;ClinicalTrials.gov;SARSCoV2;clinical trial;coronavirus disease 2019;registration	DA 2020/09/29 06:01		Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis.	
725	33204763	Editorial	O  NNLM;COVID19;adaptive clinical trials;diffusion of innovations;implementation science	DA 2020/11/19 06:01		"Bringing New Meaning to the Term ""Adaptive Trial"": Challenges of Conducting Clinical "	
726	32474009	Journal Article;Review	O  NNLM;COVID19;Prevention;SARSCoV2;Transmission;Treatment	Adrenal Cortex Hormones/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/*drug effects/pathogenicity;COVID19/*epidemiology/prevention & control/*therapy/transmission;COVID19 Vaccines;Clinical Trials as Topic;Coronavirus Infections/*epidemiology/prevention & control/*therapy/transmission;Drug Repositioning;Humans;Immunization, Passive/methods;Immunologic Factors/therapeutic use;Molecular Targeted Therapy/methods;*Pandemics/prevention & control;Personal Protective Equipment;Physical Distancing;Pneumonia, Viral/*epidemiology/prevention & control/*therapy/transmission;SARSCoV2;Viral Vaccines/biosynthesis;DA 2020/07/23 06:00		COVID-19: Transmission, prevention, and potential therapeutic opportunities.	
727	32547625	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;pandemic;remdesivir	DA 2020/06/18 06:01		The journey of remdesivir: from Ebola to COVID-19.	
728	32397688	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*coronavirus;*pandemic;*viral genomics	Betacoronavirus/*physiology;COVID19;COVID19 Vaccines;Coronavirus Infections/drug therapy/*epidemiology/genetics/immunology/prevention & ;Genomics;Humans;Pandemics;Pneumonia, Viral/*epidemiology/genetics/immunology/*therapy;SARSCoV2;Viral Vaccines/immunology;DA 2020/05/20 06:00		SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic 	
729	32754463	Editorial	O  NNLM;COVID19;SARSCoV2;pandemic;quarantine;remdesivir;social distancing	DA 2020/08/06 06:01		Preventive and treatment strategies of COVID-19: From community to clinical trials.	
730	32607499	Journal Article;Review		DA 2020/07/02 06:01		Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a 	
731	32777550	Journal Article;Systematic Review	O  NNLM;*COVID19;*Crohn’s Disease;*Inflammatory Bowel Disease;*SARSCoV2;*Ulcerative Colitis	*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/*epidemiology;*Disease Management;Global Health;Humans;Inflammatory Bowel Diseases/*epidemiology/therapy;*Intensive Care Units;*Pandemics;Pneumonia, Viral/*epidemiology;Prevalence;SARSCoV2;DA 2020/11/06 06:00		Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 	
732	32734394	Journal Article	O  NNLM;COVID19;Cancer;Coronavirus;Intensive care unit;Management;Pandemic	Adult;Aged;Aged, 80 and over;*Betacoronavirus;COVID19;Coronavirus Infections/*complications;Female;Hospitalization;Humans;*Intensive Care Units;Male;Middle Aged;Neoplasms/complications/epidemiology/*therapy;Pandemics;Pneumonia, Viral/*complications;SARSCoV2;Young Adult;DA 2020/09/02 06:00		COVID-19 management in a cancer center: the ICU storm.	
733	33204764	Journal Article	O  NNLM;*COVID19;*SARSCov2;*hydroxychloroquine;*safety;*side effects	DA 2020/11/19 06:01	ClinicalTrials.gov/NCT04328467	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for 	R01 NS110519/NS/NINDS NIH HHS/United States;R01 NS086312/NS/NINDS NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;U01 AI125003/AI/NIAID NIH HHS/United States;T32 GM007347/GM/NIGMS NIH HHS/United States;L30 TW011500/TW/FIC NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States;K08 AI134262/AI/NIAID NIH HHS/United States
734	32868989	Case Reports	O  NNLM;ARDS, acute respiratory distress syndrome;COPD;COPD, chronic obstructive pulmonary disease;COVID19;COVID19, coronavirus disease 2019;CRP, Creactive protein;CT, computed tomography;Favipiravir;GOLD, The Global Initiative for Chronic Obstructive Lung Disease;ICU, intensive care unit;MERS, middle east respiratory syndrome;PCR, polymerase chain reaction;Pneumonia;RSV, respiratory syncytial virus;SARSCoV2;SFTSV, severe fever with thrombocytopenia syndrome virus;SRASCoV2, severe acute respiratory syndrome coronavirus 2;SpO2, peripheral capillary oxygen saturation;Systemic corticosteroid;WBC, white blood cell	DA 2020/09/02 06:01		Combination treatment of short-course systemic corticosteroid and favipiravir in a 	
735	32391719	Journal Article;Review	O  NNLM;COVID19;Coronavirus;SARSCoV2;cardiovascular;comorbidities;risk factors	COVID19;Cardiovascular Agents/*administration & dosage/pharmacology;Cardiovascular Diseases/diagnosis/*drug therapy/*epidemiology;*Cause of Death;Comorbidity;Coronavirus Infections/*epidemiology/prevention & control;Europe/epidemiology;Female;Humans;Male;Pandemics/prevention & control/*statistics & numerical data;Pneumonia, Viral/*epidemiology/prevention & control;Prevalence;Risk Assessment;Survival Analysis;DA 2020/07/07 06:00		Cardiovascular disease and COVID-19: les liaisons dangereuses.	
736	32630746	Journal Article;Review	O  NNLM;SARSCoV2;chloroquine;convalescent plasma;hydroxychloroquine;lopinavir/ritonavir;remdesivir	DA 2020/07/08 06:01		SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical 	
737	32880806	Comment;Letter		*Betacoronavirus;COVID19;*Coronavirus Infections/drug therapy;Humans;Immunomodulation;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/10/02 06:00		"Authors' Reply to Vrachatis et al. ""Pharmaco-Immunomodulatory Therapy I COVID-19""."	
738	33138839	Journal Article;Observational Study;Research Support, NonU.S. Gov't	O  NNLM;*Acute respiratory distress syndrome;*Biomarker;*Bronchoalveolar lavage;*COVID19;*CXCL10;*Immune response;*Mechanical ventilation;*Mitochondrial DNA;*SARSCoV2	Adult;Aged;COVID19;CaseControl Studies;Chemokine CXCL10/*metabolism;Coronavirus Infections/*complications;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications;Prospective Studies;Respiration, Artificial/*statistics & numerical data;Respiratory Distress Syndrome/*etiology/*therapy;Time Factors;DA 2020/11/06 06:00	ClinicalTrials.gov/NCT03955887	CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS.	
739	32563812	Journal Article;Review	O  NNLM;Antiviral;COVID19;Coronavirus;RdRP inhibitor;Remdesivir (GS5734)	Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Alanine/*analogs & derivatives/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/virology;Humans;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/08/11 06:00		A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of 	
740	32282502	Journal Article;Review		Betacoronavirus/isolation & purification;COVID19;Cardiovascular Diseases/*drug therapy/metabolism/*virology;Clinical Trials, Phase III as Topic;Coronavirus Infections/*drug therapy/metabolism/virology;Drug Interactions;Humans;Pandemics;Pneumonia, Viral/*drug therapy/metabolism/virology;Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/05/20 06:00		Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 	UL1 TR002649/TR/NCATS NIH HHS/United States
741	32888871	Comparative Study;Journal Article;Review	O  NNLM;Chinese experience;Coronavirus disease 2019 (COVID19);Pandemic;SARS;SARSCoV2	Betacoronavirus;COVID19;COVID19 Vaccines;China/epidemiology;Clinical Trials as Topic;Coronavirus Infections/drug therapy/*epidemiology/immunology/prevention & ;Humans;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/drug therapy/*epidemiology/transmission;*Public Health;SARS Virus;SARSCoV2;Severe Acute Respiratory Syndrome/drug therapy/*epidemiology/transmission;Viral Vaccines/immunology;World Health Organization;DA 2020/11/18 06:00		From SARS to COVID-19: What lessons have we learned?	
742	32871238	Comparative Study;Journal Article;Randomized Controlled Trial	O  NNLM;*1α, 25(OH)2D or 1α, 25dihydroxyvitamin D or calcitriol;*Acute respiratory distress syndrome (ARDS);*COVID19;*Calcifediol or 25hydroxyvitamin D3;*Cathelicidin peptide;*Chloroquine;*Covidiol;*Cuboidal alveolar coating cells type II;*Cytokine/Chemokine storm;*Defensins;*Hydroxychloroquine;*Hypercoagulability;*Neutrophil activity;*Reninangiotensin system;*SARSCoV2;*TLR coreceptor CD14;*Vitamin D;*Vitamin D endocrine system;*Vitamin D receptor;*Vitamin D3 or cholecalciferol	Betacoronavirus/*isolation & purification;Bone Density Conservation Agents/*therapeutic use;COVID19;Calcifediol/*therapeutic use;Coronavirus Infections/drug therapy/*mortality/virology;DoubleBlind Method;Female;Hospitalization/*statistics & numerical data;Humans;Intensive Care Units/*statistics & numerical data;Male;Middle Aged;Pandemics;Pilot Projects;Pneumonia, Viral/drug therapy/*mortality/virology;Prognosis;SARSCoV2;DA 2020/10/21 06:00		"""Effect of calcifediol treatment and best available therapy versus best available "	
743	33087047	Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;Coronavirus disease 2019;Intravenous immunoglobulin;SARSCoV2;Severe infection	Adult;Aged;Betacoronavirus/*genetics;COVID19;Coronavirus Infections/*drug therapy/*epidemiology/mortality/virology;DoubleBlind Method;Female;Hospital Mortality;Humans;Immunoglobulin G/*therapeutic use;Immunoglobulins, Intravenous/*therapeutic use;Iran/epidemiology;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/*epidemiology/mortality/virology;Retrospective Studies;SARSCoV2;Severity of Illness Index;Treatment Outcome;DA 2020/10/28 06:00		The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus 	
744	33245507	Comment;Letter		*COVID19/drug therapy;*DrugRelated Side Effects and Adverse Reactions;Female;Humans;*Long QT Syndrome/chemically induced/diagnosis;Lopinavir/adverse effects;Male;*Pharmaceutical Preparations;SARSCoV2;Sex Characteristics;DA 2021/02/05 06:00		Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc 	
745	33406353	Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Aged;Aged, 80 and over;Blood Component Transfusion;COVID19/complications/*therapy;Disease Progression;DoubleBlind Method;Female;Humans;Immunization, Passive;Immunoglobulin G/*blood;Intention to Treat Analysis;KaplanMeier Estimate;Male;Respiratory Insufficiency/etiology/*prevention & control;SARSCoV2/*immunology;Severity of Illness Index;DA 2021/02/24 06:00	ClinicalTrials.gov/NCT04479163	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.	001/WHO_/World Health Organization/International
746	32437797	Journal Article;Review	O  NNLM;COVID19;Repurposing drugs;SARSCoV2;Spike proteins;Zoonotic origin	Animals;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*epidemiology/*therapy/virology;Pandemics/prevention & control;Pneumonia, Viral/*epidemiology/*therapy/virology;SARSCoV2;Zoonoses/epidemiology/therapy/virology;DA 2020/06/23 06:00		The current understanding and potential therapeutic options to combat COVID-19.	
747	33519949	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Influenza, Pulmonary drug delivery;MERS, Nanomedicine;Nanotechnology;Nanotherapeutics;Pathophysiology;SARS, SARSCoV2	DA 2021/02/02 06:01		Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary 	
748	33234158	Letter;Randomized Controlled Trial	O  NNLM;COVID19;Hospitalization;Ivermectin;Protocol;Randomized controlled trial	Adult;Antiparasitic Agents/administration & dosage/*therapeutic use;Argentina/epidemiology;COVID19/*drug therapy/epidemiology/virology;CaseControl Studies;DoubleBlind Method;Female;Hospitalization/statistics & numerical data;Humans;Ivermectin/administration & dosage/*therapeutic use;Male;Pandemics/prevention & control;Placebos/administration & dosage;Prospective Studies;SARSCoV2/*genetics;Time Factors;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04529525	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): 	
749	32432996	Comparative Study;Journal Article;Multicenter Study;Observational Study;Research Support, N.I.H., Extramural	O  NNLM;*COVID19;*coronavirus;*diagnosis;*pandemic;*troponin	Adult;Aged;*Betacoronavirus;Biomarkers;Blood Sedimentation;Brain Ischemia/blood/*epidemiology/etiology/therapy;COVID19;Causality;Cerebral Small Vessel Diseases/complications/diagnostic imaging/epidemiology;Comorbidity;Coronavirus Infections/blood/complications/*epidemiology;Female;Fibrin Fibrinogen Degradation Products/analysis;Humans;Incidence;Male;Middle Aged;Neuroimaging;New York City/epidemiology;*Pandemics;Patient Admission/statistics & numerical data;Pneumonia, Viral/blood/complications/*epidemiology;Retrospective Studies;SARSCoV2;Severity of Illness Index;Stroke/blood/*epidemiology/etiology/therapy;Thrombophilia/etiology;Troponin/blood;DA 2020/07/07 06:00		SARS-CoV-2 and Stroke in a New York Healthcare System.	K08 NS091499/NS/NINDS NIH HHS/United States
750	32847594	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*1,25(OH)2D3;*25(OH)D;*COVID19;*Coronavirus;*Extrarenal;*IL6;*Immunomodulation;*Infection;*Metabolism;*NFkB;*NGF;*TNF;*Vitamin D	Betacoronavirus/drug effects/physiology;Brain/drug effects/physiology;COVID19;Chemoprevention/*methods;Coronavirus Infections/epidemiology/physiopathology/*prevention & control/*therapy;Dietary Supplements;Humans;Immune System/drug effects/physiology;Immunomodulation/*drug effects;Neuroprotection/drug effects;Neuroprotective Agents/*therapeutic use;Pandemics/*prevention & control;Pneumonia, Viral/epidemiology/physiopathology/*prevention & control/*therapy;SARSCoV2;Vitamin D/metabolism/pharmacology/*therapeutic use;Vitamin D Deficiency/diet therapy/epidemiology/metabolism/virology;DA 2020/09/15 06:00		The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory 	ASP2020/Loma Linda University/International;RIG/Loma Linda University/International
751	33173808	Journal Article;Review	O  NNLM;COVID‐19;antivirals;anti‐inflammatory drugs;convalescent plasma;immune therapy;nanomedicines;vaccines	DA 2020/11/12 06:00		Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to 	
752	32681537	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*drug repurposing;*drug safety;*toxicology	Antiviral Agents/*adverse effects/*therapeutic use;COVID19/*drug therapy;Drug Repositioning;Humans;Pandemics;Risk Assessment;Safety;DA 2020/12/18 06:00		Safety perspectives on presently considered drugs for the treatment of COVID-19.	MR/L006758/1/MRC_/Medical Research Council/United Kingdom;G0700654/MRC_/Medical Research Council/United Kingdom
753	32586363	Clinical Trial Protocol;Clinical Trial, Phase II;Clinical Trial, Phase III;Letter;Multicenter Study	O  NNLM;Acute Lymphoid Leukemia;Acute Myeloid Leukemia;Breast cancer;COVID19;Colon cancer;Hydroxychloroquine;Prophylaxis;Protocol;Randomised controlled trial	Adolescent;Adult;Aged;Aged, 80 and over;*Betacoronavirus;COVID19;Coronavirus Infections/*prevention & control;Humans;Hydroxychloroquine/*therapeutic use;Middle Aged;Neoplasms/*complications/therapy;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control;SARSCoV2;Young Adult;DA 2020/07/08 06:00		Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing 	990046/Mashhad University of Medical Sciences/
754	33330858	Preprint		DA 2020/12/18 06:01		Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, 	R01 AG066749/AG/NIA NIH HHS/United States;R01 LM012806/LM/NLM NIH HHS/United States
755	33138974	Journal Article;Multicenter Study;Observational Study	O  NNLM;*COVID19;*Coronavirus;*Intensive care unit;*Mexico;*Outcomes;*SARSCoV2 infection	*COVID19;Critical Illness;Humans;Intensive Care Units;Male;Mexico/epidemiology;Middle Aged;SARSCoV2;DA 2020/12/22 06:00	ClinicalTrials.gov/NCT04336345	Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A 	
756	32451271	Journal Article;Review	O  NNLM;*cardiac complications;*cardiac injury;*coronavirus disease2019;*inflammatory factors;*pneumonia	*COVID19;*Cardiovascular Diseases/diagnosis/epidemiology/etiology;*Coronavirus;*Coronavirus Infections/diagnosis/epidemiology/therapy;Humans;Pandemics;SARSCoV2;DA 2021/04/29 06:00		Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications.	
757	32835256	Journal Article		DA 2020/08/25 06:01		GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic 	R01 HL085453/HL/NHLBI NIH HHS/United States;R01 HL118342/HL/NHLBI NIH HHS/United States
758	33376717	Journal Article		Aged;Anticoagulants/therapeutic use;Biopsy/methods;COVID19/*drug therapy/*pathology/virology;Glucocorticoids/therapeutic use;Humans;Lung/*drug effects/*pathology/virology;Male;Respiration, Artificial;Respiratory Distress Syndrome/*drug therapy/virology;SARSCoV2/drug effects;DA 2021/01/12 06:00		What Open-Lung Biopsy Teaches Us about ARDS in COVID-19 Patients: Mechanisms, 	
759	33472855	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adolescent;Adult;Aged;Aged, 80 and over;AntiInflammatory Agents/*therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/diagnosis/*drug therapy/mortality/therapy;Critical Illness;Female;FollowUp Studies;Hospitalization;Humans;Infusions, Intravenous;Male;Middle Aged;Respiration, Artificial;Severity of Illness Index;Treatment Outcome;Young Adult;DA 2021/01/28 06:00	ClinicalTrials.gov/NCT04403685	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or 	
760	32341910	Case Reports	O  NNLM;COVID19;Hydroxychloroquine;Pandemic;SARSCoV2	DA 2020/04/29 06:01		SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: 	
761	32405236	Comparative Study;Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Coronaviruses;*Diagnosis;*Influenza A viruses;*Prevention;*Therapy;*Transmission	Age Factors;Animals;Betacoronavirus;COVID19;Coronavirus Infections/complications/*diagnosis/prevention & control/transmission;Humans;Influenza A virus/pathogenicity;Influenza, Human/complications/*diagnosis/prevention & control/transmission;Middle East Respiratory Syndrome Coronavirus/pathogenicity;Pandemics/prevention & control;Pneumonia, Viral/complications/*diagnosis/prevention & control/transmission;Public Health;Respiratory Tract Infections/transmission/*virology;SARS Virus/pathogenicity;SARSCoV2;*Seasons;Severe Acute Respiratory Syndrome/diagnosis/virology;DA 2020/08/15 06:00		Comparative review of respiratory diseases caused by coronaviruses and influenza A 	
762	32838354	News		DA 2020/08/25 06:01		What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials.	NIHRRP011053/DH_/Department of Health/United Kingdom
763	32294495	Editorial		Animals;Antimalarials/therapeutic use;Antiviral Agents/*therapeutic use;Azithromycin/therapeutic use;Betacoronavirus/*drug effects;COVID19;Chlorocebus aethiops;Chloroquine/*therapeutic use;Coronavirus Infections/drug therapy/*prevention & control;Drug Therapy, Combination;Humans;Hydroxychloroquine/*therapeutic use;Pandemics/*prevention & control;Pneumonia, Viral/drug therapy/*prevention & control;PreExposure Prophylaxis/*methods;SARSCoV2;Vero Cells;DA 2020/06/17 06:00		Chloroquine as a prophylactic agent against COVID-19?	
764	33373644	Journal Article;Research Support, N.I.H., Extramural	O  NNLM;*COVID19;*Clinical features;*Physiopathology;*Treatment	COVID19/*complications/transmission/virology;Cardiovascular Diseases/*drug therapy/epidemiology/physiopathology/virology;Disease Management;Global Health;Humans;Lung Diseases/*drug therapy/epidemiology/physiopathology/virology;SARSCoV2/*isolation & purification;United States/epidemiology;DA 2021/04/21 06:00		Pathophysiology and pharmacological management of pulmonary and cardiovascular 	T32 HL007824/HL/NHLBI NIH HHS/United States;R01 HL133554/HL/NHLBI NIH HHS/United States
765	33493590	Journal Article		DA 2021/01/26 06:00	ClinicalTrials.gov/NCT04333693	Outcomes After Vascular Surgery Procedures in Patients with COVID-19 Infection: A 	
766	32247318	Journal Article		*Antimalarials/adverse effects/therapeutic use;*Betacoronavirus;COVID19;*Chloroquine/adverse effects/therapeutic use;Coronavirus Infections/*drug therapy;Humans;*Hydroxychloroquine/adverse effects/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;*Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/05/12 06:00		A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and 	
767	32835273	Case Reports	O  NNLM;CAD, cationic amphiphilic drug;COVID19;COVID19, coronavirus disease2019;SARSCoV2;SARSCoV2, severe acute respiratory syndromecoronavirus2;amiodarone	DA 2020/08/25 06:01		Safety and Efficacy of Amiodarone in a Patient With COVID-19.	
768	32395418	Journal Article;Review	O  NNLM;Anakinra;Azithromycin;COVID19;Chloroquine;Convalescent plasma;Epoprostenol;Favipiravir;Hydroxychloroquine;Lopinavir;Methylprednisolone;Nitric oxide;Oseltamivir;Remdesivir;SARCoV2;Sarilumab;Sirolimus;Tocilizumab;Traditional Chinese Medicine;Umifenovir;Vitamin C	DA 2020/05/13 06:00		An Update on Current Therapeutic Drugs Treating COVID-19.	
769	33227708	Journal Article;Review	O  NNLM;Azithromycin;COVID19;Chloroquine/hydroxychloroquine;Interferons;Treatment;Vaccine	Antiviral Agents/*therapeutic use;Azithromycin/*therapeutic use;COVID19/*prevention & control;COVID19 Vaccines/*therapeutic use;Chloroquine/*therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Interferons/*therapeutic use;Treatment Outcome;DA 2021/01/01 06:00		Prevention and treatment of COVID-19: Focus on interferons, 	
770	32984620	Journal Article;Review	O  NNLM;Antisense;Aptamers;Biotechnology;Covid19;DNAzymes;Epidemiology;Microbiology;Molecular biology;Nucleic acid based therapy;Oligonucleotide;Regenerative medicine;Ribozymes;SARSCoV2;Virology;siRNA	DA 2020/09/29 06:01		Nucleic acid-based therapy for coronavirus disease 2019.	
771	32557532	Case Reports;Letter		Antibodies, Monoclonal, Humanized/*adverse effects;Betacoronavirus/*immunology/isolation & purification;Brugada Syndrome/complications;COVID19;COVID19 Testing;Ceftriaxone/therapeutic use;Clinical Laboratory Techniques/methods;Continuous Positive Airway Pressure;Coronavirus Infections/diagnosis/drug therapy/*immunology/therapy/virology;Humans;Hydroxychloroquine/therapeutic use;Lung Diseases, Interstitial/diagnosis/*immunology/therapy/virology;Male;Middle Aged;Nasopharynx/virology;Pandemics;Pneumonia, Viral/diagnosis/*immunology/therapy/virology;Psoriasis/complications/*drug therapy/immunology;SARSCoV2;Treatment Outcome;DA 2020/07/21 06:00		Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with 	
772	33079850	Journal Article;Review		AntiInflammatory Agents/adverse effects/*therapeutic use;Anticoagulants/adverse effects/*therapeutic use;Betacoronavirus/*pathogenicity;Biomarkers/blood;Blood Coagulation/*drug effects;COVID19;Coronavirus Infections/blood/mortality/*therapy/virology;EvidenceBased Medicine;Fibrin Fibrinogen Degradation Products/analysis;Hospital Mortality;HostPathogen Interactions;Humans;Inflammation/blood/mortality/*therapy/virology;Inflammation Mediators/blood;Pandemics;Pneumonia, Viral/blood/mortality/*therapy/virology;Prognosis;Pulmonary Embolism/blood/mortality/*therapy/virology;Risk Factors;SARSCoV2;Venous Thromboembolism/blood/mortality/*therapy/virology;Venous Thrombosis/blood/mortality/*therapy/virology;DA 2020/10/29 06:00		COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already 	
773	32807209	Clinical Trial Protocol;Clinical Trial, Phase II;Clinical Trial, Phase III;Comparative Study;Journal Article;Multicenter Study	O  NNLM;Azithromycin;COVID19;Coronavirus;Macrolide;Mortality;Randomised controlled trial;Respiratory failure;SARCoV2;Trial	AntiBacterial Agents/*therapeutic use;Azithromycin/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Humans;Pandemics;Pneumonia, Viral/*drug therapy;Prospective Studies;*Randomized Controlled Trials as Topic;Research Design;SARSCoV2;Severity of Illness Index;DA 2020/08/26 06:00	ClinicalTrials.gov/NCT04381962	A multi-centre open-label two-arm randomised superiority clinical trial of 	
774	33376955	Journal Article;Review	O  NNLM;ACE2;COVID‐19;Interferon;SARS‐CoV‐2;Treatment	DA 2020/12/31 06:01		Type I interferon: From innate response to treatment for COVID-19.	
775	33181328	Journal Article;Randomized Controlled Trial		Administration, Oral;Adult;Aged;Amides/*administration & dosage;Antiviral Agents/*administration & dosage;COVID19/*drug therapy/virology;Drug Therapy, Combination;Female;Hospitalization;Humans;Hydroxychloroquine/administration & dosage;Interferon beta1b/*administration & dosage;Male;Middle Aged;Pyrazines/*administration & dosage;SARSCoV2/drug effects/physiology;Treatment Outcome;DA 2021/01/20 06:00		Randomized controlled open label trial on the use of favipiravir combined with 	
776	33397585	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Cytokine storm;*Cytokines/chemokines;*Mesenchymal stromal/stem cells;*Pleiotropic therapy;*SARSCoV2	COVID19/epidemiology/*therapy;Cell and TissueBased Therapy/methods/trends;Humans;*Mesenchymal Stem Cell Transplantation/methods/trends;Mesenchymal Stem Cells/*physiology;Multiple Organ Failure/prevention & control/therapy;SARSCoV2/pathogenicity;DA 2021/04/21 06:00		Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic 	
777	32632960	Journal Article;Review	O  NNLM;COVID19;clinical trial;drug repurposing;drug targets;therapeutics;vaccines	DA 2020/07/08 06:00		Revisiting potential druggable targets against SARS-CoV-2 and repurposing 	Ministry of Science, ICT and Future Planning/;National Research Foundation of Korea/;2018H1D3A1A01074712/Korea Research Fellowship Program/
778	33482902	Clinical Trial;Journal Article	O  NNLM;Amniotic fluid;Creactive protein;COVID19;Inflammation	Adult;Aged;*Amniotic Fluid;Biomarkers/blood;COVID19/blood/diagnosis/mortality/*therapy;Female;Hospital Mortality;Humans;Inflammation Mediators/blood;Male;Middle Aged;Pilot Projects;Pregnancy;Time Factors;Treatment Outcome;Young Adult;DA 2021/01/28 06:00	ClinicalTrials.gov/NCT04319731	A pilot trial of human amniotic fluid for the treatment of COVID-19.	
779	33193349	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*coronavirus disease 2019;*inflammasome;*obesity;*pyroptosis;*severe acute respiratory syndrome coronavirus 2	Animals;COVID19/genetics/*immunology/virology;Cytokine Release Syndrome/genetics/*immunology/virology;Cytokines/genetics/immunology;Diabetes Mellitus, Type 2/genetics/*immunology/virology;Humans;Inflammasomes/genetics/*immunology;NLR Family, Pyrin DomainContaining 3 Protein/genetics/*immunology;SARSCoV2/genetics/*physiology;DA 2020/12/15 06:00		NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19.	
780	33307029	Journal Article;Multicenter Study	O  NNLM;*COVID19;*Liver transplantation;*Outcome;*Tacrolimus	Adult;Age Factors;Aged;COVID19/*complications;Comorbidity;Female;Hospitalization;Humans;Immunosuppressive Agents/*therapeutic use;Liver Transplantation/*adverse effects/mortality;Male;Middle Aged;Proportional Hazards Models;*SARSCoV2;Tacrolimus/*therapeutic use;Thrombosis/prevention & control;DA 2021/03/24 06:00		Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver 	
781	32307245	Journal Article;Review	O  NNLM;Angiotensin converting enzyme inhibitors;Coronavirus disease 2019 (COVID19);Hydroxychloroquine;Nonsteroidal antiinflammatory drugs;Remdesivir;Severe acute respiratory syndrome coronavirus 2 (SARSCoV2)	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Amides/therapeutic use;Antiviral Agents/*therapeutic use;Azithromycin/therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/therapy;Drug Combinations;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive/methods;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;Pyrazines/therapeutic use;RNADependent RNA Polymerase/antagonists & inhibitors;Ritonavir/therapeutic use;SARSCoV2;Teicoplanin/therapeutic use;DA 2020/06/17 06:00		Treatment options for COVID-19: The reality and challenges.	
782	33551672	Journal Article;Review	O  NNLM;Batlike CoV;In silico analyses;MERSCoV;Pangolin CoV;SARSCoV;nCoV	DA 2021/02/09 06:00		The COVID-19 puzzle: a global nightmare.	
783	33230386	Journal Article;Review	O  NNLM;COVID19;Drug repurposing;Drug targets;Interaction network;Network biology	DA 2020/11/25 06:01		Molecular targets and system biology approaches for drug repurposing against 	
784	33403480	Journal Article;Review	O  NNLM;Endoplasmic reticulum;Replication;Sigma1 receptor	Animals;COVID19/*drug therapy;Central Nervous System Agents/*therapeutic use;*Drug Repositioning;Gene Knockout Techniques;Humans;Receptors, sigma/*drug effects/genetics;DA 2021/03/19 06:00		Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 	17H04243/Japan Society for the Promotion of Science London/;19H05203/Japan Society for the Promotion of Science/;JP20dm0107119/Japan Agency for Medical Research and Development/
785	33150094	Clinical Trial	O  NNLM;COVID19;Clinical trials;Data science	DA 2020/11/06 06:01		Computerized monitoring of COVID-19 trials, studies and registries in 	
786	33521623	Journal Article	O  NNLM;AI drug repurposing;COVID19;LTRA;Machine learning;SARSCoV2;Zafirlukast	DA 2021/02/02 06:01		AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing 	
787	32423027	Journal Article	O  NNLM;COVID19;SARSCoV2;chloroquine;hydroxychloroquine;lopinavir/ritonavir;plasma;remdesivir	DA 2020/05/20 06:01		COVID-19: An Update About the Discovery Clinical Trial.	
788	33014462	Journal Article		DA 2020/10/06 06:01		Lactate Arterial-Central Venous Gradient among COVID-19 Patients in ICU: A Potential 	
789	33359375	Journal Article	O  NNLM;COVID19;Coronavirus;Pneumonia;SARSCoV2;Therapy	COVID19/diagnosis/*drug therapy/epidemiology/therapy;Humans;Italy/epidemiology;*Practice Guidelines as Topic;Randomized Controlled Trials as Topic;SARSCoV2/isolation & purification;Societies, Medical/*standards;Standard of Care;DA 2021/03/12 06:00		Therapeutic strategies for severe COVID-19: a position paper from the Italian 	
790	33573699	Journal Article;Randomized Controlled Trial	O  NNLM;2019nCoV;COVID19;Hydroxychloroquine;Lopinavir;Pneumonia;Ritonavir;SARSCOV2;Vitamin C	Antiviral Agents/administration & dosage/*therapeutic use;Ascorbic Acid/*administration & dosage/therapeutic use;Body Temperature;COVID19/*drug therapy;Female;Humans;Hydroxychloroquine/therapeutic use;Intensive Care Units;Length of Stay;Lopinavir/therapeutic use;Male;Middle Aged;Oxygen/blood;Respiratory Distress Syndrome/drug therapy/virology;Ritonavir/therapeutic use;Treatment Outcome;DA 2021/02/20 06:00		Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a 	99110147277/Tehran University of Medical Sciences and Health Services/
791	33465165	Journal Article;Research Support, N.I.H., Extramural		Animals;COVID19/drug therapy/*prevention & control;Chlorocebus aethiops/virology;Humans;Hydroxychloroquine/*pharmacology;SARSCoV2/*drug effects;Serine Endopeptidases/*drug effects;Spike Glycoprotein, Coronavirus/*drug effects/metabolism;Vero Cells/virology;Virus Internalization/*drug effects;DA 2021/02/18 06:00		Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.	R01 AI129868/AI/NIAID NIH HHS/United States
792	32425260	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Epidemiology;*Pediatric rheumatology;*Rheumatic diseases;*Targeted disease modifying antirheumatic drugs	Adolescent;Adult;Aged;Antirheumatic Agents/*therapeutic use;Betacoronavirus/drug effects;Biological Products/*therapeutic use;COVID19;CaseControl Studies;Child;Child, Preschool;Coronavirus Infections/diagnosis/*epidemiology/physiopathology;CrossSectional Studies;Female;Humans;Incidence;Infant;Male;Middle Aged;Pandemics;Pneumonia, Viral/diagnosis/*epidemiology/physiopathology;Retrospective Studies;Rheumatic Diseases/*drug therapy/epidemiology;SARSCoV2;Spain/epidemiology;Young Adult;DA 2020/09/17 06:00		Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic 	
793	32536564	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*Cytokine storm;*Immune cells;*Interleukin15;*Pulmonary inflammation;*SARSCoV2	Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/immunology;CD8Positive TLymphocytes/immunology;COVID19;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/*drug therapy;Cytokines/blood;Humans;Immunity, Innate/immunology;Immunotherapy/*methods;Interleukin15/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Virus Replication/physiology;DA 2020/09/29 06:00		IL-15 immunotherapy is a viable strategy for COVID-19.	R01 AI080581/AI/NIAID NIH HHS/United States
794	32708504	Journal Article;Review	O  NNLM;antidiabetic drugs;coronavirus disease 2019 (COVID19);diabetes mellitus;glycemic control;mortality;severe acute respiratory distress syndrome coronavirus 2 (SARSCoV2);severity	DA 2020/07/28 06:01		Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, 	
795	33264669	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Chronic disorders;*Management plans;*Multiorgan damage;*Prognosis	COVID19/*complications/virology;Chronic Disease;Comorbidity;Humans;Prognosis;Risk Factors;SARSCoV2/isolation & purification;DA 2021/01/20 06:00		The dynamic association between COVID-19 and chronic disorders: An updated insight 	
796	32781571	Journal Article;Review	O  NNLM;B cells;COVID19;T cells;vaccine development	DA 2020/08/13 06:01		Investigating Virological, Immunological, and Pathological Avenues to Identify 	
797	32683801	Journal Article	O  NNLM;COVID19;Child;Treatment	DA 2020/07/21 06:01		Overview of management of children with COVID-19.	
798	32647807	Journal Article;Review		DA 2020/07/11 06:01		The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.	
799	32837982	Journal Article;Review	O  NNLM;COVID19;Chloroquine;Coronavirus;Famotidine;Ivermectin;Nicotine;Remdesivir;SARSCov2	DA 2020/08/25 06:01		Known drugs and small molecules in the battle for COVID-19 treatment.	
800	32616710	Journal Article;Research Support, NonU.S. Gov't;Review		DA 2020/07/04 06:00		Overcoming cancer therapeutic bottleneck by drug repurposing.	
801	32425199	Journal Article;Review		Adenosine Monophosphate/administration & dosage/adverse effects/analogs & ;Alanine/administration & dosage/adverse effects/analogs & derivatives;AntiInfective Agents/administration & dosage/*adverse effects;Azithromycin/administration & dosage/adverse effects;*Betacoronavirus;COVID19;Cardiovascular Diseases/*chemically induced;Coronavirus Infections/*drug therapy;Drug Combinations;Enzyme Inhibitors/administration & dosage/*adverse effects;Humans;Hydroxychloroquine/administration & dosage/adverse effects;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;Ritonavir/therapeutic use;SARSCoV2;DA 2020/07/23 06:00		Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 	
802	32423059	Journal Article;Review	O  NNLM;Covid19;SARSCoV2;T cell repertoire;antiviral immunity;coronavirus;cytokine storm;immune response	DA 2020/05/20 06:01		Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment 	
803	33352056	Journal Article	O  NNLM;*COVID19;*SARSCoV2;*antiviral;*coronavirus;*nitazoxanide;*pharmacokinetics;*tizoxanide	DA 2020/12/23 06:00		Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus 	MR/N023005/1/MRC_/Medical Research Council/United Kingdom;MR/S00467X/1/MRC_/Medical Research Council/United Kingdom
804	33403500	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*Antibodies;*Antivirals;*COVID19 therapeutics;*SARSCoV2;*Vaccine	Antibodies, Viral/therapeutic use;Antiviral Agents/pharmacology;COVID19/*drug therapy/prevention & control/transmission;COVID19 Vaccines;Drug Repositioning;Humans;DA 2021/03/19 06:00		Pharmacotherapeutics of SARS-CoV-2 Infections.	P30 MH062261/MH/NIMH NIH HHS/United States;R01 AG043530, P01 DA028555, P30 MH062261, R01 MH115860, R01 NS034249, R01 ;R01 AG043530, P01 DA028555, P30 MH062261, R01 MH115860, R01 NS034249, R01 ;P01 DA028555/DA/NIDA NIH HHS/United States;P30 MH062261/MH/NIMH NIH HHS/United States;R01 MH115860/MH/NIMH NIH HHS/United States;R01 NS033249/NS/NINDS NIH HHS/United States;R01 NS036126/NS/NINDS NIH HHS/United States
805	32574264	Journal Article;Review	O  NNLM;COVID19;adult onset Still's disease;catastrophic antiphospholipid syndrome;haemophagocytic lymphohistiocytosis;hyperinflammation;hyperferritinaemic syndrome;hyperferritinemia	COVID19;Coronavirus Infections/*immunology/physiopathology/therapy;Cytokines/immunology;Ferritins/blood;Fever;Humans;*Immunotherapy;Inflammation;Iron Metabolism Disorders/*immunology;Lung/metabolism/physiopathology;Pandemics;Pneumonia, Viral/*immunology/physiopathology/therapy;Syndrome;DA 2020/07/11 06:00		Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An 	
806	32960186	Journal Article;Multicenter Study;Observational Study;Research Support, NonU.S. Gov't		Adolescent;Age Factors;*Betacoronavirus;COVID19;Child;Child, Preschool;Cohort Studies;Coronavirus Infections/complications/*epidemiology/therapy;Critical Care;Female;Hospital Mortality;Hospitalization/*statistics & numerical data;Humans;Infant;Infant, Newborn;Male;Pandemics;Pneumonia, Viral/complications/*epidemiology/therapy;Respiration, Artificial;SARSCoV2;Systemic Inflammatory Response Syndrome/diagnosis/*epidemiology/therapy;United Kingdom;Young Adult;DA 2020/10/02 06:00	ISRCTN/ISRCTN66726260	Clinical characteristics of children and young people admitted to hospital with 	ISHPU111210117/DH_/Department of Health/United Kingdom;MR/S032304/1/MRC_/Medical Research Council/United Kingdom;MC_PC_19025/MRC_/Medical Research Council/United Kingdom;MR/V033441/1/MRC_/Medical Research Council/United Kingdom;MC_UU_12014/2/MRC_/Medical Research Council/United Kingdom
807	32339662	Journal Article;Review	O  NNLM;*Bone marrow transplantation;*COVID19;*Cell therapy;*Coronavirus;*Hematopoietic cell transplantation;*Immunocompromise;*SARSCoV2;*Severe acute respiratory syndrome	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Betacoronavirus/immunology/*pathogenicity;*Bone Marrow Transplantation;COVID19;COVID19 Testing;Clinical Laboratory Techniques/methods;Coronavirus Infections/*diagnosis/*epidemiology/immunology/therapy;Drug Combinations;Education, Distance/organization & administration;*Hematopoietic Stem Cell Transplantation;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive/methods;Infection Control;Information Dissemination/methods;Lopinavir/therapeutic use;*Pandemics;Pneumonia, Viral/*diagnosis/*epidemiology/immunology/therapy;Practice Guidelines as Topic;RealTime Polymerase Chain Reaction;Ritonavir/therapeutic use;SARSCoV2;Severity of Illness Index;Tissue Donors/education/supply & distribution;DA 2020/07/01 06:00		Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on 	
808	32965395	Clinical Trial Protocol;Journal Article;Multicenter Study;Randomized Controlled Trial		AntiInflammatory Agents/pharmacology/*therapeutic use;Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use;Brazil;COVID19;Coronavirus Infections/*drug therapy/physiopathology;Humans;Interleukin6/antagonists & inhibitors;Pandemics;Pneumonia, Viral/*drug therapy/physiopathology;Severity of Illness Index;DA 2020/10/27 06:00		"Rationale and design of the ""Tocilizumab in patients with moderate to severe "	
809	33289973	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;AntiInfective Agents/adverse effects/*therapeutic use;COVID19/*prevention & control/transmission/virology;Disease Transmission, Infectious/prevention & control;DoubleBlind Method;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Male;Middle Aged;Patient Compliance;*SARSCoV2;Treatment Failure;Viral Load;DA 2021/02/10 06:00	ClinicalTrials.gov/NCT04304053	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.	
810	32505227	Journal Article;Research Support, N.I.H., Extramural;Review		Animals;Betacoronavirus/*physiology;COVID19;Coronavirus Infections/diagnosis/*immunology/pathology/therapy;Disease Susceptibility;Humans;Immunity, Innate;Immunologic Memory;Inflammation/immunology/virology;Lymphocytes/immunology;Myeloid Cells/immunology;Pandemics;Pneumonia, Viral/diagnosis/*immunology/pathology/therapy;SARSCoV2;DA 2020/06/26 06:00		Immunology of COVID-19: Current State of the Science.	T32 HD075735/HD/NICHD NIH HHS/United States;R01 AI081848/AI/NIAID NIH HHS/United States;R01 DK112296/DK/NIDDK NIH HHS/United States;K00 CA223043/CA/NCI NIH HHS/United States;DP5 OD028171/OD/NIH HHS/United States;U19 AI118610/AI/NIAID NIH HHS/United States;R01 AI073450/AI/NIAID NIH HHS/United States;T32 GM007280/GM/NIGMS NIH HHS/United States
811	32499832	Journal Article;Review	O  NNLM;antivirals;biologics;coronavirus;corticosteroids;pneumonia;severe acute respiratory syndrome	DA 2020/06/06 06:01		Pharmacologicaltreatment of COVID-19: lights and shadows.	
812	32401715	Clinical Trial, Phase II;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Combinations;Drug Therapy, Combination;Female;Hong Kong;Hospitalization;Humans;Interferon beta1b/*therapeutic use;Lopinavir/*therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy;Ribavirin/*therapeutic use;Ritonavir/*therapeutic use;SARSCoV2;DA 2020/06/03 06:00	ClinicalTrials.gov/NCT04276688	Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the 	
813	32719683	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*clinical trials;*mesenchymal stem cells;*stem celltherapy	Betacoronavirus/*immunology;COVID19;Clinical Trials as Topic;*Coronavirus Infections/epidemiology/immunology/therapy;*Disease Outbreaks;Humans;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/*immunology;*Pandemics;*Pneumonia, Viral/epidemiology/immunology/therapy;SARSCoV2;DA 2020/08/04 06:00		Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.	
814	32527699	Journal Article;Review	O  NNLM;Angiotensin receptor blocker;Angiotensinconverting enzyme inhibitors;Antagonistas del receptor de angiotensina II;High blood pressure;Hipertensión arterial;Inhibidores de la enzima convertidora de angiotensina;Reninangiotensinaldosterone system;SARSCoV2;Sistema reninaangiotensinaaldosterona	ADAM17 Protein/physiology;Angiotensin II/physiology;Angiotensin Receptor Antagonists/adverse effects/pharmacology/therapeutic use;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/adverse effects/pharmacology/therapeutic ;Antihypertensive Agents/adverse effects/pharmacology/therapeutic use;*Betacoronavirus;COVID19;COVID19 Vaccines;Coronavirus Infections/complications/immunology/*physiopathology/prevention & ;Humans;Hypertension/complications/physiopathology;Lung/physiopathology;Models, Biological;*Pandemics/prevention & control;PeptidylDipeptidase A/drug effects/physiology;Pneumonia, Viral/complications/immunology/*physiopathology/prevention & control;Receptors, Virus/drug effects;ReninAngiotensin System/drug effects/*physiology;Respiratory Distress Syndrome/etiology/physiopathology;SARSCoV2;Serine Endopeptidases/physiology;Viral Vaccines;Virus Internalization/drug effects;DA 2020/10/03 06:00		[The RAAS and SARS-CoV-2: A riddle to solve].	
815	32828489	Journal Article;Review	O  NNLM;*COVID19;*coronavirus;*epigenetic drugs;*epigenetics;*host–viral interactions;*influenza virus;*intensive care;*severe acute respiratory syndrome	Betacoronavirus/genetics;COVID19;Coronavirus Infections/*genetics/*therapy;*Epigenesis, Genetic;Genetic Predisposition to Disease/*genetics;Humans;Influenza, Human/*genetics/*therapy;Pandemics;Pneumonia, Viral/*genetics/*therapy;Respiratory Tract Infections/*genetics/*therapy;SARSCoV2;DA 2020/11/26 06:00		Epigenetic susceptibility to severe respiratory viral infections and its therapeutic 	
816	33010945	Editorial		DA 2020/10/05 06:01		SGLT-2 inhibitors as cardioprotective agents in COVID-19.	
817	32222466	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Antiinflammation treatment;*Coronavirus disease 2019 (COVID19);*Cytokine storm	AntiInflammatory Agents/*therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Betacoronavirus;COVID19;Chloroquine/therapeutic use;Coronavirus Infections/*drug therapy;Cytokines/immunology;Glucocorticoids/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Inflammation/pathology;Interleukin6/antagonists & inhibitors;Janus Kinases/antagonists & inhibitors;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Thrombosis/virology;Vasculitis/virology;DA 2020/05/06 06:00		The use of anti-inflammatory drugs in the treatment of people with severe 	
818	32764907	Journal Article;Review	O  NNLM;ACEI;ARB;SARI;age;coronavirus;hypertension	Aged;Animals;*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/genetics/*therapy;Eye Diseases, Hereditary;Gene Frequency;Genotype;Humans;Pandemics;Pneumonia, Viral/genetics/*therapy;Retinal Diseases;SARSCoV2;DA 2020/08/14 06:00		COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of 	
819	32864299	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Hydroxychloroquine;Pandemic;QT prolongation;SARSCoV2	DA 2020/08/31 06:00		Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2.	
820	33065092	Journal Article;Review	O  NNLM;COVID19;Convalescent plasma therapy and mesenchymal stem cell therapy;Coronavirus;Drug repurposing;SARSCOV2;Vaccines	Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*epidemiology;Humans;*Pandemics;*SARSCoV2;DA 2020/12/29 06:00		Pharmacological insight into potential therapeutic agents for the deadly Covid-19 	
821	33225307	Journal Article	O  NNLM;coronavirus disease 2019;hyperinflammation;interleukin 6;respiratory failure;survival;tocilizumab	DA 2020/11/24 06:01		A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus 	
822	32867852	Clinical Trial Protocol;Letter;Randomized Controlled Trial	O  NNLM;COVID19;Randomised controlled trial;health personnel;hydroxychloroquine;protocol	Betacoronavirus;COVID19;Chemoprevention;Coronavirus Infections/*prevention & control/transmission;Enzyme Inhibitors/*therapeutic use;*Health Personnel;Humans;Hydroxychloroquine/*therapeutic use;India;Infectious Disease Transmission, PatienttoProfessional/*prevention & control;Occupational Diseases/*prevention & control;Pandemics/*prevention & control;*Personal Protective Equipment;Pneumonia, Viral/*prevention & control/transmission;SARSCoV2;DA 2020/09/04 06:00		Hydroxychloroquine plus personal protective equipment versus standard personal 	
823	32518419	Journal Article;Research Support, NonU.S. Gov't		Adult;Aged;Aged, 80 and over;AntiInflammatory Agents/*therapeutic use;Betacoronavirus/drug effects/immunology/pathogenicity;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/enzymology/immunology/virology;Cytokine Release Syndrome/*drug therapy/enzymology/immunology/virology;Cytokines/antagonists & inhibitors/genetics/immunology;Drug Administration Schedule;Female;Gene Expression Regulation;Humans;Immunity, Innate/drug effects;Inflammation;Janus Kinase 1/*antagonists & inhibitors/genetics/immunology;Janus Kinase 2/*antagonists & inhibitors/genetics/immunology;Male;Middle Aged;Pandemics;Patient Safety;Pneumonia, Viral/*drug therapy/enzymology/immunology/virology;Protein Kinase Inhibitors/*therapeutic use;Pyrazoles/*therapeutic use;Retrospective Studies;SARSCoV2;Severe Acute Respiratory Syndrome/*drug therapy/enzymology/immunology/virology;TLymphocytes/drug effects/immunology/virology;Treatment Outcome;DA 2020/07/15 06:00	ClinicalTrials.gov/NCT04338958	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic 	
824	32771032	Clinical Trial Protocol;Letter;Multicenter Study;Observational Study;Randomized Controlled Trial	O  NNLM;Azithromycin;COVID19;Hydroxychloroquine;Oseltamivir;Randomised controlled trial;SARSCoV2;adaptive;multicenter;protocol;randomization	Azithromycin/*therapeutic use;*Betacoronavirus;COVID19;Comorbidity;Coronavirus Infections/*drug therapy;Humans;Hydroxychloroquine/*therapeutic use;Oseltamivir/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;*Randomized Controlled Trials as Topic;Research Design;SARSCoV2;DA 2020/08/18 06:00	ClinicalTrials.gov/NCT04338698	Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment 	
825	32243297	Journal Article;Review		Anesthesiologists;*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*therapy/transmission;Critical Care;Humans;Pandemics;Pneumonia, Viral/drug therapy/*therapy/transmission;SARSCoV2;DA 2020/06/26 06:00		Coronaviruses and SARS-CoV-2: A Brief Overview.	
826	33055059	Journal Article	O  NNLM;2019nCoV;COVID19;SARS;SARSCoV2;coronavirus;dexamethasone;hydroxychloroquine;ivermectin;remdesivir;statin;statins	DA 2020/10/16 06:01		Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities 	
827	32243270	Journal Article;Review		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;*Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Drug Combinations;Humans;Hydroxychloroquine/therapeutic use;Interferonalpha/therapeutic use;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;Ritonavir/therapeutic use;SARSCoV2;DA 2020/06/17 06:00		Potential therapeutic agents against COVID-19: What we know so far.	
828	32951151	Journal Article	O  NNLM;Adult respiratory distress syndrome;COVID19;COVID19 serotherapy;Hospital mortality;Length of stay;Phase II clinical trial;Plasma;Prospective studies;Severe acute respiratory syndrome coronavirus 2;Ventilation	DA 2020/09/21 06:01	ClinicalTrials.gov/NCT04343261	Factors Associated with Good Patient Outcomes Following Convalescent Plasma in 	
829	33346365	Journal Article;Multicenter Study	O  NNLM;*COVID19;*cardiology;*heart disease;*mortality;*prognosis;*registry	Aged;COVID19/*epidemiology;Comorbidity;Female;Global Health;Heart Diseases/*epidemiology;Humans;Male;Middle Aged;*Pandemics;Prognosis;*Registries;Retrospective Studies;Risk Factors;SARSCoV2;DA 2021/05/07 06:00		Underlying heart diseases and acute COVID-19 outcomes.	
830	32658389	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*angiotensinconverting enzyme;*inflammation;*therapy	Angiotensin Receptor Antagonists/therapeutic use;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Animals;Antiviral Agents/therapeutic use;Betacoronavirus/drug effects/*pathogenicity;COVID19;Coronavirus Infections/diagnosis/drug therapy/*virology;EvidenceBased Medicine;HostPathogen Interactions;Humans;Pandemics;PeptidylDipeptidase A/*metabolism/therapeutic use;Pneumonia, Viral/diagnosis/drug therapy/*virology;*ReninAngiotensin System/drug effects;SARSCoV2;DA 2020/07/23 06:00		The renin-angiotensin-aldosterone system: Role in pathogenesis and potential 	
831	33178016	Journal Article;Review	O  NNLM;Middle East respiratory syndrome coronavirus;coronavirus;coronavirus disease 2019;severe acute respiratory syndrome coronavirus2;therapeutic interventions;transmission	DA 2020/11/13 06:01		COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future 	
832	33024717	Journal Article;Review	O  NNLM;Antiviral drugs;COVID19;Coronavirus;Eculizumab;Enoxaparin;Hydroxychloroquine;Opinion review;Pandemic;SARSCoV2;Tocilizumab;Treatment	DA 2020/10/08 06:01		Current status of COVID-19 treatment: An opinion review.	
833	33108622	Clinical Trial, Phase II;Clinical Trial, Phase III;Journal Article;Randomized Controlled Trial	O  NNLM;*Acute lung injury;*COVID19;*Dociparstat;*HMGB1;*NETs;*Neutrophil extracellular traps;*Pselectin;*Platelet factor 4	Acute Lung Injury/*drug therapy/etiology;Adult;Aged;Aged, 80 and over;AntiInflammatory Agents/*therapeutic use;COVID19/*complications/*drug therapy;DoubleBlind Method;Female;Heparin/*therapeutic use;Humans;Male;Middle Aged;Respiratory Insufficiency/*drug therapy/etiology;SARSCoV2/drug effects;Treatment Outcome;DA 2021/02/23 06:00	ClinicalTrials.gov/NCT04389840	Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 	
834	33225960	Clinical Trial, Phase II;Journal Article;Randomized Controlled Trial	O  NNLM;COVID19;IFNβ1a;SARSCoV2	Adult;Antiviral Agents/administration & dosage/*therapeutic use;Betacoronavirus/*drug effects/genetics;COVID19;Coronavirus Infections/diagnosis/*drug therapy/epidemiology/virology;Data Management;Female;Humans;Injections, Subcutaneous;Interferon beta1a/administration & dosage/*therapeutic use;Italy/epidemiology;Length of Stay/statistics & numerical data;Male;Mortality/trends;Oxygen/administration & dosage/therapeutic use;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/epidemiology/virology;SARSCoV2;Treatment Outcome;Viral Load/drug effects;DA 2020/11/27 06:00	ClinicalTrials.gov/NCT04449380	Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a 	
835	32267979	Editorial	O  NNLM;*COVID19;*acute respiratory distress syndrome;*corona virus;*intensive care unit	Antiviral Agents/therapeutic use;Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/*epidemiology;Glucocorticoids/therapeutic use;Humans;Immunomodulation;*Intensive Care Units;Pandemics;Pneumonia, Viral/*drug therapy/*epidemiology;SARSCoV2;DA 2020/05/21 06:00		COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for 	R01 GM111400/GM/NIGMS NIH HHS/United States
836	33245577	Journal Article;Review	O  NNLM;COVID 19;GS 5734;remdesivir;scoping review;severe acute respiratory syndrome coronavirus 2	DA 2020/11/28 06:00		Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in 	
837	32616063	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Hydroxychloroquine;Pregnant;Protocol;Randomised controlled trial;Women	Antiviral Agents/*administration & dosage/adverse effects/pharmacokinetics;Betacoronavirus/*drug effects/pathogenicity;COVID19;*Chemoprevention;Coronavirus Infections/diagnosis/drug therapy/mortality/*prevention & ;DoubleBlind Method;Drug Administration Schedule;Female;HostPathogen Interactions;Humans;Hydroxychloroquine/*administration & dosage/adverse effects/pharmacokinetics;Multicenter Studies as Topic;Pandemics/*prevention & control;Pneumonia, Viral/diagnosis/mortality/*prevention & control/virology;Pregnancy;Pregnancy Complications, Infectious/diagnosis/mortality/*prevention & ;Protective Factors;Randomized Controlled Trials as Topic;Risk Assessment;Risk Factors;SARSCoV2;Severity of Illness Index;Spain;Time Factors;Treatment Outcome;Virus Shedding/drug effects;DA 2020/07/11 06:00	ClinicalTrials.gov/NCT04410562	Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and 	COV20/00286/Instituto de Salud Carlos III/
838	32546018	Journal Article;Review	O  NNLM;*COVID19;*Favipiravir;*acute respiratory distress syndrome;*chloroquine;*interferons;*nucleocapsid protein;*spike protein;*treatment	Antibodies, Monoclonal/therapeutic use;Antiviral Agents/*therapeutic use;*Betacoronavirus/chemistry/genetics/physiology;COVID19;Coronavirus Infections/complications/*drug therapy/epidemiology;*Drug Discovery;Humans;Pandemics;Pneumonia, Viral/complications/*drug therapy/epidemiology;SARSCoV2;Serine Endopeptidases/physiology;Serine Proteinase Inhibitors/therapeutic use;Virus Replication;DA 2020/08/04 06:00		The broad-spectrum antiviral recommendations for drug discovery against COVID-19.	
839	33173161	Journal Article		Adult;Aged;COVID19/*complications/*drug therapy/transmission/virology;CaseControl Studies;DoseResponse Relationship, Drug;Drug Therapy, Combination;Female;FollowUp Studies;Humans;Male;Middle Aged;NonRandomized Controlled Trials as Topic;Pneumonia, Viral/epidemiology/*pathology/therapy/virology;Prognosis;Pyrazoles/*administration & dosage;SARSCoV2/*isolation & purification;Steroids/*administration & dosage;DA 2021/02/16 06:00	ClinicalTrials.gov/NCT04337359	Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.	
840	32737082	Journal Article		DA 2020/08/02 06:00		Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.	WT_/Wellcome Trust/United Kingdom
841	32599963	Journal Article	O  NNLM;G proteincoupled receptor;SARSCoV2;antiviral therapy;inhibitors;proteases	Administration, Intravenous;Antiviral Agents/administration & dosage/pharmacokinetics/*therapeutic use;COVID19;Computer Simulation;Coronavirus Infections/*drug therapy;Drug Repositioning;Famotidine/administration & dosage/pharmacokinetics/*therapeutic use;Humans;Models, Molecular;Molecular Docking Simulation;Pandemics;Pneumonia, Viral/*drug therapy;Protease Inhibitors/administration & dosage/pharmacokinetics/therapeutic use;Receptors, GProteinCoupled/*antagonists & inhibitors;Virus Replication/drug effects;DA 2020/07/14 06:00		Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic 	EY025214/NH/NIH HHS/United States
842	33207589	Journal Article	O  NNLM;COVID19;coronavirus;cytotoxic T lymphocyte antigen4;immune checkpoint inhibitors;programmed cell death protein	DA 2020/11/20 06:01		Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection.	
843	33413329	Journal Article		COVID19/*drug therapy;Cells, Cultured;*Drug Repositioning;Epithelial Cells/virology;Gene Ontology;Humans;*Pharmaceutical Preparations;SARSCoV2/drug effects;*Signal Transduction;*Transcription, Genetic;DA 2021/01/14 06:00		Computational analysis to repurpose drugs for COVID-19 based on transcriptional 	
844	33477376	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*SARS CoV2;*antiviral drugs;*quinacrine;*virus replication	Animals;Antiviral Agents/*pharmacology;COVID19/*drug therapy;Cell Line;Chlorocebus aethiops;Microscopy, Electron, Transmission;Quinacrine/*pharmacology;SARSCoV2/*drug effects;Vero Cells;Viral Load/drug effects;Virus Internalization/drug effects;Virus Replication/*drug effects;DA 2021/02/03 06:00		Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral 	
845	33284679	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents/adverse effects/*therapeutic use;COVID19/diagnosis/*drug therapy/*prevention & control;COVID19 Nucleic Acid Testing;DoubleBlind Method;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Male;Middle Aged;*PostExposure Prophylaxis;SARSCoV2;Time Factors;Treatment Outcome;United States;Young Adult;DA 2021/03/24 06:00	ClinicalTrials.gov/NCT04328961	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory 	R01 CA213130/CA/NCI NIH HHS/United States;T32 AI007524/AI/NIAID NIH HHS/United States
846	32563675	Journal Article;Review		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antirheumatic Agents/*therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;Chloroquine/therapeutic use;Clinical Trials as Topic;Coronavirus Infections/drug therapy/*therapy;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive/methods;Immunologic Factors/*therapeutic use;Pandemics;Pneumonia, Viral/*therapy;Receptors, Interleukin6/antagonists & inhibitors;SARSCoV2;DA 2020/08/21 06:00		Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing 	
847	32503877	Journal Article;Research Support, N.I.H., Intramural		Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors/metabolism;Aged;Aged, 80 and over;Benzamides/*pharmacology/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/virology;Critical Illness;Female;FollowUp Studies;Humans;Inflammation/drug therapy/virology;Interleukin6/metabolism;Male;Middle Aged;Monocytes/metabolism;Pandemics;Pneumonia, Viral/*drug therapy/virology;Prospective Studies;Pyrazines/*pharmacology/*therapeutic use;Respiration, Artificial;SARSCoV2;Treatment Outcome;DA 2020/06/20 06:00		Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.	
848	32706953	Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Aged;Aged, 80 and over;Antiviral Agents/*administration & dosage/therapeutic use;Azithromycin/*administration & dosage/therapeutic use;Betacoronavirus;Brazil;COVID19;Coronavirus Infections/*drug therapy;Drug Therapy, Combination;Female;Hospitalization;Humans;Hydroxychloroquine/*administration & dosage/therapeutic use;Male;Middle Aged;Pandemics;Patient Acuity;Pneumonia, Viral/*drug therapy;SARSCoV2;Treatment Failure;DA 2020/12/02 06:00	ClinicalTrials.gov/NCT04322123	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.	
849	32756480	Journal Article;Review	O  NNLM;COVID19;MERSCoV;SARSCoV;SARSCoV2;adjunctive therapy;antiparasite;antiviral;clinical trial;immunotherapy;molecular immune response	*Adaptive Immunity;AntiInflammatory Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification/*physiology;COVID19;Coronavirus Infections/immunology/*pathology/therapy/virology;Humans;Immunotherapy;Middle East Respiratory Syndrome Coronavirus/isolation & purification/physiology;Open Reading Frames/genetics;Pandemics;Pneumonia, Viral/immunology/*pathology/therapy/virology;SARSCoV2;DA 2020/08/13 06:00		COVID-19: The Immune Responses and Clinical Therapy Candidates.	
850	32868970	Journal Article;Review	O  NNLM;Antiinflammatory agents;Antiviral drugs;COVID19;Corona virus;SARSCoV2	DA 2020/09/02 06:01		Novel β-Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological 	
851	33227287	Journal Article;Review	O  NNLM;COVID19;Repurposed drugs;SARSCoV2;Therapeutic targets;Vaccines	Adrenal Cortex Hormones/*therapeutic use;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology/*therapy;Drug Repositioning;Epidemics;Humans;Immunization, Passive;*Medicine, Ayurvedic;*Medicine, Chinese Traditional;*SARSCoV2/immunology;Viral Vaccines;DA 2020/12/30 06:00		A comprehensive review on potential therapeutics interventions for COVID-19.	
852	33489300	Journal Article	O  NNLM;COVID19;immunology;vitamin D	DA 2021/01/26 06:01		Vitamin D and COVID-19: evidence and recommendations for supplementation.	
853	32397174	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;autoimmunity;baricitinib;cytokine release syndrome;hydroxychloroquine;immunomodulation;rheumatoid arthritis;tocilizumab	Antiviral Agents/*therapeutic use;Autoimmune Diseases/complications/drug therapy/pathology;Betacoronavirus/physiology;COVID19;Clinical Trials as Topic;Coronavirus Infections/complications/*drug therapy/*immunology/pathology;Cytokine Release Syndrome/drug therapy/immunology/*pathology;Humans;Immunosuppressive Agents/therapeutic use;Pandemics;Pneumonia, Viral/complications/*drug therapy/*immunology/pathology;SARSCoV2;DA 2020/05/15 06:00		Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: 	
854	33352298	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review		Antibodies, Antiphospholipid/immunology;COVID19/epidemiology/*etiology/immunology;Complement System Proteins/physiology;Extracellular Traps/physiology;Health Services Accessibility;Humans;Interferon Type I/physiology;Lupus Erythematosus, Systemic/*complications/immunology;*SARSCoV2;TOR SerineThreonine Kinases/physiology;DA 2021/05/18 06:00		COVID-19 in patients with systemic lupus erythematosus: lessons learned from the 	R01 AR057781/AR/NIAMS NIH HHS/United States;AR060861/NH/NIH HHS/United States;AR065964/NH/NIH HHS/United States;AI071651/NH/NIH HHS/United States
855	33009982	Journal Article;Review	O  NNLM;*COVID19;*Cellbased therapy;*Clinical trials;*Cost;*Stem cell	COVID19/*drug therapy/economics/*therapy/virology;Clinical Trials as Topic;CostBenefit Analysis/*economics;Humans;Pandemics/*economics/prevention & control;SARSCoV2/pathogenicity;DA 2021/03/03 06:00		Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility.	
856	32493609	Letter		*Betacoronavirus;Blood Glucose/*drug effects/metabolism;COVID19;Coronavirus Infections/blood/*drug therapy/epidemiology;Humans;Pandemics;Pneumonia, Viral/blood/*drug therapy/epidemiology;Prognosis;SARSCoV2;SodiumGlucose Transporter 2 Inhibitors/*therapeutic use;DA 2020/10/03 06:00		SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat 	
857	32302280	Journal Article;Review		Betacoronavirus;COVID19;*Coronavirus;Coronavirus Infections/drug therapy/epidemiology/*therapy;Emergency Service, Hospital;Humans;Immunization, Passive;Pandemics;Pneumonia, Viral/epidemiology/*therapy;PreExposure Prophylaxis;SARSCoV2;United States;DA 2020/05/22 06:00		Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the 	
858	32354800	Journal Article;Review	O  NNLM;cardiac risk factors and prevention;myocarditis;systemic inflammatory diseases	Angiotensin Receptor Antagonists/therapeutic use;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Anticoagulants/therapeutic use;Azithromycin/therapeutic use;Betacoronavirus;Biomarkers/blood;COVID19;Cardiovascular Diseases/*epidemiology/therapy;Chloroquine/therapeutic use;Comorbidity;Coronavirus Infections/*epidemiology/mortality;Cytokine Release Syndrome/epidemiology;Disseminated Intravascular Coagulation/epidemiology;Extracorporeal Membrane Oxygenation;Humans;Hydroxychloroquine/therapeutic use;Immunosuppressive Agents/therapeutic use;Influenza, Human/mortality;Lung/metabolism/pathology;Myocardium/metabolism/pathology;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*epidemiology;SARSCoV2;Severe Acute Respiratory Syndrome/mortality;Troponin/blood;Venous Thromboembolism/epidemiology/prevention & control;DA 2020/08/11 06:00		Cardiovascular manifestations and treatment considerations in COVID-19.	R01 HL148103/HL/NHLBI NIH HHS/United States
859	33193949	Case Reports	O  NNLM;Hydroxychloroquine;SARSCoV2;chronic inflammatory rheumatic disease;urticaria	Antirheumatic Agents/adverse effects/*therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/complications/*drug therapy;Disease Susceptibility;Etanercept/adverse effects/*therapeutic use;Humans;Hydroxychloroquine/*therapeutic use;Male;Mixed Connective Tissue Disease/complications/*drug therapy;Pandemics;Pneumonia, Viral/complications/*drug therapy;SARSCoV2;Skin Diseases, Viral/*etiology;Spondylarthropathies/complications/*drug therapy;Tumor Necrosis Factoralpha/adverse effects/*antagonists & inhibitors;Urticaria/*etiology;Young Adult;DA 2020/11/21 06:00		[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for 	
860	32483554	Journal Article;Review		DA 2020/06/03 06:01		Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use 	
861	32535032	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*1α, 25(OH)2D or 1α, 25dihydroxyvitamin D or calcitriol;*Acute respiratory distress syndrome (ARDS);*Calcifediol or 25hydroxyvitamin D3;*Corona virus;*Cytokine storm;*Hypercoagulability;*Lung diseases;*Reninangiotensin system;*SARSCoV2;*Vitamin D, vitamin D3 or cholecalciferol	Administration, Oral;Betacoronavirus/drug effects;COVID19;Calcifediol/administration & dosage/*therapeutic use;Coronavirus Infections/complications/*drug therapy/pathology;Humans;Pandemics;Pilot Projects;Pneumonia, Viral/complications/*drug therapy/pathology;Randomized Controlled Trials as Topic;ReninAngiotensin System/drug effects;Respiratory Distress Syndrome/complications/*drug therapy/pathology;SARSCoV2;Vitamin D/administration & dosage/*therapeutic use;Vitamin D Deficiency/complications/drug therapy/pathology;Vitamins/administration & dosage/*therapeutic use;DA 2020/09/15 06:00		Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) 	
862	33072869	Journal Article	O  NNLM;COVID;Hospitalized;Mortality;SARSCoV2;Treatments	DA 2020/10/20 06:01		Therapeutic agents tested in 238 COVID-19 hospitalized patients and their 	
863	32299202	Journal Article;Review	O  NNLM;*COVID19;*cytokine storm;*inflammation;*rheumatology;*treatment;*antiinflammatory	AntiInflammatory Agents/*therapeutic use;Antirheumatic Agents/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/*immunology;Cytokines/immunology;*Drug Repositioning;Humans;Immune System;Immunity, Cellular;Immunosuppressive Agents/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/*immunology;SARSCoV2;DA 2020/04/23 06:00		COVID-19, immune system response, hyperinflammation and repurposing antirheumatic 	
864	33437924	Journal Article		DA 2021/01/14 06:01		Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.	
865	32956644	Journal Article;Review	O  NNLM;Medications;Novel corona virus;SARSCoV2	AntiInflammatory Agents/pharmacology/therapeutic use;Antiviral Agents/pharmacology/therapeutic use;COVID19;Chloroquine/analogs & derivatives/therapeutic use;Coronavirus Infections/*drug therapy/*physiopathology;DNADirected RNA Polymerases/antagonists & inhibitors;Humans;Pandemics;Pneumonia, Viral/*drug therapy/*physiopathology;DA 2020/11/06 06:00		A review of medications used to control and improve the signs and symptoms of 	
866	32125458	Journal Article		COVID19;Capacity Building;Coronavirus Infections/*epidemiology/prevention & control;Health Personnel/psychology;*Hospital Bed Capacity;Humans;*Intensive Care Units;Pandemics/prevention & control;Personal Protective Equipment;Pneumonia, Viral/*epidemiology/prevention & control;*Surge Capacity;DA 2020/05/15 06:00		COVID-19: a novel coronavirus and a novel challenge for critical care.	
867	33277573	Journal Article		Adrenal Cortex Hormones/*therapeutic use;Age Factors;Aged;COVID19/*drug therapy/epidemiology;Female;Hospitalization;Humans;Italy/epidemiology;Male;Middle Aged;Pandemics;Retrospective Studies;Time Factors;Treatment Outcome;Viral Load/*drug effects;DA 2020/12/18 06:00		Viral clearance after early corticosteroid treatment in patients with moderate or 	
868	33509275	Clinical Trial Protocol;Journal Article	O  NNLM;Adaptive trial;COVID19;Clinical trial;Coronavirus;Platform trial;SARSCoV2	AntiBacterial Agents/therapeutic use;Antiviral Agents/therapeutic use;COVID19/*therapy;Clinical Trials, Phase IV as Topic;CommunityAcquired Infections/*therapy;EvidenceBased Medicine;Humans;Multicenter Studies as Topic;Pneumonia/*therapy;PointofCare Systems;Randomized Controlled Trials as Topic;SARSCoV2;DA 2021/02/09 06:00	ClinicalTrials.gov/NCT02735707	Implementation of the Randomized Embedded Multifactorial Adaptive Platform for 	K23 GM132688/GM/NIGMS NIH HHS/United States
869	33035643	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*HIV;*Molecular mechanisms;*Origin and taxonomy;*Potential therapeutics	Antiviral Agents/pharmacology/therapeutic use;COVID19/drug therapy/*epidemiology/virology;China;Drug Repositioning;HIV/*classification/genetics/immunology;HIV Infections/drug therapy/*epidemiology/virology;Humans;Pandemics/prevention & control;Phylogeny;SARSCoV2/*classification/genetics/immunology;DA 2020/12/15 06:00		Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and 	
870	32329520	Journal Article;Review	O  NNLM;*COVID19;*antiinflammatory agents;*antivirals;*clinical practice;*clinical research;*immunomodulatory agents;*pharmacological treatments	Animals;Antiviral Agents/*administration & dosage/adverse effects/pharmacology;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/virology;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/10/28 06:00		Current pharmacological treatments for COVID-19: What's next?	
871	32895641	Journal Article	O  NNLM;Omics;Virology	DA 2020/09/09 06:01		Integrative Network Biology Framework Elucidates Molecular Mechanisms of SARS-CoV-2 	U54 ES030246/ES/NIEHS NIH HHS/United States
872	32886331	Journal Article;Systematic Review	O  NNLM;COVID19;Coronavirus;Epidemiology;Intrinsic disorder region;SARSCoV;SARSCoV2 therapeutics;Spike protein	Amino Acid Sequence;Animals;COVID19/drug therapy/epidemiology/*transmission/*virology;Coronavirus Infections/drug therapy/epidemiology/transmission/virology;Humans;Protein Binding;Protein Folding;SARSCoV2/chemistry/metabolism/*physiology;Spike Glycoprotein, Coronavirus/chemistry/genetics/*metabolism;Virus Internalization;DA 2021/04/07 06:00		COVID-19 outbreak: history, mechanism, transmission, structural studies and 	MSC/2020/000319/Department of Science and Technology, Ministry of Science and 
873	32998763	Journal Article;Review	O  NNLM;ARDS;Coagulopathy;Coronavirus;Cytokine storm;Neuroinflammation;Neurotropism;Neutrophil extracellular traps;SARSCoV2;Stroke	Betacoronavirus;COVID19;Coronavirus Infections/*complications;Humans;Nervous System Diseases/*virology;Pandemics;Pneumonia, Viral/*complications;SARSCoV2;DA 2020/10/09 06:00		Neurological consequences of COVID-19: what have we learned and where do we go from 	R01NS112511/NS/NINDS NIH HHS/United States;R01NS114560/NS/NINDS NIH HHS/United States;R01 NS114560/NS/NINDS NIH HHS/United States;R03 HD094606/HD/NICHD NIH HHS/United States;R01NS099455/NS/NINDS NIH HHS/United States;U01NS113356/NS/NINDS NIH HHS/United States;R01NS01117565/NS/NINDS NIH HHS/United States;R01NS110378/NS/NINDS NIH HHS/United States;R03HD094606/National Institute of Child Health and Human Development/
874	32473109	Clinical Trial;Journal Article;Multicenter Study;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Adult;Aged;Betacoronavirus/genetics;COVID19;Coronavirus Infections/*therapy;Female;Humans;Immunization, Passive;Investigational New Drug Application;Male;Middle Aged;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;Texas;Whole Genome Sequencing;Young Adult;DA 2020/08/01 06:00		Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.	75N93019C00050/AI/NIAID NIH HHS/United States;R21 AI139369/AI/NIAID NIH HHS/United States;R21 AI146771/AI/NIAID NIH HHS/United States
875	32798602	Journal Article;Research Support, N.I.H., Extramural;Research Support, N.I.H., Intramural	O  NNLM;*Antiviral;*Ebola;*Lysosomotropic;*Machine learning	DA 2020/08/18 06:00		Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.	R21 TR001718/TR/NCATS NIH HHS/United States;R43 GM122196/GM/NIGMS NIH HHS/United States;R43 ES031038/ES/NIEHS NIH HHS/United States;R44 GM122196/GM/NIGMS NIH HHS/United States
876	32992245	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Antiviral;*COVID19;*Coronavirus;*Repurposed drugs;*SARSCoV2	Antiviral Agents/chemistry/*therapeutic use;COVID19/immunology/*therapy;COVID19 Vaccines/*immunology;*Drug Repositioning;Humans;SARSCoV2/*drug effects/immunology;DA 2020/12/22 06:00		COVID-19 therapy: What weapons do we bring into battle?	
877	33227067	Editorial		DA 2020/11/24 06:01		Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of 	
878	32721449	Journal Article;Review	O  NNLM;Antiviral drugs;COVID19;Diagnostic kits;Hydroxychloroquine;Plasma therapy	Antiviral Agents/classification/pharmacology;*Betacoronavirus/drug effects/physiology;COVID19;COVID19 Testing;Clinical Laboratory Techniques/*methods;Communicable Disease Control/*methods;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/therapy;Humans;Immunization, Passive/methods;*Pandemics;*Pneumonia, Viral/diagnosis/epidemiology/therapy;SARSCoV2;Treatment Outcome;DA 2020/09/23 06:00		OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath.	
879	32425269	Journal Article	O  NNLM;COVID19;CRP;IL6;hyperinflammation;mechanical ventilation;prediction;respiratory failure	Adolescent;Adult;Aged;Betacoronavirus;Biomarkers/*blood;CReactive Protein/analysis/*metabolism;COVID19;Coronavirus Infections/*blood/therapy;Female;Humans;Interleukin6/*blood;Male;Middle Aged;Pandemics;Pneumonia, Viral/*blood/therapy;*Respiration, Artificial;Respiratory Insufficiency/blood/therapy/virology;SARSCoV2;Young Adult;DA 2020/07/17 06:00		Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in 	
880	32801052	Journal Article;Review		DA 2020/08/18 06:00		Derivatization and combination therapy of current COVID-19 therapeutic agents: a 	
881	33542047	Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't	O  NNLM;*cytokines;*health care;*inflammation;*outcome assessment	Adult;Aged;COVID19/*drug therapy/mortality/virology;Colchicine/*administration & dosage/adverse effects;Diarrhea/chemically induced;DoubleBlind Method;Female;Humans;Intensive Care Units;*Length of Stay;Male;Middle Aged;*Oxygen Inhalation Therapy;Reverse Transcriptase Polymerase Chain Reaction;SARSCoV2/*genetics;*Severity of Illness Index;Time Factors;Treatment Outcome;DA 2021/02/20 06:00		Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, 	
882	33017170	Journal Article;Systematic Review		Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & ;Alanine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic ;Antiviral Agents/administration & dosage/adverse effects/*therapeutic use;COVID19/*drug therapy;Drug Administration Schedule;Humans;Length of Stay;Randomized Controlled Trials as Topic;SARSCoV2;Severity of Illness Index;DA 2021/02/25 06:00		Remdesivir for Adults With COVID-19 : A Living Systematic Review for American 	
883	32777212	Journal Article	O  NNLM;Anticoagulants;Antivirals;Chloroquine;Dexamethasone;Ivermectin	AntiInflammatory Agents/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/*therapeutic use;COVID19;Coronavirus Infections/*drug therapy;Dexamethasone/therapeutic use;Humans;In Vitro Techniques;Pandemics;Pneumonia, Viral/*drug therapy;DA 2020/11/06 06:00		What to expect from different drugs used in the treatment of COVID-19: A study on 	
884	33360447	Comment;Letter	O  NNLM;*COVID19;*Camostat mesylate;*Cellular entry;*Nafamostat mesylate;*SARSCoV2 pneumonia;*Thrombosis;*Transmembrane protease serine 2 (TMPRSS2)	*COVID19;Humans;PeptidylDipeptidase A;SARSCoV2;*Thrombosis;Virus Internalization;DA 2021/01/26 06:00		Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues….	
885	32673060	Journal Article;Multicenter Study;Randomized Controlled Trial		Adult;Antimalarials/therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/epidemiology;DoubleBlind Method;Female;FollowUp Studies;Humans;Hydroxychloroquine/*therapeutic use;Male;Middle Aged;*Outpatients;*Pandemics;Pneumonia, Viral/*drug therapy/epidemiology;Retrospective Studies;Risk Factors;SARSCoV2;Time Factors;DA 2020/10/28 06:00	ClinicalTrials.gov/NCT04308668	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized 	R01 NS110519/NS/NINDS NIH HHS/United States;UL1 TR002494/TR/NCATS NIH HHS/United States;K23 AI138851/AI/NIAID NIH HHS/United States;U01 AI125003/AI/NIAID NIH HHS/United States;T32 AI055433/AI/NIAID NIH HHS/United States;L30 TW011500/TW/FIC NIH HHS/United States;K23 MH121220/MH/NIMH NIH HHS/United States;K08 AI134262/AI/NIAID NIH HHS/United States
886	32829467	Case Reports;Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*T cells;*cytokines;*immune dysfunction	Aged, 80 and over;Betacoronavirus/*immunology/pathogenicity;COVID19;Coronavirus Infections/blood/*complications/immunology/therapy;Cytokine Release Syndrome/blood/*immunology/therapy/virology;Fatal Outcome;France;Humans;Longitudinal Studies;Lymphocyte Activation;Male;Multiple Organ Failure/blood/*immunology/therapy/virology;Pandemics;Pneumonia, Viral/blood/*complications/immunology/therapy;Prospective Studies;Respiratory Distress Syndrome/blood/*immunology/therapy/virology;SARSCoV2;Severity of Illness Index;TLymphocytes, Cytotoxic/immunology;Th1 Cells/immunology;Th2 Cells/immunology;DA 2020/10/28 06:00	ClinicalTrials.gov/NCT04262921	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress 	
887	33282284	Journal Article	O  NNLM;COVID19;Coronavirus;noninvasive ventilation;pharmacologic treatment;pneumonia;respiratory failure;severe acute respiratory syndrome	DA 2020/12/08 06:01		COVID-19: general overview, pharmacological options and ventilatory support 	
888	33560382	Journal Article;Research Support, NonU.S. Gov't		Angiopoietin2/*blood;Antiviral Agents/therapeutic use;Area Under Curve;Biomarkers/blood;COVID19/drug therapy/mortality/*pathology/virology;Hospital Mortality;Hospitalization;Humans;Interleukin6/blood;Proportional Hazards Models;ROC Curve;Risk Factors;SARSCoV2/isolation & purification;Survival Rate;DA 2021/02/20 06:00		Dynamic angiopoietin-2 assessment predicts survival and chronic course in 	
889	32534467	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*cytokine storm;*immunotherapy;*leukocyte	*Betacoronavirus;COVID19;China;Coronavirus Infections/*immunology;Cytokine Release Syndrome/*immunology;Cytokines/*immunology;Humans;Leukocytes/*immunology;Pandemics;Pneumonia, Viral/*immunology;SARSCoV2;DA 2020/07/18 06:00		Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: 	Philadelphia Foundation/International;FDCT014/2015/A1/Science and Technology Development Fund/International;FDCT201/2017/A3/Science and Technology Development Fund/International;FDCT0056/2019/AFJ/Science and Technology Development Fund/International;MYRG201600023ICMSQRCM/University of Macau/International;MYRG201700120ICMS/University of Macau/International;MYRG201900169ICMS/University of Macau/International
890	33190802	Journal Article;Review	O  NNLM;Antiviral therapy;COVID19;SARSCoV2	Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Humans;*SARSCoV2;DA 2020/12/29 06:00		Recent progress of antiviral therapy for coronavirus disease 2019.	
891	33488063	Journal Article		DA 2021/01/26 06:01		[Not Available].	
892	32391242	Journal Article;Review	O  NNLM;Biomarkers;COVID19;Coronavirus management algorithm;Precision medicine	DA 2020/05/12 06:00		A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.	
893	33162993	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Janus kinase 1/2;*chronic graftversushost disease;*hematopoietic stem cell transplantation;*immunotherapy;*tyrosine kinase inhibitors	DA 2020/11/10 06:00		New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current 	
894	33380375	Journal Article;Review	O  NNLM;Covid19;FURIN;Host cell entry inhibitor;Nasal or oral inhaler;TMPRSS2;Virushost cell interaction blocking	AngiotensinConverting Enzyme 2/antagonists & inhibitors;Animals;COVID19/*drug therapy;Furin/*antagonists & inhibitors/metabolism;Humans;Mice;Mice, Knockout;Phytochemicals/*pharmacology;Receptors, Virus/*antagonists & inhibitors;SARSCoV2;Serine Endopeptidases/*metabolism;Serine Proteinase Inhibitors/*pharmacology;Spike Glycoprotein, Coronavirus/metabolism;DA 2021/04/29 06:00		Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a 	
895	32419838	Journal Article		DA 2020/05/19 06:01		Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as 	
896	33188364	Journal Article;Review		AngiotensinConverting Enzyme 2/antagonists & inhibitors/metabolism;Blood Glucose/drug effects/metabolism;COVID19/*drug therapy/*epidemiology/metabolism;Diabetes Mellitus, Type 1/*drug therapy/*epidemiology/metabolism;Diabetes Mellitus, Type 2/*drug therapy/*epidemiology/metabolism;Disease Management;Humans;Hypoglycemic Agents/administration & dosage/metabolism;Risk Factors;DA 2020/12/29 06:00		COVID-19 and diabetes mellitus: from pathophysiology to clinical management.	
897	32773105	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Cancer;*Natural products;*Nutraceuticals;*Repurposing approved drugs	AngiotensinConverting Enzyme 2;Antineoplastic Agents/*therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/immunology/pathogenicity;COVID19;Comorbidity;Coronavirus Infections/*drug therapy/*epidemiology/immunology/virology;Drug Repositioning;Gene Expression Regulation;HostPathogen Interactions/drug effects/genetics/immunology;Humans;Hydroxychloroquine/therapeutic use;Neoplasms/*drug therapy/*epidemiology/immunology/virology;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/*drug therapy/*epidemiology/immunology/virology;SARSCoV2;Signal Transduction/genetics/immunology;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/genetics/immunology;Trace Elements/therapeutic use;Vitamins/therapeutic use;DA 2020/08/28 06:00		Cancer therapy and treatments during COVID-19 era.	
898	32894364	Journal Article	O  NNLM;Bacteria;COVID19;Coinfection;Haemophilus influenzae;SARSCoV2;Staphylococcus aureus;Streptococcus pneumoniae	DA 2020/09/08 06:01		Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia 	
899	32247925	Editorial		Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Antimalarials/*therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;*Drug Repositioning;Humans;Hydroxychloroquine/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/05/19 06:00		Repurposing antimalarials and other drugs for COVID-19.	
900	32964179	Journal Article	O  NNLM;COVID19;anakinra;haemophagocytic lymphohistiocytosis;hyperinflammation	DA 2020/09/24 06:01		Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a 	
901	32837895	Journal Article	O  NNLM;Coronavirus;Rapid review;SARSCoV2;Zinc	DA 2020/08/25 06:01		Zinc for the prevention and treatment of SARS-CoV-2 and other acute viral 	
902	32360585	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Antiviral;*COVID19;*Immunization;*Therapy	Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects;COVID19;China;Coronavirus Infections/*drug therapy;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/07/01 06:00		Current targeted therapeutics against COVID-19: Based on first-line experience in 	
903	32513231	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Dual therapy;Randomised controlled trial;SARSCoV2;hydroxychloroquine;nitazoxanide;protocol;treatment regimen	*Betacoronavirus;COVID19;Coronavirus Infections/complications/*drug therapy;Drug Therapy, Combination;Humans;Hydroxychloroquine/administration & dosage/*therapeutic use;Pandemics;Pneumonia, Viral/complications/*drug therapy;Prognosis;*Randomized Controlled Trials as Topic;Respiration, Artificial;Risk Factors;SARSCoV2;SingleBlind Method;Thiazoles/*administration & dosage;DA 2020/07/01 06:00	ClinicalTrials.gov/NCT04341493	Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 	
904	33166694	Journal Article	O  NNLM;COVID19;Hydroxychloroquine;Pandemic;Postexposure prophylaxis;Prevention;SARSCoV2	Adult;COVID19/*prevention & control;Female;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Male;Middle Aged;*PostExposure Prophylaxis;*SARSCoV2;DA 2020/12/15 06:00		Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a 	
905	32828135	Journal Article;Multicenter Study;Randomized Controlled Trial		Acetaminophen/therapeutic use;Adult;Antiviral Agents/*therapeutic use;Betacoronavirus/*pathogenicity;COVID19;Cephalosporins/therapeutic use;Coronavirus Infections/diagnosis/*drug therapy/mortality/virology;Drug Administration Schedule;Drug Repositioning;Egypt;Female;Humans;Hydrocortisone/therapeutic use;Hydroxychloroquine/*therapeutic use;Male;Middle Aged;Oseltamivir/therapeutic use;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology;Respiration, Artificial;SARSCoV2;Severity of Illness Index;Survival Analysis;Time Factors;Treatment Outcome;DA 2020/10/28 06:00		Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled 	
906	32330858	Journal Article;Review	O  NNLM;*COVID19 pandemic;*Head and neck cancer;*Head and neck oncology;*Mucosal squamous cell carcinoma;*Multilevel risk;*Risk stratification;*SARSCoV2;*Surgical barriers;*Surgical risk;*Treatment paradigms	Aerosols;Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology;Head and Neck Neoplasms/surgery/*therapy;Humans;Infection Control;Medical Oncology/*methods;Pandemics;Personal Protective Equipment;Pneumonia, Viral/*epidemiology;SARSCoV2;Surgical Oncology;DA 2020/05/21 06:00		Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional 	
907	32434788	Journal Article	O  NNLM;*TLymphocytes;*immunity;*lung neoplasms	Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/*therapeutic use;*Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/*etiology/prevention & control;Humans;Hydroxychloroquine/therapeutic use;Interleukin6/metabolism;Lung/pathology;Lung Neoplasms/*complications/drug therapy/virology;Neoplasms/virology;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/*etiology/prevention & control;Risk Factors;SARSCoV2;DA 2020/05/30 06:00		COVID-19 and lung cancer: risks, mechanisms and treatment interactions.	
908	33062949	Journal Article;Review		DA 2020/10/17 06:01		Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19.	
909	32777441	Journal Article		Antiviral Agents/*administration & dosage;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/drug therapy/*prevention & control/virology;Health Personnel;Humans;Hydroxychloroquine/*administration & dosage;India;Pandemics/*prevention & control;Pneumonia, Viral/*prevention & control/virology;PreExposure Prophylaxis/*methods;SARSCoV2;DA 2020/10/21 06:00		Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale 	
910	32532623	Journal Article;Review	O  NNLM;*COVID19;*Clinical trials;*NAATs;*SARSCoV2;*Spike protein;*Vaccine	Betacoronavirus/*drug effects/immunology/pathogenicity;COVID19;COVID19 Vaccines;Coronavirus/*drug effects;Coronavirus Infections/diagnosis/*drug therapy/*prevention & control/therapy;Humans;Immunization, Passive/methods;Pandemics/*prevention & control;Pneumonia, Viral/diagnosis/*drug therapy/*prevention & control;SARSCoV2;Viral Vaccines/*therapeutic use;DA 2020/10/30 06:00		Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.	
911	33194671	Journal Article;Review	O  NNLM;cancer;coronavirus disease;coronavirus disease 2019;severe acute respiratory syndrome;severe acute respiratory syndrome coronavirus 2	DA 2020/11/17 06:01		Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and 	
912	33493917	Journal Article;Review	O  NNLM;COVID19;Computational docking;Drug repurposing;SARSCoV2;Vaccine	Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*prevention & control;*COVID19 Vaccines;Clinical Trials as Topic;Drug Repositioning;Humans;Pandemics;DA 2021/03/03 06:00		The growing complexity of COVID-19 drug and vaccine candidates: challenges and 	
913	32589146	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*coronavirus;*cure rate model;*restricted mean survival time;*sample size adjustment;*terminal event;*type I error rate	Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Alanine/*analogs & derivatives/therapeutic use;COVID19/drug therapy;Coronavirus Infections/drug therapy;Data Interpretation, Statistical;Drug Therapy, Combination;Humans;Lopinavir/*therapeutic use;Randomized Controlled Trials as Topic/*methods;Research Design;Ritonavir/*therapeutic use;Treatment Outcome;DA 2020/07/23 06:00		Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With 	
914	32838087	Journal Article		DA 2020/08/25 06:01		Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients 	
915	33521210	Journal Article;Review	O  NNLM;ACE2;COVID19;Cytokine;GI symptoms;Inflammation;Microbiota;SARSCoV2;Vitamin D	DA 2021/02/02 06:01		Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19.	
916	32430432	Letter;Observational Study		Aged;Betacoronavirus;COVID19;Coronavirus Infections/*complications/drug therapy;Disease Progression;Drug Combinations;Female;Hemodynamics;Humans;Hydroxychloroquine/administration & dosage;Hypertension/*complications;Italy;Lopinavir/administration & dosage;Male;Middle Aged;Oxygen;Pandemics;Pneumonia, Viral/*complications;ReninAngiotensin System;Respiratory Insufficiency/*complications;Ritonavir/administration & dosage;SARSCoV2;Treatment Outcome;DA 2020/08/11 06:00		The liaison between respiratory failure and high blood pressure: evidence from 	
917	32642806	Case Reports;Journal Article	O  NNLM;Baricitinib;COVID19;Immunotherapy;SARSCoV2;Sarilumab	Acute Disease;Aged;Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/*therapeutic use;Azetidines/*therapeutic use;Azithromycin/therapeutic use;Betacoronavirus/drug effects/*pathogenicity;COVID19;Coronavirus Infections/*drug therapy/physiopathology/virology;Drug Combinations;Drug Repositioning;Humans;Hydroxychloroquine/therapeutic use;Lopinavir/therapeutic use;Male;Pandemics;Pneumonia, Viral/*drug therapy/physiopathology/virology;Respiratory Insufficiency/*drug therapy/physiopathology/virology;Ritonavir/therapeutic use;SARSCoV2;Sulfonamides/*therapeutic use;Treatment Outcome;DA 2020/10/08 06:00		Baricitinib as rescue therapy in a patient with COVID-19 with no complete response 	
918	32511912	Journal Article;Research Support, NonU.S. Gov't;Review		Amino Acid Sequence;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Drug Repositioning;Enzyme Inhibitors/therapeutic use;Humans;Immunity, Innate/drug effects;SARSCoV2/*drug effects;DA 2020/12/15 06:00		COVID-19: Drug Targets and Potential Treatments.	
919	32733842	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*antiCOVID19 drugs;*chloroquine;*glucocorticoid;*lopinavir/ritonavir;*plasma therapy;*remdesivir	Antiviral Agents/therapeutic use;*COVID19;Humans;*Pharmaceutical Preparations;Research;SARSCoV2;DA 2020/08/01 06:01		Progress in the Research and Development of Anti-COVID-19 Drugs.	
920	32561873	Journal Article;Research Support, NonU.S. Gov't;Review		Antibodies, Monoclonal, Humanized/therapeutic use;Antirheumatic Agents/therapeutic use;Arthralgia;Arthritis, Rheumatoid/drug therapy/*immunology;Azetidines/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/complications/drug therapy/*immunology;Cytokine Release Syndrome/*immunology;Delivery of Health Care;Interleukin 1 Receptor Antagonist Protein/therapeutic use;Interleukin1beta/immunology;Interleukin6/immunology;Janus Kinase Inhibitors/therapeutic use;Myalgia;Pandemics;Pneumonia, Viral/complications/drug therapy/*immunology;Pulmonary Alveoli/*immunology;Rheumatology;SARSCoV2;Sulfonamides/therapeutic use;Tumor Necrosis Factor Inhibitors/therapeutic use;Tumor Necrosis Factoralpha/immunology;DA 2020/07/31 06:00		COVID-19 revisiting inflammatory pathways of arthritis.	
921	32551862	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV1;*SARSCoV2;*coronavirus;*pulmonary vascular diseases;*vascular remodeling	AngiotensinConverting Enzyme 2;*Betacoronavirus/pathogenicity/physiology;COVID19;Coronavirus Infections/*complications/physiopathology/virology;Cytokines/blood;DNA Damage;Heart Injuries/etiology;Host Microbial Interactions/physiology;Humans;Hypoxia/etiology;Inflammation Mediators/blood;Lung/*blood supply/*physiopathology/virology;Lung Diseases/*etiology/physiopathology/virology;Mitochondria/physiology;Myocardium;Oxidative Stress;Pandemics;PeptidylDipeptidase A/physiology;Pneumonia, Viral/*complications/physiopathology/virology;Pulmonary Circulation;Pulmonary Embolism/etiology;Receptors, Virus/physiology;Risk Factors;SARSCoV2;Vasculitis/etiology;DA 2020/08/06 06:00		Novel insights on the pulmonary vascular consequences of COVID-19.	Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de ;Heart and Stroke Foundation of Canada (Fondation des maladies du cœur du 
922	33153629	Journal Article;Multicenter Study;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;COVID19/*drug therapy/epidemiology/metabolism;DoseResponse Relationship, Drug;Female;GranulocyteMacrophage ColonyStimulating Factor/*antagonists & ;Humans;Infusions, Intravenous;Male;Middle Aged;Pandemics;*SARSCoV2;Treatment Outcome;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04351152	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort 	K12 CA090628/CA/NCI NIH HHS/United States;R01 AI110173/AI/NIAID NIH HHS/United States;R01 AI120698/AI/NIAID NIH HHS/United States
923	32840614	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;children;novel coronavirus;pediatrics	Asymptomatic Diseases;*Betacoronavirus;COVID19;COVID19 Testing;Child;Child Health Services;Clinical Laboratory Techniques;*Coronavirus Infections/diagnosis/prevention & control/therapy/transmission;Female;Humans;Infant, Newborn;Infant, Newborn, Diseases/epidemiology/prevention & control;Infectious Disease Transmission, Vertical;*Pandemics/prevention & control;Pediatrics;*Pneumonia, Viral/diagnosis/prevention & control/therapy/transmission;Practice Guidelines as Topic;Pregnancy;Pregnancy Complications, Infectious;SARSCoV2;DA 2020/11/18 06:00		A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome 	
924	32832437	Journal Article		DA 2020/08/25 06:01		Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic 	
925	33204745	Journal Article	O  NNLM;COVID19;dermatology;exanthema;pandemics;pneumonia	DA 2020/11/19 06:01		Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for 	
926	33411707	Journal Article;Observational Study;Research Support, NonU.S. Gov't		Aged;Brazil/epidemiology;COVID19/epidemiology/*mortality/*therapy;Cohort Studies;Emergency Service, Hospital;Female;Hospitalization;Humans;Male;Middle Aged;Prospective Studies;Seasons;DA 2021/01/15 06:00		Mortality and other outcomes of patients with coronavirus disease pneumonia admitted 	
927	33447984	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Environmental implications;Hydroxychloroquine;Pandemic;SARSCoV2;Treatment	DA 2021/01/16 06:00		Hydroxychloroquine in COVID-19: therapeutic promises, current status, and 	
928	33096026	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*ARDS;*COVID19;*ICU;*RNA sequencing;*machine learning;*mass spectrometry;*multiomics;*outcomes;*severity	Aged;Aged, 80 and over;COVID19/*blood/*genetics/therapy;Cohort Studies;Female;Gelsolin/blood/genetics;Humans;Inflammation Mediators/blood;*Machine Learning;Male;Middle Aged;Neutrophils/metabolism;Principal Component Analysis/methods;Sequence Analysis, RNA/*methods;*Severity of Illness Index;DA 2021/02/04 06:00		Large-Scale Multi-omic Analysis of COVID-19 Severity.	R01 HL049426/HL/NHLBI NIH HHS/United States;T32 HG002760/HG/NHI NIH HHS/United States;P41 GM108538/GM/NIGMS NIH HHS/United States;R01 GM124133/GM/NIGMS NIH HHS/United States;K01 HL130704/HL/NHLBI NIH HHS/United States
929	33323479	Journal Article;Review	O  NNLM;ARDS;cytokine biology;pneumonia;respiratory infection;viral infection	DA 2020/12/17 06:00		Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the 	
930	32473681	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Aged;Antiviral Agents/therapeutic use;Azithromycin/therapeutic use;Betacoronavirus;COVID19;Cause of Death;Comorbidity;Coronavirus Infections/drug therapy/*epidemiology/mortality;Databases, Factual;Female;Humans;Hydroxychloroquine/therapeutic use;Male;Middle Aged;Neoplasms/*epidemiology/mortality/therapy;Pandemics;Pneumonia, Viral/drug therapy/*epidemiology/mortality;Prognosis;Risk Factors;SARSCoV2;DA 2020/07/03 06:00	ClinicalTrials.gov/NCT04354701	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.	UL1 TR000445/TR/NCATS NIH HHS/United States;P30 CA016056/CA/NCI NIH HHS/United States;U01 CA231840/CA/NCI NIH HHS/United States;UG1 CA189974/CA/NCI NIH HHS/United States;P30 CA060553/CA/NCI NIH HHS/United States;UG1 CA189828/CA/NCI NIH HHS/United States;P30 CA068485/CA/NCI NIH HHS/United States;P30 CA054174/CA/NCI NIH HHS/United States;P30 CA016672/CA/NCI NIH HHS/United States;T32 HG008341/HG/NHI NIH HHS/United States;T32 CA203703/CA/NCI NIH HHS/United States;T32 CA009515/CA/NCI NIH HHS/United States;P30 CA023100/CA/NCI NIH HHS/United States;P30 CA013696/CA/NCI NIH HHS/United States;U10 CA180888/CA/NCI NIH HHS/United States;P30 CA196521/CA/NCI NIH HHS/United States
931	33451007	Journal Article;Review	O  NNLM;favipiravir;influenza;viral infection	DA 2021/01/17 06:01		Favipiravir in Therapy of Viral Infections.	
932	33154498	Journal Article		COVID19;Chloroquine/*adverse effects/therapeutic use;Cohort Studies;Coronavirus Infections/drug therapy;Female;Heart/*drug effects;Humans;Hydroxychloroquine/*adverse effects/therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral/drug therapy;*Product Surveillance, Postmarketing;*Safety;DA 2020/12/01 06:00		Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure 	R35 GM131881/GM/NIGMS NIH HHS/United States
933	32645974	Journal Article;Review	O  NNLM;ACE2;COVID19;SARSCoV2;cardiovascular disease (CVD);cardiovascular system;hydroxychloroquine;therapeutics	DA 2020/07/11 06:01		SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, 	K99 DK120876/DK/NIDDK NIH HHS/United States;19CDA34490009/American Heart Association/;K99DK120876/DK/NIDDK NIH HHS/United States
934	32506258	Journal Article;Review	O  NNLM;COVID19;Critical care;Expert statement	DA 2020/06/09 06:01		Management of critically ill patients with COVID-19 in ICU: statement from 	
935	33322733	Journal Article;Review	O  NNLM;COVID19;antiinflammatory drugs;cytokine storm;immunomodulation	DA 2020/12/17 06:01		Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 	Ricerca Scientifica di Ateneo (RSA) 20192020/Università Politecnica delle Marche/
936	33318491	Case Reports;Journal Article;Research Support, NonU.S. Gov't		Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Adult;Alanine/*analogs & derivatives/therapeutic use;Antiviral Agents/therapeutic use;COVID19/virology;Fever/prevention & control;Humans;Immunity, Humoral/*drug effects/immunology;Lymphocyte Count;Male;SARSCoV2/*drug effects/immunology/physiology;Treatment Outcome;DA 2020/12/29 06:00		Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case 	RG95376/MRC_/Medical Research Council/United Kingdom;WT109965MA/WT_/Wellcome Trust/United Kingdom;MR/S035362/1/MRC_/Medical Research Council/United Kingdom;DH_/Department of Health/United Kingdom;MR/M501621/1/MRC_/Medical Research Council/United Kingdom;MC_UU_00025/12/MRC_/Medical Research Council/United Kingdom;206298/B/17/Z/WT_/Wellcome Trust/United Kingdom;MR/J014370/1/MRC_/Medical Research Council/United Kingdom;200871/Z/16/Z/WT_/Wellcome Trust/United Kingdom;207498/Z/17/Z/WT_/Wellcome Trust/United Kingdom;MR/V028448/1/MRC_/Medical Research Council/United Kingdom;210688/Z/18/Z/WT_/Wellcome Trust/United Kingdom;MR/P008801/1/MRC_/Medical Research Council/United Kingdom
937	33466743	Journal Article	O  NNLM;African natural products;SARSCoV2;SARSCoV2 inhibitors;coronavirus;molecular docking;molecular dynamics;virtual screening	Africa;Antiviral Agents/*chemistry/metabolism/*pharmacology;Bayes Theorem;Binding Sites;Biological Products/chemistry/metabolism/*pharmacology;Cheminformatics/methods;Coronavirus 3C Proteases/chemistry/*metabolism;Drug Evaluation, Preclinical;Fusidic Acid/chemistry/pharmacology;Ligands;Molecular Docking Simulation;Molecular Dynamics Simulation;Pentacyclic Triterpenes/chemistry/pharmacology;Protein Conformation;SARSCoV2/*drug effects;DA 2021/01/30 06:00		Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural 	
938	32433217	Journal Article;Review		*Betacoronavirus;COVID19;COVID19 Testing;*Clinical Laboratory Techniques;Clinical Trials as Topic;Coronavirus Infections/*diagnosis/drug therapy/*therapy/transmission;Humans;Pandemics;Pneumonia, Viral/*diagnosis/*therapy/transmission;SARSCoV2;DA 2020/09/25 06:00		SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and 	
939	32425365	Letter	O  NNLM;COVID19;Convalescent plasma;Passive immunotherapy	*Betacoronavirus;COVID19;Coronavirus Infections/*therapy;Humans;Immunization, Passive;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;Treatment Outcome;Viral Load;DA 2020/07/11 06:00		Why should we use convalescent plasma for COVID-19?	
940	32266694	Editorial		Betacoronavirus/*drug effects;COVID19;Chloroquine/*therapeutic use;Coronavirus Infections/*drug therapy;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/04/23 06:00		Chloroquine for COVID-19 Infection.	
941	33390967	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;antiviral;drug repurposing;prophylaxis	DA 2021/01/05 06:01		Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.	
942	32416330	Case Reports	O  NNLM;COVID19;Fingolimod;Multiple sclerosis;Tocilizumab	Antibodies, Monoclonal, Humanized/*therapeutic use;Betacoronavirus;CReactive Protein/immunology;COVID19;Coronavirus Infections/complications/*drug therapy/immunology;Deprescriptions;Female;Ferritins/metabolism;Fibrin Fibrinogen Degradation Products/metabolism;Fingolimod Hydrochloride/*therapeutic use;Humans;Immunologic Factors/therapeutic use;Immunosuppressive Agents/*therapeutic use;Interleukin6/immunology;LLactate Dehydrogenase/metabolism;Lymphopenia/chemically induced/immunology;Middle Aged;Multiple Sclerosis, RelapsingRemitting/complications/*drug therapy;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology;Respiration, Artificial;SARSCoV2;Severity of Illness Index;DA 2020/07/03 06:00		A fine balance: Immunosuppression and immunotherapy in a patient with multiple 	
943	32304488	Journal Article;Review		Adenosine Monophosphate/analogs & derivatives;Alanine/analogs & derivatives;Antibodies, Monoclonal, Humanized;Antiviral Agents/*adverse effects/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Interactions;*Drug Monitoring;Glucocorticoids;Humans;Hydroxychloroquine;Immunosuppressive Agents/*adverse effects/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;Protease Inhibitors;SARSCoV2;*Transplant Recipients;DA 2020/05/27 06:00		Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: 	
944	32903555	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*SARSCoV2;*biologics;*cytokines;*hyperinflammation;*immunomodulators	Antibodies, Monoclonal/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Colchicine/therapeutic use;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/drug therapy;Cytokines/blood;Female;Humans;Hydroxychloroquine/therapeutic use;Immunomodulation/*drug effects;Janus Kinase Inhibitors/therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy;Risk Factors;SARSCoV2;Tumor Necrosis Factoralpha/antagonists & inhibitors;DA 2020/09/29 06:00		Immunomodulatory Drugs in the Management of SARS-CoV-2.	
945	32425328	Journal Article;Review		COVID19;Cardiovascular Diseases/*diagnosis/*epidemiology/therapy;*Cause of Death;Comorbidity;Coronavirus Infections/diagnosis/*epidemiology/therapy;Female;Global Health;Hospital Mortality/trends;Humans;Male;Pandemics/*statistics & numerical data;Pneumonia, Viral/diagnosis/*epidemiology/therapy;Prevalence;Risk Assessment;Severe Acute Respiratory Syndrome/diagnosis/*epidemiology/therapy;Survival Analysis;DA 2020/08/04 06:00		Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective.	UL1 TR002649/TR/NCATS NIH HHS/United States
946	33278517	Journal Article;Review	O  NNLM;ACE2;Cytokine storm;IFN γ;IL6;SARSCoV2;TNFα;Vascular edema	COVID19/*drug therapy/*immunology/virology;Humans;Inflammation/immunology;SARSCoV2/*immunology/pathogenicity;DA 2021/02/26 06:00		The interplay between inflammatory pathways and COVID-19: A critical review on 	
947	33059711	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Acute respiratory distress syndrome;*Angiotensin converting enzyme 2;*Antiviral;*COVID19;*Chloroquine;*Cytokine release syndrome;*Immunotherapy;*Pathophysiology;*SARSCoV2;*Tocilizumab	Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;Child;Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/*drug therapy/*immunology/virology;Cytokines/*immunology;Humans;Immunity, Innate/immunology;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/*immunology/virology;SARSCoV2;Viral Load;DA 2020/11/06 06:00		Harnessing the immune system to overcome cytokine storm and reduce viral load in 	
948	32557011	Journal Article;Review	O  NNLM;COVID19;Complications;Potential cardiotoxicity;SARSCoV2	Antiviral Agents/*pharmacology;*COVID19/drug therapy/immunology;Cardiotoxicity/*prevention & control;Cardiovascular System/*drug effects;Humans;Immunologic Factors/*pharmacology;Risk Assessment;SARSCoV2/*drug effects;DA 2021/04/07 06:00		A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.	
949	33556871	Journal Article;Review	O  NNLM;3Clike protease (3CL(pro));Coronaviruses;Papainlike protease (PL(pro));RNAdependent RNA polymerase (RdRp);SARSCoV2;Transmembrane serine protease (TMPRSS2)	*Antiviral Agents/classification/pharmacology;*COVID19/drug therapy/metabolism;Enzyme Inhibitors/pharmacology;Humans;Molecular Targeted Therapy/*methods;*SARSCoV2/drug effects/enzymology;Therapies, Investigational;DA 2021/04/07 06:00		An update review of emerging small-molecule therapeutic options for COVID-19.	
950	32551971	Journal Article;Review		*Betacoronavirus;COVID19;Coronavirus Infections/*complications/epidemiology;Global Health;Humans;Incidence;Pandemics;Pneumonia, Viral/*complications/epidemiology;Pulmonary Fibrosis/diagnosis/epidemiology/*etiology;Risk Factors;SARSCoV2;Tomography, XRay Computed;DA 2020/09/12 06:00		COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead.	
951	32984784	Journal Article	O  NNLM;Aerosol inhalation;COVID19;Clinical tiral;IFNκ;SARSCoV2;TFF2;Treatment	DA 2020/09/29 06:01		An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard 	
952	33523609	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't		Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Viral/*blood;COVID19/immunology/mortality/*therapy;Female;Hospitalization;Humans;Immunization, Passive;Immunoglobulin G/blood;Male;Middle Aged;Registries;Respiration, Artificial;Retrospective Studies;Risk Factors;SARSCoV2/*immunology;TimetoTreatment;United States/epidemiology;Young Adult;DA 2021/03/30 06:00	ClinicalTrials.gov/NCT04338360	Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.	75A50120C00096/Biomedical Advanced Research and Development Authority/;U54AG044170/AG/NIA NIH HHS/United States;5T32DK07352/DK/NIDDK NIH HHS/United States;F32 HL154320/HL/NHLBI NIH HHS/United States;5R35HL139854/HL/NHLBI NIH HHS/United States;R21 AI145356/AI/NIAID NIH HHS/United States;1F32HL154320/HL/NHLBI NIH HHS/United States;R21 AI154927/AI/NIAID NIH HHS/United States;R21 AI152318/AI/NIAID NIH HHS/United States;UL1TR002377/TR/NCATS NIH HHS/United States;PDF5329262019/Natural Sciences and Engineering Research Council of Canada/;RO1 HL059842/HL/NHLBI NIH HHS/United States
953	32507883	Journal Article;Review	O  NNLM;*AngiotensinConverting Enzyme 2;*Covid19;*ReninAngiotensin System;*SARSCoV2	AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/*pharmacology;Animals;Betacoronavirus/*metabolism;COVID19;Coronavirus Infections/*drug therapy/metabolism/virology;Humans;Pandemics;PeptidylDipeptidase A/*metabolism;Pneumonia, Viral/*drug therapy/metabolism/virology;ReninAngiotensin System/*physiology;SARSCoV2;DA 2020/06/17 06:00		Covid-19: the renin-angiotensin system imbalance hypothesis.	
954	32838264	Journal Article;Review	O  NNLM;*coronavirus disease 2019;*placenta;*pregnancy;*severe acute respiratory syndrome coronavirus 2	Abnormalities, DrugInduced/etiology/*prevention & control;*Antiviral Agents/adverse effects/classification/pharmacokinetics;COVID19/*drug therapy;Compassionate Use Trials;*Drugs, Investigational/adverse effects/classification/pharmacokinetics;Female;Humans;*MaternalFetal Exchange;Pregnancy;Pregnancy Complications, Infectious/*drug therapy;SARSCoV2;DA 2020/08/25 06:01		Placental transfer and safety in pregnancy of medications under investigation to 	
955	33071609	Editorial		DA 2020/10/20 06:01		The Covid-19, Epidemiology, Clinic and Prevention.	
956	33134940	Journal Article	O  NNLM;coronavirus disease;crisis response;pharmacists;pharmacy;severe acute respiratory syndrome coronavirus 2	DA 2020/11/03 06:01		Clinical Pharmacists: An Invaluable Part of the Coronavirus Disease 2019 Frontline 	
957	33531107	Journal Article;Systematic Review		COVID19/epidemiology/*pathology/*therapy/virology;Humans;Pandemics;SARSCoV2/isolation & purification/physiology;DA 2021/02/20 06:00		The Pathogenesis and Treatment of COVID-19: A System Review.	
958	33131530	Journal Article	O  NNLM;*COVID19;*Candidate drugs;*Infection pathways;*Interactome;*Prophylaxis agents;*Proteome;*SARSCoV2;*Transcriptome	*Antiviral Agents/chemistry/pharmacokinetics/therapeutic use;*Betacoronavirus/genetics/metabolism;COVID19;*Coronavirus Infections/drug therapy/genetics/metabolism;*Databases, Genetic;*Drug Discovery;Humans;*Models, Biological;*Pandemics;*Pneumonia, Viral/drug therapy/genetics/metabolism;Proteomics;SARSCoV2;DA 2020/11/18 06:00		Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs 	
959	32366746	Journal Article		Adult;*Betacoronavirus;COVID19;COVID19 Testing;Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/epidemiology/etiology/prevention & control/*therapy;Diagnosis, Differential;Extracorporeal Membrane Oxygenation;Humans;Pandemics/prevention & control;Pneumonia, Viral/epidemiology/etiology/prevention & control/*therapy;*Practice Guidelines as Topic;Respiration, Artificial;SARSCoV2;DA 2020/09/15 06:00		Guidance for the management of adult patients with coronavirus disease 2019.	
960	32493468	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Hydroxychloroquine + Lopinavir/Ritonavir;Interferonβ 1a;Interferonβ 1b;Randomized controlled trial;SARSCOV2	Antiviral Agents/adverse effects/*therapeutic use;Betacoronavirus/*drug effects/pathogenicity;COVID19;Coronavirus Infections/diagnosis/*drug therapy/virology;Drug Combinations;Drug Therapy, Combination;HostPathogen Interactions;Humans;Hydroxychloroquine/therapeutic use;Interferon beta1a/adverse effects/*therapeutic use;Interferon beta1b/adverse effects/*therapeutic use;Iran;Lopinavir/therapeutic use;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/virology;Randomized Controlled Trials as Topic;Ritonavir/therapeutic use;SARSCoV2;Severity of Illness Index;Time Factors;Treatment Outcome;DA 2020/06/11 06:00	ClinicalTrials.gov/NCT04343768	Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual 	
961	33005486	Journal Article	O  NNLM;Diagnostics;Genetic diversity;Genome evolution;Therapeutics;Vaccines;SARSCoV2	DA 2020/10/03 06:01		Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the 	
962	32417526	Journal Article		*Arrhythmias, Cardiac/diagnosis/etiology/physiopathology/therapy;Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/complications/epidemiology/physiopathology/therapy;*Critical Pathways/organization & administration/standards;EvidenceBased Practice/trends;*Heart Diseases/diagnosis/physiopathology/therapy/virology;*Heart Failure/diagnosis/etiology/physiopathology/therapy;Humans;*Infection Control/methods/organization & administration;*Pandemics;Patient Care Management/methods;*Pneumonia, Viral/complications/epidemiology/physiopathology/therapy;SARSCoV2;United States;DA 2020/07/01 06:00		A care pathway for the cardiovascular complications of COVID-19: Insights from an 	R01 AG045551/AG/NIA NIH HHS/United States;U01 HL125511/HL/NHLBI NIH HHS/United States
963	32768974	Journal Article;Review	O  NNLM;COVID19;Challenges;Clinical trials;Infection;SARSCoV2	Antiviral Agents/administration & dosage;Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;*Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/drug therapy/*epidemiology;Disease Outbreaks;Humans;Pandemics;Pneumonia, Viral/diagnosis/drug therapy/*epidemiology;SARSCoV2;DA 2020/09/08 06:00		Outbreak of COVID-19: An emerging global pandemic threat.	
964	32683212	Journal Article;Systematic Review	O  NNLM;*COVID19;*Chloroquine;*Hydroxychloroquine;*Mortality;*SARSCoV2	Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;Chloroquine/*therapeutic use;Coronavirus Infections/*drug therapy/prevention & control;Humans;Hydroxychloroquine/*therapeutic use;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/prevention & control;PostExposure Prophylaxis;Prospective Studies;Retrospective Studies;SARSCoV2;DA 2020/10/02 06:00		Update I. A systematic review on the efficacy and safety of 	
965	33296169	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*SARSCoV2;*antibody;*diagnosis;*inhibitor;*pandemic;*pathogenesis;*therapy;*transmission;*vaccine	DA 2020/12/10 06:00		Recent Insights into Emerging Coronavirus: SARS-CoV-2.	
966	33516247	Journal Article	O  NNLM;COVID19;Coronavirus;Fecal–oral transmission;NGS;SARSCoV2	DA 2021/02/01 06:01	ClinicalTrials.gov/NCT04359836	Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing.	
967	32896310	Journal Article;Review	O  NNLM;*COVID19;*IL6;*JAK;*SARSCoV2;*STING;*TNFα;*cytokine storm;*cytokines;*hemophagocytic lymphohistiocytosis;*hyperinflammatory;*proinflammatory;*sepsis	Betacoronavirus;COVID19;Coronavirus Infections/*immunology/*therapy;Cytokine Release Syndrome/immunology/*virology;Humans;*Immunomodulation;Interleukin6/*immunology;Pandemics;Pneumonia, Viral/*immunology/*therapy;SARSCoV2;Sepsis/immunology;DA 2020/09/17 06:00		The role of IL-6 and other mediators in the cytokine storm associated with 	P50 GM115305/GM/NIGMS NIH HHS/United States;R01 AI152183/AI/NIAID NIH HHS/United States;R01 HG010863/HG/NHI NIH HHS/United States;R21 AI139021/AI/NIAID NIH HHS/United States
968	32755653	Journal Article	O  NNLM;Covid19;azithromycin;hydroxychloroquine;pneumonia	Adult;Aged;AntiInfective Agents/*therapeutic use;Azithromycin/*therapeutic use;Betacoronavirus/*drug effects/pathogenicity;CReactive Protein/metabolism;COVID19;Coronavirus Infections/diagnostic imaging/*drug therapy/mortality/pathology;Disease Progression;Drug Combinations;Female;Humans;Hydroxychloroquine/*therapeutic use;Intensive Care Units;Lopinavir/*therapeutic use;Male;Middle Aged;Multivariate Analysis;Pandemics;Pneumonia, Viral/diagnostic imaging/*drug therapy/mortality/pathology;Prognosis;Retrospective Studies;Ritonavir/*therapeutic use;SARSCoV2;Survival Analysis;TLymphocytes/pathology/virology;Tomography, XRay Computed;Treatment Outcome;DA 2020/10/02 06:00		Impact of medical care, including use of anti-infective agents, on prognosis of 	
969	32849654	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*HLA;*MHC presentation;*T cells;*coronavirus;*immune response;*memory T cell	Animals;Antigen Presentation/immunology;Antiviral Agents/therapeutic use;Betacoronavirus/chemistry/*genetics;COVID19;Coronavirus Infections/drug therapy/*immunology/virology;Cytokines/biosynthesis;Genome, Viral;Humans;Immune Evasion;Immunization, Passive/methods;Mice;Middle East Respiratory Syndrome Coronavirus/chemistry/*genetics;Pandemics;Phylogeny;Pneumonia, Viral/drug therapy/*immunology/virology;SARS Virus/chemistry/*genetics;SARSCoV2;Severe Acute Respiratory Syndrome/drug therapy/*immunology/virology;TLymphocytes/immunology;Virus Replication;DA 2020/09/22 06:00		Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.	
970	33251593	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*antiinflammatory;*antivirals;*clinical trials;*immunotherapy	DA 2020/12/01 06:00		Review of registered clinical trials for the treatment of COVID-19.	
971	33045577	Journal Article;Review	O  NNLM;Actemra;COVID19;Coronavirus disease;Tocilizumab	Antibodies, Monoclonal, Humanized/adverse effects/pharmacology/*therapeutic use;COVID19/complications/*drug therapy;Humans;Interleukin6/physiology;Receptors, Interleukin6/*antagonists & inhibitors;*SARSCoV2;DA 2020/12/16 06:00		Tocilizumab for treatment patients with COVID-19: Recommended medication for novel 	
972	32980462	Journal Article	O  NNLM;*Artificial intelligence;*Computational biology;*Covid19;*Evolutionary peptides;*SARSCoV2	Antibodies, Viral/immunology/therapeutic use;Antiviral Agents/therapeutic use;*Artificial Intelligence;COVID19/*drug therapy/pathology/prevention & control/virology;Humans;Molecular Dynamics Simulation;Peptide Library;Peptides/pharmacology/*therapeutic use;SARSCoV2/immunology/isolation & purification/physiology;Viral Vaccines/immunology;Virus Replication/drug effects;DA 2020/12/17 06:00		Evolutionary artificial intelligence based peptide discoveries for effective 	
973	32417709	Journal Article;Review	O  NNLM;Diabetes mellitus;Hypertension arterial;Immune response;Obesity;Vitamin D	AngiotensinConverting Enzyme Inhibitors;Betacoronavirus/*immunology;COVID19;Comorbidity;Coronavirus Infections/drug therapy/*immunology/physiopathology/*therapy;Cytokine Release Syndrome/*physiopathology/therapy;Humans;Hypertension/*immunology/physiopathology;Obesity/complications/*immunology/physiopathology;Pandemics;Pneumonia, Viral/*immunology/physiopathology/*therapy;SARSCoV2;Vitamin D Deficiency/diet therapy/physiopathology;DA 2020/07/28 06:00		Mechanism of inflammatory response in associated comorbidities in COVID-19.	
974	32426374	Journal Article	O  NNLM;Coronavirus Disease 2019;cardiovascular antiinflammatory therapy;cardiovascular diseases;cardiovascular impairment;inflammation	DA 2020/05/20 06:01		Cardiovascular Impairment in COVID-19: Learning From Current Options for 	
975	32991900	Journal Article;Review	O  NNLM;COVID19;Global pandemic;Investigational drugs;SARSCoV2;Vaccine development;Virus mechanism	Antiviral Agents/therapeutic use;COVID19/drug therapy/immunology/*therapy;*Clinical Trials as Topic;Humans;SARSCoV2/drug effects/immunology/physiology;Viral Vaccines/immunology;DA 2020/12/18 06:00		Novel insights into the treatment of SARS-CoV-2 infection: An overview of current 	R01 AI050875/AI/NIAID NIH HHS/United States;R21 AI121700/AI/NIAID NIH HHS/United States
976	33029758	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;angiotensinconverting enzyme 2;cytokine storm;multiple organ failure;reninangiotensin system	AngiotensinConverting Enzyme 2/*metabolism;Biomarkers/metabolism;COVID19/metabolism/*physiopathology;Cytokine Release Syndrome/metabolism/physiopathology/*virology;Cytokines/metabolism;Humans;Inflammation/metabolism/physiopathology/*virology;Multiple Organ Failure/metabolism/physiopathology/*virology;Receptors, Coronavirus/*metabolism;Severity of Illness Index;DA 2021/01/16 06:00		Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure 	
977	33510484	News		Antibodies, Monoclonal/therapeutic use;Biological Products/*therapeutic use;COVID19/drug therapy;Cell and TissueBased Therapy;Drug Approval;Humans;Immunoconjugates/therapeutic use;Internationality;Rare Diseases/drug therapy;United States;United States Food and Drug Administration;DA 2021/03/10 06:00		Refreshing the biologic pipeline 2020.	
978	32432127	Journal Article;Review	O  NNLM;COVID19;QT;QTc;arrhythmia;drug safety;hERG	DA 2020/05/21 06:01		COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating 	MR/S021299/1/MRC_/Medical Research Council/United Kingdom
979	32574287	Journal Article;Review	O  NNLM;COVID 19 infection;SARS CoV2;breast milk;newborn;pregnancy	DA 2020/06/24 06:01		SARS-CoV-2 Infection and the Newborn.	
980	32838323	Journal Article		DA 2020/08/25 06:01	ClinicalTrials.gov/NCT04347993	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre 	
981	32939324	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Coronavirus;*Covid19;*SarsCoV2;*cellular;*humoral;*immune response;*immunity	COVID19/diagnosis/*immunology/virology;Host Microbial Interactions/*immunology;Humans;Immunity, Cellular;Immunity, Humoral;Middle East Respiratory Syndrome Coronavirus/immunology;Protective Factors;Risk Factors;SARS Virus/immunology;SARSCoV2/*immunology;Severity of Illness Index;DA 2020/09/18 06:01		Immune responses during COVID-19 infection.	
982	32373347	Journal Article	O  NNLM;Cell biology;Molecular biology	DA 2020/05/07 06:01		The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in 	
983	32737841	Journal Article		Amiodarone/*pharmacology;AngiotensinConverting Enzyme 2;AntiArrhythmia Agents/pharmacology;Antiviral Agents/pharmacology;*Arrhythmias, Cardiac/drug therapy/virology;*Betacoronavirus/drug effects/physiology;COVID19;*Coronavirus Infections/drug therapy/metabolism/physiopathology/prevention & control;Humans;*Pandemics/prevention & control;PeptidylDipeptidase A/metabolism;*Pneumonia, Viral/drug therapy/metabolism/physiopathology/prevention & control;Risk Assessment;SARSCoV2;Treatment Outcome;Virus Internalization/drug effects;DA 2020/10/21 06:00		Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to 	
984	32313885	Journal Article;Review	O  NNLM;ACE, angiotensinconverting enzyme;ACE2;AT1R, angiotensin II type 1 receptor;CI, confidence interval;COVID19;COVID19, coronavirus disease2019;CoV, coronavirus;FDA, Food and Drug Administration;IFN, interferon;IL, interleukin;IQR, interquartile range;MERS, Middle East respiratory syndrome;RAS, reninangiotensin system;RNA, ribonucleic acid;SARSCoV2;SARSCoV2, severe acute respiratory syndromecoronavirus2;TMPRSS2, transmembrane protease serine 2;clinical trials;renin angiotensin system;sACE2, soluble angiotensinconverting enzyme 2	DA 2020/04/22 06:01		COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology 	R01 HL107594/HL/NHLBI NIH HHS/United States;R21 HL141802/HL/NHLBI NIH HHS/United States;U10 HL110309/HL/NHLBI NIH HHS/United States;R01 HL118018/HL/NHLBI NIH HHS/United States;R34 HL146927/HL/NHLBI NIH HHS/United States
985	32855992	Journal Article	O  NNLM;ARDS;COVID19;IRIS;SARSCoV2;granulocytecolony stimulating factor;immune reconstitution inflammatory syndrome	DA 2020/08/29 06:01		A Case of Steroid-Responsive, COVID-19 Immune Reconstitution Inflammatory Syndrome 	
986	32473020	Journal Article;Research Support, NonU.S. Gov't;Review		*Betacoronavirus;COVID19;Clinical Trials as Topic/*methods;Coronavirus Infections/*drug therapy/metabolism;Drug Administration Schedule;Humans;Hydroxychloroquine/*administration & dosage;Pandemics;Pneumonia, Viral/*drug therapy/metabolism;SARSCoV2;DA 2020/09/04 06:00		Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 	
987	33387629	Journal Article	O  NNLM;COVID19;Chlorpromazine;Human cells;Repurposing of molecules;SARSCoV2	A549 Cells;Animals;Antiviral Agents/*pharmacology;COVID19/drug therapy;Cell Line;Chlorocebus aethiops;Chlorpromazine/pharmacokinetics/*pharmacology;*Drug Repositioning;Humans;SARSCoV2/*drug effects;Tissue Distribution;Vero Cells;Virus Replication/*drug effects;DA 2021/03/23 06:00		Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug 	
988	33117535	Journal Article	O  NNLM;Antioxidant;COVID19;coronavirus;dyspnea;erdosteine;quality of life	DA 2020/10/30 06:01		Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients 	
989	32450198	Journal Article;Review	O  NNLM;COVID19;Chloroquine;Hydroxychloroquine;Pandemic;SARSCoV2	AngiotensinConverting Enzyme 2;Antiviral Agents/*pharmacology;Betacoronavirus/*metabolism;COVID19;Chloroquine/*pharmacology;Coronavirus Infections/*drug therapy/metabolism;*Drug Repositioning;Humans;Hydroxychloroquine/*pharmacology;*Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*drug therapy/metabolism;SARSCoV2;DA 2020/08/22 06:00		A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing 	
990	32623267	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Pandemic;Review;SARSCoV2	*Betacoronavirus/genetics/immunology/physiology;COVID19;Coronavirus Infections/diagnosis/epidemiology/immunology/*virology;Genome, Viral/genetics;HIV Infections/complications;Humans;Pandemics;Pneumonia, Viral/diagnosis/epidemiology/immunology/*virology;SARSCoV2;Virus Replication;DA 2020/08/18 06:00		Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus 	
991	32671688	Journal Article;Review	O  NNLM;HCQ;Protease inhibitor;Remdesivir;SARSCoV2;Vaccines	Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;COVID19 Vaccines;Coronavirus Infections/epidemiology/prevention & control/*therapy;Humans;Pandemics/prevention & control;Pneumonia, Viral/epidemiology/*therapy;Protease Inhibitors/*therapeutic use;SARSCoV2;Viral Vaccines/*therapeutic use;DA 2020/09/15 06:00		Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 	R01AG042178, R01AG47812, R01NS105473, and AG060767/U.S. Department of Health and 
992	33162266	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Infectious disease;Pregnancy	Algorithms;COVID19/*diagnosis/*therapy;Emergency Medicine;Female;Humans;Postpartum Period;Pregnancy;Pregnancy Complications, Infectious/*diagnosis/*therapy;*Pregnancy Outcome;DA 2021/02/26 06:00		COVID-19 in pregnancy and the puerperium: A review for emergency physicians.	
993	32485894	Journal Article	O  NNLM;DPP4 inhibitors;HCV protease inhibitors;SARSCoV2;athrombin inhibitors;coronavirus;docking;protease inhibitors	Amino Acid Sequence;Anticoagulants/*chemistry/pharmacology;Antiviral Agents/*chemistry/pharmacology;Betacoronavirus/chemistry/*drug effects/enzymology/genetics;Binding Sites;COVID19;Coronavirus 3C Proteases;Coronavirus Infections/drug therapy;Cysteine Endopeptidases/chemistry/genetics/metabolism;Dipeptidyl Peptidase 4/chemistry/genetics/metabolism;DipeptidylPeptidase IV Inhibitors/*chemistry/pharmacology;Factor Xa/chemistry/genetics/metabolism;Hepacivirus/chemistry/enzymology/genetics;Humans;Molecular Docking Simulation;Pandemics;Pneumonia, Viral/drug therapy;Protease Inhibitors/*chemistry/pharmacology;Protein Binding;Protein Conformation;Protein Interaction Domains and Motifs;SARSCoV2;Sequence Alignment;Structural Homology, Protein;Substrate Specificity;Thermodynamics;Thrombin/antagonists & inhibitors/chemistry/genetics/metabolism;Viral Nonstructural Proteins/*antagonists & inhibitors/chemistry/genetics/metabolism;DA 2020/06/13 06:00		In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the 	
994	32464097	Journal Article;Research Support, N.I.H., Extramural;Review		Animals;Antiviral Agents/pharmacology;Betacoronavirus/*physiology;COVID19;Coronavirus Infections/drug therapy/*immunology/pathology/virology;Humans;Immune Evasion;Interferon Type I/genetics/*immunology/pharmacology;Interferons/genetics/*immunology/pharmacology;Pandemics;Pneumonia, Viral/drug therapy/*immunology/pathology/virology;Recombinant Proteins/pharmacology;SARSCoV2;Signal Transduction;DA 2020/06/20 06:00		Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to 	R01 AI127429/AI/NIAID NIH HHS/United States;R01 NS111242/NS/NINDS NIH HHS/United States;T32 GM007205/GM/NIGMS NIH HHS/United States;U19 AI089992/AI/NIAID NIH HHS/United States;75N93019C00051/AI/NIAID NIH HHS/United States
995	32376394	Journal Article;Review	O  NNLM;Acute respiratory distress syndrome;COVID19;Cytokine storm;Immunosuppressive;SARSCoV2;Treatment	AngiotensinConverting Enzyme Inhibitors/therapeutic use;Anticoagulants/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents;Betacoronavirus;COVID19;Coronavirus Infections/*therapy;Cytokines/antagonists & inhibitors;Glucocorticoids/therapeutic use;Humans;HydroxymethylglutarylCoA Reductase Inhibitors/therapeutic use;Immunoglobulins, Intravenous/therapeutic use;*Immunomodulation;Janus Kinases/antagonists & inhibitors;Pandemics;Pneumonia, Viral/*therapy;Risk Factors;SARSCoV2;DA 2020/06/11 06:00		Immunomodulatory therapy for the management of severe COVID-19. Beyond the 	
996	32405783	Journal Article;Review	O  NNLM;*COVID19;*Coronavirus;*Diabetes;*SARSCoV2	Betacoronavirus/*pathogenicity;Blood Glucose/metabolism;COVID19;Comorbidity;Coronavirus Infections/blood/complications/*prevention & control;Diabetes Mellitus/*virology;Humans;Pandemics/*prevention & control;Pneumonia, Viral/blood/complications/*prevention & control;SARSCoV2;DA 2020/07/28 06:00		Prevention and management of COVID-19 among patients with diabetes: an appraisal of 	
997	32781244	Journal Article;Multicenter Study	O  NNLM;Age;Creactive proteine;Coronavirus disease 2019;Lactate dehydrogenase;Obesity;Prognostic tool;Severe acute respiratory syndrome coronavirus 2;Severe respiratory failure	Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;COVID19;Child;Child, Preschool;Coronavirus Infections/*diagnosis/epidemiology;Female;Hospitalization;Humans;Italy/epidemiology;*Logistic Models;Male;Middle Aged;Multivariate Analysis;Pandemics;Pneumonia, Viral/*diagnosis/epidemiology;Prognosis;Reproducibility of Results;Respiratory Insufficiency/*diagnosis/epidemiology;Retrospective Studies;Risk Assessment;Risk Factors;SARSCoV2;Sensitivity and Specificity;Young Adult;DA 2020/11/21 06:00	ClinicalTrials.gov/NCT04316949	Development and validation of a prediction model for severe respiratory failure in 	
998	32539378	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review		Amino Acid Sequence;AngiotensinConverting Enzyme 2/chemistry/metabolism;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/prevention & control;Cathepsin L/antagonists & inhibitors;Cell Line;Humans;Protein Domains;SARSCoV2/*drug effects;Spike Glycoprotein, Coronavirus/antagonists & inhibitors;Virus Internalization/*drug effects;DA 2020/12/15 06:00		Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.	R01 AI150491/AI/NIAID NIH HHS/United States;R01 NS089435/NS/NINDS NIH HHS/United States
999	32873977	Journal Article		COVID19;Clinical Trials as Topic/*standards;Coronavirus Infections/*epidemiology;Humans;Informed Consent/standards;*Pandemics;Patient Selection;Pneumonia, Viral/*epidemiology;Quality Improvement;Telemedicine/standards;DA 2020/10/21 06:00		The COVID-19 pandemic: a catalyst to improve clinical trials.	
1000	33138197	Journal Article;Review	O  NNLM;2019nCoV;SARSCoV2;antiviral activity;antiviral agent;antiviral immunity	Animals;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy;Forecasting;Honey/*analysis;Humans;Immunologic Factors/therapeutic use;Pandemics;Phytochemicals/isolation & purification/*pharmacology;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/11/18 06:00		Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against 	
1001	32754159	Journal Article	O  NNLM;*COVID19;*autoimmunity;*critical care;*cytokine storm;*guidelines;*immunological mechanisms;*immunotherapies;*neuroimmunology	Adrenal Cortex Hormones/therapeutic use;AngiotensinConverting Enzyme 2;AntiInflammatory Agents, NonSteroidal/therapeutic use;Betacoronavirus/*immunology;CD4CD8 Ratio;CD4Positive TLymphocytes/immunology;CD8Positive TLymphocytes/immunology;COVID19;Clinical DecisionMaking/methods;Coronavirus Infections/blood/*drug therapy/*immunology/mortality;Critical Care/*methods;Critical Illness;Cytokines/*blood;Endothelial Cells/metabolism;Female;Humans;Immunocompromised Host;Interleukin6/antagonists & inhibitors;Janus Kinase Inhibitors/therapeutic use;Male;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/blood/*drug therapy/*immunology/mortality;SARSCoV2;Sex Factors;Thrombosis;DA 2020/08/22 06:00		Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, 	001/WHO_/World Health Organization/International
1002	32992048	Journal Article;Multicenter Study;Observational Study	O  NNLM;*ACEI;*ARB;*Angiotensin converting enzyme inhibitors;*Angiotensin receptor blockers;*COVID−19;*Mortality;*Sartans	Aged;Aged, 80 and over;Angiotensin Receptor Antagonists/adverse effects/*therapeutic use;AngiotensinConverting Enzyme Inhibitors/adverse effects/*therapeutic use;Antihypertensive Agents/adverse effects/*therapeutic use;COVID19/diagnosis/*mortality/therapy;Female;*Hospital Mortality;Hospitalization;Humans;Hypertension/*drug therapy/epidemiology/physiopathology;Incidence;Italy/epidemiology;Male;MetaAnalysis as Topic;Middle Aged;ReninAngiotensin System/*drug effects;Risk Assessment;Risk Factors;Severity of Illness Index;DA 2020/12/15 06:00	ClinicalTrials.gov/NCT04318418	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings 	
1003	33199136	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Pandemic;Repurposed medicine;SARSCoV2;Vaccine	DA 2020/11/18 06:00		In-line treatments and clinical initiatives to fight against COVID-19 outbreak.	
1004	33065275	Journal Article	O  NNLM;*COVID19;*Older adults;*Quasiexperimental study;*SARSCoV2;*Therapeutics;*Vitamin D	Aged;Aged, 80 and over;Betacoronavirus/genetics/pathogenicity;COVID19;Cholecalciferol/*administration & dosage;Coronavirus Infections/*genetics/mortality/pathology/virology;Female;Hospitalization;Humans;Male;Middle Aged;NonRandomized Controlled Trials as Topic;Pandemics;Pneumonia, Viral/*genetics/mortality/pathology/virology;SARSCoV2;Severity of Illness Index;Survival Rate;Vitamin D/*genetics/metabolism;DA 2020/12/01 06:00		Vitamin D and survival in COVID-19 patients: A quasi-experimental study.	
1005	32694043	Clinical Trial;Journal Article;Multicenter Study	O  NNLM;COVID19;Clinical trial;Convalescent plasma;Hospital stay;Mortality rate	Adult;Aged;Aged, 80 and over;COVID19/immunology/*therapy;Female;Humans;Immunization, Passive/adverse effects;Male;Middle Aged;SARSCoV2/immunology/physiology;Treatment Outcome;Young Adult;DA 2020/12/15 06:00		Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: 	
1006	32924956	Journal Article	O  NNLM;COVID19;SARSCoV2;antimalarial;coronavirus;drug;immune system;immunology;mortality;observational;pharmacological;protocol;rheumatic diseases	DA 2020/09/15 06:01		Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With 	
1007	32411941	Journal Article	O  NNLM;COVID19;chloroquine;hydroxychloroquine;pandemic	DA 2020/05/16 06:01		When there is a pandemic there is no time to waste: should we have 	
1008	32841640	Journal Article	O  NNLM;ACE2;COVID19;Drug repurposition;Molecular docking;Molecular dynamics simulations;RdRp;Spike protein	Amino Acid Sequence;AngiotensinConverting Enzyme 2;COVID19;*Computational Biology;Coronavirus Infections/*drug therapy/metabolism;*Drug Repositioning;Humans;Molecular Docking Simulation;Molecular Dynamics Simulation;Molecular Targeted Therapy;Pandemics;PeptidylDipeptidase A/chemistry/metabolism;Pneumonia, Viral/*drug therapy/metabolism;Protein Structure, Tertiary;RNADependent RNA Polymerase/chemistry/metabolism;Spike Glycoprotein, Coronavirus/chemistry/metabolism;DA 2020/10/21 06:00		Viroinformatics approach to explore the inhibitory mechanism of existing drugs 	
1009	32452888	Journal Article;Observational Study		Aged;*Betacoronavirus;COVID19;Cohort Studies;Comorbidity;Coronavirus Infections/complications/*mortality/therapy;Critical Illness;Female;Georgia/epidemiology;Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Organ Dysfunction Scores;Pandemics;Pneumonia, Viral/complications/*mortality/therapy;*Respiration, Artificial;Respiratory Distress Syndrome/etiology/*mortality/therapy;SARSCoV2;Socioeconomic Factors;DA 2020/09/04 06:00		ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 	K23 AI134182/AI/NIAID NIH HHS/United States;UL1 TR002378/TR/NCATS NIH HHS/United States
1010	32334062	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*ACE2 blocker;*Antimalaria;*Antiviral: Chinese traditional medicine;*COVID19;*Immunoenhancer;*Monoclonal antibody;*Vaccine	Adrenal Cortex Hormones/therapeutic use;AngiotensinConverting Enzyme 2;AntiInflammatory Agents, NonSteroidal/therapeutic use;Antibodies, Monoclonal, Humanized/therapeutic use;Anticoagulants/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;Bevacizumab/therapeutic use;COVID19;COVID19 Vaccines;Chloroquine/therapeutic use;Coronavirus Infections/drug therapy/prevention & control/*therapy;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive;Immunoglobulins, Intravenous/therapeutic use;Immunologic Factors/therapeutic use;Interferons/therapeutic use;Janus Kinase Inhibitors/therapeutic use;Killer Cells, Natural;Medicine, Chinese Traditional;Mesenchymal Stem Cell Transplantation;Nitric Oxide/therapeutic use;Pandemics;PeptidylDipeptidase A;Pneumonia, Viral/*therapy;SARSCoV2;Spike Glycoprotein, Coronavirus;Trace Elements/therapeutic use;Viral Vaccines/therapeutic use;Vitamins/therapeutic use;Zinc/therapeutic use;DA 2020/07/03 06:00		Current status of potential therapeutic candidates for the COVID-19 crisis.	
1011	32344166	Journal Article;Review	O  NNLM;COVID19;Coronavirus;Novel coronavirus;SARSCoV2	Betacoronavirus/genetics/*pathogenicity/physiology;COVID19;Communicable Disease Control/*methods;Coronavirus Infections/*diagnosis/epidemiology/*pathology/transmission;Humans;Pandemics;Pneumonia, Viral/*diagnosis/epidemiology/*pathology/transmission;SARSCoV2;Virus Shedding/physiology;DA 2020/07/01 06:00		COVID-19 pandemic-a focused review for clinicians.	MC_PC_19026/MRC_/Medical Research Council/United Kingdom;MC_UU_12014/9/MRC_/Medical Research Council/United Kingdom
1012	33015643	Journal Article		DA 2020/10/06 06:01	ClinicalTrials.gov/NCT04333420	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for 	
1013	32603692	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Coronavirus;Pharmacological treatments;SARSCoV2;Therapies	Adenosine Monophosphate/analogs & derivatives/pharmacology/therapeutic use;Adjuvants, Immunologic/*pharmacology/therapeutic use;Alanine/analogs & derivatives/pharmacology/therapeutic use;Antiviral Agents/*pharmacology/therapeutic use;Betacoronavirus/*drug effects/immunology/pathogenicity;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy/epidemiology/virology;Glucocorticoids/pharmacology/therapeutic use;Heparin, LowMolecularWeight/pharmacology/therapeutic use;Humans;Hydroxychloroquine/pharmacology/therapeutic use;Immunity, Innate/drug effects;Inflammation Mediators/*pharmacology/therapeutic use;Oseltamivir/pharmacology/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;SARSCoV2;Treatment Outcome;DA 2020/08/08 06:00		Current pharmacological treatments for SARS-COV-2: A narrative review.	
1014	32470470	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID19;*Camostat mesylate;*Cathepsin L;*Chloroquine;*Nafamostat mesylate;*Protease inhibitor cocktail;*SARSCoV2	AntiBacterial Agents/pharmacology/therapeutic use;AntigenPresenting Cells/metabolism;Antimalarials/pharmacology/therapeutic use;Antiviral Agents/administration & dosage/adverse effects/*pharmacology/*therapeutic ;Betacoronavirus;COVID19;Cathepsin L/*antagonists & inhibitors;Clinical Trials as Topic/statistics & numerical data;Coronavirus Infections/*drug therapy/*physiopathology;DoseResponse Relationship, Drug;Drug Approval;Drug Therapy, Combination;Humans;Immunologic Factors/pharmacology/therapeutic use;Medicine, Chinese Traditional/methods;Pandemics;Pneumonia, Viral/*drug therapy/*physiopathology;SARSCoV2;Serine Endopeptidases/metabolism;United States;United States Food and Drug Administration;DA 2020/09/04 06:00		Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 	HL080472/NH/NIH HHS/United States;HL134892/NH/NIH HHS/United States;HL123568/NH/NIH HHS/United States;HL60942/NH/NIH HHS/United States;AG063839/NH/NIH HHS/United States
1015	32968487	Journal Article	O  NNLM;COVID19;Clinical practice;Clinical trials;Compassionate use;Conditional approval;Early access scheme;Emergency use;Expanded access;Remdesivir	DA 2020/09/25 06:01		The use of remdesivir outside of clinical trials during the COVID-19 pandemic.	
1016	33551661	Journal Article	O  NNLM;COVID19;Coronavirus;Multiple sequence alignment;Saudi Arabia;Tanshinones	DA 2021/02/09 06:01		Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a 	
1017	32895599	Journal Article;Review	O  NNLM;Antiviral drugs;COVID19;Favipiravir;SARSCoV2	DA 2020/09/09 06:01		Favipiravir: A new and emerging antiviral option in COVID-19.	
1018	33044642	Journal Article;Review	O  NNLM;*Biologics;*Giant cell arteritis;*Glucocorticoids;*Large vessel vasculitis;*Takayasu arteritis;*Treatment	DA 2020/10/13 06:00		Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.	MR/N011775/1/MRC_/Medical Research Council/United Kingdom
1019	33422689	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*ACE2;*Coagulation;*Endothelial cells;*Inflammation;*SARSCoV2	AngiotensinConverting Enzyme 2/metabolism;Animals;Blood Coagulation;COVID19/complications/therapy/*virology;Cardiovascular Diseases/metabolism/pathology/therapy/*virology;Endothelium, Vascular/metabolism/pathology/*virology;HostPathogen Interactions;Humans;Inflammation/metabolism/pathology/therapy/*virology;Inflammation Mediators/metabolism;Neoplasms/metabolism/pathology;Pulmonary Edema/metabolism/pathology/virology;SARSCoV2/*pathogenicity;Signal Transduction;DA 2021/03/26 06:00		Endothelial cells and SARS-CoV-2: An intimate relationship.	
1020	33165755	Journal Article	O  NNLM;COVID19;Mortality;Prognosis;Registry;Score	DA 2020/11/10 06:00	ClinicalTrials.gov/NCT04334291	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 	
1021	32838309	Journal Article		DA 2020/08/25 06:01		COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre 	
1022	32329408	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Coronavirus;*MPro;*RdRp;*SARSCoV2 virus;*hACE2;*multitargetdirected ligand;*protease inhibitor	DA 2020/04/25 06:00		Discovery of potential multi-target-directed ligands by targeting host-specific 	
1023	32966814	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*AR12;*ATG16L1;*Autophagy;*OSU03012;*SARSCoV2;*Spike protein;*Virus	Animals;Antiviral Agents/*pharmacology;COVID19/drug therapy;Cell Line, Tumor;Chlorocebus aethiops;Female;HeatShock Proteins/*antagonists & inhibitors;Humans;Pyrazoles/*pharmacology;SARSCoV2/*drug effects;Spike Glycoprotein, Coronavirus/biosynthesis;Sulfonamides/*pharmacology;Vero Cells;Virus Replication/*drug effects;DA 2020/12/16 06:00		AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.	
1024	33216772	Journal Article;Research Support, NonU.S. Gov't		Adult;Aged;Apolipoprotein AI/*blood;Betacoronavirus;Biomarkers/blood;COVID19;Coronavirus Infections/*blood/epidemiology;Female;France;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*blood/epidemiology;Retrospective Studies;SARSCoV2;United States;DA 2020/12/02 06:00	ClinicalTrials.gov/NCT01927133	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19.	
1025	32579876	Case Reports;Letter	O  NNLM;COVID19;G6PD;SARS CoV2;coronavirus;coronavirus disease;deficiency;glucose6phosphate dehydrogenase;hemolytic anemia;methemoglobinemia;respiratory infections;severe acute respiratory syndrome coronavirus 2;viruses;zoonoses	*Betacoronavirus;COVID19;Coronavirus Infections/blood/*complications/virology;Glucosephosphate Dehydrogenase Deficiency/blood/*virology;Humans;Male;Methemoglobinemia/blood/*virology;Middle Aged;Pandemics;Pneumonia, Viral/blood/*complications/virology;SARSCoV2;DA 2020/09/01 06:00		Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection.	
1026	32743614	Preprint		DA 2020/08/04 06:01		Large-scale Multi-omic Analysis of COVID-19 Severity.	R01 HL049426/HL/NHLBI NIH HHS/United States;T32 HG002760/HG/NHI NIH HHS/United States;P41 GM108538/GM/NIGMS NIH HHS/United States;R01 GM124133/GM/NIGMS NIH HHS/United States;K01 HL130704/HL/NHLBI NIH HHS/United States
1027	32547788	Journal Article	O  NNLM;Infectious diseases;Medical research	DA 2020/06/18 06:01		Off-label therapy targeting pathogenic inflammation in COVID-19.	
1028	32922804	Case Reports	O  NNLM;Coronavirus disease 2019;NETosis;dornase alfa;neutrophil extracellular traps;severe acute respiratory syndrome coronavirus 2	DA 2020/09/15 06:01		Preliminary report of in vitro and in vivo effectiveness of dornase alfa on 	
1029	33096261	Editorial	O  NNLM;*COVID19;*SARSCoV2;*antiinfective agents;*antiparasitic agent;*antiviral agent;*antibiotic agent	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;AntiBacterial Agents/therapeutic use;Antiparasitic Agents/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Drug Development/*trends;*Drug Repositioning;Humans;*SARSCoV2/physiology;Virus Physiological Phenomena;DA 2020/12/29 06:00		Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?	
1030	32665963	Journal Article;Review		DA 2020/07/16 06:01		Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.	
1031	33362758	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*immune response;*treatments;*vaccines	AngiotensinConverting Enzyme 2/metabolism;Antibodies, Monoclonal/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*pathology/prevention & control/therapy;COVID19 Vaccines/*immunology;Female;Humans;Immunization, Passive/methods;Male;RNA, Viral/genetics;Receptors, Virus/metabolism;SARSCoV2/*genetics/*immunology;TLymphocytes/immunology;DA 2021/01/16 06:00		SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and 	
1032	32595934	Journal Article		DA 2020/07/01 06:01		Management of hospitalized patients with pulmonary arterial hypertension and 	
1033	33259989	Journal Article	O  NNLM;Asthma;COPD;COVID19;Coronavirus;SARSCoV2	DA 2020/12/02 06:00		Clinical characteristics of and outcomes for patients with COVID-19 and comorbid 	
1034	33526007	Journal Article;Review	O  NNLM;ACE2 receptor;COVID19;Coronavirus;Drug repurposing	DA 2021/02/03 06:01		Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a 	
1035	32482597	Journal Article	O  NNLM;*COVID19;*Coronavirus;*Efficacy;*Interleukin6;*Italy;*Safety;*Tocilizumab	Aged;*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects;Antiviral Agents/adverse effects;Betacoronavirus/drug effects/isolation & purification;COVID19;*Coronavirus Infections/blood/mortality/physiopathology/therapy;Female;Humans;Italy/epidemiology;Male;Middle Aged;Outcome and Process Assessment, Health Care;*Oxygen Inhalation Therapy/methods;*Pandemics;*Pneumonia, Viral/blood/diagnosis/drug ;Receptors, Interleukin6/*antagonists & inhibitors;*Respiratory Insufficiency/etiology/therapy;Retrospective Studies;SARSCoV2;DA 2020/06/19 06:00		Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre 	
1036	33110944	Journal Article	O  NNLM;COVID19;Chloroquine;Randomised Clinical Trial;SARSCoV2;Vietnam;coronaviruses	DA 2020/10/29 06:01	ClinicalTrials.gov/NCT04328493	A multi centre randomized open label trial of chloroquine for the treatment of 	
1037	32674818	Journal Article;Multicenter Study	O  NNLM;Angiotensinconverting enzyme inhibitors;COVID19;angiotensin II receptor blockers;nursing home residents;statins	Aged;Aged, 80 and over;Angiotensin Receptor Antagonists/*administration & dosage;AngiotensinConverting Enzyme Inhibitors/*administration & dosage;Belgium/epidemiology;COVID19;Cause of Death;Cohort Studies;Coronavirus Infections/*drug therapy/*epidemiology;Female;Geriatric Assessment;Homes for the Aged/statistics & numerical data;Humans;HydroxymethylglutarylCoA Reductase Inhibitors/*administration & dosage;Logistic Models;Male;Nursing Homes/statistics & numerical data;Odds Ratio;Pandemics/statistics & numerical data;Pneumonia, Viral/*drug therapy/*epidemiology;Retrospective Studies;Risk Assessment;Severity of Illness Index;Survival Rate;Treatment Outcome;DA 2020/07/31 06:00		The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection 	171/ALZS_/Alzheimer's Society/United Kingdom;MC_PC_17214/MRC_/Medical Research Council/United Kingdom
1038	33189613	Journal Article;Review	O  NNLM;COVID19;Effective therapies;Radiotherapy;Safety;Vaccines	Adrenal Cortex Hormones/*therapeutic use;Anticoagulants/*therapeutic use;COVID19/*therapy;COVID19 Vaccines/*immunology;Delivery of Health Care;Humans;Hyperbaric Oxygenation;Immunization, Passive;Immunoglobulins, Intravenous/*therapeutic use;Immunotherapy/*methods;Pandemics;SARSCoV2/*physiology;DA 2021/01/29 06:00		Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.	
1039	32917848	Case Reports;Journal Article		Adult;Antibodies, Monoclonal, Humanized/*therapeutic use;Betacoronavirus;COVID19;Complement C5/drug effects/immunology/*metabolism;Complement Inactivating Agents/therapeutic use;Coronavirus Infections/*complications/epidemiology;Female;Hemoglobinuria, Paroxysmal/complications/*drug therapy/immunology;Humans;Middle Aged;Pandemics;Pneumonia, Viral/*complications/epidemiology;SARSCoV2;Thrombotic Microangiopathies/complications/*drug therapy/immunology;DA 2020/09/26 06:00		Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal 	
1040	32812025	Comparative Study;Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Aged;Antiviral Agents/*administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/diagnosis/*drug therapy/epidemiology;Drug Therapy, Combination;Female;Hospitalization/trends;Humans;Imidazoles/*administration & dosage;Iran/epidemiology;Male;Middle Aged;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/epidemiology;Ribavirin/*administration & dosage;SARSCoV2;Sofosbuvir/*administration & dosage;Treatment Outcome;DA 2020/10/30 06:00		Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with 	
1041	32494931	Journal Article;Review	O  NNLM;*Acute respiratory distress syndrome;*COVID19;*Cell therapy;*Coronavirus;*Severe acute respiratory syndrome;*Therapeutic approaches	Adrenal Cortex Hormones/therapeutic use;Antibodies, Monoclonal/therapeutic use;Antiviral Agents/therapeutic use;BCG Vaccine/therapeutic use;Betacoronavirus/genetics/*immunology;COVID19;Coronavirus Infections/*drug therapy/*immunology/prevention & ;Humans;Immunization, Passive/methods;Immunotherapy, Adoptive/methods;Janus Kinase Inhibitors/therapeutic use;Mesenchymal Stem Cell Transplantation/methods;Nanomedicine/methods;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/*immunology/prevention & control/virology;SARSCoV2;Serine Proteinase Inhibitors/therapeutic use;DA 2020/07/08 06:00		Novel therapeutic approaches for treatment of COVID-19.	
1042	32485970	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;animal models;antivirals	DA 2020/06/04 06:01		A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral 	
1043	32727485	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Cardiovascular disease;*Cytokine storm;*Myocardial injury;*SARSCoV2;*Treatment;*Venous thromboembolism	AngiotensinConverting Enzyme 2;Antiviral Agents/therapeutic use;Asymptomatic Infections;*Betacoronavirus/chemistry/classification/pathogenicity/physiology;COVID19;Comorbidity;*Coronavirus Infections/drug therapy/epidemiology/immunology/pathology/therapy;Disease Susceptibility;Evolution, Molecular;Genome, Viral;Humans;Immunization, Passive;*Pandemics;PeptidylDipeptidase A/metabolism;*Pneumonia, Viral/epidemiology/immunology/pathology/therapy;Receptors, Coronavirus;Receptors, Virus/metabolism;SARS Virus/chemistry/classification/pathogenicity/physiology;SARSCoV2;Viral Proteins/chemistry;DA 2020/08/05 06:00		SARS-CoV-2: characteristics and current advances in research.	2018YFC1602206/National Key R&amp;D Program of China/International;2019010/Yangjiang Science and Technology Program key projects/International;201803040006/Guangzhou Science and Technology Program key projects/International;2018B020207006/Guangdong Science and Technology Program key projects/International
1044	32580969	Journal Article;Review	O  NNLM;COVID19;One Health;SARSCoV2;diagnosis;emerging coronavirus;therapy;vaccines	Animals;Betacoronavirus/physiology;COVID19;*Coronavirus Infections/diagnosis/epidemiology/therapy/virology;Humans;*Pandemics;*Pneumonia, Viral/diagnosis/epidemiology/therapy/virology;SARSCoV2;DA 2020/07/09 06:00		Coronavirus Disease 2019-COVID-19.	
1045	32849658	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARS CoV2;*azithromycin (AZM);*clinical trial;*hydroxychloroquine	Animals;Antiviral Agents/*therapeutic use;Azithromycin/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/virology;Disease Models, Animal;Drug Therapy, Combination;Humans;Hydroxychloroquine/*adverse effects/*therapeutic use;Mice;Pandemics;Pneumonia, Viral/*drug therapy/virology;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;Virus Replication/drug effects;DA 2020/09/22 06:00		Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining 	P30 AI028697/AI/NIAID NIH HHS/United States;R01 AI069120/AI/NIAID NIH HHS/United States
1046	33363098	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*combination therapy;*economic impact;*treatment possibilities	COVID19/*diagnosis/*epidemiology/*physiopathology/transmission;*COVID19 Vaccines;Humans;Personal Protective Equipment;SARSCoV2;DA 2021/01/21 06:00		Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global 	
1047	32705976	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review		*Artemisia/chemistry;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Humans;Pandemics;Plant Extracts/pharmacology/*therapeutic use;Pneumonia, Viral/*drug therapy;*Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/09/17 06:00		Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, 	D43 TW010131/TW/FIC NIH HHS/United States;D43 TW010937/TW/FIC NIH HHS/United States;R25 TW011217/TW/FIC NIH HHS/United States;U01 AI069521/AI/NIAID NIH HHS/United States
1048	33253764	Journal Article;Review	O  NNLM;Biologics;Covid19;Drug design;Food and nutrients;Natural products;Repurposed drugs;SARSCoV2;Vaccines	Antiviral Agents/*pharmacology;Biological Products;COVID19/*drug therapy;Drug Design;Drug Discovery;Humans;Pandemics;SARSCoV2/chemistry/*drug effects/ultrastructure;DA 2021/01/08 06:00		Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper 	
1049	32812039	Clinical Trial, Phase III;Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adult;Aged;Antiviral Agents/*administration & dosage;*Betacoronavirus;COVID19;Coronavirus Infections/diagnostic imaging/*drug therapy/epidemiology;Drug Therapy, Combination;Female;Humans;Imidazoles/*administration & dosage;Iran/epidemiology;Male;Middle Aged;Pandemics;Patient Admission/*trends;Pneumonia, Viral/diagnostic imaging/*drug therapy/epidemiology;SARSCoV2;Severity of Illness Index;Sofosbuvir/*administration & dosage;Treatment Outcome;DA 2020/10/30 06:00		Sofosbuvir and daclatasvir compared with standard of care in the treatment of 	
1050	32837847	Journal Article	O  NNLM;Azvudine;COVID‐19;SARS‐CoV‐2	DA 2020/08/25 06:00		A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the 	
1051	32923374	Journal Article;Review		DA 2020/09/15 06:01		Potential use of polyphenols in the battle against COVID-19.	R01 AT010271/AT/NCCIH NIH HHS/United States
1052	32994187	Comment;Journal Article;Research Support, NonU.S. Gov't		Betacoronavirus;COVID19;*Coronavirus;*Coronavirus Infections;*Diabetes Mellitus, Type 2/drug therapy;Hospitalization;Humans;Italy;*Pandemics;*Pneumonia, Viral;Retrospective Studies;SARSCoV2;Sitagliptin Phosphate/therapeutic use;DA 2020/11/27 06:00	figshare/10.2337/figshare.12907490	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced 	
1053	32775986	Journal Article	O  NNLM;COVID19;SarsCoV2 virus;coronavirus disease 2019;immunosuppression;kidney transplantation;outcomes	DA 2020/08/11 06:01		COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 	
1054	32664990	Letter	O  NNLM;*Adjuvant therapies;*Atorvastatin;*COVID19;*Critical care;*Emerging disease;*Immunomodulators;*Statins	Aged;Atorvastatin/*therapeutic use;COVID19;Coronavirus Infections/drug therapy/mortality;Female;Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral/mortality;Retrospective Studies;Treatment Outcome;DA 2020/07/17 06:00		Atorvastatin associated with decreased hazard for death in COVID-19 patients 	
1055	33045350	Journal Article	O  NNLM;Ambroxol;Azithromycin;COVID19;Lysosomotropic agent;SARSCoV2	Administration, Inhalation;Ambroxol/*administration & dosage;Azithromycin/*administration & dosage;COVID19/*drug therapy;Drug Delivery Systems;Humans;*SARSCoV2;DA 2020/12/15 06:00		Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.	
1056	32636754	Journal Article;Review	O  NNLM;COVID19;SARSCoV2;clinical trial;coronavirus;immune response;public health;vaccine	DA 2020/07/09 06:01		A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 	
1057	33353888	Journal Article	O  NNLM;*COVID19;*activities of daily living;*hydroxychloroquine;*nasopharyngeal swab;*sensitivity and specificity;*serology	Activities of Daily Living;Age Factors;Aged;Aged, 80 and over;COVID19/diagnosis/*mortality/therapy/virology;Dietary Supplements;Female;Humans;Italy/epidemiology;Male;Middle Aged;Mortality;*Nursing Homes;Pandemics;*SARSCoV2;Sensitivity and Specificity;Sex Factors;Vitamin D/administration & dosage;DA 2021/02/23 06:00		Mortality in an Italian nursing home during COVID-19 pandemic: correlation with 	
1058	32570302	Journal Article;Practice Guideline	O  NNLM;*COVID19;*Hepatitis;*Hepatocelluar carcinoma;*Liver cirrhosis;*SARSCoV2	Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Carcinoma, Hepatocellular/pathology/therapy;Coronavirus Infections/complications/drug therapy/epidemiology/*pathology;Cross Infection/prevention & control;Drug Interactions;Humans;Immunosuppressive Agents/therapeutic use;Liver Diseases/complications/pathology/*prevention & control;Liver Neoplasms/pathology/therapy;Liver Transplantation;Pandemics;Pneumonia, Viral/complications/drug therapy/epidemiology/*pathology;SARSCoV2;DA 2020/07/25 06:00		Management of liver diseases during the pandemic of coronavirus disease-19.	
1059	33031764	Journal Article		DA 2020/10/09 06:00	ClinicalTrials.gov/NCT04381936	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a 	WT_/Wellcome Trust/United Kingdom
1060	32473812	Journal Article;Review	O  NNLM;COVID19;Chloroquine;Coronavirus;Hydroxychloroquine;SARSCov2	COVID19;Chloroquine/*administration & dosage/adverse effects;Coronavirus Infections/*drug therapy/virology;Drug Monitoring;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;Pandemics;Pneumonia, Viral/*drug therapy/virology;Treatment Outcome;DA 2020/09/02 06:00		Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but 	
1061	33081849	Comparative Study;Letter;Randomized Controlled Trial	O  NNLM;COVID19;Hydroxychloroquine;Lopinavir/Ritonavir combination;Protocol;Randomised controlled trial;Ribavirin	Administration, Oral;Adult;Antimalarials/administration & dosage/therapeutic use;Antiviral Agents/administration & dosage/*therapeutic use;Betacoronavirus/*drug effects/genetics;COVID19;Clinical Protocols;Combined Modality Therapy;Coronavirus Infections/*drug therapy/epidemiology/virology;Cytochrome P450 CYP3A Inhibitors/administration & dosage/therapeutic use;Female;Humans;Hydroxychloroquine/administration & dosage/therapeutic use;India/epidemiology;Informed Consent;Lopinavir/administration & dosage/therapeutic use;Male;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Ribavirin/administration & dosage/*therapeutic use;Ritonavir/administration & dosage/therapeutic use;SARSCoV2;Safety;Time Factors;Treatment Outcome;DA 2020/11/04 06:00		Safety and efficacy of antiviral combination therapy in symptomatic patients of 	
1062	32983179	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*chloroquine;*hydroxychloroquine;*immune modulation	Antimalarials/adverse effects/pharmacology/*therapeutic use;Antiviral Agents/adverse effects/pharmacology/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/immunology/virology;Drug Repositioning/methods;Humans;Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use;Immunologic Factors/adverse effects/pharmacology/*therapeutic use;*Immunomodulation;Pandemics;Pneumonia, Viral/*drug therapy/immunology/virology;SARSCoV2;DA 2020/10/21 06:00		Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case 	
1063	33384605	Journal Article;Review	O  NNLM;COVID19;ICU admission;antiIL6 signaling agents;clinical improvement;mechanical ventilation;mortality;secondary infections	DA 2021/01/02 06:01		Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A 	
1064	33333256	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Cytokine storm;*IL6;*Immunotherapy;*Influenza;*SARS	COVID19/*immunology;Coronavirus Infections/*immunology;Cytokine Release Syndrome/*immunology;Cytokines/metabolism;Humans;Immunomodulation;Immunotherapy/*methods;Inflammation;Influenza, Human/*immunology;Middle East Respiratory Syndrome Coronavirus/*physiology;Orthomyxoviridae/*physiology;SARS Virus/*physiology;SARSCoV2/*physiology;Severe Acute Respiratory Syndrome/*immunology;DA 2021/01/29 06:00		Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common 	
1065	33128197	Journal Article;Review	O  NNLM;Antivirals;COVID19;Convalescent plasma;Remdesivir;SARSCoV2;Vaccines	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;Amides/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*therapy;COVID19 Vaccines/therapeutic use;Chloroquine/therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Immunization, Passive/methods;Palliative Care;Pyrazines/therapeutic use;SARSCoV2/*drug effects/immunology;Treatment Outcome;DA 2021/04/27 06:00		Emerging treatment strategies for COVID-19 infection.	
1066	33217576	Journal Article	O  NNLM;Anakinra;COVID19;COVID19 pneumonia;Hyperinflammation;Mechanical ventilation	Adult;Aged;Aged, 80 and over;COVID19/*therapy;Female;Hospitalization;Humans;Interleukin 1 Receptor Antagonist Protein/*therapeutic use;Male;Middle Aged;Oxygen/*therapeutic use;Prospective Studies;Respiration, Artificial;*SARSCoV2;DA 2021/02/18 06:00		Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen 	
1067	33312453	Journal Article		DA 2020/12/15 06:01		Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of 	
1068	32935090	Preprint		DA 2020/09/17 06:01		Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or 	
1069	33434221	Clinical Trial;Journal Article;Observational Study		Adult;Aged;Aged, 80 and over;Biomarkers/blood;COVID19/*blood/pathology/therapy;Chemokine CXCL10/*blood;*Decision Support Systems, Clinical;Female;Humans;Male;Middle Aged;Practice Guidelines as Topic;DA 2021/01/20 06:00	ClinicalTrials.gov/NCT04389645	Observational cohort study of IP-10's potential as a biomarker to aid in 	
1070	32752010	Journal Article;Review	O  NNLM;ACE2 receptor;COVID19;SARSCoV2;antioxidant therapy;sepsis	Antioxidants/*pharmacology;Betacoronavirus/*physiology;COVID19;*Coronavirus Infections/drug therapy/metabolism/virology;Humans;Oxidative Stress/drug effects/physiology;*Pandemics;*Pneumonia, Viral/drug therapy/metabolism/virology;SARSCoV2;DA 2020/08/12 06:00		Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An 	
1071	32654267	Journal Article;Review	O  NNLM;*COVID19 pneumonia;*animal models and immunotherapy;*diagnosis;*entry mechanism;*possible vaccines;*symptoms;*transmission	Animals;Antiviral Agents/therapeutic use;COVID19/*pathology/prevention & control/therapy/transmission;Humans;*Immunotherapy;Middle East Respiratory Syndrome Coronavirus/genetics/isolation & ;Models, Animal;Respiratory Tract Infections/*pathology/transmission/virology;SARSCoV2/genetics/isolation & purification/pathogenicity;Viral Vaccines/*immunology;DA 2020/12/15 06:00		The recent challenges of highly contagious COVID-19, causing respiratory infections: 	
1072	33113295	Clinical Trial, Phase II;Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't		Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects;Antibodies, Neutralizing/*administration & dosage/adverse effects;COVID19/*drug therapy/virology;DoseResponse Relationship, Drug;DoubleBlind Method;Female;Hospitalization/statistics & numerical data;Humans;Immunologic Factors/*administration & dosage/adverse effects;Male;Middle Aged;Outpatients;RNA, Viral/blood;Reverse Transcriptase Polymerase Chain Reaction;SARSCoV2/genetics/*isolation & purification;Severity of Illness Index;Viral Load/*drug effects;Young Adult;DA 2021/02/04 06:00	ClinicalTrials.gov/NCT04427501	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.	UL1 TR001422/TR/NCATS NIH HHS/United States
1073	33532135	Journal Article;Review	O  NNLM;COVID19;Chinese Medicine;strategies;treatment	DA 2021/02/04 06:01		A Comprehensive Summary of the Knowledge on COVID-19 Treatment.	
1074	33133611	Journal Article;Review	O  NNLM;COVID19;Cov2;SARS;coronavirus;diagnostics;disease;global;pandemic;ssRNA;virus	DA 2020/11/03 06:01		Coronavirus disease 2019: scientific overview of the global pandemic.	
1075	33171706	Journal Article;Review	O  NNLM;Plasmodium;antimalarial agents;kinase inhibitors;kinases;malaria	Animals;Antimalarials/*pharmacology;Calcium/metabolism;Casein Kinase I/metabolism;Culicidae;Drug Design;Drug Discovery/*trends;Drug Resistance;Glycogen Synthase Kinase 3/metabolism;Humans;Imidazoles/pharmacology;Inhibitory Concentration 50;Life Cycle Stages/drug effects;MAP Kinase Signaling System;Malaria/*drug therapy;Phosphotransferases/chemistry;Plasmodium/*drug effects/enzymology;Protein Kinase Inhibitors/*pharmacology;Pyridines/pharmacology;DA 2021/04/22 06:00		An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.	
1076	33269093	Journal Article	O  NNLM;COVID19;immunomodulation;microbiome;mitochondrial dysfunction;photobiomodulation	DA 2020/12/04 06:01		A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention 	
1077	33421462	Journal Article;Review	O  NNLM;Acute respiratory distress syndrome;Anticoagulant;COVID19;Heparin;Tissuetype plasminogen activator;Toxicological side effects	COVID19/*physiopathology;Hemostasis/*drug effects;Heparin/pharmacology/*therapeutic use;Humans;Thrombosis/*complications;Tissue Plasminogen Activator/pharmacology/*therapeutic use;DA 2021/02/09 06:00		Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of 	
1078	32718560	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*Nitric oxide;*RRx001;*SARSCoV2	Antihypertensive Agents/therapeutic use;Azetidines/*therapeutic use;Bosentan/therapeutic use;COVID19/*drug therapy/epidemiology/virology;Drug Repositioning/methods/trends;Humans;Lung/drug effects/physiopathology/virology;Nitric Oxide Donors/therapeutic use;Nitro Compounds/*therapeutic use;Pandemics;SARSCoV2/*drug effects/physiology;DA 2020/12/15 06:00		Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of 	
1079	33007369	Journal Article;Review	O  NNLM;*Cytokine release syndrome;*Cytokine storm;*Treatment	Antibodies, Monoclonal, Humanized/therapeutic use;COVID19/*complications/*therapy;Clinical Trials as Topic;Cytokine Release Syndrome/*etiology/immunology/pathology/*therapy;Humans;Immunomodulation;Inflammation;SARSCoV2;DA 2020/12/23 06:00		"""Cytokine storm"", not only in COVID-19 patients. Mini-review."	
1080	32397911	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*infection;*repurposed therapies;*vaccine;*viruses	Antiviral Agents/therapeutic use;*Betacoronavirus/genetics;COVID19;COVID19 Testing;COVID19 Vaccines;Clinical Laboratory Techniques;Coronavirus/genetics;*Coronavirus Infections/diagnosis/drug ;Disease Progression;Humans;*Pandemics/prevention & control;*Pneumonia, Viral/diagnosis/epidemiology/prevention & control/therapy;RNA, Viral;SARSCoV2;*Viral Vaccines/genetics/immunology;DA 2020/05/23 06:00		COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and 	
1081	32877828	Journal Article;Review	O  NNLM;Antibodies;COVID19;Immunotherapy;Pandemic;Plasma therapy;Severe acute respiratory syndrome coronavirus 2	Antibodies, Monoclonal/administration & dosage/therapeutic use;Antibodies, Viral/blood;Betacoronavirus;COVID19;COVID19 Vaccines;Coronavirus Infections/*drug therapy/immunology/prevention & control/therapy;Humans;Immunization, Passive;Immunotherapy/*methods;Interferons/administration & dosage/therapeutic use;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/immunology/prevention & control;SARSCoV2;Treatment Outcome;Viral Vaccines/administration & dosage/immunology;DA 2020/11/24 06:00		Immunotherapeutic approaches to curtail COVID-19.	
1082	32302379	Journal Article		Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors;Aged;Betacoronavirus/*isolation & purification;COVID19;Coronavirus Infections/complications/*drug therapy;Female;Humans;Lung Injury/*prevention & control;Male;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy;Protein Kinase Inhibitors/administration & dosage/*therapeutic use;Pyrazoles/administration & dosage/*therapeutic use;Pyrimidines/administration & dosage/*therapeutic use;SARSCoV2;Waldenstrom Macroglobulinemia/complications/*drug therapy;DA 2020/06/02 06:00		The BTK inhibitor ibrutinib may protect against pulmonary injury in 	P50 CA100707/CA/NCI NIH HHS/United States
1083	33031856	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Bioactive metabolites;*COVID19;*Cardiovascular disorders;*Inflammation;*n3 polyunsaturated fatty acids	Animals;COVID19/*complications/diagnosis/*drug therapy;Cardiovascular Diseases/diagnosis/*drug therapy/*etiology;Chemotherapy, Adjuvant/methods;Cytokine Release Syndrome/diagnosis/drug therapy/etiology;Fatty Acids, Omega3/*administration & dosage;Humans;Oxidative Stress/drug effects/physiology;Randomized Controlled Trials as Topic/methods;DA 2021/02/24 06:00		Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for 	
1084	32923016	Journal Article	O  NNLM;Coronavirus disease 2019;Efficacy;Safety;Triazavirin	DA 2020/09/15 06:01		Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot 	
1085	32380051	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*Chinese patent medicines;*Current evidence;*Review	Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*drug therapy;Drugs, Chinese Herbal/*therapeutic use;Humans;Nonprescription Drugs/*therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/07/01 06:00		The clinical benefits of Chinese patent medicines against COVID-19 based on current 	
1086	33217545	Journal Article;Research Support, N.I.H., Extramural;Review		Adrenal Cortex Hormones/therapeutic use;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/*prevention & control;COVID19 Vaccines/*immunology;Complement Inactivating Agents/therapeutic use;Humans;*SARSCoV2;DA 2021/01/29 06:00		COVID-19: A review of therapeutic strategies and vaccine candidates.	R61 AR078075/AR/NIAMS NIH HHS/United States;R01 AR076440/AR/NIAMS NIH HHS/United States;K08 AR070891/AR/NIAMS NIH HHS/United States
1087	33162887	Journal Article;Review	O  NNLM;acute respiratory distress syndrome;coronavirus disease 2019;neutrophil extracellular trap;neutrophils;severe acute respiratory syndrome coronavirus 2	DA 2020/11/10 06:01		Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus 	
1088	33163634	Journal Article	O  NNLM;ALT, Alanine Transaminase;AST, Aspartate Transaminase;ATS/IDSA, American Thoracic Society and Infectious Disease Society of America;Antigen presenting cells, (APCs);BUN, Blood Urea Nitrogen;COVID19;COVID19, Coronavirus Disease 2019;CRP, CReactive Protein;CSF, Cerebrospinal fluid;CT, Computed Tomography;DMT, Disease Modifying Therapy;EDSS, Expanded Disability Status Score;IV, Intravenous;Immunotherapies;JCV, John Cunnigham virus;L, Liters;MS, Multiple Sclerosis;Multiple sclerosis;NK cells, Natural Killer Cells;Novel coronavirus;Ocrelizumab;PPMS, Primary Progressive Multiple Sclerosis;Progressive multifocal leukoencephalopathy, (PML).;RRMS, Relapsing Remitting Multiple Sclerosis;RT PCR, Reverse Transcription Polymerase Chain Reaction;SARSCoV2;SARSCoV2, Severe Acute Respiratory Syndrome Coronavirus 2;Terminally differentiated late effector memory T cells, (TEMRA);nCov2, Novel coronavirus 2;ul, Microliters	DA 2020/11/10 06:01		A case series and literature review of multiple sclerosis and COVID-19: Clinical 	
1089	33154452	Journal Article		Antibodies, Monoclonal, Humanized/*administration & dosage/*pharmacology/therapeutic ;COVID19;Coronavirus Infections/*drug therapy/*mortality;Female;*Hospital Mortality;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/*mortality;DA 2020/12/01 06:00		Impact of tocilizumab administration on mortality in severe COVID-19.	
1090	32650818	Clinical Trial Protocol;Letter	O  NNLM;Ambulatory;COVID19;Doubleblind;Early treatment;Elderly patients;Hydroxychloroquine;Moderate disease;Outpatient;Placebocontrolled;Protocol;Randomised controlled trial	Age Factors;Aged;Aging;*Ambulatory Care;Antiviral Agents/*administration & dosage/adverse effects;Betacoronavirus/*drug effects/pathogenicity;COVID19;COVID19 Testing;Cause of Death;*Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/*drug therapy/mortality/virology;DoubleBlind Method;Drug Administration Schedule;Female;Germany;Hospitalization;HostPathogen Interactions;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;Male;Multicenter Studies as Topic;Pandemics;Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology;Predictive Value of Tests;Randomized Controlled Trials as Topic;Risk Factors;SARSCoV2;Time Factors;Treatment Outcome;DA 2020/07/16 06:00	ClinicalTrials.gov/NCT04351516	Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory 	
1091	33213829	Journal Article;Review	O  NNLM;ATMP;Advanced therapeutic approaches;COVID19;SARSCoV2	Antibodies, Monoclonal/therapeutic use;Anticoagulants/therapeutic use;Antiviral Agents/therapeutic use;COVID19/*drug therapy/etiology/immunology/prevention & control;COVID19 Vaccines/immunology;Cytokine Release Syndrome/immunology;Humans;*Regenerative Medicine;*SARSCoV2;DA 2020/12/15 06:00		Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.	
1092	32321635	Editorial	O  NNLM;*BDMARDs;*Covid19;*DMARDs;*TsDMARDs	AngiotensinConverting Enzyme 2;Antirheumatic Agents/*therapeutic use;Betacoronavirus/immunology/*pathogenicity;COVID19;Coronavirus Infections/*drug therapy/immunology;*Cytokines/metabolism;Humans;Pandemics;PeptidylDipeptidase A;Pneumonia, Viral/*drug therapy/immunology;SARSCoV2;DA 2020/04/28 06:00	ClinicalTrials.gov/NCT04320277	Old and new antirheumatic drugs for the treatment of COVID-19.	
1093	32961361	Journal Article	O  NNLM;*Adverse events;*Data safety monitoring boards;*Pandemic;*Randomized controlled trials;*SARSCoV2	COVID19/diagnosis/*drug therapy/epidemiology/prevention & control;*COVID19 Testing;*Clinical Trials Data Monitoring Committees/organization & ;Computer Simulation;Ethics Committees, Research;Humans;Randomized Controlled Trials as Topic/ethics/methods/statistics & numerical data;Research Design/*trends;SARSCoV2;*Vaccination;DA 2020/12/15 06:00		Data monitoring committees for clinical trials evaluating treatments of COVID-19.	
1094	33123144	Journal Article;Review	O  NNLM;*ACE2;*COVID19;*EMMPRIN;*SARSCoV2;*monoclonal antibodies;*nonstructural protein;*remdesivir;*spike receptor	Adenosine Monophosphate/analogs & derivatives/therapeutic use;Alanine/analogs & derivatives/therapeutic use;AngiotensinConverting Enzyme 2;Antibodies, Monoclonal/therapeutic use;Antibodies, Viral/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/genetics/immunology;COVID19;COVID19 Testing;Clinical Laboratory Techniques/*methods;*Coronavirus Infections/diagnosis/pathology/therapy;Disease Reservoirs/virology;Drug Repositioning/methods;Humans;Immunoenzyme Techniques;Immunotherapy;*Pandemics;PeptidylDipeptidase A/metabolism;*Pneumonia, Viral/diagnosis/pathology/therapy;Receptors, Virus/metabolism;Reverse Transcriptase Polymerase Chain Reaction;SARSCoV2;Serologic Tests/methods;Spike Glycoprotein, Coronavirus/metabolism;DA 2020/11/11 06:00		SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment.	
1095	32681385	Case Reports;Journal Article	O  NNLM;*COVID19;*NET;*Neuroendocrine tumors;*Thymus	Aged;Axitinib/adverse effects/therapeutic use;Azithromycin/therapeutic use;*Betacoronavirus;COVID19;Carcinoid Tumor/*drug therapy/epidemiology;Comorbidity;Coronavirus Infections/diagnosis/*epidemiology;Humans;Hydroxychloroquine/therapeutic use;Italy/epidemiology;Male;Neuroendocrine Tumors/*drug therapy/epidemiology;Pandemics;Pneumonia, Viral/diagnosis/*epidemiology;ProteinTyrosine Kinases/antagonists & inhibitors;Randomized Controlled Trials as Topic;SARSCoV2;Thymus Neoplasms/*drug therapy/epidemiology;Tomography, XRay Computed;Treatment Outcome;DA 2020/10/08 06:00		SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic 	
1096	32779824	Journal Article;Review	O  NNLM;1,8cineole;COVID19;SARSCoV2;antiviral drug;asymptomatic COVID19;lung elimination;monoterpenes;volatile drugs	DA 2020/08/12 06:00		Volatile molecules for COVID-19: A possible pharmacological strategy?	
1097	32736597	Clinical Trial Protocol;Comparative Study;Journal Article;Observational Study	O  NNLM;Asymptomatic;COVID19;Early treatment;Hydroxychloroquine;Paucisymptomatic;Prevention;Prophylaxis;Protocol;Randomized controlled clinical trial	*Betacoronavirus;COVID19;Cluster Analysis;Coronavirus Infections/*prevention & control;Female;Humans;Hydroxychloroquine/*therapeutic use;Male;Pandemics/*prevention & control;Patient Reported Outcome Measures;Pneumonia, Viral/*prevention & control;*Randomized Controlled Trials as Topic;SARSCoV2;Telemedicine;DA 2020/08/19 06:00	ClinicalTrials.gov/NCT04363827	PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus 	
1098	32564623	Journal Article;Review	O  NNLM;*COVID19;*SARSCoV2;*antivirals;*drug targets;*repurposed drugs;*therapeutics	Animals;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/growth & development;COVID19;Coronavirus Infections/*drug therapy;*Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;Receptors, Virus/drug effects;SARSCoV2;DA 2020/10/02 06:00		Tackling SARS-CoV-2: proposed targets and repurposed drugs.	
1099	32527868	Journal Article;Multicenter Study	O  NNLM;*cytokines;*inflammation;*outcome and process assessment, health care	Adolescent;*Betacoronavirus;COVID19;Child;Child, Preschool;Cohort Studies;Coronavirus Infections/*diagnosis/epidemiology/virology;Diagnosis, Differential;Female;Humans;Male;Mucocutaneous Lymph Node Syndrome/*diagnosis/virology;Pandemics;Paris/epidemiology;Pneumonia, Viral/*diagnosis/epidemiology/virology;SARSCoV2;Systemic Inflammatory Response Syndrome/*diagnosis/epidemiology/virology;DA 2020/07/23 06:00	ClinicalTrials.gov/NCT02377245	Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 	
1100	33196003	Journal Article;Review	O  NNLM;ACE2 receptor;COVID19;IL6;SARSCoV2;colchicine;cytokine storm;hydroxychloroquine;spike protein;tocilizumab	DA 2020/11/17 06:01		Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection 	
1101	33270225	Journal Article;Research Support, NonU.S. Gov't;Systematic Review	O  NNLM;*Antiviral agents;*Coronavirus;*Immnopathology;*Immunodulators;*Respiratory tract;*pandemic	COVID19/*prevention & control;*COVID19 Vaccines;Humans;SARSCoV2/genetics/immunology;Vaccines, DNA;Vaccines, Inactivated;Vaccines, Live, Unattenuated;Vaccines, Subunit;DA 2021/03/06 06:00		Interpretative immune targets and contemporary position for vaccine development 	EMR/2016/007564/Science and Engineering Research Board/;TDP/BDTD/33/2019/Department Of Science &amp; Technology, India/;BT/IIPME0211/02/16/Biotechnology Industry Research Assistance Council/
1102	32639233	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*bayesian;*chloroquine;*human;*human biology;*medicine;*overdose;*pharmacodynamics;*pharmacokinetics	Adult;Antimalarials/administration & dosage/poisoning/therapeutic use;Biotransformation;COVID19;Chloroquine/administration & dosage/adverse effects/analogs & ;Coronavirus Infections/drug therapy;DoseResponse Relationship, Drug;Drug Overdose/*mortality;Drug Repositioning;Electrocardiography;Female;Heart Diseases/chemically induced/mortality;Humans;Hydroxychloroquine/administration & dosage/adverse effects/poisoning/therapeutic use;Long QT Syndrome/chemically induced;Malaria/drug therapy;Male;Pandemics;Pneumonia, Viral/drug therapy;Randomized Controlled Trials as Topic/statistics & numerical data;Risk Assessment;*Suicide;*Suicide, Attempted;DA 2020/08/22 06:00		Concentration-dependent mortality of chloroquine in overdose.	Principal Research Fellowship 093956/Z/10/C/WT_/Wellcome Trust/United Kingdom
1103	32273253	Journal Article;Research Support, NonU.S. Gov't		COVID19/mortality/prevention & control/*therapy;*Hospitalization;Humans;Patient Care/methods;Patient Care Team/organization & administration;Pharmacists/*organization & administration;Pharmacy Service, Hospital/*organization & administration;Professional Role;DA 2020/12/23 06:00		Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: 	
1104	32667492	Journal Article		BCG Vaccine/therapeutic use;Betacoronavirus;COVID19;Chloroquine/therapeutic use;*Clinical Trials as Topic;Coronavirus Infections/*immunology/*therapy;Humans;*Immunity, Innate;Pandemics;Pneumonia, Viral/*immunology/*therapy;SARSCoV2;Vaccination;DA 2020/07/22 06:00		Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.	
1105	32791263	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Hanshiyi Formula;*Mild COVID19;*Moderate COVID19;*The proportion to severe status;*Traditional Chinese medicine	Adolescent;Adult;Aged;Aged, 80 and over;COVID19/*drug therapy/epidemiology;Child;Child, Preschool;China;Cohort Studies;Disease Progression;Drugs, Chinese Herbal/*therapeutic use;Female;Humans;Infant;Infant, Newborn;Male;Middle Aged;Risk Factors;Sex Factors;Treatment Outcome;Young Adult;DA 2021/01/01 06:00		Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the 	
1106	32984987	Journal Article	O  NNLM;*COVID19;*Mpro;*SARSCoV2;*antiplatelet;*molecular docking;*spike glycoprotein	COVID19/*drug therapy;Cilostazol/metabolism/therapeutic use;Coronavirus 3C Proteases/*metabolism;Drug Approval;Drug Evaluation, Preclinical;Drug Repositioning;Eicosapentaenoic Acid/analogs & derivatives/metabolism/therapeutic use;Epoprostenol/metabolism/therapeutic use;Humans;Iloprost/metabolism/therapeutic use;Molecular Docking Simulation;Platelet Aggregation Inhibitors/*metabolism/therapeutic use;Prasugrel Hydrochloride/metabolism/therapeutic use;SARSCoV2/*metabolism;Spike Glycoprotein, Coronavirus/*metabolism;United States;United States Food and Drug Administration;DA 2021/04/15 06:00		Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 	
